<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Bicalutamide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Bicalutamide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/mediawiki.page.gallery.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/mediawiki.page.gallery.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Bicalutamide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Bicalutamide</b>, sold under the brand name <b>Casodex</b> among others, is an antiandrogen medication that is primarily used to treat prostate cancer.<span class="mw-ref" id="cite_ref-AHFS2016_11-0"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat advanced prostate cancer.<span class="mw-ref" id="cite_ref-WassStewart2011_12-0"><a href="#cite_note-WassStewart2011-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2016_11-1"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-ShergillArya2010_13-0"><a href="#cite_note-ShergillArya2010-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Bicalutamide may also be used to treat excessive hair growth in women,<span class="mw-ref" id="cite_ref-WilliamsBigby2009_14-0"><a href="#cite_note-WilliamsBigby2009-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> as a component of feminizing hormone therapy for transgender women,<span class="mw-ref" id="cite_ref-pmid30256230_15-0"><a href="#cite_note-pmid30256230-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> to treat early puberty in boys,<span class="mw-ref" id="cite_ref-JamesonGroot2015_16-0"><a href="#cite_note-JamesonGroot2015-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> and to prevent overly long-lasting erections in men.<span class="mw-ref" id="cite_ref-YuanDeSouza2008_17-0"><a href="#cite_note-YuanDeSouza2008-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2016_11-2"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Bicalutamide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Bicalutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bicalutamide.svg.png" data-file-width="512" data-file-height="184" data-file-type="drawing" height="90" width="250"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Bicalutamide_3D_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bicalutamide_3D_ball.png" data-file-width="2192" data-file-height="1000" data-file-type="bitmap" height="114" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td>Bicalutamide:<br>• <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>b</span><span>aɪ</span><span>k</span><span>ə</span><span>ˈ</span><span>l</span><span>uː</span><span>t</span><span>ə</span><span>m</span><span>aɪ</span><span>d</span></span>/</span></span><span class="mw-ref" id="cite_ref-(PharmD.)Clark2009_1-0"><a href="#cite_note-(PharmD.)Clark2009-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><br>• <i title="English pronunciation respelling">bye-kə-<span style="font-size:90%">LOO</span>-tə-myde</i><span class="mw-ref" id="cite_ref-(PharmD.)Clark2009_1-1"><a href="#cite_note-(PharmD.)Clark2009-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><br>Casodex:<br>• <span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˈ</span><span>k</span><span>eɪ</span><span>s</span><span>oʊ</span><span>d</span><span>ɛ</span><span>k</span><span>s</span></span>/</span></span><span class="mw-ref" id="cite_ref-SiftonStaff2002_2-0"><a href="#cite_note-SiftonStaff2002-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><br>• <i title="English pronunciation respelling"><span style="font-size:90%">KAY</span>-soh-deks</i><span class="mw-ref" id="cite_ref-SiftonStaff2002_2-1"><a href="#cite_note-SiftonStaff2002-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Casodex, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>ICI-176,334; ZD-176,334</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/bicalutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/bicalutamide.html'" tppabs="https://www.drugs.com/monograph/bicalutamide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a697047.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a697047.html'" tppabs="https://medlineplus.gov/druginfo/meds/a697047.html" class="external text external">a697047</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bicalutamide&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bicalutamide&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Bicalutamide&SearchType=BasicSearch" class="external text external">Bicalutamide</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>X (Contraindicated)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth<span class="mw-ref" id="cite_ref-Cockshott2004_3-0"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Nonsteroidal antiandrogen</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L02BB03<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L02BB03  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L02BB03'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L02BB03" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>Well-absorbed; absolute bioavailability unknown<span class="mw-ref" id="cite_ref-Dart2004_4-0"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>Racemate: 96.1%<span class="mw-ref" id="cite_ref-Cockshott2004_3-1"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><br>(<i>R</i>)-Isomer: 99.6%<span class="mw-ref" id="cite_ref-Cockshott2004_3-2"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><br>(Mainly to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a>)<span class="mw-ref" id="cite_ref-Cockshott2004_3-3"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (extensively):<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-0"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-GrosseCampeau2013_6-0"><a href="#cite_note-GrosseCampeau2013-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><br>• Hydroxylation (CYP3A4)<br>• Glucuronidation (UGT1A9)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td>• Bicalutamide glucuronide<br>• Hydroxybicalutamide<br>• Hydroxybicalutamide <abbr>gluc.</abbr><br>(All inactive)<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-1"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-4"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid8997470_7-0"><a href="#cite_note-pmid8997470-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Schellhammer2005_8-0"><a href="#cite_note-Schellhammer2005-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>Single-dose: 5.8 days<span class="mw-ref" id="cite_ref-Skidmore-Roth2013_9-0"><a href="#cite_note-Skidmore-Roth2013-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><br>Continuous: 7–10 days<span class="mw-ref" id="cite_ref-JordanFurr2010_10-0"><a href="#cite_note-JordanFurr2010-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Feces: 43%<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-2"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><br>Urine: 34%<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-3"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(<i>RS</i>)-<i>N</i>-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=90357-06-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=90357-06-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=90357-06-5" class="external text external">90357-06-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup> <br><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-40-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-40-4'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-40-4" class="external text external">113299-40-4</a> ((<i>R</i>)-isomer)<br><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-38-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-38-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=113299-38-0" class="external text external">113299-38-0</a> ((<i>S</i>)-isomer)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/2375  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/2375'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/2375" class="external text external">2375</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863" class="external text external">2863</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB01128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB01128'" tppabs="https://www.drugbank.ca/drugs/DB01128" class="external text external">DB01128</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.2284.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.2284.html'" tppabs="http://www.chemspider.com/Chemical-Structure.2284.html" class="external text external">2284</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=A0Z3NAU9DP  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=A0Z3NAU9DP'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=A0Z3NAU9DP" class="external text external">A0Z3NAU9DP</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/C08160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/C08160'" tppabs="https://www.kegg.jp/entry/C08160" class="external text external">C08160</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91617'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91617" class="external text external">CHEBI:91617</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL409  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL409'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL409" class="external text external">ChEMBL409</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PDB ligand</th><td><div class="plainlist"><ul><li>198 (<span><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=198  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=198'" tppabs="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=198" class="external text external">PDBe</a></span>, <span><a href="javascript:if(confirm('http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=198&polymericType=Any  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=198&polymericType=Any'" tppabs="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=198&polymericType=Any" class="external text external">RCSB<span>&nbsp;</span>PDB</a></span>)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID2022678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID2022678'" tppabs="https://comptox.epa.gov/dashboard/DTXSID2022678" class="external text external">DTXSID2022678</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.126.100  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.126.100'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.126.100" class="external text external">100.126.100</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>18</sub><span>H</span><sub>14</sub><span>F</span><sub>4</sub><span>N</span><sub>2</sub><span>O</span><sub>4</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">430.37</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28CS%28%3DO%29%28%3DO%29C1%3DCC%3DC%28C%3DC1%29F%29%28C%28%3DO%29NC2%3DCC%28%3DC%28C%3DC2%29C%23N%29C%28F%29%28F%29F%29O  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28CS%28%3DO%29%28%3DO%29C1%3DCC%3DC%28C%3DC1%29F%29%28C%28%3DO%29NC2%3DCC%28%3DC%28C%3DC2%29C%23N%29C%28F%29%28F%29F%29O'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28CS%28%3DO%29%28%3DO%29C1%3DCC%3DC%28C%3DC1%29F%29%28C%28%3DO%29NC2%3DCC%28%3DC%28C%3DC2%29C%23N%29C%28F%29%28F%29F%29O" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Chirality</th><td>Racemic mixture (of (<i>R</i>)- and (<i>S</i>)-enantiomers)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>191 to 193<span>&nbsp;</span>°C (376 to 379<span>&nbsp;</span>°F) (experimental)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Boiling point</th><td>650<span>&nbsp;</span>°C (1,202<span>&nbsp;</span>°F) (predicted)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Solubility in water</th><td>0.005</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:LKJPYSCBVHEWIU-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459978482&page2=Bicalutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459978482&page2=Bicalutamide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459978482&page2=Bicalutamide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects in men include breast enlargement, breast tenderness, and hot flashes.<span class="mw-ref" id="cite_ref-AHFS2016_11-3"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Other side effects in men include feminization and sexual dysfunction.<span class="mw-ref" id="cite_ref-pmid20626600_18-0"><a href="#cite_note-pmid20626600-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> While the medication appears to produce few side effects in women, its use in women is not recommended by the Food and Drug Administration (FDA).<span class="mw-ref" id="cite_ref-Shapiro2012_19-0"><a href="#cite_note-Shapiro2012-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2016_11-4"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Use during pregnancy may harm the baby.<span class="mw-ref" id="cite_ref-AHFS2016_11-5"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> Bicalutamide causes elevated liver enzymes in around 1% of people.<span class="mw-ref" id="cite_ref-FDALabel_20-0"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Wellington2006_21-0"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Rarely, it has been associated with cases of liver damage,<span class="mw-ref" id="cite_ref-AHFS2016_11-6"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> lung toxicity,<span class="mw-ref" id="cite_ref-Dart2004_4-1"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> and sensitivity to light.<span class="mw-ref" id="cite_ref-LeeOda2016_22-0"><a href="#cite_note-LeeOda2016-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-ReactionsWeekly2016_23-0"><a href="#cite_note-ReactionsWeekly2016-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Although the risk of adverse liver changes is small, monitoring of liver function is recommended during treatment.<span class="mw-ref" id="cite_ref-AHFS2016_11-7"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


<p>Bicalutamide is a member of the nonsteroidal antiandrogen (NSAA) group of medications.<span class="mw-ref" id="cite_ref-Dart2004_4-2"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It works by blocking the androgen receptor (AR), the biological target of the androgen sex hormones <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT).<span class="mw-ref" id="cite_ref-SinghGauthier2000_24-0"><a href="#cite_note-SinghGauthier2000-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> It does not lower androgen levels.<span class="mw-ref" id="cite_ref-Dart2004_4-3"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> The medication can have some estrogen-like effects in men.<span class="mw-ref" id="cite_ref-IIIBarbieri2013a_25-0"><a href="#cite_note-IIIBarbieri2013a-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-MarcusFeldman2007_26-0"><a href="#cite_note-MarcusFeldman2007-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-MahlerVerhelst1998_27-0"><a href="#cite_note-MahlerVerhelst1998-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Bicalutamide is well-absorbed, and its absorption is not affected by food.<span class="mw-ref" id="cite_ref-Cockshott2004_3-5"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The elimination half-life of the medication is around one week.<span class="mw-ref" id="cite_ref-Cockshott2004_3-6"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2016_11-8"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> It is believed to cross the blood–brain barrier and affect both the body and brain.<span class="mw-ref" id="cite_ref-Cockshott2004_3-7"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


<p>Bicalutamide was patented in 1982 and approved for medical use in 1995.<span class="mw-ref" id="cite_ref-FischerGanellin2006_28-0"><a href="#cite_note-FischerGanellin2006-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_29-0"><a href="#cite_note-WHO21st-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> Bicalutamide is available as a generic medication.<span class="mw-ref" id="cite_ref-Ric2015_30-0"><a href="#cite_note-Ric2015-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> The drug is sold in more than 80<span>&nbsp;</span>countries, including most developed countries.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-0"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-Ak1999_32-0"><a href="#cite_note-Ak1999-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca1999_33-0"><a href="#cite_note-AstraZeneca1999-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> It is the most widely used antiandrogen in the treatment of prostate cancer, and has been prescribed to millions of men with the disease.<span class="mw-ref" id="cite_ref-MukherjiPezaro2012_34-0"><a href="#cite_note-MukherjiPezaro2012-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-PchejetskiAlshaker2014_35-0"><a href="#cite_note-PchejetskiAlshaker2014-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span><span class="mw-ref" id="cite_ref-Campbell2014_36-0"><a href="#cite_note-Campbell2014-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-HHS2010_37-0"><a href="#cite_note-HHS2010-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


<p>Bicalutamide is approved for and mainly used in the following indications:<span class="mw-ref" id="cite_ref-BagatellBremner2003_38-0"><a href="#cite_note-BagatellBremner2003-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>

<ul><li>Metastatic prostate cancer (mPC) in men in combination with a <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH) analogue or surgical castration at moderate doses<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-4"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid15882477_39-0"><a href="#cite_note-pmid15882477-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></li>
<li>Locally advanced prostate cancer (LAPC) in men as a monotherapy in high doses<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-5"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-8"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Wellington2006_21-1"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-pmid9301693_40-0"><a href="#cite_note-pmid9301693-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></li></ul>

<p>It can also be and is used to a lesser extent for the following off-label (non-approved) indications:</p>

<ul><li>To reduce the effects of the testosterone flare at the initiation of <abbr>GnRH</abbr> agonist therapy in men<span class="mw-ref" id="cite_ref-Melmed2016_41-0"><a href="#cite_note-Melmed2016-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-SugionoWinkler2005_42-0"><a href="#cite_note-SugionoWinkler2005-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></li>
<li>Androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss in women as well as high testosterone levels due to polycystic ovary syndrome (PCOS) in women, at low to moderate doses generally in combination with a birth control pill<span class="mw-ref" id="cite_ref-WilliamsBigby2009_14-1"><a href="#cite_note-WilliamsBigby2009-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-pmid24455796_43-0"><a href="#cite_note-pmid24455796-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-AscensoMarques2009_44-0"><a href="#cite_note-AscensoMarques2009-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-pmid27512185_45-0"><a href="#cite_note-pmid27512185-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span><span class="mw-ref" id="cite_ref-LottiMaggi2015_46-0"><a href="#cite_note-LottiMaggi2015-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span><span class="mw-ref" id="cite_ref-MüderrisÖner2009_47-0"><a href="#cite_note-MüderrisÖner2009-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-pmid29211888_48-0"><a href="#cite_note-pmid29211888-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></li>
<li>Feminizing hormone therapy for transgender women in combination with an estrogen<span class="mw-ref" id="cite_ref-pmid30256230_15-1"><a href="#cite_note-pmid30256230-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-FishmanPaliou2019_49-0"><a href="#cite_note-FishmanPaliou2019-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-pmid30612811_50-0"><a href="#cite_note-pmid30612811-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-Gooren2011_51-0"><a href="#cite_note-Gooren2011-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-Deutsch2016_52-0"><a href="#cite_note-Deutsch2016-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Vincent2018_53-0"><a href="#cite_note-Vincent2018-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-WierckxGooren2014_54-0"><a href="#cite_note-WierckxGooren2014-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></li>
<li>Peripheral precocious puberty in boys at moderate doses in combination with an aromatase inhibitor like <a href="Anastrozole.htm" tppabs="https://ptable.com/wiki/compounds/A/Anastrozole" title="Anastrozole">anastrozole</a>, especially for familial male-limited precocious puberty (testotoxicosis)<span class="mw-ref" id="cite_ref-FDALabel_20-1"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-SchoelwerEugster2015_55-0"><a href="#cite_note-SchoelwerEugster2015-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span><span class="mw-ref" id="cite_ref-HaddadEugster2019_56-0"><a href="#cite_note-HaddadEugster2019-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span><span class="mw-ref" id="cite_ref-HaddadEugster2012_57-0"><a href="#cite_note-HaddadEugster2012-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span><span class="mw-ref" id="cite_ref-pmid31144045_58-0"><a href="#cite_note-pmid31144045-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-KliegmanStanton2015_59-0"><a href="#cite_note-KliegmanStanton2015-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span class="mw-ref" id="cite_ref-JamesonGroot2015_16-1"><a href="#cite_note-JamesonGroot2015-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-ReiterMauras2010_60-0"><a href="#cite_note-ReiterMauras2010-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span></li>
<li>Overly long-lasting erections in men at low to very low doses<span class="mw-ref" id="cite_ref-LeveyKutlu2011_61-0"><a href="#cite_note-LeveyKutlu2011-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span><span class="mw-ref" id="cite_ref-BroderickKadioglu2010_62-0"><a href="#cite_note-BroderickKadioglu2010-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-ChowPayne2008_63-0"><a href="#cite_note-ChowPayne2008-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-DahmRao2002_64-0"><a href="#cite_note-DahmRao2002-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-Dart2004_4-4"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Skidmore-Roth2013_9-1"><a href="#cite_note-Skidmore-Roth2013-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-YuanDeSouza2008_17-1"><a href="#cite_note-YuanDeSouza2008-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></li></ul>

<p>The medication has been suggested for but has uncertain effectiveness in the following indication:</p>

<ul><li>Hypersexuality and paraphilias, particularly in combination with chemical castration<span class="mw-ref" id="cite_ref-pmid21956411_65-0"><a href="#cite_note-pmid21956411-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-pmid19297634_66-0"><a href="#cite_note-pmid19297634-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span><span class="mw-ref" id="cite_ref-pmid27032060_67-0"><a href="#cite_note-pmid27032060-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-APA1999_68-0"><a href="#cite_note-APA1999-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-pmid22005210_69-0"><a href="#cite_note-pmid22005210-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span><span class="mw-ref" id="cite_ref-pmid2189544_70-0"><a href="#cite_note-pmid2189544-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span></li></ul>

<p>For more information on these uses, see the medical uses of bicalutamide article.</p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Available_forms">Available forms</h3></summary>
    

<p>Bicalutamide is available for the treatment of prostate cancer in most developed countries,<span class="mw-ref" id="cite_ref-IndexNominum2000_71-0"><a href="#cite_note-IndexNominum2000-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com-2_31-1"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-Martindale2011_72-0"><a href="#cite_note-Martindale2011-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span> including over 80<span>&nbsp;</span>countries worldwide.<span class="mw-ref" id="cite_ref-Ak1999_32-1"><a href="#cite_note-Ak1999-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca1999_33-1"><a href="#cite_note-AstraZeneca1999-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> It is available in 50<span>&nbsp;</span>mg, 80<span>&nbsp;</span>mg (in Japan),<span class="mw-ref" id="cite_ref-SuzukiKamiya2008_73-0"><a href="#cite_note-SuzukiKamiya2008-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span> and 150<span>&nbsp;</span>mg tablets for oral administration.<span class="mw-ref" id="cite_ref-WhiteBradnam2015_74-0"><a href="#cite_note-WhiteBradnam2015-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall2001_75-0"><a href="#cite_note-MortonHall2001-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> The drug is registered for use as a 150<span>&nbsp;</span>mg/day monotherapy for the treatment of <abbr>LAPC</abbr> in at least 55 countries,<span class="mw-ref" id="cite_ref-Cockshott2004_3-9"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> with the <abbr>U.S.</abbr> being a notable exception where it is registered only for use at a dosage of 50<span>&nbsp;</span>mg/day in combination with castration.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_76-0"><a href="#cite_note-ChabnerLongo2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> No other formulations or routes of administration are available or used.<span class="mw-ref" id="cite_ref-WhiteBradnam2015_74-1"><a href="#cite_note-WhiteBradnam2015-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span> All formulations of bicalutamide are specifically indicated for the treatment of prostate cancer alone or in combination with surgical or medication castration.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-6"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> A combined formulation of bicalutamide and the <abbr>GnRH</abbr> agonist <a href="Goserelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Goserelin" title="Goserelin">goserelin</a> in which goserelin is provided as a subcutaneous implant for injection and bicalutamide is included as 50<span>&nbsp;</span>mg tablets for oral ingestion is marketed in Australia and New Zealand under the brand name ZolaCos CP (Zoladex–Cosudex Combination Pack).<span class="mw-ref" id="cite_ref-Martindale2011_72-1"><a href="#cite_note-Martindale2011-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com-3_77-0"><a href="#cite_note-Drugs.com-3-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-ZolacosCPLabelAu_78-0"><a href="#cite_note-ZolacosCPLabelAu-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-ZolacosCPLabelNZ_79-0"><a href="#cite_note-ZolacosCPLabelNZ-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Bicalutamide is pregnancy category X, or "contraindicated in pregnancy", in the <abbr>U.S.</abbr>,<span class="mw-ref" id="cite_ref-FDALabel_20-2"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> and pregnancy category D, the second most restricted rating, in Australia.<span class="mw-ref" id="cite_ref-TGALabel_80-0"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> As such, it is contraindicated in women during pregnancy, and women who are sexually active and who can or may become pregnant are strongly recommended to take bicalutamide only in combination with adequate contraception.<span class="mw-ref" id="cite_ref-IswaranImai1997_81-0"><a href="#cite_note-IswaranImai1997-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-Smith2013_82-0"><a href="#cite_note-Smith2013-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> It is unknown whether bicalutamide is excreted in breast milk, but many drugs are excreted in breast milk, and for this reason, bicalutamide treatment is similarly not recommended while breastfeeding.<span class="mw-ref" id="cite_ref-Dart2004_4-5"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-FDALabel_20-3"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>In individuals with severe, though not mild-to-moderate hepatic impairment, there is evidence that the elimination of bicalutamide is slowed, and hence, caution may be warranted in these patients as circulating levels of bicalutamide may be increased.<span class="mw-ref" id="cite_ref-Cockshott2004_3-10"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-SkeelKhleif2011_83-0"><a href="#cite_note-SkeelKhleif2011-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> In severe hepatic impairment, the elimination half-life of the active (<i>R</i>)-enantiomer of bicalutamide is increased by about 1.75-fold (76% increase; elimination half-life of 5.9 and 10.4<span>&nbsp;</span>days for normal and impaired patients, respectively).<span class="mw-ref" id="cite_ref-Wellington2006_21-2"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-84"><a href="#cite_note-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span><span class="mw-ref" id="cite_ref-PDR2004_85-0"><a href="#cite_note-PDR2004-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> The elimination half-life of bicalutamide is unchanged in renal impairment.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_76-1"><a href="#cite_note-ChabnerLongo2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    

<span>
</span><table class="wikitable floatright" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption> <span style="font-size:105%;">Major side effects of bicalutamide alone</span></caption>
<tbody><tr>
<th>Frequency</th><th>Class</th><th>Side effect</th></tr>
<tr>
<td style="text-align: center; ">Very common<br>(≥10%)</td><td>Reproductive system<br>and breast disorders</td><td>• Breast tenderness<sup>a</sup><br>• Gynecomastia<sup>a</sup></td></tr>
<tr>
<td rowspan="3" style="text-align: center; ">Common<br>(≥1% and &lt;10%)</td><td>General and psychiatric<br>disorders</td><td>• Asthenia<br> • Decreased libido<br> • Erectile dysfunction<br> • Hot flashes</td></tr>
<tr>
<td>Skin and subcutaneous<br>tissue disorders</td><td>• Decreased body hair</td></tr>
<tr>
<td>Hepato-biliary disorders</td><td>• Elevated liver enzymes<sup>b</sup></td></tr>
<tr>
<td style="text-align: center; ">Uncommon<br>(≥0.1% and &lt;1%)</td><td>Immune system disorders</td><td>• Hypersensitivity reactions,<br>(angioedema and hives)</td></tr>
<tr>
<td rowspan="3" style="text-align: center; ">Rare (&lt;0.1%)<br>and unknown</td><td>Respiratory, thoracic, and<br>mediastinal disorders</td><td>• Interstitial lung disease<sup>c</sup></td></tr>
<tr>
<td>Skin and subcutaneous<br>tissue disorders</td><td>• Sensitivity to light</td></tr>
<tr>
<td>Hepato-biliary disorders</td><td>• Liver toxicity<sup>d</sup></td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><div class="mw-collapsible  mw-collapsed " style="box-sizing:border-box;width:100%;font-size:95%;padding:4px;border:none;"><div style="font-size:100%;line-height:1.6;font-weight:bold;background:transparent;text-align:center;;">Footnotes and sources</div><div class="mw-collapsible-content" style="background:transparent;text-align:left;;">
<sup>a</sup> = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration.<br><sup>b</sup> = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose 4,000-patient trial.<br><sup>c</sup> = 6 case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort.<br><sup>d</sup> = 7 case reports of liver toxicity published (as of 2018). No cases in a high-dose 4,000-patient trial (suggesting incidence of &lt;0.03%).<br><div class="center" style="width:auto; margin-left:auto; margin-right:auto;"><i>Sources:</i> See template.</div></div></div></td></tr>
</tbody></table>

<p>The side effect profile of bicalutamide is highly dependent on sex; that is, on whether the person is male or female. In men, due to androgen deprivation, a variety of side effects of varying severity may occur during bicalutamide treatment, with breast pain/tenderness and gynecomastia (breast development/enlargement) being the most common.<span class="mw-ref" id="cite_ref-Lehne2013_86-0"><a href="#cite_note-Lehne2013-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-WirthHakenberg2007_87-0"><a href="#cite_note-WirthHakenberg2007-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span> Gynecomastia occurs in up to 80% of men treated with bicalutamide monotherapy, though is of only mild-to-moderate severity in more than 90% of affected men.<span class="mw-ref" id="cite_ref-WirthHakenberg2007_87-1"><a href="#cite_note-WirthHakenberg2007-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-0"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> In addition to breast changes, physical feminization and demasculinization in general, including reduced body hair growth, decreased muscle mass and strength, feminine changes in fat mass and distribution, reduced penile length, and decreased semen/ejaculate volume, may occur in men.<span class="mw-ref" id="cite_ref-Lehne2013_86-1"><a href="#cite_note-Lehne2013-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-Higano2003_89-0"><a href="#cite_note-Higano2003-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-pmid20626600_18-1"><a href="#cite_note-pmid20626600-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-pmid23008326_90-0"><a href="#cite_note-pmid23008326-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> Other side effects that have been observed in men and that are similarly related to androgen deprivation include hot flashes, sexual dysfunction (e.g., loss of libido, erectile dysfunction), depression, fatigue, weakness, and anemia.<span class="mw-ref" id="cite_ref-Lehne2013_86-2"><a href="#cite_note-Lehne2013-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-Kolvenbag1996_91-0"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-ResnickThompson2000_92-0"><a href="#cite_note-ResnickThompson2000-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span> However, most men have preserved sexual function with bicalutamide monotherapy.<span class="mw-ref" id="cite_ref-IversenMelezinek2001_93-0"><a href="#cite_note-IversenMelezinek2001-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-0"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> In females, due to the minimal biological importance of androgens in this sex,<span class="mw-ref" id="cite_ref-pmid28343552_95-0"><a href="#cite_note-pmid28343552-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-pmid26358173_96-0"><a href="#cite_note-pmid26358173-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span> the side effects of pure antiandrogens or <abbr>NSAAs</abbr> are few, and bicalutamide has been found to be very well tolerated.<span class="mw-ref" id="cite_ref-Shapiro2012_19-1"><a href="#cite_note-Shapiro2012-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> General side effects of bicalutamide that may occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash.<span class="mw-ref" id="cite_ref-Kolvenbag1996_91-1"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-Dart2004_4-6"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-pmid7579554_97-0"><a href="#cite_note-pmid7579554-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span><span class="mw-ref" id="cite_ref-pmid10388026_98-0"><a href="#cite_note-pmid10388026-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span><span class="mw-ref" id="cite_ref-MDMD2008_99-0"><a href="#cite_note-MDMD2008-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span><span class="mw-ref" id="cite_ref-JamnickyNam2012_100-0"><a href="#cite_note-JamnickyNam2012-100" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span> The drug is well tolerated at higher dosages than the 50<span>&nbsp;</span>mg/day dosage, with rare additional side effects.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_76-2"><a href="#cite_note-ChabnerLongo2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span></p>

<p>Bicalutamide monotherapy has been associated with abnormal liver function tests such as elevated liver enzymes in 3.4% of men relative to 1.9% for standard care.<span class="mw-ref" id="cite_ref-Wellington2006_21-3"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-SeeWirth2002_101-0"><a href="#cite_note-SeeWirth2002-101" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span> Hepatic changes such as marked increases in liver enzymes or hepatitis that necessitated discontinuation of bicalutamide have occurred in approximately 0.3 to 1% of men in clinical trials.<span class="mw-ref" id="cite_ref-FDALabel_20-4"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-MahlerVerhelst1998_27-1"><a href="#cite_note-MahlerVerhelst1998-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Monitoring of liver function during treatment is recommended, particularly in the first few months.<span class="mw-ref" id="cite_ref-Wellington2006_21-4"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_86-3"><a href="#cite_note-Lehne2013-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> In men of advanced age with prostate cancer, bicalutamide monotherapy has been associated with an increase in non-prostate cancer mortality, in part due to an increase in the rate of heart failure.<span class="mw-ref" id="cite_ref-IversenJohansson2004_102-0"><a href="#cite_note-IversenJohansson2004-102" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span><span class="mw-ref" id="cite_ref-Wellington2006_21-5"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> These mortality-related effects are thought to be a consequence of androgen deprivation, rather than a specific drug-related toxicity of bicalutamide.<span class="mw-ref" id="cite_ref-pmid17130095_103-0"><a href="#cite_note-pmid17130095-103" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span></p>

<p>A total of 7<span>&nbsp;</span>cases of hepatotoxicity or liver failure, two of which resulted in death, have been reported in association with bicalutamide.<span class="mw-ref" id="cite_ref-GretarsdottirBjornsdottir2018_104-0"><a href="#cite_note-GretarsdottirBjornsdottir2018-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span><span class="mw-ref" id="cite_ref-pmid24967002_105-0"><a href="#cite_note-pmid24967002-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span><span class="mw-ref" id="cite_ref-pmid27099451_106-0"><a href="#cite_note-pmid27099451-106" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span><span class="mw-ref" id="cite_ref-GretarsdottirBjornsdottir2018_104-1"><a href="#cite_note-GretarsdottirBjornsdottir2018-104" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span> Symptoms that may indicate liver dysfunction include nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, and jaundice.<span class="mw-ref" id="cite_ref-FDALabel_20-5"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Bicalutamide has also been associated with several case reports of interstitial pneumonitis, which can potentially progress to pulmonary fibrosis.<span class="mw-ref" id="cite_ref-Dart2004b_107-0"><a href="#cite_note-Dart2004b-107" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span><span class="mw-ref" id="cite_ref-MasagoWatanabe2011_108-0"><a href="#cite_note-MasagoWatanabe2011-108" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2014_109-0"><a href="#cite_note-Aronson2014-109" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> Symptoms that may indicate lung dysfunction include dyspnea (difficult breathing or shortness of breath), cough, and pharyngitis (inflammation of the pharynx, resulting in sore throat).<span class="mw-ref" id="cite_ref-pmid15195196_110-0"><a href="#cite_note-pmid15195196-110" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span> Both hepatotoxicity and interstitial pneumonitis are said to be extremely rare events with bicalutamide.<span class="mw-ref" id="cite_ref-pmid24967002_105-1"><a href="#cite_note-pmid24967002-105" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span><span class="mw-ref" id="cite_ref-TholeManso2004_111-0"><a href="#cite_note-TholeManso2004-111" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span><span class="mw-ref" id="cite_ref-RicciBuzzatti2014_112-0"><a href="#cite_note-RicciBuzzatti2014-112" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span> A few cases of photosensitivity have been reported with bicalutamide.<span class="mw-ref" id="cite_ref-LeeOda2016_22-1"><a href="#cite_note-LeeOda2016-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Hypersensitivity reactions (drug allergy) like angioedema and hives have also uncommonly been reported in association with bicalutamide.<span class="mw-ref" id="cite_ref-FDALabel_20-6"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Because it is an antiandrogen, bicalutamide has a theoretical risk of birth defects like ambiguous genitalia and brain feminization in male fetuses.<span class="mw-ref" id="cite_ref-IswaranImai1997_81-1"><a href="#cite_note-IswaranImai1997-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-Smith2013_82-1"><a href="#cite_note-Smith2013-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span><span class="mw-ref" id="cite_ref-113"><a href="#cite_note-113" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-Paoletti2012_114-0"><a href="#cite_note-Paoletti2012-114" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Comparison">Comparison</h3></summary>
    


<p>The side effect profile of bicalutamide in men and women differs from that of other antiandrogens and is considered favorable in comparison.<span class="mw-ref" id="cite_ref-RamonDenis2007_115-0"><a href="#cite_note-RamonDenis2007-115" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-1"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-Moser2008_116-0"><a href="#cite_note-Moser2008-116" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span><span class="mw-ref" id="cite_ref-Demos2011_117-0"><a href="#cite_note-Demos2011-117" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span> Relative to <abbr>GnRH</abbr> analogues and the steroidal antiandrogen (SAA) cyproterone acetate (CPA), bicalutamide monotherapy has a much lower incidence and severity of hot flashes and sexual dysfunction.<span class="mw-ref" id="cite_ref-IversenMelezinek2001_93-1"><a href="#cite_note-IversenMelezinek2001-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-2"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-1"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_118-0"><a href="#cite_note-Aronson2009-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span> In addition, unlike <abbr>GnRH</abbr> analogues and <abbr>CPA</abbr>, bicalutamide monotherapy is not associated with decreased bone mineral density or osteoporosis.<span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-2"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-3"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> Conversely, bicalutamide monotherapy is associated with much higher rates of breast tenderness, gynecomastia, and feminization in men than <abbr>GnRH</abbr> analogues and <abbr>CPA</abbr>.<span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-3"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> However, gynecomastia with bicalutamide is rarely severe and discontinuation rates due to this side effect are fairly low.<span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-4"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-4"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> These differences in side effects between bicalutamide monotherapy, <abbr>GnRH</abbr> analogues, and <abbr>CPA</abbr> are attributed to the fact that whereas <abbr>GnRH</abbr> analogues and <abbr>CPA</abbr> suppress estrogen production, bicalutamide monotherapy does not lower estrogen levels and in fact actually increases them.<span class="mw-ref" id="cite_ref-WellingtonKeam2006_88-5"><a href="#cite_note-WellingtonKeam2006-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span></p>

<p>Bicalutamide does not share the high risk of neuropsychiatric side effects like depression, anxiety, and suicidality as well as cardiovascular side effects like coagulation changes, thrombosis, fluid retention, ischemic cardiomyopathy, and adverse serum lipid changes that <abbr>CPA</abbr> is associated with.<span class="mw-ref" id="cite_ref-Aronson2009_118-1"><a href="#cite_note-Aronson2009-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span><span class="mw-ref" id="cite_ref-Barrett2007_119-0"><a href="#cite_note-Barrett2007-119" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></span><span class="mw-ref" id="cite_ref-pmid12190640_120-0"><a href="#cite_note-pmid12190640-120" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span><span class="mw-ref" id="cite_ref-pmid10936469_121-0"><a href="#cite_note-pmid10936469-121" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span> It has a far lower risk of hepatotoxicity than <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a> and <abbr>CPA</abbr> and of interstitial pneumonitis than <a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">nilutamide</a>.<span class="mw-ref" id="cite_ref-pmid15604569_122-0"><a href="#cite_note-pmid15604569-122" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></span><span class="mw-ref" id="cite_ref-pmid12603397_94-5"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-pmid18657023_123-0"><a href="#cite_note-pmid18657023-123" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></span><span class="mw-ref" id="cite_ref-CRAIGFurr2010_124-0"><a href="#cite_note-CRAIGFurr2010-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span><span class="mw-ref" id="cite_ref-pmid12353966_125-0"><a href="#cite_note-pmid12353966-125" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span><span class="mw-ref" id="cite_ref-pmid25270521_126-0"><a href="#cite_note-pmid25270521-126" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span> The drug also does not share the unique risks of diarrhea with flutamide and nausea, vomiting, visual disturbances, and alcohol intolerance with nilutamide.<span class="mw-ref" id="cite_ref-pmid12603397_94-6"><a href="#cite_note-pmid12603397-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_118-2"><a href="#cite_note-Aronson2009-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span><span class="mw-ref" id="cite_ref-CRAIGFurr2010_124-1"><a href="#cite_note-CRAIGFurr2010-124" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span> Unlike enzalutamide, bicalutamide is not associated with seizures or related central side effects like anxiety and insomnia.<span class="mw-ref" id="cite_ref-pmid20878947_127-0"><a href="#cite_note-pmid20878947-127" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span><span class="mw-ref" id="cite_ref-pmid24881730_128-0"><a href="#cite_note-pmid24881730-128" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> However, although the risk of adverse liver changes with bicalutamide is low, enzalutamide differs from bicalutamide in having no known risk of elevated liver enzymes or hepatotoxicity.<span class="mw-ref" id="cite_ref-pmid25711765_129-0"><a href="#cite_note-pmid25711765-129" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span><span class="mw-ref" id="cite_ref-pmid25354111_130-0"><a href="#cite_note-pmid25354111-130" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span> In contrast to the <abbr>SAA</abbr> <a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">spironolactone</a>, bicalutamide does not have antimineralocorticoid effects,<span class="mw-ref" id="cite_ref-pmid8560673_131-0"><a href="#cite_note-pmid8560673-131" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span> and hence is not associated with hyperkalemia, urinary frequency, dehydration, hypotension, or other related side effects.<span class="mw-ref" id="cite_ref-LenzShulman2010_132-0"><a href="#cite_note-LenzShulman2010-132" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></span><span class="mw-ref" id="cite_ref-Greenblatt1973_133-0"><a href="#cite_note-Greenblatt1973-133" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span><span class="mw-ref" id="cite_ref-MunozCruz2014_134-0"><a href="#cite_note-MunozCruz2014-134" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_118-3"><a href="#cite_note-Aronson2009-118" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span> In women, unlike <abbr>CPA</abbr> and spironolactone, bicalutamide does not produce menstrual irregularity or amenorrhea and does not interfere with ovulation or fertility.<span class="mw-ref" id="cite_ref-pmid24455796_43-1"><a href="#cite_note-pmid24455796-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-BahceciTuzcu2004_135-0"><a href="#cite_note-BahceciTuzcu2004-135" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    
<p>A single oral dose of bicalutamide in humans that results in symptoms of overdose or that is considered to be life-threatening has not been established.<span class="mw-ref" id="cite_ref-FDALabel_20-7"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Springhouse2000_136-0"><a href="#cite_note-Springhouse2000-136" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span> Dosages of up to 600<span>&nbsp;</span>mg/day have been well tolerated in clinical trials,<span class="mw-ref" id="cite_ref-TYRRElLIversen2006_137-0"><a href="#cite_note-TYRRElLIversen2006-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span> and it is notable that there is a saturation of absorption with bicalutamide such that circulating levels of its active (<i>R</i>)-enantiomer do not further increase above a dosage of 300<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-Cockshott2004_3-11"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-TYRRElLIversen2006_137-1"><a href="#cite_note-TYRRElLIversen2006-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span> Overdose is considered unlikely to be life-threatening with bicalutamide or other first-generation <abbr>NSAAs</abbr> (i.e., flutamide and nilutamide).<span class="mw-ref" id="cite_ref-Griffith2008_138-0"><a href="#cite_note-Griffith2008-138" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span> A massive overdose of nilutamide (13 grams, or 43 times the normal maximum 300<span>&nbsp;</span>mg/day clinical dosage) in a 79-year-old man was uneventful, producing no clinical signs, symptoms, or toxicity.<span class="mw-ref" id="cite_ref-Genrx1999_139-0"><a href="#cite_note-Genrx1999-139" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> There is no specific antidote for bicalutamide or <abbr>NSAA</abbr> overdose, and treatment should be based on symptoms, if any are present.<span class="mw-ref" id="cite_ref-FDALabel_20-8"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Springhouse2000_136-1"><a href="#cite_note-Springhouse2000-136" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<p>Bicalutamide is almost exclusively metabolized by CYP3A4.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-7"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> As such, its levels in the body may be altered by inhibitors and inducers of CYP3A4.<span class="mw-ref" id="cite_ref-Skidmore-Roth2013_9-2"><a href="#cite_note-Skidmore-Roth2013-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> (For a list of CYP3A4 inhibitors and inducers, see here.) However, in spite of the fact bicalutamide is metabolized by CYP3A4, there is no evidence of clinically significant drug interactions when bicalutamide at a dosage of 150<span>&nbsp;</span>mg/day or less is co-administered with drugs that inhibit or induce cytochrome P450 enzyme activity.<span class="mw-ref" id="cite_ref-Wellington2006_21-6"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>Because bicalutamide circulates at relatively high concentrations and is highly protein-bound, it has the potential to displace other highly protein-bound drugs like <a href="Warfarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Warfarin" title="Warfarin">warfarin</a>, <a href="Phenytoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenytoin" title="Phenytoin">phenytoin</a>, <a href="Theophylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Theophylline" title="Theophylline">theophylline</a>, and <a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">aspirin</a> from plasma binding proteins.<span class="mw-ref" id="cite_ref-WirthHakenberg2007_87-2"><a href="#cite_note-WirthHakenberg2007-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-Kolvenbag1996_91-2"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span> This could, in turn, result in increased free concentrations of such drugs and increased effects and/or side effects, potentially necessitating dosage adjustments.<span class="mw-ref" id="cite_ref-WirthHakenberg2007_87-3"><a href="#cite_note-WirthHakenberg2007-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span> Bicalutamide has specifically been found to displace <a href="Coumarin.htm" tppabs="https://ptable.com/wiki/compounds/A/Coumarin" title="Coumarin">coumarin</a> anticoagulants like warfarin from their plasma binding proteins (namely <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a>) <i>in vitro</i>, potentially resulting in an increased anticoagulant effect, and for this reason, close monitoring of <a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prothrombin" title="Prothrombin" class="mw-redirect">prothrombin</a> time and dosage adjustment as necessary is recommended when bicalutamide is used in combination with these drugs.<span class="mw-ref" id="cite_ref-Weber2015_140-0"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-Mosby2001_141-0"><a href="#cite_note-Mosby2001-141" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span><span class="mw-ref" id="cite_ref-SprattoWoods2008_142-0"><a href="#cite_note-SprattoWoods2008-142" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span> However, in spite of this, no conclusive evidence of an interaction between bicalutamide and other drugs was found in clinical trials of nearly 3,000 patients.<span class="mw-ref" id="cite_ref-Kolvenbag1996_91-3"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    



    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Antiandrogenic_activity">Antiandrogenic activity</h4></summary>
    
<p>Bicalutamide acts as a highly selective competitive silent antagonist of the <abbr>AR</abbr> (<abbr>IC<sub>50</sub></abbr> = 159–243<span>&nbsp;</span>nM), the major biological target of the androgen sex hormones <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone"><abbr>DHT</abbr></a>, and hence is an antiandrogen.<span class="mw-ref" id="cite_ref-SinghGauthier2000_24-1"><a href="#cite_note-SinghGauthier2000-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Balaji2016_143-0"><a href="#cite_note-Balaji2016-143" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span><span class="mw-ref" id="cite_ref-MasielloCheng2002_144-0"><a href="#cite_note-MasielloCheng2002-144" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span><span class="mw-ref" id="cite_ref-Denis2012_145-0"><a href="#cite_note-Denis2012-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span> The activity of bicalutamide lies in the (<i>R</i>)-isomer.<span class="mw-ref" id="cite_ref-SchellensMcLeod2005_146-0"><a href="#cite_note-SchellensMcLeod2005-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> Due to its selectivity for the <abbr>AR</abbr>, bicalutamide does not interact importantly with other steroid hormone receptors and hence has no clinically relevant off-target hormonal activity (e.g., progestogenic, estrogenic, glucocorticoid, antimineralocorticoid).<span class="mw-ref" id="cite_ref-Becker2001_147-0"><a href="#cite_note-Becker2001-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-FurrTucker1996_148-0"><a href="#cite_note-FurrTucker1996-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-SchellensMcLeod2005_146-1"><a href="#cite_note-SchellensMcLeod2005-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span><span class="mw-ref" id="cite_ref-BagatellBremner2003_38-1"><a href="#cite_note-BagatellBremner2003-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> However, it has been reported that bicalutamide has weak affinity for the progesterone receptor (PR), where it is an antagonist, and hence it could have some antiprogestogenic activity.<span class="mw-ref" id="cite_ref-pmid29497605_149-0"><a href="#cite_note-pmid29497605-149" style="counter-reset: mw-Ref 149;"><span class="mw-reflink-text">[149]</span></a></span> Bicalutamide does not inhibit 5α-reductase nor is known to inhibit other enzymes involved in androgen steroidogenesis (e.g., CYP17A1).<span class="mw-ref" id="cite_ref-Furr1995_150-0"><a href="#cite_note-Furr1995-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span> Although it does not bind to the estrogen receptors (ERs), bicalutamide can increase <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogen</a> levels secondarily to <abbr>AR</abbr> blockade when used as a monotherapy in males, and hence can have some <i>indirect</i> estrogenic effects in males.<span class="mw-ref" id="cite_ref-pmid18231613_151-0"><a href="#cite_note-pmid18231613-151" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span> Bicalutamide neither suppresses nor inhibits androgen production in the body (i.e., it does not act as an antigonadotropin or androgen steroidogenesis inhibitor or lower androgen levels) and hence exclusively mediates its antiandrogenic effects by antagonizing the <abbr>AR</abbr>.<span class="mw-ref" id="cite_ref-Dart2004_4-7"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Becker2001_147-1"><a href="#cite_note-Becker2001-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-SchellensMcLeod2005_146-2"><a href="#cite_note-SchellensMcLeod2005-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> In addition to the classical nuclear <abbr>AR</abbr>, bicalutamide has been assessed at the membrane androgen receptors (mARs) and found to act as a potent antagonist of ZIP9 (<abbr>IC<sub>50</sub></abbr> = 66.3<span>&nbsp;</span>nM), whereas it does not appear to interact with GPRC6A.<span class="mw-ref" id="cite_ref-pmid28943399_152-0"><a href="#cite_note-pmid28943399-152" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span><span class="mw-ref" id="cite_ref-pmid20947496_153-0"><a href="#cite_note-pmid20947496-153" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span></p>

<p>The affinity of bicalutamide for the <abbr>AR</abbr> is relatively low as it is approximately 30 to 100<span>&nbsp;</span>times lower than that of <abbr>DHT</abbr>, which is 2.5- to 10-fold as potent as an <abbr>AR</abbr> agonist as testosterone in bioassays and is the main endogenous ligand of the receptor in the prostate gland.<span class="mw-ref" id="cite_ref-Furr2009_154-0"><a href="#cite_note-Furr2009-154" style="counter-reset: mw-Ref 154;"><span class="mw-reflink-text">[154]</span></a></span><span class="mw-ref" id="cite_ref-Denis2012_145-1"><a href="#cite_note-Denis2012-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-12"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid19359544_155-0"><a href="#cite_note-pmid19359544-155" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span> However, typical clinical dosages of bicalutamide result in circulating levels of the drug that are thousands of times higher than those of testosterone and <abbr>DHT</abbr>, allowing it to powerfully prevent them from binding to and activating the receptor.<span class="mw-ref" id="cite_ref-Furr1997_156-0"><a href="#cite_note-Furr1997-156" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span><span class="mw-ref" id="cite_ref-FiggChau2010_157-0"><a href="#cite_note-FiggChau2010-157" style="counter-reset: mw-Ref 157;"><span class="mw-reflink-text">[157]</span></a></span><span class="mw-ref" id="cite_ref-FurrTucker1996_148-1"><a href="#cite_note-FurrTucker1996-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-pmid8717469_158-0"><a href="#cite_note-pmid8717469-158" style="counter-reset: mw-Ref 158;"><span class="mw-reflink-text">[158]</span></a></span><span class="mw-ref" id="cite_ref-FDALabel_20-9"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-TGALabel_80-1"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span><span class="mw-ref" id="cite_ref-DenisMahler1996_159-0"><a href="#cite_note-DenisMahler1996-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span><span class="mw-ref" id="cite_ref-Wellington2006_21-7"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-pmid15838655_160-0"><a href="#cite_note-pmid15838655-160" style="counter-reset: mw-Ref 160;"><span class="mw-reflink-text">[160]</span></a></span> This is especially true in the case of surgical or medical castration, in which testosterone levels in the circulation are approximately 95% reduced and <abbr>DHT</abbr> levels in the prostate gland are about 50 to 60% reduced.<span class="mw-ref" id="cite_ref-Denis2012_145-2"><a href="#cite_note-Denis2012-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span><span class="mw-ref" id="cite_ref-LuoMartel1997_161-0"><a href="#cite_note-LuoMartel1997-161" style="counter-reset: mw-Ref 161;"><span class="mw-reflink-text">[161]</span></a></span> In women, levels of testosterone are substantially lower (20- to 40-fold) than in men,<span class="mw-ref" id="cite_ref-MelmedPolonsky2015_162-0"><a href="#cite_note-MelmedPolonsky2015-162" style="counter-reset: mw-Ref 162;"><span class="mw-reflink-text">[162]</span></a></span> so much smaller doses of bicalutamide (e.g., 25<span>&nbsp;</span>mg/day in the hirsutism studies) are necessary.<span class="mw-ref" id="cite_ref-WilliamsBigby2009_14-2"><a href="#cite_note-WilliamsBigby2009-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-pmid24455796_43-2"><a href="#cite_note-pmid24455796-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-MorettiGuccione2016_163-0"><a href="#cite_note-MorettiGuccione2016-163" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span><span class="mw-ref" id="cite_ref-MahlerVerhelst1998_27-2"><a href="#cite_note-MahlerVerhelst1998-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>Blockade of the <abbr>AR</abbr> by bicalutamide in the pituitary gland and hypothalamus results in prevention of the negative feedback of androgens on the hypothalamic–pituitary–gonadal axis (HPG axis) in males and consequent disinhibition of pituitary <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) secretion.<span class="mw-ref" id="cite_ref-IversenMelezinek2001_93-2"><a href="#cite_note-IversenMelezinek2001-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span> This, in turn, results in an increase in circulating <abbr>LH</abbr> levels and activation of the gonadal production of testosterone and by extension production of <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>.<span class="mw-ref" id="cite_ref-pmid7537602_164-0"><a href="#cite_note-pmid7537602-164" style="counter-reset: mw-Ref 164;"><span class="mw-reflink-text">[164]</span></a></span> Levels of testosterone have been found to increase 1.5- to 2-fold (59–97% increase) and levels of estradiol about 1.5- to 2.5-fold (65–146% increase) in men treated with 150<span>&nbsp;</span>mg/day bicalutamide monotherapy.<span class="mw-ref" id="cite_ref-IIIBarbieri2013a_25-1"><a href="#cite_note-IIIBarbieri2013a-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-MarcusFeldman2007_26-1"><a href="#cite_note-MarcusFeldman2007-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-MahlerVerhelst1998_27-3"><a href="#cite_note-MahlerVerhelst1998-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> In addition to testosterone and estradiol, there are smaller increases in concentrations of <abbr>DHT</abbr>, sex hormone-binding globulin, and prolactin.<span class="mw-ref" id="cite_ref-MahlerVerhelst1998_27-4"><a href="#cite_note-MahlerVerhelst1998-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Estradiol levels with bicalutamide monotherapy are similar to those in the low-normal premenopausal female range while testosterone levels generally remain in the high end of the normal male range.<span class="mw-ref" id="cite_ref-MarcusFeldman2007_26-2"><a href="#cite_note-MarcusFeldman2007-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-WeinKavoussi2011_165-0"><a href="#cite_note-WeinKavoussi2011-165" style="counter-reset: mw-Ref 165;"><span class="mw-reflink-text">[165]</span></a></span><span class="mw-ref" id="cite_ref-Becker2001_147-2"><a href="#cite_note-Becker2001-147" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span> Testosterone concentrations do not typically exceed the normal male range due to negative feedback on the <abbr>HPG</abbr> axis by the increased concentrations of estradiol.<span class="mw-ref" id="cite_ref-IversenMelezinek2001_93-3"><a href="#cite_note-IversenMelezinek2001-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span> Bicalutamide influences the <abbr>HPG</abbr> axis and increases hormone levels only in men and not also in women.<span class="mw-ref" id="cite_ref-Diamanti-KandarakisNestler2009_166-0"><a href="#cite_note-Diamanti-KandarakisNestler2009-166" style="counter-reset: mw-Ref 166;"><span class="mw-reflink-text">[166]</span></a></span><span class="mw-ref" id="cite_ref-CarrellPeterson2010_167-0"><a href="#cite_note-CarrellPeterson2010-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-BouchardCaraty1993_168-0"><a href="#cite_note-BouchardCaraty1993-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span> This is due to the much lower levels of androgens in women and their lack of basal suppression of the <abbr>HPG</abbr> axis in this sex.<span class="mw-ref" id="cite_ref-Diamanti-KandarakisNestler2009_166-1"><a href="#cite_note-Diamanti-KandarakisNestler2009-166" style="counter-reset: mw-Ref 166;"><span class="mw-reflink-text">[166]</span></a></span><span class="mw-ref" id="cite_ref-CarrellPeterson2010_167-1"><a href="#cite_note-CarrellPeterson2010-167" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span><span class="mw-ref" id="cite_ref-BouchardCaraty1993_168-1"><a href="#cite_note-BouchardCaraty1993-168" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span> As evidenced by its effectiveness in the treatment of prostate cancer and other androgen-dependent conditions, the antiandrogenic actions of bicalutamide considerably exceed any impact of the increased levels of testosterone it results in.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_76-3"><a href="#cite_note-ChabnerLongo2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> However, the elevated levels of estradiol remain unopposed by bicalutamide and are responsible for the gynecomastia and feminizing side effects it causes in men.<span class="mw-ref" id="cite_ref-pmid18062751_169-0"><a href="#cite_note-pmid18062751-169" style="counter-reset: mw-Ref 169;"><span class="mw-reflink-text">[169]</span></a></span> Although bicalutamide monotherapy increases gonadotropin and sex hormone levels in men, this will not occur if bicalutamide is combined with an antigonadotropin such as a <abbr>GnRH</abbr> analogue, estrogen, or progestogen, as these medications maintain negative feedback on the HPG axis.<span class="mw-ref" id="cite_ref-Melmed2016_41-1"><a href="#cite_note-Melmed2016-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-AsschemanGooren1989_170-0"><a href="#cite_note-AsschemanGooren1989-170" style="counter-reset: mw-Ref 170;"><span class="mw-reflink-text">[170]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_171-0"><a href="#cite_note-Raode_Voogt1988-171" style="counter-reset: mw-Ref 171;"><span class="mw-reflink-text">[171]</span></a></span></p>

<p><abbr>NSAA</abbr> monotherapy, including with bicalutamide, shows a number of tolerability differences from methods of androgen deprivation therapy that incorporate surgical or medical castration. For example, the rates of hot flashes, depression, fatigue, and sexual dysfunction are all much higher with <abbr>GnRH</abbr> analogues than with <abbr>NSAA</abbr> monotherapy. It is thought that this is because <abbr>GnRH</abbr> analogues suppress estrogen production in addition to androgen production, resulting in estrogen deficiency.<span class="mw-ref" id="cite_ref-WibowoSchellhammer2011_172-0"><a href="#cite_note-WibowoSchellhammer2011-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span><span class="mw-ref" id="cite_ref-MotofeiRowland2011_173-0"><a href="#cite_note-MotofeiRowland2011-173" style="counter-reset: mw-Ref 173;"><span class="mw-reflink-text">[173]</span></a></span><span class="mw-ref" id="cite_ref-pmid23484454_174-0"><a href="#cite_note-pmid23484454-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> In contrast, <abbr>NSAA</abbr> monotherapy does not decrease estrogen levels and in fact increases them, resulting in an excess of estrogens that compensates for androgen deficiency and allows for a preservation of mood, energy, and sexual function.<span class="mw-ref" id="cite_ref-WibowoSchellhammer2011_172-1"><a href="#cite_note-WibowoSchellhammer2011-172" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span><span class="mw-ref" id="cite_ref-MotofeiRowland2011_173-1"><a href="#cite_note-MotofeiRowland2011-173" style="counter-reset: mw-Ref 173;"><span class="mw-reflink-text">[173]</span></a></span><span class="mw-ref" id="cite_ref-pmid23484454_174-1"><a href="#cite_note-pmid23484454-174" style="counter-reset: mw-Ref 174;"><span class="mw-reflink-text">[174]</span></a></span> Neurosteroids that are produced from testosterone like 3α-androstanediol and 3β-androstanediol, which are <abbr>ERβ</abbr> agonists and the former a potent GABA<sub>A</sub> receptor positive allosteric modulator, may also be involved.<span class="mw-ref" id="cite_ref-King2008_175-0"><a href="#cite_note-King2008-175" style="counter-reset: mw-Ref 175;"><span class="mw-reflink-text">[175]</span></a></span><span class="mw-ref" id="cite_ref-pmid7803627_176-0"><a href="#cite_note-pmid7803627-176" style="counter-reset: mw-Ref 176;"><span class="mw-reflink-text">[176]</span></a></span><span class="mw-ref" id="cite_ref-pmid20646182_177-0"><a href="#cite_note-pmid20646182-177" style="counter-reset: mw-Ref 177;"><span class="mw-reflink-text">[177]</span></a></span><span class="mw-ref" id="cite_ref-Chedrese2009_178-0"><a href="#cite_note-Chedrese2009-178" style="counter-reset: mw-Ref 178;"><span class="mw-reflink-text">[178]</span></a></span><span class="mw-ref" id="cite_ref-pmid20552051_179-0"><a href="#cite_note-pmid20552051-179" style="counter-reset: mw-Ref 179;"><span class="mw-reflink-text">[179]</span></a></span><span class="mw-ref" id="cite_ref-HuangZhu2008_180-0"><a href="#cite_note-HuangZhu2008-180" style="counter-reset: mw-Ref 180;"><span class="mw-reflink-text">[180]</span></a></span><span class="mw-ref" id="cite_ref-FryeKoonce2008_181-0"><a href="#cite_note-FryeKoonce2008-181" style="counter-reset: mw-Ref 181;"><span class="mw-reflink-text">[181]</span></a></span> In the specific case of sexual dysfunction, an additional possibility for the difference is that without concomitant suppression of androgen production, blockade of the <abbr>AR</abbr> by the bicalutamide in the brain is incomplete and insufficient to markedly influence sexual function.</p>

<p>Under normal circumstances, bicalutamide has no capacity to activate the <abbr>AR</abbr>.<span class="mw-ref" id="cite_ref-pmid25797385_182-0"><a href="#cite_note-pmid25797385-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span><span class="mw-ref" id="cite_ref-BamburyRathkopf2015_183-0"><a href="#cite_note-BamburyRathkopf2015-183" style="counter-reset: mw-Ref 183;"><span class="mw-reflink-text">[183]</span></a></span> However, in prostate cancer, mutations and overexpression of the <abbr>AR</abbr> can accumulate in prostate gland cells which can convert bicalutamide from an antagonist of the <abbr>AR</abbr> into an agonist.<span class="mw-ref" id="cite_ref-pmid25797385_182-1"><a href="#cite_note-pmid25797385-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span><span class="mw-ref" id="cite_ref-pmid24100689_184-0"><a href="#cite_note-pmid24100689-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span> This can result in paradoxical stimulation of prostate cancer growth with bicalutamide and is responsible for the phenomenon of the antiandrogen withdrawal syndrome, where antiandrogen discontinuation paradoxically slows the rate of prostate cancer growth.<span class="mw-ref" id="cite_ref-pmid25797385_182-2"><a href="#cite_note-pmid25797385-182" style="counter-reset: mw-Ref 182;"><span class="mw-reflink-text">[182]</span></a></span><span class="mw-ref" id="cite_ref-pmid24100689_184-1"><a href="#cite_note-pmid24100689-184" style="counter-reset: mw-Ref 184;"><span class="mw-reflink-text">[184]</span></a></span></p>

<p>In transgender women, breast development is a desired effect of antiandrogen or estrogen treatment.<span class="mw-ref" id="cite_ref-WierckxGooren2014_54-1"><a href="#cite_note-WierckxGooren2014-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-OrentreichDurr1974_185-0"><a href="#cite_note-OrentreichDurr1974-185" style="counter-reset: mw-Ref 185;"><span class="mw-reflink-text">[185]</span></a></span> Breast development and gynecomastia induced by bicalutamide is thought to be mediated by increased activation of the <abbr>ER</abbr> secondary to blockade of the <abbr>AR</abbr> (resulting in disinhibition of the <abbr>ER</abbr> in breast tissue) and increased levels of estradiol.<span class="mw-ref" id="cite_ref-JamesonGroot2015_16-2"><a href="#cite_note-JamesonGroot2015-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-IIIBarbieri2013b_186-0"><a href="#cite_note-IIIBarbieri2013b-186" style="counter-reset: mw-Ref 186;"><span class="mw-reflink-text">[186]</span></a></span><span class="mw-ref" id="cite_ref-WilsonNizet2015_187-0"><a href="#cite_note-WilsonNizet2015-187" style="counter-reset: mw-Ref 187;"><span class="mw-reflink-text">[187]</span></a></span> In addition to fat deposition, connective tissue growth, and ductal development, bicalutamide has been found to produce moderate lobuloalveolar development of the breasts.<span class="mw-ref" id="cite_ref-KanhaiHage2000_188-0"><a href="#cite_note-KanhaiHage2000-188" style="counter-reset: mw-Ref 188;"><span class="mw-reflink-text">[188]</span></a></span><span class="mw-ref" id="cite_ref-Lawrence2007_189-0"><a href="#cite_note-Lawrence2007-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span><span class="mw-ref" id="cite_ref-Rosen2009_190-0"><a href="#cite_note-Rosen2009-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span> However, full lobuloalveolar maturation necessary for lactation and breastfeeding will not occur without progestogen treatment.<span class="mw-ref" id="cite_ref-KanhaiHage2000_188-1"><a href="#cite_note-KanhaiHage2000-188" style="counter-reset: mw-Ref 188;"><span class="mw-reflink-text">[188]</span></a></span><span class="mw-ref" id="cite_ref-Lawrence2007_189-1"><a href="#cite_note-Lawrence2007-189" style="counter-reset: mw-Ref 189;"><span class="mw-reflink-text">[189]</span></a></span><span class="mw-ref" id="cite_ref-Rosen2009_190-1"><a href="#cite_note-Rosen2009-190" style="counter-reset: mw-Ref 190;"><span class="mw-reflink-text">[190]</span></a></span></p>

<p>Bicalutamide monotherapy seems to have minimal effect on testicular spermatogenesis, testicular ultrastructure, and certain aspects of male fertility.<span class="mw-ref" id="cite_ref-MorganteGradini2001_191-0"><a href="#cite_note-MorganteGradini2001-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span><span class="mw-ref" id="cite_ref-Mulhall2013_192-0"><a href="#cite_note-Mulhall2013-192" style="counter-reset: mw-Ref 192;"><span class="mw-reflink-text">[192]</span></a></span><span class="mw-ref" id="cite_ref-IswaranImai1997_81-2"><a href="#cite_note-IswaranImai1997-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span><span class="mw-ref" id="cite_ref-MorganteGradini2001_191-1"><a href="#cite_note-MorganteGradini2001-191" style="counter-reset: mw-Ref 191;"><span class="mw-reflink-text">[191]</span></a></span> This seems to be because testosterone levels in the testes (where ≈95% of testosterone in males is produced) are extremely high (up to 200-fold higher than circulating levels) and only a small fraction (less than 10%) of the normal levels of testosterone in the testes are actually necessary to maintain spermatogenesis.<span class="mw-ref" id="cite_ref-SchillComhaire2006_193-0"><a href="#cite_note-SchillComhaire2006-193" style="counter-reset: mw-Ref 193;"><span class="mw-reflink-text">[193]</span></a></span><span class="mw-ref" id="cite_ref-NieschlagBehre2012_194-0"><a href="#cite_note-NieschlagBehre2012-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span><span class="mw-ref" id="cite_ref-NieschlagBehre2012_194-1"><a href="#cite_note-NieschlagBehre2012-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span><span class="mw-ref" id="cite_ref-Cheng2009_195-0"><a href="#cite_note-Cheng2009-195" style="counter-reset: mw-Ref 195;"><span class="mw-reflink-text">[195]</span></a></span> As a result, bicalutamide appears to not be able to compete with testosterone in this sole part of the body to an extent sufficient to considerably interfere with androgen signaling and function.<span class="mw-ref" id="cite_ref-SchillComhaire2006_193-1"><a href="#cite_note-SchillComhaire2006-193" style="counter-reset: mw-Ref 193;"><span class="mw-reflink-text">[193]</span></a></span><span class="mw-ref" id="cite_ref-NieschlagBehre2012_194-2"><a href="#cite_note-NieschlagBehre2012-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span><span class="mw-ref" id="cite_ref-NieschlagBehre2012_194-3"><a href="#cite_note-NieschlagBehre2012-194" style="counter-reset: mw-Ref 194;"><span class="mw-reflink-text">[194]</span></a></span><span class="mw-ref" id="cite_ref-Cheng2009_195-1"><a href="#cite_note-Cheng2009-195" style="counter-reset: mw-Ref 195;"><span class="mw-reflink-text">[195]</span></a></span> However, while bicalutamide does not seem to be able to adversely influence testicular spermatogenesis, it may interfere with <abbr>AR</abbr>-dependent sperm maturation and transport outside of the testes in the epididymides and vas deferens where androgen levels are far lower, and hence may still be able to impair male fertility.<span class="mw-ref" id="cite_ref-NeumannSchenck1980_196-0"><a href="#cite_note-NeumannSchenck1980-196" style="counter-reset: mw-Ref 196;"><span class="mw-reflink-text">[196]</span></a></span> In addition, the combination of bicalutamide with other medications, such as estrogens, progestogens, and <abbr>GnRH</abbr> analogues, can compromise spermatogenesis due to their own adverse effects on male fertility.<span class="mw-ref" id="cite_ref-Johnson2003_197-0"><a href="#cite_note-Johnson2003-197" style="counter-reset: mw-Ref 197;"><span class="mw-reflink-text">[197]</span></a></span><span class="mw-ref" id="cite_ref-JonesReiter2016_198-0"><a href="#cite_note-JonesReiter2016-198" style="counter-reset: mw-Ref 198;"><span class="mw-reflink-text">[198]</span></a></span><span class="mw-ref" id="cite_ref-PayneHardy2007_199-0"><a href="#cite_note-PayneHardy2007-199" style="counter-reset: mw-Ref 199;"><span class="mw-reflink-text">[199]</span></a></span><span class="mw-ref" id="cite_ref-WakelinMaibach2002_200-0"><a href="#cite_note-WakelinMaibach2002-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-pmid8005205_201-0"><a href="#cite_note-pmid8005205-201" style="counter-reset: mw-Ref 201;"><span class="mw-reflink-text">[201]</span></a></span><span class="mw-ref" id="cite_ref-Salam2003_202-0"><a href="#cite_note-Salam2003-202" style="counter-reset: mw-Ref 202;"><span class="mw-reflink-text">[202]</span></a></span> These medications are able to strongly suppress gonadal androgen production, which can severely impair or abolish testicular spermatogenesis, and estrogens also appear to have direct and potentially long-lasting cytotoxic effects in the testes at sufficiently high concentrations.<span class="mw-ref" id="cite_ref-Johnson2003_197-1"><a href="#cite_note-Johnson2003-197" style="counter-reset: mw-Ref 197;"><span class="mw-reflink-text">[197]</span></a></span><span class="mw-ref" id="cite_ref-JonesReiter2016_198-1"><a href="#cite_note-JonesReiter2016-198" style="counter-reset: mw-Ref 198;"><span class="mw-reflink-text">[198]</span></a></span><span class="mw-ref" id="cite_ref-PayneHardy2007_199-1"><a href="#cite_note-PayneHardy2007-199" style="counter-reset: mw-Ref 199;"><span class="mw-reflink-text">[199]</span></a></span><span class="mw-ref" id="cite_ref-WakelinMaibach2002_200-1"><a href="#cite_note-WakelinMaibach2002-200" style="counter-reset: mw-Ref 200;"><span class="mw-reflink-text">[200]</span></a></span><span class="mw-ref" id="cite_ref-pmid8005205_201-1"><a href="#cite_note-pmid8005205-201" style="counter-reset: mw-Ref 201;"><span class="mw-reflink-text">[201]</span></a></span><span class="mw-ref" id="cite_ref-Salam2003_202-1"><a href="#cite_note-Salam2003-202" style="counter-reset: mw-Ref 202;"><span class="mw-reflink-text">[202]</span></a></span></p>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Other_activities">Other activities</h4></summary>
    
<p>Bicalutamide has been found to act as an inhibitor or inducer of certain cytochrome P450 enzymes including CYP3A4, CYP2C9, CYP2C19, and CYP2D6 in preclinical research, but no evidence of this has been found in humans treated with up to 150<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-Cockshott2004_3-13"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> It has also been identified <i>in vitro</i> as a strong inhibitor of CYP27A1 (cholesterol 27-hydroxylase) and as an inhibitor of CYP46A1 (cholesterol 24-hydroxylase), but this has yet to be assessed or confirmed <i>in vivo</i> or in humans and the clinical significance remains unknown.<span class="mw-ref" id="cite_ref-pmid26082378_203-0"><a href="#cite_note-pmid26082378-203" style="counter-reset: mw-Ref 203;"><span class="mw-reflink-text">[203]</span></a></span><span class="mw-ref" id="cite_ref-MastZheng2013_204-0"><a href="#cite_note-MastZheng2013-204" style="counter-reset: mw-Ref 204;"><span class="mw-reflink-text">[204]</span></a></span> Bicalutamide has been found to be a P-glycoprotein (ABCB1) inhibitor.<span class="mw-ref" id="cite_ref-ZhuLiu2015_205-0"><a href="#cite_note-ZhuLiu2015-205" style="counter-reset: mw-Ref 205;"><span class="mw-reflink-text">[205]</span></a></span><span class="mw-ref" id="cite_ref-Fenner2015_206-0"><a href="#cite_note-Fenner2015-206" style="counter-reset: mw-Ref 206;"><span class="mw-reflink-text">[206]</span></a></span><span class="mw-ref" id="cite_ref-pmid26309896_207-0"><a href="#cite_note-pmid26309896-207" style="counter-reset: mw-Ref 207;"><span class="mw-reflink-text">[207]</span></a></span> Like other first-generation <abbr>NSAAs</abbr> and enzalutamide, it has been found to act as a weak non-competitive inhibitor of GABA<sub>A</sub> receptor-mediated currents <i>in vitro</i> (<abbr>IC<sub>50</sub></abbr> = 5.2<span>&nbsp;</span>μM).<span class="mw-ref" id="cite_ref-FosterCar2011_208-0"><a href="#cite_note-FosterCar2011-208" style="counter-reset: mw-Ref 208;"><span class="mw-reflink-text">[208]</span></a></span><span class="mw-ref" id="cite_ref-BarrishCarter2010_209-0"><a href="#cite_note-BarrishCarter2010-209" style="counter-reset: mw-Ref 209;"><span class="mw-reflink-text">[209]</span></a></span> However, unlike enzalutamide, bicalutamide has not been found to be associated with seizures or other related adverse central effects, so the clinical relevance of this finding is uncertain.<span class="mw-ref" id="cite_ref-FosterCar2011_208-1"><a href="#cite_note-FosterCar2011-208" style="counter-reset: mw-Ref 208;"><span class="mw-reflink-text">[208]</span></a></span><span class="mw-ref" id="cite_ref-BarrishCarter2010_209-1"><a href="#cite_note-BarrishCarter2010-209" style="counter-reset: mw-Ref 209;"><span class="mw-reflink-text">[209]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>Though its absolute bioavailability in humans is unknown, bicalutamide is known to be extensively and well-absorbed.<span class="mw-ref" id="cite_ref-Cockshott2004_3-14"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Dart2004_4-8"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Its absorption is not affected by food.<span class="mw-ref" id="cite_ref-Dart2004_4-9"><a href="#cite_note-Dart2004-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Weber2015_140-1"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span> The absorption of bicalutamide is linear at doses up to 150<span>&nbsp;</span>mg/day and is saturable at doses above this, with no further increases in steady-state levels of bicalutamide occurring at doses above 300<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-Cockshott2004_3-15"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Wellington2006_21-8"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-KolvenbagBlackledge1998_210-0"><a href="#cite_note-KolvenbagBlackledge1998-210" style="counter-reset: mw-Ref 210;"><span class="mw-reflink-text">[210]</span></a></span><span class="mw-ref" id="cite_ref-TYRRElLIversen2006_137-2"><a href="#cite_note-TYRRElLIversen2006-137" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span> Whereas absorption of (<i>R</i>)-bicalutamide is slow, with levels peaking at 31 to 39<span>&nbsp;</span>hours after a dose, (<i>S</i>)-bicalutamide is much more rapidly absorbed.<span class="mw-ref" id="cite_ref-Wellington2006_21-9"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-FDALabel_20-10"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-16"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Steady-state concentrations of the drug are reached after 4 to 12<span>&nbsp;</span>weeks of treatment independently of dosage, with a 10- to 20-fold progressive accumulation in levels of (<i>R</i>)-bicalutamide.<span class="mw-ref" id="cite_ref-Wellington2006_21-10"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-pmid8717470_211-0"><a href="#cite_note-pmid8717470-211" style="counter-reset: mw-Ref 211;"><span class="mw-reflink-text">[211]</span></a></span><span class="mw-ref" id="cite_ref-Jr.Lawrence2015_212-0"><a href="#cite_note-Jr.Lawrence2015-212" style="counter-reset: mw-Ref 212;"><span class="mw-reflink-text">[212]</span></a></span><span class="mw-ref" id="cite_ref-DenisMahler1996_159-1"><a href="#cite_note-DenisMahler1996-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span> The long time to steady-state levels is the result of bicalutamide's very long elimination half-life.<span class="mw-ref" id="cite_ref-DenisMahler1996_159-2"><a href="#cite_note-DenisMahler1996-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span> Although it takes a long time for bicalutamide to reach steady-state concentrations, it appears to have antiandrogenic efficacy equivalent to that of flutamide (which has a much shorter elimination half-life and reaches steady-state levels much faster) by the end of the first day of treatment.<span class="mw-ref" id="cite_ref-pmid8717470_211-1"><a href="#cite_note-pmid8717470-211" style="counter-reset: mw-Ref 211;"><span class="mw-reflink-text">[211]</span></a></span></p>

<p>The tissue distribution of bicalutamide is not well-characterized.<span class="mw-ref" id="cite_ref-ChuJr.2012_213-0"><a href="#cite_note-ChuJr.2012-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span> The amount of bicalutamide in semen that could potentially be transferred to a female partner during sexual intercourse is low and is not thought to be important.<span class="mw-ref" id="cite_ref-TGALabel_80-2"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> Based on animal studies with rats and dogs it was thought that bicalutamide could not cross the blood–brain barrier and hence could not enter the brain.<span class="mw-ref" id="cite_ref-HelsenVan_den_Broeck2014_214-0"><a href="#cite_note-HelsenVan_den_Broeck2014-214" style="counter-reset: mw-Ref 214;"><span class="mw-reflink-text">[214]</span></a></span><span class="mw-ref" id="cite_ref-FurrTucker1996_148-2"><a href="#cite_note-FurrTucker1996-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-Furr1989_215-0"><a href="#cite_note-Furr1989-215" style="counter-reset: mw-Ref 215;"><span class="mw-reflink-text">[215]</span></a></span><span class="mw-ref" id="cite_ref-FurrValcaccia1987_216-0"><a href="#cite_note-FurrValcaccia1987-216" style="counter-reset: mw-Ref 216;"><span class="mw-reflink-text">[216]</span></a></span> As such, it was initially thought to be a peripherally selective antiandrogen.<span class="mw-ref" id="cite_ref-HelsenVan_den_Broeck2014_214-1"><a href="#cite_note-HelsenVan_den_Broeck2014-214" style="counter-reset: mw-Ref 214;"><span class="mw-reflink-text">[214]</span></a></span><span class="mw-ref" id="cite_ref-FurrTucker1996_148-3"><a href="#cite_note-FurrTucker1996-148" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span> However, subsequent clinical studies found that this was not also the case for humans, indicating species differences; bicalutamide crosses into the human brain and, in accordance, produces effects and side effects consistent with central antiandrogenic action.<span class="mw-ref" id="cite_ref-Cockshott2004_3-17"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-IversenMelezinek2001_93-4"><a href="#cite_note-IversenMelezinek2001-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-SolowaySchellhammer1995_217-0"><a href="#cite_note-SolowaySchellhammer1995-217" style="counter-reset: mw-Ref 217;"><span class="mw-reflink-text">[217]</span></a></span><span class="mw-ref" id="cite_ref-GaoDalton2007_218-0"><a href="#cite_note-GaoDalton2007-218" style="counter-reset: mw-Ref 218;"><span class="mw-reflink-text">[218]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-18"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-GaoDalton2007_218-1"><a href="#cite_note-GaoDalton2007-218" style="counter-reset: mw-Ref 218;"><span class="mw-reflink-text">[218]</span></a></span><span class="mw-ref" id="cite_ref-pmid16896883_219-0"><a href="#cite_note-pmid16896883-219" style="counter-reset: mw-Ref 219;"><span class="mw-reflink-text">[219]</span></a></span> Bicalutamide is highly plasma protein bound (96.1% for racemic bicalutamide, 99.6% for (<i>R</i>)-bicalutamide) and is bound mainly to <a href="Human_serum_albumin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_serum_albumin" title="Human serum albumin">albumin</a>, with negligible binding to <abbr>SHBG</abbr> and corticosteroid-binding globulin.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-8"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-19"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-ChuJr.2012_213-1"><a href="#cite_note-ChuJr.2012-213" style="counter-reset: mw-Ref 213;"><span class="mw-reflink-text">[213]</span></a></span><span class="mw-ref" id="cite_ref-Furr1995_150-1"><a href="#cite_note-Furr1995-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span></p>

<p>Bicalutamide is metabolized in the liver.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-9"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Weber2015_140-2"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span> (<i>R</i>)-Bicalutamide is metabolized slowly and almost exclusively via hydroxylation by CYP3A4 into (<i>R</i>)-hydroxybicalutamide.<span class="mw-ref" id="cite_ref-Weber2015_140-3"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-20"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-10"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_220-0"><a href="#cite_note-LemkeWilliams2012-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span> This metabolite is then glucuronidated by UGT1A9.<span class="mw-ref" id="cite_ref-Weber2015_140-4"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-21"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-GrosseCampeau2013_6-1"><a href="#cite_note-GrosseCampeau2013-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Schellhammer2005_8-1"><a href="#cite_note-Schellhammer2005-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> In contrast to (<i>R</i>)-bicalutamide, (<i>S</i>)-bicalutamide is metabolized rapidly and mainly by glucuronidation (without hydroxylation).<span class="mw-ref" id="cite_ref-Weber2015_140-5"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span> None of the metabolites of bicalutamide are known to be active and levels of the metabolites are low in plasma, where unchanged biclautamide predominates.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-11"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-pmid8997470_7-1"><a href="#cite_note-pmid8997470-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Cockshott2004_3-22"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Due to the stereoselective metabolism of bicalutamide, (<i>R</i>)-bicalutamide has a far longer terminal half-life than (<i>S</i>)-bicalutamide and its levels are about 10- to 20-fold higher in comparison following a single dose and 100-fold higher at steady-state.<span class="mw-ref" id="cite_ref-Wellington2006_21-11"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_220-1"><a href="#cite_note-LemkeWilliams2012-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span><span class="mw-ref" id="cite_ref-ButlerGovindan2010_221-0"><a href="#cite_note-ButlerGovindan2010-221" style="counter-reset: mw-Ref 221;"><span class="mw-reflink-text">[221]</span></a></span> (<i>R</i>)-Bicalutamide has a relatively long elimination half-life of 5.8<span>&nbsp;</span>days with a single dose and 7 to 10<span>&nbsp;</span>days following repeated administration.<span class="mw-ref" id="cite_ref-JordanFurr2010_10-1"><a href="#cite_note-JordanFurr2010-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>Bicalutamide is eliminated in similar proportions in feces (43%) and urine (34%), while its metabolites are eliminated roughly equally in urine and bile.<span class="mw-ref" id="cite_ref-LemkeWilliams2008_5-12"><a href="#cite_note-LemkeWilliams2008-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Weber2015_140-6"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-pmid14748655_222-0"><a href="#cite_note-pmid14748655-222" style="counter-reset: mw-Ref 222;"><span class="mw-reflink-text">[222]</span></a></span><span class="mw-ref" id="cite_ref-pmid22495777_223-0"><a href="#cite_note-pmid22495777-223" style="counter-reset: mw-Ref 223;"><span class="mw-reflink-text">[223]</span></a></span> The drug is excreted to a substantial extent in unmetabolized form, and both bicalutamide and its metabolites are eliminated mainly as glucuronide conjugates.<span class="mw-ref" id="cite_ref-SchellensMcLeod2005_146-3"><a href="#cite_note-SchellensMcLeod2005-146" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> The glucuronide conjugates of bicalutamide and its metabolites are eliminated from the circulation rapidly, unlike unconjugated bicalutamide.<span class="mw-ref" id="cite_ref-Cockshott2004_3-23"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Weber2015_140-7"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-AndersonKnoben2001_224-0"><a href="#cite_note-AndersonKnoben2001-224" style="counter-reset: mw-Ref 224;"><span class="mw-reflink-text">[224]</span></a></span></p>

<p>The pharmacokinetics of bicalutamide are not affected by consumption of food, a person's age or body weight, renal impairment, or mild-to-moderate hepatic impairment.<span class="mw-ref" id="cite_ref-Cockshott2004_3-24"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-DenisMahler1996_159-3"><a href="#cite_note-DenisMahler1996-159" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span> However, steady-state levels of bicalutamide are higher in Japanese individuals than in white people.<span class="mw-ref" id="cite_ref-Cockshott2004_3-25"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>
<span>
</span><table role="presentation" cellpadding="0" style="border-spacing:0; margin-left: auto; margin-right: auto; border: none;">
<tbody><tr>
<td><div class="thumb center" style="margin: 1em auto;">
<div class="thumbinner" style="width:702px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: aliceblue;margin-bottom:3px;"> Bicalutamide metabolism in humans<span class="mw-ref" id="cite_ref-Cockshott2004_3-26"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-GrosseCampeau2013_6-2"><a href="#cite_note-GrosseCampeau2013-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></div>
<div style="position:relative; width:700px; height:250px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:700px; position:absolute"> <figure-inline><span><img src="../I/m/Bicalutamide_metabolism.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bicalutamide_metabolism.svg.png" data-file-width="1271" data-file-height="411" data-file-type="drawing" height="226" width="700"></span></figure-inline>
</div> 
<div style="text-align:center; font-size:16px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_85x82" style="position:absolute; left:85px; top:82px;      line-height:110% "><span style="background-color:transparent; ">Bicalutamide</span></div>
<div id="annotation_400x82" style="position:absolute; left:400px; top:82px;      line-height:110% "><span style="background-color:transparent; ">(<i>S</i>)-Bicalutamide glucuronide</span></div>
<div id="annotation_40x228" style="position:absolute; left:40px; top:228px;      line-height:110% "><span style="background-color:transparent; ">(<i>R</i>)-Hydroxybicalutamide</span></div>
<div id="annotation_380x228" style="position:absolute; left:380px; top:228px;      line-height:110% "><span style="background-color:transparent; ">(<i>R</i>)-Hydroxybicalutamide glucuronide</span></div>

<div id="annotation_260x25" style="position:absolute; left:260px; top:25px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">Glucuronidation</span></div>
<div id="annotation_270x45" style="position:absolute; left:270px; top:45px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">via UGT1A9</span></div>
<div id="annotation_260x176" style="position:absolute; left:260px; top:176px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">Glucuronidation</span></div>
<div id="annotation_270x196" style="position:absolute; left:270px; top:196px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">via UGT1A9</span></div>
<div id="annotation_37x118" style="position:absolute; left:37px; top:118px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">Hydroxylation</span></div>
<div id="annotation_130x118" style="position:absolute; left:130px; top:118px;   font-size:14px;   line-height:16px; "><span style="background-color:transparent; ">via CYP3A4</span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>This diagram illustrates the primary metabolic pathways involved in the metabolism of bicalutamide in humans.</div>
</div>
</div></td></tr>
</tbody></table>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Bicalutamide is a racemic mixture consisting of equal proportions of enantiomers (<i>R</i>)-bicalutamide (dextrorotatory) and (<i>S</i>)-bicalutamide (levorotatory).<span class="mw-ref" id="cite_ref-FDALabel_20-11"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Its systematic name (<abbr>IUPAC</abbr>) is (<i>RS</i>)-<i>N</i>-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide.<span class="mw-ref" id="cite_ref-Publishing2013_225-0"><a href="#cite_note-Publishing2013-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span><span class="mw-ref" id="cite_ref-KomstaWaksmundzka-Hajnos2013_226-0"><a href="#cite_note-KomstaWaksmundzka-Hajnos2013-226" style="counter-reset: mw-Ref 226;"><span class="mw-reflink-text">[226]</span></a></span> The compound has a chemical formula of C<sub>18</sub>H<sub>14</sub>F<sub>4</sub>N<sub>2</sub>O<sub>4</sub>S, a molecular weight of 430.373<span>&nbsp;</span>g/mol, and is a fine white to off-white powder.<span class="mw-ref" id="cite_ref-FDALabel_20-12"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-TGALabel_80-3"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>

<p>The acid dissociation constant (pKa') of bicalutamide is approximately 12.<span class="mw-ref" id="cite_ref-TGALabel_80-4"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> It is a highly lipophilic compound (log P = 2.92).<span class="mw-ref" id="cite_ref-Cockshott2004_3-27"><a href="#cite_note-Cockshott2004-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pmid21369450_227-0"><a href="#cite_note-pmid21369450-227" style="counter-reset: mw-Ref 227;"><span class="mw-reflink-text">[227]</span></a></span> At 37<span>&nbsp;</span>°C (98.6<span>&nbsp;</span>°F), or normal human body temperature, bicalutamide is practically insoluble in water (4.6<span>&nbsp;</span>mg/L), acid (4.6<span>&nbsp;</span>mg/L at pH 1), and alkali (3.7<span>&nbsp;</span>mg/L at pH 8).<span class="mw-ref" id="cite_ref-FDALabel_20-13"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-TGALabel_80-5"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> In organic solvents, it is slightly soluble in <a href="Chloroform.htm" tppabs="https://ptable.com/wiki/compounds/A/Chloroform" title="Chloroform">chloroform</a> and <a href="Ethanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethanol" title="Ethanol">absolute ethanol</a>, sparingly soluble in <a href="Methanol.htm" tppabs="https://ptable.com/wiki/compounds/A/Methanol" title="Methanol">methanol</a>, and freely soluble in <a href="Acetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetone" title="Acetone">acetone</a> and <a href="Tetrahydrofuran.htm" tppabs="https://ptable.com/wiki/compounds/A/Tetrahydrofuran" title="Tetrahydrofuran">tetrahydrofuran</a>.<span class="mw-ref" id="cite_ref-FDALabel_20-14"><a href="#cite_note-FDALabel-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-TGALabel_80-6"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></p>

<p>Bicalutamide is a synthetic and nonsteroidal compound which was derived from <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a>.<span class="mw-ref" id="cite_ref-MohlerBohl2009_228-0"><a href="#cite_note-MohlerBohl2009-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span> It is a bicyclic compound (has two rings) and can be classified as and has variously been referred to as an anilide (<i>N</i>-phenylamide) or <a href="Aniline.htm" tppabs="https://ptable.com/wiki/compounds/A/Aniline" title="Aniline">aniline</a>, a diaryl<a href="Propanamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Propanamide" title="Propanamide">propionamide</a>, and a <a href="Toluidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Toluidide" title="Toluidide" class="mw-redirect">toluidide</a>.<span class="mw-ref" id="cite_ref-MohlerBohl2009_228-1"><a href="#cite_note-MohlerBohl2009-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_220-2"><a href="#cite_note-LemkeWilliams2012-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Analogues">Analogues</h3></summary>
    


<p>First-generation <abbr>NSAAs</abbr> including bicalutamide, <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a>, and <a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">nilutamide</a> are all synthetic, nonsteroidal anilide derivatives and structural analogues of each other.<span class="mw-ref" id="cite_ref-MohlerBohl2009_228-2"><a href="#cite_note-MohlerBohl2009-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span> Bicalutamide is a diarylpropionamide while flutamide is a monoarylpropionamide and nilutamide is a <a href="Hydantoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydantoin" title="Hydantoin">hydantoin</a>.<span class="mw-ref" id="cite_ref-MohlerBohl2009_228-3"><a href="#cite_note-MohlerBohl2009-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span> Bicalutamide and flutamide, though not nilutamide, can also be classified as toluidides.<span class="mw-ref" id="cite_ref-LemkeWilliams2012_220-3"><a href="#cite_note-LemkeWilliams2012-220" style="counter-reset: mw-Ref 220;"><span class="mw-reflink-text">[220]</span></a></span> All three of the compounds share a common 3-trifluoromethyl<a href="Aniline.htm" tppabs="https://ptable.com/wiki/compounds/A/Aniline" title="Aniline">aniline</a> moiety.<span class="mw-ref" id="cite_ref-BéguéBonnet-Delpon2008_229-0"><a href="#cite_note-BéguéBonnet-Delpon2008-229" style="counter-reset: mw-Ref 229;"><span class="mw-reflink-text">[229]</span></a></span> Bicalutamide is a modification of flutamide in which a 4-<a href="Fluorine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoro" title="Fluoro" class="mw-redirect">fluoro</a>phenylsulfonyl moiety has been added and the nitro group on the original phenyl ring has been replaced with a cyano group.<span class="mw-ref" id="cite_ref-BallKamalian2016_230-0"><a href="#cite_note-BallKamalian2016-230" style="counter-reset: mw-Ref 230;"><span class="mw-reflink-text">[230]</span></a></span> Topilutamide, also known as fluridil, is another <abbr>NSAA</abbr> that is closely related structurally to the first-generation <abbr>NSAAs</abbr>, but, in contrast to them, is not used in the treatment of prostate cancer and is instead used exclusively as a topical antiandrogen in the treatment of pattern hair loss.<span class="mw-ref" id="cite_ref-pmid16821162_231-0"><a href="#cite_note-pmid16821162-231" style="counter-reset: mw-Ref 231;"><span class="mw-reflink-text">[231]</span></a></span><span class="mw-ref" id="cite_ref-AvramRogers2009_232-0"><a href="#cite_note-AvramRogers2009-232" style="counter-reset: mw-Ref 232;"><span class="mw-reflink-text">[232]</span></a></span><span class="mw-ref" id="cite_ref-HaberStough2006_233-0"><a href="#cite_note-HaberStough2006-233" style="counter-reset: mw-Ref 233;"><span class="mw-reflink-text">[233]</span></a></span></p>

<div class="mw-collapsible  mw-collapsed " style="box-sizing:border-box;width:100%;font-size:95%;padding:4px;border:none;padding: 0px;"><div style="font-size:100%;line-height:1.6;font-weight:bold;background:transparent;text-align:center;;padding: 0px;">Chemical structures of first-generation <abbr>NSAAs</abbr></div><div class="mw-collapsible-content" style="background:transparent;text-align:center;;padding: 0px;"> <ul class="gallery mw-gallery-traditional center">
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Flutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Flutamide.svg.png" data-file-width="512" data-file-height="306" data-file-type="drawing" height="134" width="225"></figure-inline></div><div class="gallerytext"><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Nilutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Nilutamide.svg.png" data-file-width="512" data-file-height="379" data-file-type="drawing" height="167" width="225"></figure-inline></div><div class="gallerytext"><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Bicalutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bicalutamide.svg.png" data-file-width="512" data-file-height="184" data-file-type="drawing" height="81" width="225"></figure-inline></div><div class="gallerytext">Bicalutamide</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Topilutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Topilutamide.svg.png" data-file-width="512" data-file-height="212" data-file-type="drawing" height="93" width="225"></figure-inline></div><div class="gallerytext">Topilutamide</div></li>
</ul>
</div></div>

<p>The second-generation <abbr>NSAAs</abbr> enzalutamide and apalutamide were derived from and are analogues of the first-generation <abbr>NSAAs</abbr>,<span class="mw-ref" id="cite_ref-Weber2015_140-8"><a href="#cite_note-Weber2015-140" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span><span class="mw-ref" id="cite_ref-KawaharaMiyamoto2014_234-0"><a href="#cite_note-KawaharaMiyamoto2014-234" style="counter-reset: mw-Ref 234;"><span class="mw-reflink-text">[234]</span></a></span> while another second-generation <abbr>NSAA</abbr>, darolutamide, is said to be structurally distinct and chemically unrelated to the other <abbr>NSAAs</abbr>.<span class="mw-ref" id="cite_ref-pmid26137992_235-0"><a href="#cite_note-pmid26137992-235" style="counter-reset: mw-Ref 235;"><span class="mw-reflink-text">[235]</span></a></span> Enzalutamide is a modification of bicalutamide in which the inter-ring linking chain has been altered and cyclized into a 5,5-di<a href="Methyl_group.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyl_group" title="Methyl group">methyl</a>-4-<a href="Oxygen.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxygen" title="Oxygen">oxo</a>-2-thioxo imidazolidine moiety. In apalutamide, the 5,5-dimethyl groups of the imidazolidine ring of enzalutamide are cyclized to form an accessory <a href="Cyclobutane.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclobutane" title="Cyclobutane">cyclobutane</a> ring and one of its phenyl rings is replaced with a <a href="Pyridine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pyridine" title="Pyridine">pyridine</a> ring.</p>

<div class="mw-collapsible  mw-collapsed " style="box-sizing:border-box;width:100%;font-size:95%;padding:4px;border:none;padding: 0px;"><div style="font-size:100%;line-height:1.6;font-weight:bold;background:transparent;text-align:center;;padding: 0px;">Chemical structures of second-generation <abbr>NSAAs</abbr></div><div class="mw-collapsible-content" style="background:transparent;text-align:center;;padding: 0px;"> <ul class="gallery mw-gallery-traditional center">
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Enzalutamide-01.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Enzalutamide-01.svg.png" data-file-width="512" data-file-height="249" data-file-type="drawing" height="109" width="225"></figure-inline></div><div class="gallerytext">Enzalutamide</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Apalutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Apalutamide.svg.png" data-file-width="512" data-file-height="254" data-file-type="drawing" height="112" width="225"></figure-inline></div><div class="gallerytext">Apalutamide</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Proxalutamide_skeletal.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Proxalutamide_skeletal.svg.png" data-file-width="687" data-file-height="321" data-file-type="drawing" height="105" width="225"></figure-inline></div><div class="gallerytext">Proxalutamide</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/ODM-201.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/ODM-201.svg.png" data-file-width="512" data-file-height="160" data-file-type="drawing" height="70" width="225"></figure-inline></div><div class="gallerytext">Darolutamide</div></li>
</ul>
</div></div>

<p>The first nonsteroidal androgens, the arylpropionamides, were discovered via structural modification of bicalutamide.<span class="mw-ref" id="cite_ref-SegalNarayanan2006_236-0"><a href="#cite_note-SegalNarayanan2006-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span> Unlike bicalutamide (which is purely antiandrogenic), these compounds show tissue-selective androgenic effects and were classified as selective androgen receptor modulators (SARMs).<span class="mw-ref" id="cite_ref-SegalNarayanan2006_236-1"><a href="#cite_note-SegalNarayanan2006-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span> Lead <abbr>SARMs</abbr> of this series included acetothiolutamide, enobosarm (ostarine; S-22), and andarine (acetamidoxolutamide or androxolutamide; S-4).<span class="mw-ref" id="cite_ref-MohlerBohl2009_228-4"><a href="#cite_note-MohlerBohl2009-228" style="counter-reset: mw-Ref 228;"><span class="mw-reflink-text">[228]</span></a></span><span class="mw-ref" id="cite_ref-SegalNarayanan2006_236-2"><a href="#cite_note-SegalNarayanan2006-236" style="counter-reset: mw-Ref 236;"><span class="mw-reflink-text">[236]</span></a></span><span class="mw-ref" id="cite_ref-Yin2002_237-0"><a href="#cite_note-Yin2002-237" style="counter-reset: mw-Ref 237;"><span class="mw-reflink-text">[237]</span></a></span> They are very close to bicalutamide structurally, with the key differences being that the linker sulfone of bicalutamide has been replaced with an <a href="Ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Ether" title="Ether">ether</a> or thioether group to confer agonism of the <abbr>AR</abbr> and the 4-fluoro atom of the pertinent phenyl ring has been substituted with an <a href="Acetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetamide" title="Acetamide">acetamido</a> or cyano group to eliminate reactivity at the position.<span class="mw-ref" id="cite_ref-OttowWeinmann2008_238-0"><a href="#cite_note-OttowWeinmann2008-238" style="counter-reset: mw-Ref 238;"><span class="mw-reflink-text">[238]</span></a></span></p>

<div class="mw-collapsible  mw-collapsed " style="box-sizing:border-box;width:100%;font-size:95%;padding:4px;border:none;padding: 0px;"><div style="font-size:100%;line-height:1.6;font-weight:bold;background:transparent;text-align:center;;padding: 0px;">Chemical structures of arylpropionamide <abbr>SARMs</abbr></div><div class="mw-collapsible-content" style="background:transparent;text-align:center;;padding: 0px;"> <ul class="gallery mw-gallery-traditional center">
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Acetothiolutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Acetothiolutamide.svg.png" data-file-width="512" data-file-height="166" data-file-type="drawing" height="73" width="225"></figure-inline></div><div class="gallerytext">Acetothiolutamide</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Ostarine.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Ostarine.svg.png" data-file-width="512" data-file-height="172" data-file-type="drawing" height="76" width="225"></figure-inline></div><div class="gallerytext">Enobosarm</div></li>
<li class="gallerybox" style="width: 260px;"><div class="thumb" style="width: 255px; height: 255px;"><figure-inline><img src="../I/m/Andarine.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Andarine.svg.png" data-file-width="512" data-file-height="176" data-file-type="drawing" height="77" width="225"></figure-inline></div><div class="gallerytext">Andarine</div></li>
</ul>
</div></div>

<p>A few radiolabeled derivatives of bicalutamide have been developed for potential use as radiotracers in medical imaging.<span class="mw-ref" id="cite_ref-pmid17328524_239-0"><a href="#cite_note-pmid17328524-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span><span class="mw-ref" id="cite_ref-DierckxOtte2014_240-0"><a href="#cite_note-DierckxOtte2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span> They include [<sup>18</sup>F]bicalutamide, 4-[<sup>76</sup>Br]bromobicalutamide, and [<sup>76</sup>Br]bromo-thiobicalutamide.<span class="mw-ref" id="cite_ref-pmid17328524_239-1"><a href="#cite_note-pmid17328524-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span><span class="mw-ref" id="cite_ref-DierckxOtte2014_240-1"><a href="#cite_note-DierckxOtte2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span> The latter two were found to have substantially increased affinity for the <abbr>AR</abbr> relative to that of bicautamide.<span class="mw-ref" id="cite_ref-pmid17328524_239-2"><a href="#cite_note-pmid17328524-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span> However, none of these agents have been evaluated in humans.<span class="mw-ref" id="cite_ref-pmid17328524_239-3"><a href="#cite_note-pmid17328524-239" style="counter-reset: mw-Ref 239;"><span class="mw-reflink-text">[239]</span></a></span><span class="mw-ref" id="cite_ref-DierckxOtte2014_240-2"><a href="#cite_note-DierckxOtte2014-240" style="counter-reset: mw-Ref 240;"><span class="mw-reflink-text">[240]</span></a></span></p>

<p>5<i>N</i>-Bicalutamide, or 5-azabicalutamide, is a minor structural modification of bicalutamide which acts as a reversible covalent antagonist of the <abbr>AR</abbr> and has approximately 150-fold higher affinity for the <abbr>AR</abbr> and about 20-fold greater functional inhibition of the <abbr>AR</abbr> relative to bicalutamide.<span class="mw-ref" id="cite_ref-pmid28981251_241-0"><a href="#cite_note-pmid28981251-241" style="counter-reset: mw-Ref 241;"><span class="mw-reflink-text">[241]</span></a></span><span class="mw-ref" id="cite_ref-US20170101384_242-0"><a href="#cite_note-US20170101384-242" style="counter-reset: mw-Ref 242;"><span class="mw-reflink-text">[242]</span></a></span> It is among the most potent <abbr>AR</abbr> antagonists to have been developed and is being researched for potential use in the treatment of antiandrogen-resistant prostate cancer.<span class="mw-ref" id="cite_ref-pmid28981251_241-1"><a href="#cite_note-pmid28981251-241" style="counter-reset: mw-Ref 241;"><span class="mw-reflink-text">[241]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Synthesis">Synthesis</h3></summary>
    
<p>A number of chemical syntheses of bicalutamide have been published in the literature.<span class="mw-ref" id="cite_ref-Publishing2013_225-1"><a href="#cite_note-Publishing2013-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span><span class="mw-ref" id="cite_ref-pmid3361581_243-0"><a href="#cite_note-pmid3361581-243" style="counter-reset: mw-Ref 243;"><span class="mw-reflink-text">[243]</span></a></span><span class="mw-ref" id="cite_ref-JamesEkwuribe2002_244-0"><a href="#cite_note-JamesEkwuribe2002-244" style="counter-reset: mw-Ref 244;"><span class="mw-reflink-text">[244]</span></a></span><span class="mw-ref" id="cite_ref-245"><a href="#cite_note-245" style="counter-reset: mw-Ref 245;"><span class="mw-reflink-text">[245]</span></a></span><span class="mw-ref" id="cite_ref-ChandShukla2012_246-0"><a href="#cite_note-ChandShukla2012-246" style="counter-reset: mw-Ref 246;"><span class="mw-reflink-text">[246]</span></a></span> The procedure of the first published synthesis of bicalutamide can be seen below.<span class="mw-ref" id="cite_ref-pmid3361581_243-1"><a href="#cite_note-pmid3361581-243" style="counter-reset: mw-Ref 243;"><span class="mw-reflink-text">[243]</span></a></span></p>
<span>
</span><table role="presentation" cellpadding="0" style="border-spacing:0; margin-left: auto; margin-right: auto; border: none;">
<tbody><tr>
<td><div class="thumb center" style="margin: 1em auto;">
<div class="thumbinner" style="width:652px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: transparent;margin-bottom:3px;">Bicalutamide synthesis<span class="mw-ref" id="cite_ref-pmid3361581_243-2"><a href="#cite_note-pmid3361581-243" style="counter-reset: mw-Ref 243;"><span class="mw-reflink-text">[243]</span></a></span></div>
<div style="position:relative; width:650px; height:277px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:650px; position:absolute"> <figure-inline><img src="../I/m/Bicalutamide_synthesis.png" tppabs="https://ptable.com/wiki/compounds/I/m/Bicalutamide_synthesis.png" data-file-width="1484" data-file-height="633" data-file-type="bitmap" height="277" width="650"></figure-inline>
</div> 
<div style="text-align:center; line-height:110%;">
<div style="background-color:transparent; color:black"></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>Where the starting material is 4-cyano-3-(trifluoromethyl)aniline (also known as 4-amino-2-(trifluoromethyl)benzonitrile), DMA is <a href="Dimethylacetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethylacetamide" title="Dimethylacetamide">dimethylacetamide</a>, and <i>m</i>CPBA is <a href="Meta-Chloroperoxybenzoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Meta-Chloroperoxybenzoic_acid" title="Meta-Chloroperoxybenzoic acid"><i>meta</i>-chloroperoxybenzoic acid</a>.</div>
</div>
</div></td></tr>
</tbody></table>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Bicalutamide as well as all of the other currently marketed <abbr>NSAAs</abbr> were derived from structural modification of flutamide, which itself was originally synthesized as a bacteriostatic agent in 1967 at Schering Plough Corporation and was subsequently and serendipitously found to possess antiandrogenic activity.<span class="mw-ref" id="cite_ref-Diamanti-Kandarakis_1999_247-0"><a href="#cite_note-Diamanti-Kandarakis_1999-247" style="counter-reset: mw-Ref 247;"><span class="mw-reflink-text">[247]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_248-0"><a href="#cite_note-DenisGriffiths1999-248" style="counter-reset: mw-Ref 248;"><span class="mw-reflink-text">[248]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014-2_249-0"><a href="#cite_note-Elks2014-2-249" style="counter-reset: mw-Ref 249;"><span class="mw-reflink-text">[249]</span></a></span> Bicalutamide was discovered by Tucker and colleagues at Imperial Chemical Industries (ICI) in the 1980s and was selected for development from a group of over 2,000<span>&nbsp;</span>synthesized compounds.<span class="mw-ref" id="cite_ref-pmid11844311_250-0"><a href="#cite_note-pmid11844311-250" style="counter-reset: mw-Ref 250;"><span class="mw-reflink-text">[250]</span></a></span><span class="mw-ref" id="cite_ref-Furr1995_150-2"><a href="#cite_note-Furr1995-150" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span><span class="mw-ref" id="cite_ref-pmid16515480_251-0"><a href="#cite_note-pmid16515480-251" style="counter-reset: mw-Ref 251;"><span class="mw-reflink-text">[251]</span></a></span><span class="mw-ref" id="cite_ref-Publishing2013_225-2"><a href="#cite_note-Publishing2013-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span> It was first patented in 1982<span class="mw-ref" id="cite_ref-EngelKleemann2014_252-0"><a href="#cite_note-EngelKleemann2014-252" style="counter-reset: mw-Ref 252;"><span class="mw-reflink-text">[252]</span></a></span> and was first reported in the scientific literature in June 1987.<span class="mw-ref" id="cite_ref-pmid3625091_253-0"><a href="#cite_note-pmid3625091-253" style="counter-reset: mw-Ref 253;"><span class="mw-reflink-text">[253]</span></a></span></p>

<p>Bicalutamide was first studied in a phase I clinical trial in 1987<span class="mw-ref" id="cite_ref-Kolvenbag1996_91-4"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span> and the results of the first phase II clinical trial in prostate cancer were published in 1990.<span class="mw-ref" id="cite_ref-pmid2094607_254-0"><a href="#cite_note-pmid2094607-254" style="counter-reset: mw-Ref 254;"><span class="mw-reflink-text">[254]</span></a></span> The pharmaceutical division of <abbr>ICI</abbr> was split out into an independent company called Zeneca in 1993, and in April and May 1995, Zeneca (now AstraZeneca, after merging with Astra AB in 1999) began pre-approval marketing of bicalutamide for the treatment of prostate cancer in the <abbr>U.S.</abbr>.<span class="mw-ref" id="cite_ref-Patents1997_255-0"><a href="#cite_note-Patents1997-255" style="counter-reset: mw-Ref 255;"><span class="mw-reflink-text">[255]</span></a></span> It was first launched in the <abbr>U.K.</abbr> in May 1995,<span class="mw-ref" id="cite_ref-ChaurasiyaSingh2012_256-0"><a href="#cite_note-ChaurasiyaSingh2012-256" style="counter-reset: mw-Ref 256;"><span class="mw-reflink-text">[256]</span></a></span> and was subsequently approved by the <abbr>U.S.</abbr> <abbr>FDA</abbr> on 4 October 1995, for the treatment of prostate cancer at a dosage of 50<span>&nbsp;</span>mg/day in combination with a <abbr>GnRH</abbr> analogue.<span class="mw-ref" id="cite_ref-Klotz2006_257-0"><a href="#cite_note-Klotz2006-257" style="counter-reset: mw-Ref 257;"><span class="mw-reflink-text">[257]</span></a></span><span class="mw-ref" id="cite_ref-pmid26236143_258-0"><a href="#cite_note-pmid26236143-258" style="counter-reset: mw-Ref 258;"><span class="mw-reflink-text">[258]</span></a></span></p>

<p>Following its introduction for use in combination with a <abbr>GnRH</abbr> analogue, bicalutamide was developed as a monotherapy at a dosage of 150<span>&nbsp;</span>mg/day for the treatment of prostate cancer, and was approved for this indication in Europe, Canada, and a number of other countries in the late 1990s and early 2000s.<span class="mw-ref" id="cite_ref-Wellington2006_21-12"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Denis2012_145-3"><a href="#cite_note-Denis2012-145" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span><span class="mw-ref" id="cite_ref-pmid11502439_259-0"><a href="#cite_note-pmid11502439-259" style="counter-reset: mw-Ref 259;"><span class="mw-reflink-text">[259]</span></a></span><span class="mw-ref" id="cite_ref-CarswellFiggitt2002_260-0"><a href="#cite_note-CarswellFiggitt2002-260" style="counter-reset: mw-Ref 260;"><span class="mw-reflink-text">[260]</span></a></span> This application of bicalutamide was also under review by the <abbr>FDA</abbr> in the <abbr>U.S.</abbr> in 2002,<span class="mw-ref" id="cite_ref-JasminCapanna2005_261-0"><a href="#cite_note-JasminCapanna2005-261" style="counter-reset: mw-Ref 261;"><span class="mw-reflink-text">[261]</span></a></span> but ultimately was not approved in this country.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_76-4"><a href="#cite_note-ChabnerLongo2010-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> In Japan, bicalutamide is licensed at a dosage of 80<span>&nbsp;</span>mg/day alone or in combination with a <abbr>GnRH</abbr> analogue for prostate cancer.<span class="mw-ref" id="cite_ref-SuzukiKamiya2008_73-1"><a href="#cite_note-SuzukiKamiya2008-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span> The unique 80<span>&nbsp;</span>mg dosage of bicalutamide used in Japan was selected for development in this country on the basis of observed pharmacokinetic differences with bicalutamide in Japanese men.<span class="mw-ref" id="cite_ref-pmid17199134_262-0"><a href="#cite_note-pmid17199134-262" style="counter-reset: mw-Ref 262;"><span class="mw-reflink-text">[262]</span></a></span></p>

<p>Subsequent to negative findings of bicalutamide monotherapy for <abbr>LPC</abbr> in the <abbr>EPC</abbr> trial, approval of bicalutamide for use specifically in the treatment of <abbr>LPC</abbr> was withdrawn in a number of countries<span class="mw-ref" id="cite_ref-pmid18093474_263-0"><a href="#cite_note-pmid18093474-263" style="counter-reset: mw-Ref 263;"><span class="mw-reflink-text">[263]</span></a></span> including the <abbr>U.K.</abbr> (in October or November 2003)<span class="mw-ref" id="cite_ref-BowsherCarter2008_264-0"><a href="#cite_note-BowsherCarter2008-264" style="counter-reset: mw-Ref 264;"><span class="mw-reflink-text">[264]</span></a></span> and several other European countries and Canada (in August 2003).<span class="mw-ref" id="cite_ref-Wellington2006_21-13"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Nations2005_265-0"><a href="#cite_note-Nations2005-265" style="counter-reset: mw-Ref 265;"><span class="mw-reflink-text">[265]</span></a></span><span class="mw-ref" id="cite_ref-Bono2004_266-0"><a href="#cite_note-Bono2004-266" style="counter-reset: mw-Ref 266;"><span class="mw-reflink-text">[266]</span></a></span> In addition, the <abbr>U.S.</abbr> and Canada explicitly recommended against the use of 150<span>&nbsp;</span>mg/day bicalutamide for this indication.<span class="mw-ref" id="cite_ref-NargundRaghavan2015_267-0"><a href="#cite_note-NargundRaghavan2015-267" style="counter-reset: mw-Ref 267;"><span class="mw-reflink-text">[267]</span></a></span> The drug is effective for, remains approved for, and continues to be used in the treatment of <abbr>LAPC</abbr> and <abbr>mPC</abbr>, on the other hand.<span class="mw-ref" id="cite_ref-Wellington2006_21-14"><a href="#cite_note-Wellington2006-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>The patent protection of bicalutamide expired in the <abbr>U.S.</abbr> in March 2009 and the drug has subsequently been available as a generic,<span class="mw-ref" id="cite_ref-Moul2009_268-0"><a href="#cite_note-Moul2009-268" style="counter-reset: mw-Ref 268;"><span class="mw-reflink-text">[268]</span></a></span> at greatly reduced cost.<span class="mw-ref" id="cite_ref-Kampel2012_269-0"><a href="#cite_note-Kampel2012-269" style="counter-reset: mw-Ref 269;"><span class="mw-reflink-text">[269]</span></a></span></p>

<p>Bicalutamide was the fourth antiandrogen (and the third <abbr>NSAA</abbr>) to be introduced for the treatment of prostate cancer, following the <abbr>SAA</abbr> <abbr>CPA</abbr> in 1973<span class="mw-ref" id="cite_ref-TobiasHochhauser2014_270-0"><a href="#cite_note-TobiasHochhauser2014-270" style="counter-reset: mw-Ref 270;"><span class="mw-reflink-text">[270]</span></a></span> and the <abbr>NSAAs</abbr> flutamide in 1983 (1989 in the <abbr>U.S.</abbr>)<span class="mw-ref" id="cite_ref-Publishing2013_225-3"><a href="#cite_note-Publishing2013-225" style="counter-reset: mw-Ref 225;"><span class="mw-reflink-text">[225]</span></a></span><span class="mw-ref" id="cite_ref-Neal1994_271-0"><a href="#cite_note-Neal1994-271" style="counter-reset: mw-Ref 271;"><span class="mw-reflink-text">[271]</span></a></span> and nilutamide in 1989 (1996 in the <abbr>U.S.</abbr>).<span class="mw-ref" id="cite_ref-BéguéBonnet-Delpon2008_229-1"><a href="#cite_note-BéguéBonnet-Delpon2008-229" style="counter-reset: mw-Ref 229;"><span class="mw-reflink-text">[229]</span></a></span><span class="mw-ref" id="cite_ref-Regitz-Zagrosek2012_272-0"><a href="#cite_note-Regitz-Zagrosek2012-272" style="counter-reset: mw-Ref 272;"><span class="mw-reflink-text">[272]</span></a></span><span class="mw-ref" id="cite_ref-pmid15833816_273-0"><a href="#cite_note-pmid15833816-273" style="counter-reset: mw-Ref 273;"><span class="mw-reflink-text">[273]</span></a></span> It has been followed by abiraterone acetate in 2011, enzalutamide in 2012, apalutamide in 2018, and darolutamide in 2019, and may also be followed by in-development drugs such as proxalutamide and seviteronel.<span class="mw-ref" id="cite_ref-pmid26585581_274-0"><a href="#cite_note-pmid26585581-274" style="counter-reset: mw-Ref 274;"><span class="mw-reflink-text">[274]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p><i>Bicalutamide</i> is the generic name of the drug in English and French and its <abbr>INN</abbr>, <abbr>USAN</abbr>, <abbr>USP</abbr>,<span class="mw-ref" id="cite_ref-KEGG_275-0"><a href="#cite_note-KEGG-275" style="counter-reset: mw-Ref 275;"><span class="mw-reflink-text">[275]</span></a></span> <abbr>BAN</abbr>, <abbr>DCF</abbr>, <abbr>AAN</abbr>,<span class="mw-ref" id="cite_ref-TGALabel_80-7"><a href="#cite_note-TGALabel-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> and <abbr>JAN</abbr>.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-2"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall2012_276-0"><a href="#cite_note-MortonHall2012-276" style="counter-reset: mw-Ref 276;"><span class="mw-reflink-text">[276]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_71-1"><a href="#cite_note-IndexNominum2000-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-GanellinTriggle1996_277-0"><a href="#cite_note-GanellinTriggle1996-277" style="counter-reset: mw-Ref 277;"><span class="mw-reflink-text">[277]</span></a></span> It is also referred to as <i>bicalutamidum</i> in Latin, <i>bicalutamida</i> in Spanish and Portuguese, <i>bicalutamid</i> in German, and <i>bikalutamid</i> in Russian and other Slavic languages.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-3"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_71-2"><a href="#cite_note-IndexNominum2000-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span> The "bica-" prefix corresponds to the fact that bicalutamide is a <i>bicyclic</i> compound, while the "-lutamide" suffix is the standard suffix for <abbr>NSAAs</abbr>.<span class="mw-ref" id="cite_ref-WHO2013_278-0"><a href="#cite_note-WHO2013-278" style="counter-reset: mw-Ref 278;"><span class="mw-reflink-text">[278]</span></a></span><span class="mw-ref" id="cite_ref-NLM-DrugPortal_279-0"><a href="#cite_note-NLM-DrugPortal-279" style="counter-reset: mw-Ref 279;"><span class="mw-reflink-text">[279]</span></a></span> Bicalutamide is also known by its former developmental code name <abbr>ICI</abbr>-176,334.<span class="mw-ref" id="cite_ref-MortonHall2012_276-1"><a href="#cite_note-MortonHall2012-276" style="counter-reset: mw-Ref 276;"><span class="mw-reflink-text">[276]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_71-3"><a href="#cite_note-IndexNominum2000-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com-2_31-4"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Bicalutamide is marketed by AstraZeneca in oral tablet form under the brand names Casodex, Cosudex, Calutide, Calumid, and Kalumid in many countries.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-5"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_71-4"><a href="#cite_note-IndexNominum2000-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-HuangJo2009_280-0"><a href="#cite_note-HuangJo2009-280" style="counter-reset: mw-Ref 280;"><span class="mw-reflink-text">[280]</span></a></span><span class="mw-ref" id="cite_ref-DhasIge2015_281-0"><a href="#cite_note-DhasIge2015-281" style="counter-reset: mw-Ref 281;"><span class="mw-reflink-text">[281]</span></a></span> It is also marketed under the brand names Bicadex, Bical, Bicalox, Bicamide, Bicatlon, Bicusan, Binabic, Bypro, Calutol, and Ormandyl among others in various countries.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-6"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> The drug is sold under a large number of generic trade names such as Apo-Bicalutamide, Bicalutamide Accord, Bicalutamide Actavis, Bicalutamide Bluefish, Bicalutamide Kabi, Bicalutamide Sandoz, and Bicalutamide Teva as well.<span class="mw-ref" id="cite_ref-Drugs.com-2_31-7"><a href="#cite_note-Drugs.com-2-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> A combination formulation of bicalutamide and goserelin is marketed by AstraZeneca in Australia and New Zealand under the brand name ZolaCos-CP.<span class="mw-ref" id="cite_ref-Martindale2011_72-2"><a href="#cite_note-Martindale2011-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com-3_77-1"><a href="#cite_note-Drugs.com-3-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-ZolacosCPLabelAu_78-1"><a href="#cite_note-ZolacosCPLabelAu-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-ZolacosCPLabelNZ_79-1"><a href="#cite_note-ZolacosCPLabelNZ-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Cost_and_generics">Cost and generics</h3></summary>
    
<p>Bicalutamide is off-patent and available as a generic, and its cost is low in comparison to a number of other similar medications (from <span>US$10</span> to <span>US$15.44</span> for a 30-day supply of once-daily 50<span>&nbsp;</span>mg tablets).<span class="mw-ref" id="cite_ref-Drugs.com-1_282-0"><a href="#cite_note-Drugs.com-1-282" style="counter-reset: mw-Ref 282;"><span class="mw-reflink-text">[282]</span></a></span><span class="mw-ref" id="cite_ref-NADAC2016_283-0"><a href="#cite_note-NADAC2016-283" style="counter-reset: mw-Ref 283;"><span class="mw-reflink-text">[283]</span></a></span> Brand name Casodex costs <span>US$556.17</span> for a 30-day supply of once-daily 50<span>&nbsp;</span>mg tablets <span>as of 2017</span>.<span class="mw-ref" id="cite_ref-Drugs.com-4_284-0"><a href="#cite_note-Drugs.com-4-284" style="counter-reset: mw-Ref 284;"><span class="mw-reflink-text">[284]</span></a></span> Unlike bicalutamide, the newer <abbr>NSAA</abbr> enzalutamide is still on-patent, and for this reason, is considerably more expensive in comparison (<span>US$7,450</span> for a 30-day supply <span>as of 2015</span>).<span class="mw-ref" id="cite_ref-RamadanKabbara2015_285-0"><a href="#cite_note-RamadanKabbara2015-285" style="counter-reset: mw-Ref 285;"><span class="mw-reflink-text">[285]</span></a></span></p>

<p>The patent protection of all three of the first-generation <abbr>NSAAs</abbr> has expired and flutamide and bicalutamide are both available as low-cost generics.<span class="mw-ref" id="cite_ref-Stuhan2013_286-0"><a href="#cite_note-Stuhan2013-286" style="counter-reset: mw-Ref 286;"><span class="mw-reflink-text">[286]</span></a></span><span class="mw-ref" id="cite_ref-pmid16604181_287-0"><a href="#cite_note-pmid16604181-287" style="counter-reset: mw-Ref 287;"><span class="mw-reflink-text">[287]</span></a></span> Nilutamide, on the other hand, has always been a poor third competitor to flutamide and bicalutamide and, in relation to this fact, has not been developed as a generic and is only available as brand name Nilandron, at least in the <abbr>U.S.</abbr><span class="mw-ref" id="cite_ref-Stuhan2013_286-1"><a href="#cite_note-Stuhan2013-286" style="counter-reset: mw-Ref 286;"><span class="mw-reflink-text">[286]</span></a></span><span class="mw-ref" id="cite_ref-pmid16604181_287-1"><a href="#cite_note-pmid16604181-287" style="counter-reset: mw-Ref 287;"><span class="mw-reflink-text">[287]</span></a></span></p>

<p>Bicalutamide is considerably less costly than <abbr>GnRH</abbr> analogues, which, in spite of some having been off-patent many years, have been reported (in 2013) to typically cost <span>US$10,000</span>–$15,000 per year (or about <span>US$1,000</span> per month) of treatment.<span class="mw-ref" id="cite_ref-EmansLaufer2012_288-0"><a href="#cite_note-EmansLaufer2012-288" style="counter-reset: mw-Ref 288;"><span class="mw-reflink-text">[288]</span></a></span><span class="mw-ref" id="cite_ref-Hillard2013_289-0"><a href="#cite_note-Hillard2013-289" style="counter-reset: mw-Ref 289;"><span class="mw-reflink-text">[289]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Sales_and_usage">Sales and usage</h3></summary>
    
<p>Sales of bicalutamide (as Casodex) worldwide peaked at US$1.3<span>&nbsp;</span>billion in 2007,<span class="mw-ref" id="cite_ref-AstraZeneca2007_290-0"><a href="#cite_note-AstraZeneca2007-290" style="counter-reset: mw-Ref 290;"><span class="mw-reflink-text">[290]</span></a></span> and it has been described as a "billion-dollar-a-year" drug prior to losing its patent protection starting in 2007.<span class="mw-ref" id="cite_ref-Campbell2014_36-1"><a href="#cite_note-Campbell2014-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-Evaluate2008_291-0"><a href="#cite_note-Evaluate2008-291" style="counter-reset: mw-Ref 291;"><span class="mw-reflink-text">[291]</span></a></span><span class="mw-ref" id="cite_ref-pmid16821162_231-1"><a href="#cite_note-pmid16821162-231" style="counter-reset: mw-Ref 231;"><span class="mw-reflink-text">[231]</span></a></span> In 2014, despite the introduction of abiraterone acetate in 2011 and enzalutamide in 2012, bicalutamide was still the most commonly prescribed drug in the treatment of metastatic castration-resistant prostate cancer (mCRPC).<span class="mw-ref" id="cite_ref-Campbell2014_36-2"><a href="#cite_note-Campbell2014-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> Moreover, in spite of being off-patent, bicalutamide was said to still generate a few hundred million dollars in sales per year for AstraZeneca.<span class="mw-ref" id="cite_ref-Campbell2014_36-3"><a href="#cite_note-Campbell2014-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> Total worldwide sales of brand name Casodex were approximately US$13.4<span>&nbsp;</span>billion as of the end of 2018.<span class="mw-ref" id="cite_ref-NewMedicine1996_292-0"><a href="#cite_note-NewMedicine1996-292" style="counter-reset: mw-Ref 292;"><span class="mw-reflink-text">[292]</span></a></span><span class="mw-ref" id="cite_ref-NewYorkTimes1997_293-0"><a href="#cite_note-NewYorkTimes1997-293" style="counter-reset: mw-Ref 293;"><span class="mw-reflink-text">[293]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca1999_33-2"><a href="#cite_note-AstraZeneca1999-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2001_294-0"><a href="#cite_note-AstraZeneca2001-294" style="counter-reset: mw-Ref 294;"><span class="mw-reflink-text">[294]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2004_295-0"><a href="#cite_note-AstraZeneca2004-295" style="counter-reset: mw-Ref 295;"><span class="mw-reflink-text">[295]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2007_290-1"><a href="#cite_note-AstraZeneca2007-290" style="counter-reset: mw-Ref 290;"><span class="mw-reflink-text">[290]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2010_296-0"><a href="#cite_note-AstraZeneca2010-296" style="counter-reset: mw-Ref 296;"><span class="mw-reflink-text">[296]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2013_297-0"><a href="#cite_note-AstraZeneca2013-297" style="counter-reset: mw-Ref 297;"><span class="mw-reflink-text">[297]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2016_298-0"><a href="#cite_note-AstraZeneca2016-298" style="counter-reset: mw-Ref 298;"><span class="mw-reflink-text">[298]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2017_299-0"><a href="#cite_note-AstraZeneca2017-299" style="counter-reset: mw-Ref 299;"><span class="mw-reflink-text">[299]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2018_300-0"><a href="#cite_note-AstraZeneca2018-300" style="counter-reset: mw-Ref 300;"><span class="mw-reflink-text">[300]</span></a></span></p>

<table class="wikitable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap">Worldwide sales (millions, <abbr>USD</abbr>) of Casodex, 1995–2018</caption>
<tbody><tr>
<th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th><th>Year</th><th>Sales</th></tr>
<tr>
<td>1995</td><td>~$15m</td><td>1998</td><td>$245m</td><td>2001</td><td>$569m</td><td>2004</td><td>$1012m</td><td>2007<b>*</b></td><td>$1335m</td><td>2010</td><td>$579m</td><td>2013</td><td>$376m</td><td>2016</td><td>$247m</td></tr>
<tr>
<td>1996</td><td>$109m</td><td>1999</td><td>$340m</td><td>2002</td><td>$644m</td><td>2005</td><td>$1123m</td><td>2008</td><td>$1258m</td><td>2011</td><td>$550m</td><td>2014</td><td>$320m</td><td>2017</td><td>$215m</td></tr>
<tr>
<td>1997</td><td>$200m</td><td>2000</td><td>$433m</td><td>2003</td><td>$854m</td><td>2006</td><td>$1206m</td><td>2009</td><td>$844m</td><td>2012</td><td>$454m</td><td>2015</td><td>$267m</td><td>2018</td><td>$201m</td></tr>
<tr class="sortbottom">
<td colspan="16" style="background-color:#eaecf0; text-align: center;"><b>Notes:</b> First generic availability (*) was in 2007.<span class="mw-ref" id="cite_ref-Evaluate2008_291-1"><a href="#cite_note-Evaluate2008-291" style="counter-reset: mw-Ref 291;"><span class="mw-reflink-text">[291]</span></a></span> Total sales as of end 2018 were $13.4 billion. <b>Sources:</b> <span class="mw-ref" id="cite_ref-NewMedicine1996_292-1"><a href="#cite_note-NewMedicine1996-292" style="counter-reset: mw-Ref 292;"><span class="mw-reflink-text">[292]</span></a></span><span class="mw-ref" id="cite_ref-NewYorkTimes1997_293-1"><a href="#cite_note-NewYorkTimes1997-293" style="counter-reset: mw-Ref 293;"><span class="mw-reflink-text">[293]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca1999_33-3"><a href="#cite_note-AstraZeneca1999-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2001_294-1"><a href="#cite_note-AstraZeneca2001-294" style="counter-reset: mw-Ref 294;"><span class="mw-reflink-text">[294]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2004_295-1"><a href="#cite_note-AstraZeneca2004-295" style="counter-reset: mw-Ref 295;"><span class="mw-reflink-text">[295]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2007_290-2"><a href="#cite_note-AstraZeneca2007-290" style="counter-reset: mw-Ref 290;"><span class="mw-reflink-text">[290]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2010_296-1"><a href="#cite_note-AstraZeneca2010-296" style="counter-reset: mw-Ref 296;"><span class="mw-reflink-text">[296]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2013_297-1"><a href="#cite_note-AstraZeneca2013-297" style="counter-reset: mw-Ref 297;"><span class="mw-reflink-text">[297]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2016_298-1"><a href="#cite_note-AstraZeneca2016-298" style="counter-reset: mw-Ref 298;"><span class="mw-reflink-text">[298]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2017_299-1"><a href="#cite_note-AstraZeneca2017-299" style="counter-reset: mw-Ref 299;"><span class="mw-reflink-text">[299]</span></a></span><span class="mw-ref" id="cite_ref-AstraZeneca2018_300-1"><a href="#cite_note-AstraZeneca2018-300" style="counter-reset: mw-Ref 300;"><span class="mw-reflink-text">[300]</span></a></span></td></tr>
</tbody></table>

<p>Between January 2007 and December 2009 (a period of three years), 1,232,143 prescriptions of bicalutamide were dispensed in the <abbr>U.S.</abbr>, or about 400,000 prescriptions per year.<span class="mw-ref" id="cite_ref-HHS2010_37-1"><a href="#cite_note-HHS2010-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> During that time, bicalutamide accounted for about 87.2% of the <abbr>NSAA</abbr> market, while flutamide accounted for 10.5% of it and nilutamide for 2.3% of it.<span class="mw-ref" id="cite_ref-HHS2010_37-2"><a href="#cite_note-HHS2010-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> Approximately 96% of bicalutamide prescriptions were written for diagnosis codes that clearly indicated neoplasm.<span class="mw-ref" id="cite_ref-HHS2010_37-3"><a href="#cite_note-HHS2010-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> About 1,200, or 0.1% of bicalutamide prescriptions were dispensed to pediatric patients (age 0–16).<span class="mw-ref" id="cite_ref-HHS2010_37-4"><a href="#cite_note-HHS2010-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Regulation">Regulation</h3></summary>
    
<p>Bicalutamide is a prescription drug.<span class="mw-ref" id="cite_ref-MortonHall2001_75-1"><a href="#cite_note-MortonHall2001-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span> It is not specifically a controlled substance in any country and therefore is not an illegal drug.<span class="mw-ref" id="cite_ref-AHFS2016_11-9"><a href="#cite_note-AHFS2016-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> However, the manufacture, sale, distribution, and possession of prescription drugs are all still subject to legal regulation throughout the world.<span class="mw-ref" id="cite_ref-YagielaDowd2010_301-0"><a href="#cite_note-YagielaDowd2010-301" style="counter-reset: mw-Ref 301;"><span class="mw-reflink-text">[301]</span></a></span><span class="mw-ref" id="cite_ref-HeplerSegal2003_302-0"><a href="#cite_note-HeplerSegal2003-302" style="counter-reset: mw-Ref 302;"><span class="mw-reflink-text">[302]</span></a></span><span class="mw-ref" id="cite_ref-DukesDukes1998_303-0"><a href="#cite_note-DukesDukes1998-303" style="counter-reset: mw-Ref 303;"><span class="mw-reflink-text">[303]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Bicalutamide has been studied in combination with the 5α-reductase inhibitors <a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">finasteride</a> and <a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">dutasteride</a> in prostate cancer.<span class="mw-ref" id="cite_ref-pmid15138573_304-0"><a href="#cite_note-pmid15138573-304" style="counter-reset: mw-Ref 304;"><span class="mw-reflink-text">[304]</span></a></span><span class="mw-ref" id="cite_ref-pmid15151957_305-0"><a href="#cite_note-pmid15151957-305" style="counter-reset: mw-Ref 305;"><span class="mw-reflink-text">[305]</span></a></span><span class="mw-ref" id="cite_ref-pmid16844453_306-0"><a href="#cite_note-pmid16844453-306" style="counter-reset: mw-Ref 306;"><span class="mw-reflink-text">[306]</span></a></span><span class="mw-ref" id="cite_ref-pmid19796455_307-0"><a href="#cite_note-pmid19796455-307" style="counter-reset: mw-Ref 307;"><span class="mw-reflink-text">[307]</span></a></span><span class="mw-ref" id="cite_ref-pmid26048455_308-0"><a href="#cite_note-pmid26048455-308" style="counter-reset: mw-Ref 308;"><span class="mw-reflink-text">[308]</span></a></span><span class="mw-ref" id="cite_ref-pmid26702991_309-0"><a href="#cite_note-pmid26702991-309" style="counter-reset: mw-Ref 309;"><span class="mw-reflink-text">[309]</span></a></span><span class="mw-ref" id="cite_ref-pmid27330919_310-0"><a href="#cite_note-pmid27330919-310" style="counter-reset: mw-Ref 310;"><span class="mw-reflink-text">[310]</span></a></span> It has also been studied in combination with <a href="Raloxifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Raloxifene" title="Raloxifene">raloxifene</a>, a selective estrogen receptor modulator (SERM), for the treatment of prostate cancer.<span class="mw-ref" id="cite_ref-FujimuraTakayama2018_311-0"><a href="#cite_note-FujimuraTakayama2018-311" style="counter-reset: mw-Ref 311;"><span class="mw-reflink-text">[311]</span></a></span><span class="mw-ref" id="cite_ref-HoNunez-Nateras2017_312-0"><a href="#cite_note-HoNunez-Nateras2017-312" style="counter-reset: mw-Ref 312;"><span class="mw-reflink-text">[312]</span></a></span> Bicalutamide has been tested for the treatment of <abbr>AR</abbr>-positive <abbr>ER</abbr>/<abbr>PR</abbr>-negative locally advanced and metastatic breast cancer in women in a phase II study for this indication.<span class="mw-ref" id="cite_ref-313"><a href="#cite_note-313" style="counter-reset: mw-Ref 313;"><span class="mw-reflink-text">[313]</span></a></span><span class="mw-ref" id="cite_ref-314"><a href="#cite_note-314" style="counter-reset: mw-Ref 314;"><span class="mw-reflink-text">[314]</span></a></span><span class="mw-ref" id="cite_ref-315"><a href="#cite_note-315" style="counter-reset: mw-Ref 315;"><span class="mw-reflink-text">[315]</span></a></span> Enzalutamide is also being investigated for this type of cancer.<span class="mw-ref" id="cite_ref-CaiazzaMurray2016_316-0"><a href="#cite_note-CaiazzaMurray2016-316" style="counter-reset: mw-Ref 316;"><span class="mw-reflink-text">[316]</span></a></span><span class="mw-ref" id="cite_ref-317"><a href="#cite_note-317" style="counter-reset: mw-Ref 317;"><span class="mw-reflink-text">[317]</span></a></span> Bicalutamide has also been studied in a phase II clinical trial for ovarian cancer in women.<span class="mw-ref" id="cite_ref-pmid17918264_318-0"><a href="#cite_note-pmid17918264-318" style="counter-reset: mw-Ref 318;"><span class="mw-reflink-text">[318]</span></a></span></p>

<p>Bicalutamide has been studied in the treatment of benign prostatic hyperplasia (BPH) in a 24-week trial of 15 patients at a dosage of 50<span>&nbsp;</span>mg/day.<span class="mw-ref" id="cite_ref-Becker2001-2_319-0"><a href="#cite_note-Becker2001-2-319" style="counter-reset: mw-Ref 319;"><span class="mw-reflink-text">[319]</span></a></span><span class="mw-ref" id="cite_ref-pmid7694413_320-0"><a href="#cite_note-pmid7694413-320" style="counter-reset: mw-Ref 320;"><span class="mw-reflink-text">[320]</span></a></span> Prostate volume decreased by 26% in patients taking bicalutamide and urinary irritative symptom scores significantly decreased.<span class="mw-ref" id="cite_ref-Becker2001-2_319-1"><a href="#cite_note-Becker2001-2-319" style="counter-reset: mw-Ref 319;"><span class="mw-reflink-text">[319]</span></a></span><span class="mw-ref" id="cite_ref-pmid7694413_320-1"><a href="#cite_note-pmid7694413-320" style="counter-reset: mw-Ref 320;"><span class="mw-reflink-text">[320]</span></a></span> Conversely, peak urine flow rates and urine pressure flow examinations were not significantly different between bicalutamide and placebo.<span class="mw-ref" id="cite_ref-Becker2001-2_319-2"><a href="#cite_note-Becker2001-2-319" style="counter-reset: mw-Ref 319;"><span class="mw-reflink-text">[319]</span></a></span><span class="mw-ref" id="cite_ref-pmid7694413_320-2"><a href="#cite_note-pmid7694413-320" style="counter-reset: mw-Ref 320;"><span class="mw-reflink-text">[320]</span></a></span> The decrease in prostate volume achieved with bicalutamide was comparable to that observed with the 5α-reductase inhibitor <a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">finasteride</a>, which is approved for the treatment of BPH.<span class="mw-ref" id="cite_ref-pmid9101011_321-0"><a href="#cite_note-pmid9101011-321" style="counter-reset: mw-Ref 321;"><span class="mw-reflink-text">[321]</span></a></span><span class="mw-ref" id="cite_ref-pmid9135028_322-0"><a href="#cite_note-pmid9135028-322" style="counter-reset: mw-Ref 322;"><span class="mw-reflink-text">[322]</span></a></span> Breast tenderness (93%), gynecomastia (54%), and sexual dysfunction (60%) were all reported as side effects of bicalutamide at the dosage used in the study, although no treatment discontinuations due to adverse effects occurred and sexual functioning was maintained in 75% of patients.<span class="mw-ref" id="cite_ref-pmid7694413_320-3"><a href="#cite_note-pmid7694413-320" style="counter-reset: mw-Ref 320;"><span class="mw-reflink-text">[320]</span></a></span><span class="mw-ref" id="cite_ref-Kolvenbag1996_91-5"><a href="#cite_note-Kolvenbag1996-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p>

<p>A phase III clinical trial of bicalutamide in combination with an ethinylestradiol-containing combined oral contraceptive for the treatment of severe hirsutism in women with <abbr>PCOS</abbr> was completed in Italy in 2017 under supervision of the  Italian Agency for Drugs (AIFA).<span class="mw-ref" id="cite_ref-pmid29211888_48-1"><a href="#cite_note-pmid29211888-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></p>

<p>Antiandrogens have been suggested for treating COVID-19 in men and as of May 2020 high-dose bicalutamide is in a phase II clinical trial for this purpose.<span class="mw-ref" id="cite_ref-pmid32333494_323-0"><a href="#cite_note-pmid32333494-323" style="counter-reset: mw-Ref 323;"><span class="mw-reflink-text">[323]</span></a></span><span class="mw-ref" id="cite_ref-NCT04374279_324-0"><a href="#cite_note-NCT04374279-324" style="counter-reset: mw-Ref 324;"><span class="mw-reflink-text">[324]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Veterinary_use">Veterinary use</h2></summary>
    
<p>Bicalutamide may be used to treat hyperandrogenism and associated benign prostatic hyperplasia secondary to hyperadrenocorticism (caused by excessive adrenal androgens) in male ferrets.<span class="mw-ref" id="cite_ref-BonaguraTwedt2013_325-0"><a href="#cite_note-BonaguraTwedt2013-325" style="counter-reset: mw-Ref 325;"><span class="mw-reflink-text">[325]</span></a></span><span class="mw-ref" id="cite_ref-MitchellTully2009_326-0"><a href="#cite_note-MitchellTully2009-326" style="counter-reset: mw-Ref 326;"><span class="mw-reflink-text">[326]</span></a></span><span class="mw-ref" id="cite_ref-Pilny2014_327-0"><a href="#cite_note-Pilny2014-327" style="counter-reset: mw-Ref 327;"><span class="mw-reflink-text">[327]</span></a></span> However, it has not been formally assessed in controlled studies for this purpose.<span class="mw-ref" id="cite_ref-Pilny2014_327-1"><a href="#cite_note-Pilny2014-327" style="counter-reset: mw-Ref 327;"><span class="mw-reflink-text">[327]</span></a></span><span class="mw-ref" id="cite_ref-FoxMarini2014_328-0"><a href="#cite_note-FoxMarini2014-328" style="counter-reset: mw-Ref 328;"><span class="mw-reflink-text">[328]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>Comparison of bicalutamide with other antiandrogens</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 32em; -webkit-column-width: 32em; column-width: 32em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-(PharmD.)Clark2009-1"> <span id="mw-reference-text-cite_note-(PharmD.)Clark2009-1" class="mw-reference-text"><cite id="CITEREFFinkelClarkCubeddu2009" class="citation book cs1">Finkel R, Clark MA, Cubeddu LX (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=Q4hG2gRhy7oC&pg=PA481  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Q4hG2gRhy7oC&pg=PA481'" tppabs="https://books.google.com/books?id=Q4hG2gRhy7oC&pg=PA481" class="external text external"><i>Pharmacology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>481–. ISBN<span>&nbsp;</span><bdi>978-0-7817-7155-9</bdi>.</cite></span></li><li id="cite_note-SiftonStaff2002-2"> <span id="mw-reference-text-cite_note-SiftonStaff2002-2" class="mw-reference-text"><cite id="CITEREFSiftonPDR_Staff2002" class="citation book cs1">Sifton DW, PDR Staff (2002). <a href="javascript:if(confirm('https://books.google.com/books?id=Nd9sAAAAMAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Nd9sAAAAMAAJ'" tppabs="https://books.google.com/books?id=Nd9sAAAAMAAJ" class="external text external"><i>PDR Drug Guide for Mental Health Professionals</i></a>. Thomson/PDR. ISBN<span>&nbsp;</span><bdi>978-1-56363-457-4</bdi>.</cite></span></li><li id="cite_note-Cockshott2004-3"> <span id="mw-reference-text-cite_note-Cockshott2004-3" class="mw-reference-text"><cite id="CITEREFCockshott2004" class="citation journal cs1">Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". <i>Clinical Pharmacokinetics</i>. <b>43</b> (13): 855–878. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200443130-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200443130-00003'" tppabs="https://doi.org/10.2165%2F00003088-200443130-00003" class="external text external">10.2165/00003088-200443130-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15509184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15509184'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15509184" class="external text external">15509184</a>. <q>These data indicate that direct glucuronidation is the main metabolic pathway for the rapidly cleared (<i>S</i>)-bicalutamide, whereas hydroxylation followed by glucuronidation is a major metabolic pathway for the slowly cleared (<i>R</i>)-bicalutamide.</q></cite></span></li><li id="cite_note-Dart2004-4"> <span id="mw-reference-text-cite_note-Dart2004-4" class="mw-reference-text"><cite id="CITEREFDart2004" class="citation book cs1">Dart RC (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=BfdighlyGiwC&pg=PA497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BfdighlyGiwC&pg=PA497'" tppabs="https://books.google.com/books?id=BfdighlyGiwC&pg=PA497" class="external text external"><i>Medical Toxicology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>497, 521. ISBN<span>&nbsp;</span><bdi>978-0-7817-2845-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497'" tppabs="https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497" class="external text external">Archived</a> from the original on 11 May 2016.</cite></span></li><li id="cite_note-LemkeWilliams2008-5"> <span id="mw-reference-text-cite_note-LemkeWilliams2008-5" class="mw-reference-text"><cite id="CITEREFLemkeWilliams2008" class="citation book cs1">Lemke TL, Williams DA (2008). <a href="javascript:if(confirm('https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1288  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1288'" tppabs="https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1288" class="external text external"><i>Foye's Principles of Medicinal Chemistry</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>121, 1288, 1290. ISBN<span>&nbsp;</span><bdi>978-0-7817-6879-5</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908145128/https://books.google.com/books?id=R0W1ErpsQpkC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908145128/https://books.google.com/books?id=R0W1ErpsQpkC'" tppabs="https://web.archive.org/web/20170908145128/https://books.google.com/books?id=R0W1ErpsQpkC" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-GrosseCampeau2013-6"> <span id="mw-reference-text-cite_note-GrosseCampeau2013-6" class="mw-reference-text"><cite id="CITEREFGrosseCampeauCaronMorin2013" class="citation journal cs1">Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O (August 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647" class="external text external">"Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme"</a>. <i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i>. <b>113</b> (2): 92–102. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fbcpt.12071  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fbcpt.12071'" tppabs="https://doi.org/10.1111%2Fbcpt.12071" class="external text external">10.1111/bcpt.12071</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815647" class="external text external">3815647</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23527766  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23527766'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23527766" class="external text external">23527766</a>.</cite></span></li><li id="cite_note-pmid8997470-7"> <span id="mw-reference-text-cite_note-pmid8997470-7" class="mw-reference-text"><cite id="CITEREFDoleHoldsworth1997" class="citation journal cs1">Dole EJ, Holdsworth MT (1997). "Nilutamide: an antiandrogen for the treatment of prostate cancer". <i>The Annals of Pharmacotherapy</i>. <b>31</b> (1): 65–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809703100112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809703100112'" tppabs="https://doi.org/10.1177%2F106002809703100112" class="external text external">10.1177/106002809703100112</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8997470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8997470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8997470" class="external text external">8997470</a>. <q>page 67: Currently, information is not available regarding the activity of the major urinary metabolites of bicalutamide, bicalutamide glucuronide, and hydroxybicalutamide glucuronide.</q></cite></span></li><li id="cite_note-Schellhammer2005-8"> <span id="mw-reference-text-cite_note-Schellhammer2005-8" class="mw-reference-text"><cite id="CITEREFSchellhammer2002" class="citation journal cs1">Schellhammer PF (September 2002). "An evaluation of bicalutamide in the treatment of prostate cancer". <i>Expert Opinion on Pharmacotherapy</i>. <b>3</b> (9): 1313–28. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14656566.3.9.1313  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14656566.3.9.1313'" tppabs="https://doi.org/10.1517%2F14656566.3.9.1313" class="external text external">10.1517/14656566.3.9.1313</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12186624  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12186624'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12186624" class="external text external">12186624</a>. <q>The clearance of bicalutamide occurs pre- dominantly by hepatic metabolism and glucuronidation, with excretion of the resulting inactive metabolites in the urine and faces.</q></cite></span></li><li id="cite_note-Skidmore-Roth2013-9"> <span id="mw-reference-text-cite_note-Skidmore-Roth2013-9" class="mw-reference-text"><cite id="CITEREFSkidmore-Roth2013" class="citation book cs1">Skidmore-Roth L (17 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=ISYiAQAAQBAJ&pg=PA194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ISYiAQAAQBAJ&pg=PA194'" tppabs="https://books.google.com/books?id=ISYiAQAAQBAJ&pg=PA194" class="external text external"><i>Mosby's 2014 Nursing Drug Reference – Elsevieron VitalSource</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>193–194. ISBN<span>&nbsp;</span><bdi>978-0-323-22267-9</bdi>.</cite></span></li><li id="cite_note-JordanFurr2010-10"> <span id="mw-reference-text-cite_note-JordanFurr2010-10" class="mw-reference-text"><cite id="CITEREFJordanFurr2010" class="citation book cs1">Jordan VC, Furr BJ (5 February 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350'" tppabs="https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350" class="external text external"><i>Hormone Therapy in Breast and Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>350–. ISBN<span>&nbsp;</span><bdi>978-1-59259-152-7</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160529061703/https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160529061703/https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350'" tppabs="https://web.archive.org/web/20160529061703/https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA350" class="external text external">Archived</a> from the original on 29 May 2016.</cite></span></li><li id="cite_note-AHFS2016-11"> <span id="mw-reference-text-cite_note-AHFS2016-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/bicalutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/bicalutamide.html'" tppabs="https://www.drugs.com/monograph/bicalutamide.html" class="external text external">"Bicalutamide"</a>. The American Society of Health-System Pharmacists. <a href="javascript:if(confirm('https://web.archive.org/web/20161229173027/https://www.drugs.com/monograph/bicalutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161229173027/https://www.drugs.com/monograph/bicalutamide.html'" tppabs="https://web.archive.org/web/20161229173027/https://www.drugs.com/monograph/bicalutamide.html" class="external text external">Archived</a> from the original on 29 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">8 December</span> 2016</span>.</cite></span></li><li id="cite_note-WassStewart2011-12"> <span id="mw-reference-text-cite_note-WassStewart2011-12" class="mw-reference-text"><cite id="CITEREFWassStewart2011" class="citation book cs1">Wass JA, Stewart PM (28 July 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625'" tppabs="https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625" class="external text external"><i>Oxford Textbook of Endocrinology and Diabetes</i></a>. OUP Oxford. pp.<span>&nbsp;</span>1625–. ISBN<span>&nbsp;</span><bdi>978-0-19-923529-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160511132922/https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160511132922/https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625'" tppabs="https://web.archive.org/web/20160511132922/https://books.google.com/books?id=9R-RAAAAQBAJ&pg=PA1625" class="external text external">Archived</a> from the original on 11 May 2016.</cite></span></li><li id="cite_note-ShergillArya2010-13"> <span id="mw-reference-text-cite_note-ShergillArya2010-13" class="mw-reference-text"><cite id="CITEREFShergillAryaGrangeMundy2010" class="citation book cs1">Shergill I, Arya M, Grange PR, Mundy AR (2010). <a href="javascript:if(confirm('https://books.google.com/books?id=QmCBTQpHWaUC&pg=PA40  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QmCBTQpHWaUC&pg=PA40'" tppabs="https://books.google.com/books?id=QmCBTQpHWaUC&pg=PA40" class="external text external"><i>Medical Therapy in Urology</i></a>. Springer Science &amp; Business Media. p.<span>&nbsp;</span>40. ISBN<span>&nbsp;</span><bdi>9781848827042</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20141028071604/http://books.google.com/books?id=QmCBTQpHWaUC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20141028071604/http://books.google.com/books?id=QmCBTQpHWaUC'" tppabs="https://web.archive.org/web/20141028071604/http://books.google.com/books?id=QmCBTQpHWaUC" class="external text external">Archived</a> from the original on 28 October 2014.</cite></span></li><li id="cite_note-WilliamsBigby2009-14"> <span id="mw-reference-text-cite_note-WilliamsBigby2009-14" class="mw-reference-text"><cite id="CITEREFWilliamsBigbyDiepgenHerxheimer2009" class="citation book cs1">Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B (22 January 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529'" tppabs="https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529" class="external text external"><i>Evidence-Based Dermatology</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>529–. ISBN<span>&nbsp;</span><bdi>978-1-4443-0017-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160502212533/https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160502212533/https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529'" tppabs="https://web.archive.org/web/20160502212533/https://books.google.com/books?id=SbsQij5xkfYC&pg=PA529" class="external text external">Archived</a> from the original on 2 May 2016.</cite></span></li><li id="cite_note-pmid30256230-15"> <span id="mw-reference-text-cite_note-pmid30256230-15" class="mw-reference-text"><cite id="CITEREFRandolph2018" class="citation journal cs1">Randolph JF (December 2018). "Gender-Affirming Hormone Therapy for Transgender Females". <i>Clin Obstet Gynecol</i>. <b>61</b> (4): 705–721. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FGRF.0000000000000396  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FGRF.0000000000000396'" tppabs="https://doi.org/10.1097%2FGRF.0000000000000396" class="external text external">10.1097/GRF.0000000000000396</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30256230  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30256230'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30256230" class="external text external">30256230</a>.</cite></span></li><li id="cite_note-JamesonGroot2015-16"> <span id="mw-reference-text-cite_note-JamesonGroot2015-16" class="mw-reference-text"><cite id="CITEREFJamesonDe_Groot2015" class="citation book cs1">Jameson JL, De Groot LJ (25 February 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=xmLeBgAAQBAJ&pg=PA2425  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=xmLeBgAAQBAJ&pg=PA2425'" tppabs="https://books.google.com/books?id=xmLeBgAAQBAJ&pg=PA2425" class="external text external"><i>Edndocrinology: Adult and Pediatric</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2425–2426, 2139. ISBN<span>&nbsp;</span><bdi>978-0-323-32195-2</bdi>.</cite></span></li><li id="cite_note-YuanDeSouza2008-17"> <span id="mw-reference-text-cite_note-YuanDeSouza2008-17" class="mw-reference-text"><cite id="CITEREFYuanDesouzaWestneyWang2008" class="citation journal cs1">Yuan J, Desouza R, Westney OL, Wang R (2008). <a href="javascript:if(confirm('https://doi.org/10.1111/j.1745-7262.2008.00314.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111/j.1745-7262.2008.00314.x'" tppabs="https://doi.org/10.1111/j.1745-7262.2008.00314.x" class="external text external">"Insights of priapism mechanism and rationale treatment for recurrent priapism"</a>. <i>Asian Journal of Andrology</i>. <b>10</b> (1): 88–101. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1745-7262.2008.00314.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1745-7262.2008.00314.x'" tppabs="https://doi.org/10.1111%2Fj.1745-7262.2008.00314.x" class="external text external">10.1111/j.1745-7262.2008.00314.x</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18087648  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18087648'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18087648" class="external text external">18087648</a>.</cite></span></li><li id="cite_note-pmid20626600-18"> <span id="mw-reference-text-cite_note-pmid20626600-18" class="mw-reference-text"><cite id="CITEREFElliottLatiniWalkerWassersug2010" class="citation journal cs1">Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW (2010). "Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life". <i>The Journal of Sexual Medicine</i>. <b>7</b> (9): 2996–3010. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1743-6109.2010.01902.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1743-6109.2010.01902.x'" tppabs="https://doi.org/10.1111%2Fj.1743-6109.2010.01902.x" class="external text external">10.1111/j.1743-6109.2010.01902.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20626600  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20626600'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20626600" class="external text external">20626600</a>.</cite></span></li><li id="cite_note-Shapiro2012-19"> <span id="mw-reference-text-cite_note-Shapiro2012-19" class="mw-reference-text"><cite id="CITEREFShapiro2012" class="citation book cs1">Shapiro J (12 November 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=9rLeICotHEoC&pg=PT187  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9rLeICotHEoC&pg=PT187'" tppabs="https://books.google.com/books?id=9rLeICotHEoC&pg=PT187" class="external text external"><i>Hair Disorders: Current Concepts in Pathophysiology, Diagnosis and Management, An Issue of Dermatologic Clinics</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>187–. ISBN<span>&nbsp;</span><bdi>978-1-4557-7169-1</bdi>.</cite></span></li><li id="cite_note-FDALabel-20"> <span id="mw-reference-text-cite_note-FDALabel-20" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67" class="external text external">"Casodex- bicalutamide tablet"</a>. <i>DailyMed</i>. 1 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">7 May</span> 2020</span>.</cite></span></li><li id="cite_note-Wellington2006-21"> <span id="mw-reference-text-cite_note-Wellington2006-21" class="mw-reference-text"><cite id="CITEREFWellingtonKeam2006" class="citation journal cs1">Wellington K, Keam SJ (2006). <a href="javascript:if(confirm('https://web.archive.org/web/20160828024232/http://www.antialabs.com/reference/21018026.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160828024232/http://www.antialabs.com/reference/21018026.pdf'" tppabs="https://web.archive.org/web/20160828024232/http://www.antialabs.com/reference/21018026.pdf" class="external text external">"Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer"</a> <span class="cs1-format">(PDF)</span>. <i>Drugs</i>. <b>66</b> (6): 837–50. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200666060-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200666060-00007'" tppabs="https://doi.org/10.2165%2F00003495-200666060-00007" class="external text external">10.2165/00003495-200666060-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16706554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16706554'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16706554" class="external text external">16706554</a>. Archived from <a href="javascript:if(confirm('http://www.antialabs.com/reference/21018026.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.antialabs.com/reference/21018026.pdf'" tppabs="http://www.antialabs.com/reference/21018026.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 28 August 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2016</span>.</cite></span></li><li id="cite_note-LeeOda2016-22"> <span id="mw-reference-text-cite_note-LeeOda2016-22" class="mw-reference-text"><cite id="CITEREFLeeOdaSakaguchiYamamoto2016" class="citation journal cs1">Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide – case report and review of the literature". <i>Photodermatology, Photoimmunology &amp; Photomedicine</i>. <b>32</b> (3): 161–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fphpp.12230  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fphpp.12230'" tppabs="https://doi.org/10.1111%2Fphpp.12230" class="external text external">10.1111/phpp.12230</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26663090  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26663090'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26663090" class="external text external">26663090</a>.</cite></span></li><li id="cite_note-ReactionsWeekly2016-23"> <span id="mw-reference-text-cite_note-ReactionsWeekly2016-23" class="mw-reference-text"><cite id="CITEREFLee2016" class="citation journal cs1">Lee K,  et al. (2016). "Drug-induced photosensitivity to bicalutamide – case report and review of the literature". <i>Reactions Weekly</i>. <b>1612</b> (1): 37. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40278-016-19790-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40278-016-19790-1'" tppabs="https://doi.org/10.1007%2Fs40278-016-19790-1" class="external text external">10.1007/s40278-016-19790-1</a>.</cite></span></li><li id="cite_note-SinghGauthier2000-24"> <span id="mw-reference-text-cite_note-SinghGauthier2000-24" class="mw-reference-text"><cite id="CITEREFSinghGauthierLabrie2000" class="citation journal cs1">Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". <i>Current Medicinal Chemistry</i>. <b>7</b> (2): 211–47. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F0929867003375371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F0929867003375371'" tppabs="https://doi.org/10.2174%2F0929867003375371" class="external text external">10.2174/0929867003375371</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10637363  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10637363'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10637363" class="external text external">10637363</a>.</cite></span></li><li id="cite_note-IIIBarbieri2013a-25"> <span id="mw-reference-text-cite_note-IIIBarbieri2013a-25" class="mw-reference-text"><cite id="CITEREFStrauss_IIIBarbieri2013" class="citation book cs1">Strauss III JF, Barbieri RL (28 August 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=TTCwAAAAQBAJ&pg=PA688  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=TTCwAAAAQBAJ&pg=PA688'" tppabs="https://books.google.com/books?id=TTCwAAAAQBAJ&pg=PA688" class="external text external"><i>Yen &amp; Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>688–. ISBN<span>&nbsp;</span><bdi>978-1-4557-5972-9</bdi>. <q>Bone density improves in men receiving bicalutamide, most likely secondary to the 146% increase in estradiol and the fact that estradiol is the major mediator of bone density in men.</q></cite></span></li><li id="cite_note-MarcusFeldman2007-26"> <span id="mw-reference-text-cite_note-MarcusFeldman2007-26" class="mw-reference-text"><cite id="CITEREFMarcusFeldmanNelsonRosen2007" class="citation book cs1">Marcus R, Feldman D, Nelson D, Rosen CJ (8 November 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354'" tppabs="https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354" class="external text external"><i>Osteoporosis</i></a>. Academic Press. pp.<span>&nbsp;</span>1354–. ISBN<span>&nbsp;</span><bdi>978-0-08-055347-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160611031603/https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160611031603/https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354'" tppabs="https://web.archive.org/web/20160611031603/https://books.google.com/books?id=blFlkDHffW8C&pg=PA1354" class="external text external">Archived</a> from the original on 11 June 2016.</cite></span></li><li id="cite_note-MahlerVerhelst1998-27"> <span id="mw-reference-text-cite_note-MahlerVerhelst1998-27" class="mw-reference-text"><cite id="CITEREFMahlerVerhelstDenis1998" class="citation journal cs1">Mahler C, Verhelst J, Denis L (May 1998). "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer". <i>Clinical Pharmacokinetics</i>. <b>34</b> (5): 405–17. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-199834050-00005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-199834050-00005'" tppabs="https://doi.org/10.2165%2F00003088-199834050-00005" class="external text external">10.2165/00003088-199834050-00005</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9592622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9592622'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9592622" class="external text external">9592622</a>.</cite></span></li><li id="cite_note-FischerGanellin2006-28"> <span id="mw-reference-text-cite_note-FischerGanellin2006-28" class="mw-reference-text"><cite id="CITEREFFischerGanellin2006" class="citation book cs1">Fischer J, Ganellin CR (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA515'" tppabs="https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA515" class="external text external"><i>Analogue-based Drug Discovery</i></a>. John Wiley &amp; Sons. p.<span>&nbsp;</span>515. ISBN<span>&nbsp;</span><bdi>9783527607495</bdi>.</cite></span></li><li id="cite_note-WHO21st-29"> <span id="mw-reference-text-cite_note-WHO21st-29" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-Ric2015-30"> <span id="mw-reference-text-cite_note-Ric2015-30" class="mw-reference-text"><cite id="CITEREFHamilton2015" class="citation book cs1">Hamilton, Richart (2015). <i>Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition</i>. Jones &amp; Bartlett Learning. p.<span>&nbsp;</span>381. ISBN<span>&nbsp;</span><bdi>9781284057560</bdi>.</cite></span></li><li id="cite_note-Drugs.com-2-31"> <span id="mw-reference-text-cite_note-Drugs.com-2-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/bicalutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/bicalutamide.html'" tppabs="https://www.drugs.com/international/bicalutamide.html" class="external text external">"Bicalutamide – International Drug Names"</a>. Drugs.com. <a href="javascript:if(confirm('https://web.archive.org/web/20160918143637/https://www.drugs.com/international/bicalutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160918143637/https://www.drugs.com/international/bicalutamide.html'" tppabs="https://web.archive.org/web/20160918143637/https://www.drugs.com/international/bicalutamide.html" class="external text external">Archived</a> from the original on 18 September 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2016</span>.</cite></span></li><li id="cite_note-Ak1999-32"> <span id="mw-reference-text-cite_note-Ak1999-32" class="mw-reference-text"><cite id="CITEREFAkaza1999" class="citation journal cs1">Akaza H (1999). "[A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer—basic clinical aspects]". <i>Gan to Kagaku Ryoho. Cancer &amp; Chemotherapy</i> (in Japanese). <b>26</b> (8): 1201–7. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10431591  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10431591'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10431591" class="external text external">10431591</a>.</cite></span></li><li id="cite_note-AstraZeneca1999-33"> <span id="mw-reference-text-cite_note-AstraZeneca1999-33" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://ddd.uab.cat/pub/infanu/40172/iaASTZENa1999ieng.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ddd.uab.cat/pub/infanu/40172/iaASTZENa1999ieng.pdf'" tppabs="https://ddd.uab.cat/pub/infanu/40172/iaASTZENa1999ieng.pdf" class="external text external">"1999 Annual Report and Form 20-F"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca<span class="reference-accessdate">. Retrieved <span class="nowrap">1 July</span> 2017</span>.</cite></span></li><li id="cite_note-MukherjiPezaro2012-34"> <span id="mw-reference-text-cite_note-MukherjiPezaro2012-34" class="mw-reference-text"><cite id="CITEREFMukherjiPezaroDe-Bono2012" class="citation journal cs1">Mukherji D, Pezaro CJ, De-Bono JS (February 2012). "MDV3100 for the treatment of prostate cancer". <i>Expert Opinion on Investigational Drugs</i>. <b>21</b> (2): 227–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F13543784.2012.651125  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F13543784.2012.651125'" tppabs="https://doi.org/10.1517%2F13543784.2012.651125" class="external text external">10.1517/13543784.2012.651125</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22229405  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22229405'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22229405" class="external text external">22229405</a>.</cite></span></li><li id="cite_note-PchejetskiAlshaker2014-35"> <span id="mw-reference-text-cite_note-PchejetskiAlshaker2014-35" class="mw-reference-text"><cite id="CITEREFPchejetskiAlshakerStebbing2014" class="citation journal cs1">Pchejetski D, Alshaker H, Stebbing J (2014). <a href="javascript:if(confirm('https://ueaeprints.uea.ac.uk/61989/1/Accepted_manuscript.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ueaeprints.uea.ac.uk/61989/1/Accepted_manuscript.pdf'" tppabs="https://ueaeprints.uea.ac.uk/61989/1/Accepted_manuscript.pdf" class="external text external">"Castrate-resistant prostate cancer: the future of antiandrogens"</a> <span class="cs1-format">(PDF)</span>. <i>Trends in Urology &amp; Men's Health</i>. <b>5</b> (1): 7–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Ftre.371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Ftre.371'" tppabs="https://doi.org/10.1002%2Ftre.371" class="external text external">10.1002/tre.371</a>.</cite></span></li><li id="cite_note-Campbell2014-36"> <span id="mw-reference-text-cite_note-Campbell2014-36" class="mw-reference-text"><cite id="CITEREFCampbell2014" class="citation web cs1">Campbell T (22 January 2014). <a href="javascript:if(confirm('http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx'" tppabs="http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx" class="external text external">"Slowing Sales for Johnson &amp; Johnson's Zytiga May Be Good News for Medivation"</a>. The Motley Fool. <a href="javascript:if(confirm('https://web.archive.org/web/20160826161537/http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160826161537/http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx'" tppabs="https://web.archive.org/web/20160826161537/http://www.fool.com/investing/general/2014/01/22/slowing-sales-for-johnson-johnsons-zytiga-may-be-g.aspx" class="external text external">Archived</a> from the original on 26 August 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">20 July</span> 2016</span>. <q>[...] the most commonly prescribed treatment for metastatic castration resistant prostate cancer: bicalutamide. That was sold as AstraZeneca's billion-dollar-a-year drug Casodex before losing patent protection in 2008. AstraZeneca still generates a few hundred million dollars in sales from Casodex, [...]</q></cite></span></li><li id="cite_note-HHS2010-37"> <span id="mw-reference-text-cite_note-HHS2010-37" class="mw-reference-text"><cite id="CITEREFChang2010" class="citation cs2">Chang S (10 March 2010), <a href="javascript:if(confirm('https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf'" tppabs="https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf" class="external text external"><i>Bicalutamide BPCA Drug Use Review in the Pediatric Population</i></a> <span class="cs1-format">(PDF)</span>, U.S. Department of Health and Human Service, <a href="javascript:if(confirm('https://web.archive.org/web/20161024181831/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161024181831/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf'" tppabs="https://web.archive.org/web/20161024181831/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214400.pdf" class="external text external">archived</a> <span class="cs1-format">(PDF)</span> from the original on 24 October 2016<span class="reference-accessdate">, retrieved <span class="nowrap">20 July</span> 2016</span></cite></span></li><li id="cite_note-BagatellBremner2003-38"> <span id="mw-reference-text-cite_note-BagatellBremner2003-38" class="mw-reference-text"><cite id="CITEREFBagatelleBremner2003" class="citation book cs1">Bagatelle C, Bremner WJ (27 May 2003). <a href="javascript:if(confirm('https://books.google.com/books?id=vDcBCAAAQBAJ&pg=PA25  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vDcBCAAAQBAJ&pg=PA25'" tppabs="https://books.google.com/books?id=vDcBCAAAQBAJ&pg=PA25" class="external text external"><i>Androgens in Health and Disease</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>25–. ISBN<span>&nbsp;</span><bdi>978-1-59259-388-0</bdi>.</cite></span></li><li id="cite_note-pmid15882477-39"> <span id="mw-reference-text-cite_note-pmid15882477-39" class="mw-reference-text"><cite id="CITEREFKlotzSchellhammer2005" class="citation journal cs1">Klotz L, Schellhammer P (March 2005). "Combined androgen blockade: the case for bicalutamide". <i>Clinical Prostate Cancer</i>. <b>3</b> (4): 215–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3816%2Fcgc.2005.n.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3816%2Fcgc.2005.n.002'" tppabs="https://doi.org/10.3816%2Fcgc.2005.n.002" class="external text external">10.3816/cgc.2005.n.002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15882477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15882477'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15882477" class="external text external">15882477</a>.</cite></span></li><li id="cite_note-pmid9301693-40"> <span id="mw-reference-text-cite_note-pmid9301693-40" class="mw-reference-text"><cite id="CITEREFSchellhammerSharifiBlockSoloway1997" class="citation journal cs1">Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ (September 1997). "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group". <i>Urology</i>. <b>50</b> (3): 330–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2897%2900279-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2897%2900279-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2897%2900279-3" class="external text external">10.1016/S0090-4295(97)00279-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9301693  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9301693'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9301693" class="external text external">9301693</a>.</cite></span></li><li id="cite_note-Melmed2016-41"> <span id="mw-reference-text-cite_note-Melmed2016-41" class="mw-reference-text"><cite id="CITEREFShlomo_Melmed2016" class="citation book cs1">Shlomo Melmed (1 January 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA752  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA752'" tppabs="https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA752" class="external text external"><i>Williams Textbook of Endocrinology</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>752–. ISBN<span>&nbsp;</span><bdi>978-0-323-29738-7</bdi>. <q>GnRH analogues, both agonists and antagonists, severely suppress endogenous gonadotropin and testosterone production [...] Administration of GnRH agonists (e.g., leuprolide, goserelin) produces an initial stimulation of gonadotropin and testosterone secretion (known as a "flare"), which is followed in 1 to 2 weeks by GnRH receptor downregulation and marked suppression of gonadotropins and testosterone to castration levels. [...] To prevent the potential complications associated with the testosterone flare, AR antagonists (e.g., bicalutamide) are usually coadministered with a GnRH agonist for men with metastatic prostate cancer.399</q></cite></span></li><li id="cite_note-SugionoWinkler2005-42"> <span id="mw-reference-text-cite_note-SugionoWinkler2005-42" class="mw-reference-text"><cite id="CITEREFSugionoWinklerOkekeBenney2005" class="citation journal cs1">Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA (2005). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.pcan.4500784  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.pcan.4500784'" tppabs="https://doi.org/10.1038/sj.pcan.4500784" class="external text external">"Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study"</a>. <i>Prostate Cancer and Prostatic Diseases</i>. <b>8</b> (1): 91–4. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.pcan.4500784  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.pcan.4500784'" tppabs="https://doi.org/10.1038%2Fsj.pcan.4500784" class="external text external">10.1038/sj.pcan.4500784</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15711607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15711607'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15711607" class="external text external">15711607</a>.</cite></span></li><li id="cite_note-pmid24455796-43"> <span id="mw-reference-text-cite_note-pmid24455796-43" class="mw-reference-text"><cite id="CITEREFErem2013" class="citation journal cs1">Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". <i>Acta Clinica Belgica</i>. <b>68</b> (4): 268–74. doi:<a href="javascript:if(confirm('https://doi.org/10.2143%2FACB.3267  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2143%2FACB.3267'" tppabs="https://doi.org/10.2143%2FACB.3267" class="external text external">10.2143/ACB.3267</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24455796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24455796'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24455796" class="external text external">24455796</a>.</cite></span></li><li id="cite_note-AscensoMarques2009-44"> <span id="mw-reference-text-cite_note-AscensoMarques2009-44" class="mw-reference-text"><cite id="CITEREFAscensoMarques2009" class="citation journal cs1">Ascenso A, Marques HC (January 2009). "Acne in the adult". <i>Mini Reviews in Medicinal Chemistry</i>. <b>9</b> (1): 1–10. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F138955709787001730  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F138955709787001730'" tppabs="https://doi.org/10.2174%2F138955709787001730" class="external text external">10.2174/138955709787001730</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19149656  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19149656'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19149656" class="external text external">19149656</a>.</cite></span></li><li id="cite_note-pmid27512185-45"> <span id="mw-reference-text-cite_note-pmid27512185-45" class="mw-reference-text"><cite id="CITEREFKaurVermaSangwanDayal2016" class="citation journal cs1">Kaur S, Verma P, Sangwan A, Dayal S, Jain VK (2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398" class="external text external">"Etiopathogenesis and Therapeutic Approach to Adult Onset Acne"</a>. <i>Indian Journal of Dermatology</i>. <b>61</b> (4): 403–7. doi:<a href="javascript:if(confirm('https://doi.org/10.4103%2F0019-5154.185703  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4103%2F0019-5154.185703'" tppabs="https://doi.org/10.4103%2F0019-5154.185703" class="external text external">10.4103/0019-5154.185703</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966398" class="external text external">4966398</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27512185  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27512185'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27512185" class="external text external">27512185</a>.</cite></span></li><li id="cite_note-LottiMaggi2015-46"> <span id="mw-reference-text-cite_note-LottiMaggi2015-46" class="mw-reference-text"><cite id="CITEREFLottiMaggi2015" class="citation journal cs1">Lotti F, Maggi M (2015). "Hormonal Treatment for Skin Androgen-Related Disorders". <i>European Handbook of Dermatological Treatments</i>: 1451–1464. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-662-45139-7_142  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-662-45139-7_142'" tppabs="https://doi.org/10.1007%2F978-3-662-45139-7_142" class="external text external">10.1007/978-3-662-45139-7_142</a>. ISBN<span>&nbsp;</span><bdi>978-3-662-45138-0</bdi>.</cite></span></li><li id="cite_note-MüderrisÖner2009-47"> <span id="mw-reference-text-cite_note-MüderrisÖner2009-47" class="mw-reference-text"><cite id="CITEREFMüderrisÖner2009" class="citation journal cs1">Müderris, II; Öner, G (2009). <a href="javascript:if(confirm('http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html'" tppabs="http://www.turkiyeklinikleri.com/article/en-hirsutizm-tedavisinde-flutamid-ve-bikalutamid-kullanimi-55753.html" class="external text external">"Hirsutizm Tedavisinde Flutamid ve Bikalutamid Kullanımı"</a> <span>[</span>Flutamide and Bicalutamide Treatment in Hirsutism<span>]</span>. <i>Turkiye Klinikleri Journal of Endocrinology-Special Topics</i> (in Turkish). <b>2</b> (2): 110–2. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1304-0529  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1304-0529'" tppabs="https://www.worldcat.org/issn/1304-0529" class="external text external">1304-0529</a>.</cite></span></li><li id="cite_note-pmid29211888-48"> <span id="mw-reference-text-cite_note-pmid29211888-48" class="mw-reference-text"><cite id="CITEREFMorettiGuccioneDi_GiacintoSimonelli2018" class="citation journal cs1">Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A (March 2018). <a href="javascript:if(confirm('https://doi.org/10.1210/jc.2017-01186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210/jc.2017-01186'" tppabs="https://doi.org/10.1210/jc.2017-01186" class="external text external">"Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial"</a>. <i>J. Clin. Endocrinol. Metab</i>. <b>103</b> (3): 824–838. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2017-01186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2017-01186'" tppabs="https://doi.org/10.1210%2Fjc.2017-01186" class="external text external">10.1210/jc.2017-01186</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29211888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29211888'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29211888" class="external text external">29211888</a>.</cite></span></li><li id="cite_note-FishmanPaliou2019-49"> <span id="mw-reference-text-cite_note-FishmanPaliou2019-49" class="mw-reference-text"><cite id="CITEREFFishmanPaliouPoretskyHembree2019" class="citation book cs1">Fishman, Sarah L.; Paliou, Maria; Poretsky, Leonid; Hembree, Wylie C. (2019). "Endocrine Care of Transgender Adults". <i>Transgender Medicine</i>. Contemporary Endocrinology. pp.<span>&nbsp;</span>143–163. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-030-05683-4_8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-030-05683-4_8'" tppabs="https://doi.org/10.1007%2F978-3-030-05683-4_8" class="external text external">10.1007/978-3-030-05683-4_8</a>. ISBN<span>&nbsp;</span><bdi>978-3-030-05682-7</bdi>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2523-3785  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2523-3785'" tppabs="https://www.worldcat.org/issn/2523-3785" class="external text external">2523-3785</a>.</cite></span></li><li id="cite_note-pmid30612811-50"> <span id="mw-reference-text-cite_note-pmid30612811-50" class="mw-reference-text"><cite id="CITEREFNeymanFuquaEugster2019" class="citation journal cs1">Neyman A, Fuqua JS, Eugster EA (April 2019). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559" class="external text external">"Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents"</a>. <i>J Adolesc Health</i>. <b>64</b> (4): 544–546. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jadohealth.2018.10.296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jadohealth.2018.10.296'" tppabs="https://doi.org/10.1016%2Fj.jadohealth.2018.10.296" class="external text external">10.1016/j.jadohealth.2018.10.296</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431559" class="external text external">6431559</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30612811  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30612811'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30612811" class="external text external">30612811</a>.</cite></span></li><li id="cite_note-Gooren2011-51"> <span id="mw-reference-text-cite_note-Gooren2011-51" class="mw-reference-text"><cite id="CITEREFGooren2011" class="citation journal cs1">Gooren, LJ (31 March 2011). "Clinical practice. Care of transsexual persons". <i>The New England Journal of Medicine</i>. <b>364</b> (13): 1251–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2Fnejmcp1008161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2Fnejmcp1008161'" tppabs="https://doi.org/10.1056%2Fnejmcp1008161" class="external text external">10.1056/nejmcp1008161</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21449788  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21449788'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21449788" class="external text external">21449788</a>.</cite></span></li><li id="cite_note-Deutsch2016-52"> <span id="mw-reference-text-cite_note-Deutsch2016-52" class="mw-reference-text"><cite id="CITEREFDeutsch2016" class="citation cs2">Deutsch M (17 June 2016), <a href="javascript:if(confirm('http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf'" tppabs="http://transhealth.ucsf.edu/pdf/Transgender-PGACG-6-17-16.pdf" class="external text external"><i>Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People</i></a> <span class="cs1-format">(PDF)</span> (2nd ed.), University of California, San Francisco: Center of Excellence for Transgender Health, p.<span>&nbsp;</span>28</cite></span></li><li id="cite_note-Vincent2018-53"> <span id="mw-reference-text-cite_note-Vincent2018-53" class="mw-reference-text"><cite id="CITEREFBenjamin_Vincent2018" class="citation book cs1">Benjamin Vincent (21 June 2018). <a href="javascript:if(confirm('https://books.google.com/books?id=k_RMDwAAQBAJ&pg=PA158  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=k_RMDwAAQBAJ&pg=PA158'" tppabs="https://books.google.com/books?id=k_RMDwAAQBAJ&pg=PA158" class="external text external"><i>Transgender Health: A Practitioner's Guide to Binary and Non-Binary Trans Patient Care</i></a>. Jessica Kingsley Publishers. pp.<span>&nbsp;</span>158–. ISBN<span>&nbsp;</span><bdi>978-1-78450-475-5</bdi>.</cite></span></li><li id="cite_note-WierckxGooren2014-54"> <span id="mw-reference-text-cite_note-WierckxGooren2014-54" class="mw-reference-text"><cite id="CITEREFWierckxGoorenT'Sjoen2014" class="citation journal cs1">Wierckx K, Gooren L, T'Sjoen G (May 2014). "Clinical review: Breast development in trans women receiving cross-sex hormones". <i>The Journal of Sexual Medicine</i>. <b>11</b> (5): 1240–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fjsm.12487  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fjsm.12487'" tppabs="https://doi.org/10.1111%2Fjsm.12487" class="external text external">10.1111/jsm.12487</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24618412  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24618412'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24618412" class="external text external">24618412</a>.</cite></span></li><li id="cite_note-SchoelwerEugster2015-55"> <span id="mw-reference-text-cite_note-SchoelwerEugster2015-55" class="mw-reference-text"><cite id="CITEREFSchoelwerEugster2015" class="citation book cs1">Schoelwer, Melissa; Eugster, Erica A. (2015). "Treatment of Peripheral Precocious Puberty". <i>Puberty from Bench to Clinic</i>. Endocrine Development. <b>29</b>. pp.<span>&nbsp;</span>230–239. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000438895  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000438895'" tppabs="https://doi.org/10.1159%2F000438895" class="external text external">10.1159/000438895</a>. ISBN<span>&nbsp;</span><bdi>978-3-318-02788-4</bdi>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1421-7082  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1421-7082'" tppabs="https://www.worldcat.org/issn/1421-7082" class="external text external">1421-7082</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345994  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345994'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345994" class="external text external">5345994</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26680582  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26680582'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26680582" class="external text external">26680582</a>.</cite></span></li><li id="cite_note-HaddadEugster2019-56"> <span id="mw-reference-text-cite_note-HaddadEugster2019-56" class="mw-reference-text"><cite id="CITEREFHaddadEugster2019" class="citation journal cs1">Haddad, Nadine G.; Eugster, Erica A. (2019). "Peripheral precocious puberty including congenital adrenal hyperplasia: causes, consequences, management and outcomes". <i>Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism</i>. <b>33</b> (3): 101273. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.beem.2019.04.007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.beem.2019.04.007'" tppabs="https://doi.org/10.1016%2Fj.beem.2019.04.007" class="external text external">10.1016/j.beem.2019.04.007</a>. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/1805%2F19111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/1805%2F19111'" tppabs="https://hdl.handle.net/1805%2F19111" class="external text external">1805/19111</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1521-690X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1521-690X'" tppabs="https://www.worldcat.org/issn/1521-690X" class="external text external">1521-690X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31027974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31027974'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31027974" class="external text external">31027974</a>.</cite></span></li><li id="cite_note-HaddadEugster2012-57"> <span id="mw-reference-text-cite_note-HaddadEugster2012-57" class="mw-reference-text"><cite id="CITEREFHaddadEugster2012" class="citation book cs1">Haddad, Nadine G.; Eugster, Erica A. (2012). "Peripheral Precocious Puberty: Interventions to Improve Growth". <i>Handbook of Growth and Growth Monitoring in Health and Disease</i>. pp.<span>&nbsp;</span>1199–1212. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-4419-1795-9_71  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-4419-1795-9_71'" tppabs="https://doi.org/10.1007%2F978-1-4419-1795-9_71" class="external text external">10.1007/978-1-4419-1795-9_71</a>. ISBN<span>&nbsp;</span><bdi>978-1-4419-1794-2</bdi>.</cite></span></li><li id="cite_note-pmid31144045-58"> <span id="mw-reference-text-cite_note-pmid31144045-58" class="mw-reference-text"><cite id="CITEREFZacharin2019" class="citation book cs1">Zacharin, Margaret (2019). <i>Disorders of Puberty: Pharmacotherapeutic Strategies for Management</i>. Handbook of Experimental Pharmacology. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F164_2019_208  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F164_2019_208'" tppabs="https://doi.org/10.1007%2F164_2019_208" class="external text external">10.1007/164_2019_208</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0171-2004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0171-2004'" tppabs="https://www.worldcat.org/issn/0171-2004" class="external text external">0171-2004</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31144045  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31144045'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31144045" class="external text external">31144045</a>.</cite></span></li><li id="cite_note-KliegmanStanton2015-59"> <span id="mw-reference-text-cite_note-KliegmanStanton2015-59" class="mw-reference-text"><cite id="CITEREFKliegmanStantonSt._GemeSchor2015" class="citation book cs1">Kliegman RM, Stanton B, St Geme J, Schor NF (17 April 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=P9piCAAAQBAJ&pg=PA2661  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=P9piCAAAQBAJ&pg=PA2661'" tppabs="https://books.google.com/books?id=P9piCAAAQBAJ&pg=PA2661" class="external text external"><i>Nelson Textbook of Pediatrics</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2661–. ISBN<span>&nbsp;</span><bdi>978-0-323-26352-8</bdi>.</cite></span></li><li id="cite_note-ReiterMauras2010-60"> <span id="mw-reference-text-cite_note-ReiterMauras2010-60" class="mw-reference-text"><cite id="CITEREFReiterMaurasMcCormickKulshreshtha2010" class="citation journal cs1">Reiter EO, Mauras N, McCormick K, Kulshreshtha B, Amrhein J, De Luca F, O'Brien S, Armstrong J, Melezinkova H (October 2010). "Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT)". <i>Journal of Pediatric Endocrinology &amp; Metabolism</i>. <b>23</b> (10): 999–1009. doi:<a href="javascript:if(confirm('https://doi.org/10.1515%2Fjpem.2010.161  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1515%2Fjpem.2010.161'" tppabs="https://doi.org/10.1515%2Fjpem.2010.161" class="external text external">10.1515/jpem.2010.161</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21158211  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21158211'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21158211" class="external text external">21158211</a>.</cite></span></li><li id="cite_note-LeveyKutlu2011-61"> <span id="mw-reference-text-cite_note-LeveyKutlu2011-61" class="mw-reference-text"><cite id="CITEREFLeveyKutluBivalacqua2012" class="citation journal cs1">Levey HR, Kutlu O, Bivalacqua TJ (2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435" class="external text external">"Medical management of ischemic stuttering priapism: a contemporary review of the literature"</a>. <i>Asian Journal of Andrology</i>. <b>14</b> (1): 156–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Faja.2011.114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Faja.2011.114'" tppabs="https://doi.org/10.1038%2Faja.2011.114" class="external text external">10.1038/aja.2011.114</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753435" class="external text external">3753435</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22057380  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22057380'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22057380" class="external text external">22057380</a>.</cite></span></li><li id="cite_note-BroderickKadioglu2010-62"> <span id="mw-reference-text-cite_note-BroderickKadioglu2010-62" class="mw-reference-text"><cite id="CITEREFBroderickKadiogluBivalacquaGhanem2010" class="citation journal cs1">Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R (2010). "Priapism: pathogenesis, epidemiology, and management". <i>The Journal of Sexual Medicine</i>. <b>7</b> (1 Pt 2): 476–500. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1743-6109.2009.01625.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1743-6109.2009.01625.x'" tppabs="https://doi.org/10.1111%2Fj.1743-6109.2009.01625.x" class="external text external">10.1111/j.1743-6109.2009.01625.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20092449  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20092449'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20092449" class="external text external">20092449</a>.</cite></span></li><li id="cite_note-ChowPayne2008-63"> <span id="mw-reference-text-cite_note-ChowPayne2008-63" class="mw-reference-text"><cite id="CITEREFChowPayne2008" class="citation journal cs1">Chow K, Payne S (2008). "The pharmacological management of intermittent priapismic states". <i>BJU International</i>. <b>102</b> (11): 1515–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1464-410X.2008.07951.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1464-410X.2008.07951.x'" tppabs="https://doi.org/10.1111%2Fj.1464-410X.2008.07951.x" class="external text external">10.1111/j.1464-410X.2008.07951.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18793304  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18793304'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18793304" class="external text external">18793304</a>.</cite></span></li><li id="cite_note-DahmRao2002-64"> <span id="mw-reference-text-cite_note-DahmRao2002-64" class="mw-reference-text"><cite id="CITEREFDahmRaoDonatucci2002" class="citation journal cs1">Dahm P, Rao DS, Donatucci CF (2002). "Antiandrogens in the treatment of priapism". <i>Urology</i>. <b>59</b> (1): 138. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2801%2901492-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2801%2901492-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2801%2901492-3" class="external text external">10.1016/S0090-4295(01)01492-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11796309  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11796309'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11796309" class="external text external">11796309</a>.</cite></span></li><li id="cite_note-pmid21956411-65"> <span id="mw-reference-text-cite_note-pmid21956411-65" class="mw-reference-text"><cite class="citation journal cs1">Gooren LJ (2011). <a href="javascript:if(confirm('https://doi.org/10.1210/jc.2011-1540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210/jc.2011-1540'" tppabs="https://doi.org/10.1210/jc.2011-1540" class="external text external">"Clinical review: Ethical and medical considerations of androgen deprivation treatment of sex offenders"</a>. <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>. <b>96</b> (12): 3628–37. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1210%2Fjc.2011-1540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjc.2011-1540'" tppabs="https://doi.org/10.1210%2Fjc.2011-1540" class="external text external">10.1210/jc.2011-1540</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21956411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21956411'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21956411" class="external text external">21956411</a>.</cite></span></li><li id="cite_note-pmid19297634-66"> <span id="mw-reference-text-cite_note-pmid19297634-66" class="mw-reference-text"><cite id="CITEREFGiltayGooren2009" class="citation journal cs1">Giltay EJ, Gooren LJ (2009). "Potential side effects of androgen deprivation treatment in sex offenders". <i>The Journal of the American Academy of Psychiatry and the Law</i>. <b>37</b> (1): 53–8. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19297634  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19297634'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19297634" class="external text external">19297634</a>.</cite></span></li><li id="cite_note-pmid27032060-67"> <span id="mw-reference-text-cite_note-pmid27032060-67" class="mw-reference-text"><cite id="CITEREFKhanMashru2016" class="citation journal cs1">Khan O, Mashru A (2016). "The efficacy, safety and ethics of the use of testosterone-suppressing agents in the management of sex offending". <i>Current Opinion in Endocrinology, Diabetes and Obesity</i>. <b>23</b> (3): 271–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FMED.0000000000000257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FMED.0000000000000257'" tppabs="https://doi.org/10.1097%2FMED.0000000000000257" class="external text external">10.1097/MED.0000000000000257</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27032060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27032060'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27032060" class="external text external">27032060</a>.</cite></span></li><li id="cite_note-APA1999-68"> <span id="mw-reference-text-cite_note-APA1999-68" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA111'" tppabs="https://books.google.com/books?id=PbC8kWQ-n1sC&pg=PA111" class="external text external"><i>Dangerous Sex Offenders: A Task Force Report of the American Psychiatric Association</i></a>. American Psychiatric Pub. 1999. pp.<span>&nbsp;</span>111–. ISBN<span>&nbsp;</span><bdi>978-0-89042-280-9</bdi>.</cite></span></li><li id="cite_note-pmid22005210-69"> <span id="mw-reference-text-cite_note-pmid22005210-69" class="mw-reference-text"><cite id="CITEREFHoutsTallerTuckerBerlin2011" class="citation journal cs1">Houts FW, Taller I, Tucker DE, Berlin FS (2011). "Androgen deprivation treatment of sexual behavior". <i>Advances in Psychosomatic Medicine</i>. <b>31</b>: 149–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000330196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000330196'" tppabs="https://doi.org/10.1159%2F000330196" class="external text external">10.1159/000330196</a>. ISBN<span>&nbsp;</span><bdi>978-3-8055-9825-5</bdi>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22005210  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22005210'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22005210" class="external text external">22005210</a>.</cite></span></li><li id="cite_note-pmid2189544-70"> <span id="mw-reference-text-cite_note-pmid2189544-70" class="mw-reference-text"><cite id="CITEREFRousseauCoutureDupontLabrie1990" class="citation journal cs1">Rousseau L, Couture M, Dupont A, Labrie F, Couture N (1990). "Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism". <i>The Canadian Journal of Psychiatry</i>. <b>35</b> (4): 338–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F070674379003500412  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F070674379003500412'" tppabs="https://doi.org/10.1177%2F070674379003500412" class="external text external">10.1177/070674379003500412</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2189544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2189544'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2189544" class="external text external">2189544</a>.</cite></span></li><li id="cite_note-IndexNominum2000-71"> <span id="mw-reference-text-cite_note-IndexNominum2000-71" class="mw-reference-text"><cite id="CITEREFSwiss_Pharmaceutical_Society2000" class="citation book cs1">Swiss Pharmaceutical Society, ed. (January 2000). <a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. pp.<span>&nbsp;</span>123–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160424054101/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160424054101/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123'" tppabs="https://web.archive.org/web/20160424054101/https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA123" class="external text external">Archived</a> from the original on 24 April 2016.</cite></span></li><li id="cite_note-Martindale2011-72"> <span id="mw-reference-text-cite_note-Martindale2011-72" class="mw-reference-text"><cite id="CITEREFSweetman2011" class="citation book cs1">Sweetman SC (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=r_qfcQAACAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=r_qfcQAACAAJ'" tppabs="https://books.google.com/books?id=r_qfcQAACAAJ" class="external text external"><i>Martindale: The Complete Drug Reference</i></a>. Pharmaceutical Press. pp.<span>&nbsp;</span>750–751. ISBN<span>&nbsp;</span><bdi>978-0-85369-933-0</bdi>.</cite></span></li><li id="cite_note-SuzukiKamiya2008-73"> <span id="mw-reference-text-cite_note-SuzukiKamiya2008-73" class="mw-reference-text"><cite id="CITEREFSuzukiKamiyaImamotoKawamura2008" class="citation journal cs1">Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T (October 2008). "Current topics and perspectives relating to hormone therapy for prostate cancer". <i>International Journal of Clinical Oncology</i>. <b>13</b> (5): 401–10. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10147-008-0830-y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10147-008-0830-y'" tppabs="https://doi.org/10.1007%2Fs10147-008-0830-y" class="external text external">10.1007/s10147-008-0830-y</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18946750  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18946750'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18946750" class="external text external">18946750</a>.</cite></span></li><li id="cite_note-WhiteBradnam2015-74"> <span id="mw-reference-text-cite_note-WhiteBradnam2015-74" class="mw-reference-text"><cite id="CITEREFWhiteBradnam2015" class="citation book cs1">White R, Bradnam V (11 March 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=yyikBwAAQBAJ&pg=PA133  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=yyikBwAAQBAJ&pg=PA133'" tppabs="https://books.google.com/books?id=yyikBwAAQBAJ&pg=PA133" class="external text external"><i>Handbook of Drug Administration via Enteral Feeding Tubes</i></a> (3rd ed.). Pharmaceutical Press. pp.<span>&nbsp;</span>133–. ISBN<span>&nbsp;</span><bdi>978-0-85711-162-3</bdi>.</cite></span></li><li id="cite_note-MortonHall2001-75"> <span id="mw-reference-text-cite_note-MortonHall2001-75" class="mw-reference-text"><cite id="CITEREFMortonHall2001" class="citation book cs1">Morton I, Hall J (2001). <a href="javascript:if(confirm('https://books.google.com/?id=0MlN61X5ogkC&q=bicalutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/?id=0MlN61X5ogkC&q=bicalutamide'" tppabs="https://books.google.com/?id=0MlN61X5ogkC&q=bicalutamide" class="external text external"><i>The Avery Complete Guide to Medicines</i></a>. Avery. pp.<span>&nbsp;</span>105–106. ISBN<span>&nbsp;</span><bdi>978-1-58333-105-7</bdi>.</cite></span></li><li id="cite_note-ChabnerLongo2010-76"> <span id="mw-reference-text-cite_note-ChabnerLongo2010-76" class="mw-reference-text"><cite id="CITEREFChabnerLongo2010" class="citation book cs1">Chabner BA, Longo DL (8 November 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680'" tppabs="https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680" class="external text external"><i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>679–680. ISBN<span>&nbsp;</span><bdi>978-1-60547-431-1</bdi>. <q>From a structural standpoint, antiandrogens are classified as steroidal, including cyproterone [acetate] (Androcur) and megestrol [acetate], or nonsteroidal, including flutamide (Eulexin, others), bicalutamide (Casodex), and nilutamide (Nilandron). The steroidal antiandrogens are rarely used.</q></cite></span></li><li id="cite_note-Drugs.com-3-77"> <span id="mw-reference-text-cite_note-Drugs.com-3-77" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/zolacos-cp.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/zolacos-cp.html'" tppabs="https://www.drugs.com/international/zolacos-cp.html" class="external text external">"Zolacos CP"</a>. <i>Drugs.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20160920130215/https://www.drugs.com/international/zolacos-cp.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160920130215/https://www.drugs.com/international/zolacos-cp.html'" tppabs="https://web.archive.org/web/20160920130215/https://www.drugs.com/international/zolacos-cp.html" class="external text external">Archived</a> from the original on 20 September 2016.</cite></span></li><li id="cite_note-ZolacosCPLabelAu-78"> <span id="mw-reference-text-cite_note-ZolacosCPLabelAu-78" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20160917215734/https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160917215734/https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf'" tppabs="https://web.archive.org/web/20160917215734/https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf" class="external text external">"Zolacos CP"</a> <span class="cs1-format">(PDF)</span>. MIMS/myDr. April 2007. Archived from <a href="javascript:if(confirm('https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf'" tppabs="https://www.betterhealth.vic.gov.au/~/media/bhc/files/medicine%20guides%20library/07/cmi7435.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 17 September 2016.</cite></span></li><li id="cite_note-ZolacosCPLabelNZ-79"> <span id="mw-reference-text-cite_note-ZolacosCPLabelNZ-79" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf'" tppabs="http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf" class="external text external">"ZOLACOS CP"</a> <span class="cs1-format">(PDF)</span>. <i>New Zealand Data Sheet</i>. 25 July 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20160919034509/http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160919034509/http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf'" tppabs="https://web.archive.org/web/20160919034509/http://www.medsafe.govt.nz/profs/datasheet/z/ZolaCosCP.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 19 September 2016.</cite></span></li><li id="cite_note-TGALabel-80"> <span id="mw-reference-text-cite_note-TGALabel-80" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483" class="external text external">"COSUDEX® (bicalutamide) 150 mg tablets"</a>. TGA. <a href="javascript:if(confirm('https://web.archive.org/web/20160914231137/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160914231137/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483'" tppabs="https://web.archive.org/web/20160914231137/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05200-3&d=2016081316114622483&d=2016083016114622483" class="external text external">Archived</a> from the original on 14 September 2016.</cite></span></li><li id="cite_note-IswaranImai1997-81"> <span id="mw-reference-text-cite_note-IswaranImai1997-81" class="mw-reference-text"><cite id="CITEREFIswaranImaiBettonSiddall1997" class="citation journal cs1">Iswaran TJ, Imai M, Betton GR, Siddall RA (May 1997). <a href="javascript:if(confirm('https://doi.org/10.2131/jts.22.2_75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2131/jts.22.2_75'" tppabs="https://doi.org/10.2131/jts.22.2_75" class="external text external">"An overview of animal toxicology studies with bicalutamide (ICI 176,334)"</a>. <i>The Journal of Toxicological Sciences</i>. <b>22</b> (2): 75–88. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.2131%2Fjts.22.2_75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2131%2Fjts.22.2_75'" tppabs="https://doi.org/10.2131%2Fjts.22.2_75" class="external text external">10.2131/jts.22.2_75</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9198005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9198005'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9198005" class="external text external">9198005</a>.</cite></span></li><li id="cite_note-Smith2013-82"> <span id="mw-reference-text-cite_note-Smith2013-82" class="mw-reference-text"><cite id="CITEREFSmith2013" class="citation book cs1">Smith RE (4 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306'" tppabs="https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306" class="external text external"><i>Medicinal Chemistry – Fusion of Traditional and Western Medicine</i></a>. Bentham Science Publishers. pp.<span>&nbsp;</span>306–. ISBN<span>&nbsp;</span><bdi>978-1-60805-149-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306'" tppabs="https://web.archive.org/web/20160529034219/https://books.google.com/books?id=RkDcAwAAQBAJ&pg=PA306" class="external text external">Archived</a> from the original on 29 May 2016.</cite></span></li><li id="cite_note-SkeelKhleif2011-83"> <span id="mw-reference-text-cite_note-SkeelKhleif2011-83" class="mw-reference-text"><cite id="CITEREFSkeelKhleif2011" class="citation book cs1">Skeel RT, Khleif SN (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724'" tppabs="https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724" class="external text external"><i>Handbook of Cancer Chemotherapy</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>724–. ISBN<span>&nbsp;</span><bdi>9781608317820</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160529144852/https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160529144852/https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724'" tppabs="https://web.archive.org/web/20160529144852/https://books.google.com/books?id=6Nz_87OLrtcC&pg=PA724" class="external text external">Archived</a> from the original on 29 May 2016.</cite></span></li><li id="cite_note-84"> <span id="mw-reference-text-cite_note-84" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=QxsobYYgm8oC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QxsobYYgm8oC'" tppabs="https://books.google.com/books?id=QxsobYYgm8oC" class="external text external"><i>Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs</i></a>. Mosby. 2001. pp.<span>&nbsp;</span>289–290. ISBN<span>&nbsp;</span><bdi>978-0-323-00629-3</bdi>.</cite></span></li><li id="cite_note-PDR2004-85"> <span id="mw-reference-text-cite_note-PDR2004-85" class="mw-reference-text"><cite id="CITEREFPDR2004" class="citation book cs1">PDR T (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=_sf2G6ZPDKAC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_sf2G6ZPDKAC'" tppabs="https://books.google.com/books?id=_sf2G6ZPDKAC" class="external text external"><i>Physicians' Desk Reference</i></a>. Thomson PDR. ISBN<span>&nbsp;</span><bdi>978-1-56363-471-0</bdi>.</cite></span></li><li id="cite_note-Lehne2013-86"> <span id="mw-reference-text-cite_note-Lehne2013-86" class="mw-reference-text"><cite id="CITEREFLehne2013" class="citation book cs1">Lehne RA (2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297'" tppabs="https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297" class="external text external"><i>Pharmacology for Nursing Care</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>1297–. ISBN<span>&nbsp;</span><bdi>978-1-4377-3582-6</bdi>.</cite></span></li><li id="cite_note-WirthHakenberg2007-87"> <span id="mw-reference-text-cite_note-WirthHakenberg2007-87" class="mw-reference-text"><cite id="CITEREFWirthHakenbergFroehner2007" class="citation journal cs1">Wirth MP, Hakenberg OW, Froehner M (February 2007). "Antiandrogens in the treatment of prostate cancer". <i>European Urology</i>. <b>51</b> (2): 306–13, discussion 314. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.eururo.2006.08.043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.eururo.2006.08.043'" tppabs="https://doi.org/10.1016%2Fj.eururo.2006.08.043" class="external text external">10.1016/j.eururo.2006.08.043</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17007995  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17007995'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17007995" class="external text external">17007995</a>.</cite></span></li><li id="cite_note-WellingtonKeam2006-88"> <span id="mw-reference-text-cite_note-WellingtonKeam2006-88" class="mw-reference-text"><cite class="citation journal cs1">Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". <i>Drugs</i>. <b>66</b> (6): 837–50. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200666060-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200666060-00007'" tppabs="https://doi.org/10.2165%2F00003495-200666060-00007" class="external text external">10.2165/00003495-200666060-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16706554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16706554'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16706554" class="external text external">16706554</a>.</cite></span></li><li id="cite_note-Higano2003-89"> <span id="mw-reference-text-cite_note-Higano2003-89" class="mw-reference-text"><cite id="CITEREFHigano2003" class="citation journal cs1">Higano CS (February 2003). "Side effects of androgen deprivation therapy: monitoring and minimizing toxicity". <i>Urology</i>. <b>61</b> (2 Suppl 1): 32–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2802%2902397-X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2802%2902397-X'" tppabs="https://doi.org/10.1016%2FS0090-4295%2802%2902397-X" class="external text external">10.1016/S0090-4295(02)02397-X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12667885  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12667885'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12667885" class="external text external">12667885</a>.</cite></span></li><li id="cite_note-pmid23008326-90"> <span id="mw-reference-text-cite_note-pmid23008326-90" class="mw-reference-text"><cite id="CITEREFHigano2012" class="citation journal cs1">Higano CS (2012). "Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer". <i>Journal of Clinical Oncology</i>. <b>30</b> (30): 3720–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2012.41.8509  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2012.41.8509'" tppabs="https://doi.org/10.1200%2FJCO.2012.41.8509" class="external text external">10.1200/JCO.2012.41.8509</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23008326  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23008326'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23008326" class="external text external">23008326</a>.</cite></span></li><li id="cite_note-Kolvenbag1996-91"> <span id="mw-reference-text-cite_note-Kolvenbag1996-91" class="mw-reference-text"><cite id="CITEREFKolvenbagBlackledge1996" class="citation journal cs1">Kolvenbag GJ, Blackledge GR (January 1996). "Worldwide activity and safety of bicalutamide: a summary review". <i>Urology</i>. <b>47</b> (1A Suppl): 70–9, discussion 80–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4'" tppabs="https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4" class="external text external">10.1016/s0090-4295(96)80012-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560681'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560681" class="external text external">8560681</a>. <q>Bicalutamide is a new antiandrogen that offers the convenience of once-daily administration, demonstrated activity in prostate cancer, and an excellent safety profile. Because it is effective and offers better tolerability than flutamide, bicalutamide represents a valid first choice for antiandrogen therapy in combination with castration for the treatment of patients with advanced prostate cancer.</q></cite></span></li><li id="cite_note-ResnickThompson2000-92"> <span id="mw-reference-text-cite_note-ResnickThompson2000-92" class="mw-reference-text"><cite id="CITEREFResnickThompson2000" class="citation book cs1">Resnick MI, Thompson IM (2000). <a href="javascript:if(confirm('https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379'" tppabs="https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379" class="external text external"><i>Advanced Therapy of Prostate Disease</i></a>. PMPH-USA. pp.<span>&nbsp;</span>379–. ISBN<span>&nbsp;</span><bdi>978-1-55009-102-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160610095331/https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160610095331/https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379'" tppabs="https://web.archive.org/web/20160610095331/https://books.google.com/books?id=9AKuf7rzfjcC&pg=PA379" class="external text external">Archived</a> from the original on 10 June 2016.</cite></span></li><li id="cite_note-IversenMelezinek2001-93"> <span id="mw-reference-text-cite_note-IversenMelezinek2001-93" class="mw-reference-text"><cite id="CITEREFIversenMelezinekSchmidt2001" class="citation journal cs1">Iversen P, Melezinek I, Schmidt A (January 2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". <i>BJU International</i>. <b>87</b> (1): 47–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x'" tppabs="https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x" class="external text external">10.1046/j.1464-410x.2001.00988.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11121992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11121992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11121992" class="external text external">11121992</a>.</cite></span></li><li id="cite_note-pmid12603397-94"> <span id="mw-reference-text-cite_note-pmid12603397-94" class="mw-reference-text"><cite id="CITEREFAnderson2003" class="citation journal cs1">Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". <i>BJU Int</i>. <b>91</b> (5): 455–61. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x'" tppabs="https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x" class="external text external">10.1046/j.1464-410X.2003.04026.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12603397  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12603397'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12603397" class="external text external">12603397</a>.</cite></span></li><li id="cite_note-pmid28343552-95"> <span id="mw-reference-text-cite_note-pmid28343552-95" class="mw-reference-text"><cite id="CITEREFKathryn_KorkidakisReid2017" class="citation journal cs1">Kathryn Korkidakis A, Reid RL (2017). "Testosterone in Women: Measurement and Therapeutic Use". <i>Journal of Obstetrics and Gynaecology Canada</i>. <b>39</b> (3): 124–130. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jogc.2017.01.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jogc.2017.01.006'" tppabs="https://doi.org/10.1016%2Fj.jogc.2017.01.006" class="external text external">10.1016/j.jogc.2017.01.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28343552  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28343552'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28343552" class="external text external">28343552</a>.</cite></span></li><li id="cite_note-pmid26358173-96"> <span id="mw-reference-text-cite_note-pmid26358173-96" class="mw-reference-text"><cite id="CITEREFDavisWahlin-Jacobsen2015" class="citation journal cs1">Davis SR, Wahlin-Jacobsen S (2015). "Testosterone in women--the clinical significance". <i>The Lancet Diabetes &amp; Endocrinology</i>. <b>3</b> (12): 980–92. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS2213-8587%2815%2900284-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS2213-8587%2815%2900284-3'" tppabs="https://doi.org/10.1016%2FS2213-8587%2815%2900284-3" class="external text external">10.1016/S2213-8587(15)00284-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26358173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26358173'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26358173" class="external text external">26358173</a>.</cite></span></li><li id="cite_note-pmid7579554-97"> <span id="mw-reference-text-cite_note-pmid7579554-97" class="mw-reference-text"><cite id="CITEREFLunglmayr1995" class="citation journal cs1">Lunglmayr G (August 1995). "Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group". <i>Anti-Cancer Drugs</i>. <b>6</b> (4): 508–13. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00001813-199508000-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00001813-199508000-00003'" tppabs="https://doi.org/10.1097%2F00001813-199508000-00003" class="external text external">10.1097/00001813-199508000-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7579554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7579554'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7579554" class="external text external">7579554</a>.</cite></span></li><li id="cite_note-pmid10388026-98"> <span id="mw-reference-text-cite_note-pmid10388026-98" class="mw-reference-text"><cite id="CITEREFMcLeod1997" class="citation journal cs1">McLeod DG (1997). <a href="javascript:if(confirm('https://doi.org/10.1634/theoncologist.2-1-18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634/theoncologist.2-1-18'" tppabs="https://doi.org/10.1634/theoncologist.2-1-18" class="external text external">"Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer"</a>. <i>Oncologist</i>. <b>2</b> (1): 18–27. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1634%2Ftheoncologist.2-1-18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634%2Ftheoncologist.2-1-18'" tppabs="https://doi.org/10.1634%2Ftheoncologist.2-1-18" class="external text external">10.1634/theoncologist.2-1-18</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10388026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10388026'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10388026" class="external text external">10388026</a>.</cite></span></li><li id="cite_note-MDMD2008-99"> <span id="mw-reference-text-cite_note-MDMD2008-99" class="mw-reference-text"><cite id="CITEREFDeAngelisPosner2008" class="citation book cs1">DeAngelis LM, Posner JB (12 September 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479'" tppabs="https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479" class="external text external"><i>Neurologic Complications of Cancer</i></a>. Oxford University Press, USA. pp.<span>&nbsp;</span>479–. ISBN<span>&nbsp;</span><bdi>978-0-19-971055-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160507051525/https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160507051525/https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479'" tppabs="https://web.archive.org/web/20160507051525/https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479" class="external text external">Archived</a> from the original on 7 May 2016.</cite></span></li><li id="cite_note-JamnickyNam2012-100"> <span id="mw-reference-text-cite_note-JamnickyNam2012-100" class="mw-reference-text"><cite id="CITEREFJamnickyNam2012" class="citation book cs1">Jamnicky L, Nam R (5 November 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=EFJhvLJeWX4C&pg=PT177  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=EFJhvLJeWX4C&pg=PT177'" tppabs="https://books.google.com/books?id=EFJhvLJeWX4C&pg=PT177" class="external text external"><i>Canadian Guide to Prostate Cancer</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>177–. ISBN<span>&nbsp;</span><bdi>978-1-118-51565-5</bdi>.</cite></span></li><li id="cite_note-SeeWirth2002-101"> <span id="mw-reference-text-cite_note-SeeWirth2002-101" class="mw-reference-text"><cite id="CITEREFSeeWirthMcLeodIversen2002" class="citation journal cs1">See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D,  et al. (August 2002). "Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program". <i>The Journal of Urology</i>. <b>168</b> (2): 429–35. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2805%2964652-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2805%2964652-6'" tppabs="https://doi.org/10.1016%2FS0022-5347%2805%2964652-6" class="external text external">10.1016/S0022-5347(05)64652-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12131282  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12131282'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12131282" class="external text external">12131282</a>.</cite></span></li><li id="cite_note-IversenJohansson2004-102"> <span id="mw-reference-text-cite_note-IversenJohansson2004-102" class="mw-reference-text"><cite id="CITEREFIversenJohanssonLoddingLukkarinen2004" class="citation journal cs1">Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K (November 2004). "Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6". <i>The Journal of Urology</i>. <b>172</b> (5 Pt 1): 1871–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F01.ju.0000139719.99825.54  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F01.ju.0000139719.99825.54'" tppabs="https://doi.org/10.1097%2F01.ju.0000139719.99825.54" class="external text external">10.1097/01.ju.0000139719.99825.54</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15540741  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15540741'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15540741" class="external text external">15540741</a>.</cite></span></li><li id="cite_note-pmid17130095-103"> <span id="mw-reference-text-cite_note-pmid17130095-103" class="mw-reference-text"><cite id="CITEREFIversenJohanssonLoddingKylmälä2006" class="citation journal cs1">Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J (2006). "Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years". <i>Scandinavian Journal of Urology and Nephrology</i>. <b>40</b> (6): 441–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F00365590601017329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F00365590601017329'" tppabs="https://doi.org/10.1080%2F00365590601017329" class="external text external">10.1080/00365590601017329</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17130095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17130095'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17130095" class="external text external">17130095</a>.</cite></span></li><li id="cite_note-GretarsdottirBjornsdottir2018-104"> <span id="mw-reference-text-cite_note-GretarsdottirBjornsdottir2018-104" class="mw-reference-text"><cite id="CITEREFGretarsdottirBjornsdottirBjornsson2018" class="citation journal cs1">Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. (2018). <a href="javascript:if(confirm('https://doi.org/10.1159/000485175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159/000485175'" tppabs="https://doi.org/10.1159/000485175" class="external text external">"Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect"</a>. <i>Case Reports in Gastroenterology</i>. <b>12</b> (2): 266–70. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1159%2F000485175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000485175'" tppabs="https://doi.org/10.1159%2F000485175" class="external text external">10.1159/000485175</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1662-0631  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1662-0631'" tppabs="https://www.worldcat.org/issn/1662-0631" class="external text external">1662-0631</a>.</cite></span></li><li id="cite_note-pmid24967002-105"> <span id="mw-reference-text-cite_note-pmid24967002-105" class="mw-reference-text"><cite id="CITEREFHussainHaidarBloomZayouna2014" class="citation journal cs1">Hussain S, Haidar A, Bloom RE, Zayouna N, Piper MH, Jafri SM (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">"Bicalutamide-induced hepatotoxicity: A rare adverse effect"</a>. <i>Am J Case Rep</i>. <b>15</b>: 266–70. doi:<a href="javascript:if(confirm('https://doi.org/10.12659%2FAJCR.890679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.12659%2FAJCR.890679'" tppabs="https://doi.org/10.12659%2FAJCR.890679" class="external text external">10.12659/AJCR.890679</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">4068966</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24967002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24967002'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24967002" class="external text external">24967002</a>.</cite></span></li><li id="cite_note-pmid27099451-106"> <span id="mw-reference-text-cite_note-pmid27099451-106" class="mw-reference-text"><cite id="CITEREFYunKimKimJoo2016" class="citation journal cs1">Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, Kang SH, Moon HS, Sung JK, Lee HY, Kim KH (April 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258" class="external text external">"Atypical onset of bicalutamide-induced liver injury"</a>. <i>World J. Gastroenterol</i>. <b>22</b> (15): 4062–5. doi:<a href="javascript:if(confirm('https://doi.org/10.3748%2Fwjg.v22.i15.4062  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3748%2Fwjg.v22.i15.4062'" tppabs="https://doi.org/10.3748%2Fwjg.v22.i15.4062" class="external text external">10.3748/wjg.v22.i15.4062</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823258" class="external text external">4823258</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27099451  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27099451'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27099451" class="external text external">27099451</a>.</cite></span></li><li id="cite_note-Dart2004b-107"> <span id="mw-reference-text-cite_note-Dart2004b-107" class="mw-reference-text"><cite class="citation book cs1">Dart RC (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=BfdighlyGiwC&pg=PA497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BfdighlyGiwC&pg=PA497'" tppabs="https://books.google.com/books?id=BfdighlyGiwC&pg=PA497" class="external text external"><i>Medical Toxicology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>497–. ISBN<span>&nbsp;</span><bdi>978-0-7817-2845-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497'" tppabs="https://web.archive.org/web/20160511213240/https://books.google.com/books?id=BfdighlyGiwC&pg=PA497" class="external text external">Archived</a> from the original on 11 May 2016.</cite></span></li><li id="cite_note-MasagoWatanabe2011-108"> <span id="mw-reference-text-cite_note-MasagoWatanabe2011-108" class="mw-reference-text"><cite id="CITEREFMasagoWatanabeNemotoMotoda2011" class="citation journal cs1">Masago T, Watanabe T, Nemoto R, Motoda K (December 2011). "Interstitial pneumonitis induced by bicalutamide given for prostate cancer". <i>International Journal of Clinical Oncology</i>. <b>16</b> (6): 763–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10147-011-0239-x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10147-011-0239-x'" tppabs="https://doi.org/10.1007%2Fs10147-011-0239-x" class="external text external">10.1007/s10147-011-0239-x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21537882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21537882'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21537882" class="external text external">21537882</a>.</cite></span></li><li id="cite_note-Aronson2014-109"> <span id="mw-reference-text-cite_note-Aronson2014-109" class="mw-reference-text"><cite id="CITEREFAronson2014" class="citation book cs1">Aronson JK (4 March 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740'" tppabs="https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740" class="external text external"><i>Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions</i></a>. Newnes. pp.<span>&nbsp;</span>740–. ISBN<span>&nbsp;</span><bdi>978-0-444-62636-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160506202559/https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160506202559/https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740'" tppabs="https://web.archive.org/web/20160506202559/https://books.google.com/books?id=jTc3AAAAQBAJ&pg=PA740" class="external text external">Archived</a> from the original on 6 May 2016.</cite></span></li><li id="cite_note-pmid15195196-110"> <span id="mw-reference-text-cite_note-pmid15195196-110" class="mw-reference-text"><cite id="CITEREFDabaEl-TahirAl-ArifiGubara2004" class="citation journal cs1">Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA (June 2004). "Drug-induced pulmonary fibrosis". <i>Saudi Medical Journal</i>. <b>25</b> (6): 700–6. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15195196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15195196'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15195196" class="external text external">15195196</a>.</cite></span></li><li id="cite_note-TholeManso2004-111"> <span id="mw-reference-text-cite_note-TholeManso2004-111" class="mw-reference-text"><cite id="CITEREFTholeMansoSalgueiroRevuelta2004" class="citation journal cs1">Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A (2004). "Hepatotoxicity induced by antiandrogens: a review of the literature". <i>Urologia Internationalis</i>. <b>73</b> (4): 289–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000081585  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000081585'" tppabs="https://doi.org/10.1159%2F000081585" class="external text external">10.1159/000081585</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15604569  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15604569'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15604569" class="external text external">15604569</a>.</cite></span></li><li id="cite_note-RicciBuzzatti2014-112"> <span id="mw-reference-text-cite_note-RicciBuzzatti2014-112" class="mw-reference-text"><cite id="CITEREFRicciBuzzattiRubagottiBoccardo2014" class="citation journal cs1">Ricci F, Buzzatti G, Rubagotti A, Boccardo F (November 2014). "Safety of antiandrogen therapy for treating prostate cancer". <i>Expert Opinion on Drug Safety</i>. <b>13</b> (11): 1483–99. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14740338.2014.966686  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14740338.2014.966686'" tppabs="https://doi.org/10.1517%2F14740338.2014.966686" class="external text external">10.1517/14740338.2014.966686</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25270521  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25270521'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25270521" class="external text external">25270521</a>.</cite></span></li><li id="cite_note-113"> <span id="mw-reference-text-cite_note-113" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=JFpq6hYQRhQC&pg=PA44  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=JFpq6hYQRhQC&pg=PA44'" tppabs="https://books.google.com/books?id=JFpq6hYQRhQC&pg=PA44" class="external text external"><i>Sex Differences in the Human Brain, their underpinnings and implications</i></a>. Elsevier. 3 December 2010. pp.<span>&nbsp;</span>44–45. ISBN<span>&nbsp;</span><bdi>978-0-444-53631-0</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160526221656/https://books.google.com/books?id=JFpq6hYQRhQC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160526221656/https://books.google.com/books?id=JFpq6hYQRhQC'" tppabs="https://web.archive.org/web/20160526221656/https://books.google.com/books?id=JFpq6hYQRhQC" class="external text external">Archived</a> from the original on 26 May 2016.</cite></span></li><li id="cite_note-Paoletti2012-114"> <span id="mw-reference-text-cite_note-Paoletti2012-114" class="mw-reference-text"><cite id="CITEREFPaoletti2012" class="citation book cs1">Paoletti R (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=8YbgBwAAQBAJ&pg=PA218  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=8YbgBwAAQBAJ&pg=PA218'" tppabs="https://books.google.com/books?id=8YbgBwAAQBAJ&pg=PA218" class="external text external"><i>Chemistry and Brain Development: Proceedings of the Advanced Study Institute on "Chemistry of Brain Development," held in Milan, Italy, September 9–19, 1970</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>218–. ISBN<span>&nbsp;</span><bdi>978-1-4684-7236-3</bdi>.</cite></span></li><li id="cite_note-RamonDenis2007-115"> <span id="mw-reference-text-cite_note-RamonDenis2007-115" class="mw-reference-text"><cite id="CITEREFJ._RamonL.J._Denis2007" class="citation book cs1">J. Ramon; L.J. Denis (5 June 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256'" tppabs="https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA256" class="external text external"><i>Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>256–. ISBN<span>&nbsp;</span><bdi>978-3-540-40901-4</bdi>.</cite></span></li><li id="cite_note-Moser2008-116"> <span id="mw-reference-text-cite_note-Moser2008-116" class="mw-reference-text"><cite id="CITEREFLutz_Moser2008" class="citation book cs1">Lutz Moser (1 January 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41'" tppabs="https://books.google.com/books?id=4J4OCRyHWRYC&pg=PA41" class="external text external"><i>Controversies in the Treatment of Prostate Cancer</i></a>. Karger Medical and Scientific Publishers. pp.<span>&nbsp;</span>41–. ISBN<span>&nbsp;</span><bdi>978-3-8055-8524-8</bdi>.</cite></span></li><li id="cite_note-Demos2011-117"> <span id="mw-reference-text-cite_note-Demos2011-117" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=WJkjgbRJe3EC&pg=PA504  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WJkjgbRJe3EC&pg=PA504'" tppabs="https://books.google.com/books?id=WJkjgbRJe3EC&pg=PA504" class="external text external"><i>Prostate Cancer</i></a>. Demos Medical Publishing. 20 December 2011. pp.<span>&nbsp;</span>504–505. ISBN<span>&nbsp;</span><bdi>978-1-935281-91-7</bdi>.</cite></span></li><li id="cite_note-Aronson2009-118"> <span id="mw-reference-text-cite_note-Aronson2009-118" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2009" class="citation book cs1">Jeffrey K. Aronson (21 February 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA149  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA149'" tppabs="https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA149" class="external text external"><i>Meyler's Side Effects of Endocrine and Metabolic Drugs</i></a>. Elsevier. pp.<span>&nbsp;</span>149–150, 253–258. ISBN<span>&nbsp;</span><bdi>978-0-08-093292-7</bdi>.</cite></span></li><li id="cite_note-Barrett2007-119"> <span id="mw-reference-text-cite_note-Barrett2007-119" class="mw-reference-text"><cite id="CITEREFJames_Barrett2007" class="citation book cs1">James Barrett (2007). <a href="javascript:if(confirm('https://books.google.com/books?id=I-8qZlGIpnQC&pg=PA174  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=I-8qZlGIpnQC&pg=PA174'" tppabs="https://books.google.com/books?id=I-8qZlGIpnQC&pg=PA174" class="external text external"><i>Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management</i></a>. Radcliffe Publishing. pp.<span>&nbsp;</span>174–. ISBN<span>&nbsp;</span><bdi>978-1-85775-719-4</bdi>.</cite></span></li><li id="cite_note-pmid12190640-120"> <span id="mw-reference-text-cite_note-pmid12190640-120" class="mw-reference-text"><cite id="CITEREFRushton2002" class="citation journal cs1">Rushton DH (2002). "Nutritional factors and hair loss". <i>Clin. Exp. Dermatol</i>. <b>27</b> (5): 396–404. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2230.2002.01076.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2230.2002.01076.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2230.2002.01076.x" class="external text external">10.1046/j.1365-2230.2002.01076.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12190640  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12190640'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12190640" class="external text external">12190640</a>.</cite></span></li><li id="cite_note-pmid10936469-121"> <span id="mw-reference-text-cite_note-pmid10936469-121" class="mw-reference-text"><cite id="CITEREFBoccardo2000" class="citation journal cs1">Boccardo F (2000). "Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?". <i>Crit. Rev. Oncol. Hematol</i>. <b>35</b> (2): 121–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs1040-8428%2800%2900051-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs1040-8428%2800%2900051-2'" tppabs="https://doi.org/10.1016%2Fs1040-8428%2800%2900051-2" class="external text external">10.1016/s1040-8428(00)00051-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10936469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10936469'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10936469" class="external text external">10936469</a>.</cite></span></li><li id="cite_note-pmid15604569-122"> <span id="mw-reference-text-cite_note-pmid15604569-122" class="mw-reference-text"><cite class="citation journal cs1">Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A (2004). "Hepatotoxicity induced by antiandrogens: a review of the literature". <i>Urol. Int</i>. <b>73</b> (4): 289–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000081585  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000081585'" tppabs="https://doi.org/10.1159%2F000081585" class="external text external">10.1159/000081585</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15604569  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15604569'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15604569" class="external text external">15604569</a>.</cite></span></li><li id="cite_note-pmid18657023-123"> <span id="mw-reference-text-cite_note-pmid18657023-123" class="mw-reference-text"><cite id="CITEREFO'BryantFlaigUtz2008" class="citation journal cs1">O'Bryant CL, Flaig TW, Utz KJ (2008). "Bicalutamide-associated fulminant hepatotoxicity". <i>Pharmacotherapy</i>. <b>28</b> (8): 1071–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1592%2Fphco.28.8.1071  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1592%2Fphco.28.8.1071'" tppabs="https://doi.org/10.1592%2Fphco.28.8.1071" class="external text external">10.1592/phco.28.8.1071</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18657023  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18657023'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18657023" class="external text external">18657023</a>.</cite></span></li><li id="cite_note-CRAIGFurr2010-124"> <span id="mw-reference-text-cite_note-CRAIGFurr2010-124" class="mw-reference-text"><cite id="CITEREFJORDAN_V._CRAIGB.J.A._Furr2010" class="citation book cs1">JORDAN V. CRAIG; B.J.A. Furr (5 February 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA356  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA356'" tppabs="https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA356" class="external text external"><i>Hormone Therapy in Breast and Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>356–. ISBN<span>&nbsp;</span><bdi>978-1-59259-152-7</bdi>.</cite></span></li><li id="cite_note-pmid12353966-125"> <span id="mw-reference-text-cite_note-pmid12353966-125" class="mw-reference-text"><cite id="CITEREFBennettRaischSartor2002" class="citation journal cs1">Bennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". <i>Annals of Internal Medicine</i>. <b>137</b> (7): 625. doi:<a href="javascript:if(confirm('https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029'" tppabs="https://doi.org/10.7326%2F0003-4819-137-7-200210010-00029" class="external text external">10.7326/0003-4819-137-7-200210010-00029</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12353966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12353966'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12353966" class="external text external">12353966</a>. <q>An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.</q></cite></span></li><li id="cite_note-pmid25270521-126"> <span id="mw-reference-text-cite_note-pmid25270521-126" class="mw-reference-text"><cite class="citation journal cs1">Ricci F, Buzzatti G, Rubagotti A, Boccardo F (2014). "Safety of antiandrogen therapy for treating prostate cancer". <i>Expert Opin Drug Saf</i>. <b>13</b> (11): 1483–99. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14740338.2014.966686  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14740338.2014.966686'" tppabs="https://doi.org/10.1517%2F14740338.2014.966686" class="external text external">10.1517/14740338.2014.966686</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25270521  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25270521'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25270521" class="external text external">25270521</a>.</cite></span></li><li id="cite_note-pmid20878947-127"> <span id="mw-reference-text-cite_note-pmid20878947-127" class="mw-reference-text"><cite id="CITEREFFosterCarShiLevesque2011" class="citation journal cs1">Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM (2011). "Drug safety is a barrier to the discovery and development of new androgen receptor antagonists". <i>Prostate</i>. <b>71</b> (5): 480–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpros.21263  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpros.21263'" tppabs="https://doi.org/10.1002%2Fpros.21263" class="external text external">10.1002/pros.21263</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20878947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20878947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20878947" class="external text external">20878947</a>.</cite></span></li><li id="cite_note-pmid24881730-128"> <span id="mw-reference-text-cite_note-pmid24881730-128" class="mw-reference-text"><cite id="CITEREFBeerArmstrongRathkopfLoriot2014" class="citation journal cs1">Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931" class="external text external">"Enzalutamide in metastatic prostate cancer before chemotherapy"</a>. <i>N. Engl. J. Med</i>. <b>371</b> (5): 424–33. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa1405095  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa1405095'" tppabs="https://doi.org/10.1056%2FNEJMoa1405095" class="external text external">10.1056/NEJMoa1405095</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931" class="external text external">4418931</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24881730  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24881730'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24881730" class="external text external">24881730</a>.</cite></span></li><li id="cite_note-pmid25711765-129"> <span id="mw-reference-text-cite_note-pmid25711765-129" class="mw-reference-text"><cite id="CITEREFKeating2015" class="citation journal cs1">Keating GM (2015). "Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer". <i>Drugs Aging</i>. <b>32</b> (3): 243–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40266-015-0248-y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40266-015-0248-y'" tppabs="https://doi.org/10.1007%2Fs40266-015-0248-y" class="external text external">10.1007/s40266-015-0248-y</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25711765  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25711765'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25711765" class="external text external">25711765</a>.</cite></span></li><li id="cite_note-pmid25354111-130"> <span id="mw-reference-text-cite_note-pmid25354111-130" class="mw-reference-text"><cite id="CITEREFBeerTombal2014" class="citation journal cs1">Beer TM, Tombal B (2014). <a href="javascript:if(confirm('https://iris.unito.it/bitstream/2318/150443/1/ENZALUTAMIDE.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://iris.unito.it/bitstream/2318/150443/1/ENZALUTAMIDE.pdf'" tppabs="https://iris.unito.it/bitstream/2318/150443/1/ENZALUTAMIDE.pdf" class="external text external">"Enzalutamide in metastatic prostate cancer before chemotherapy"</a> <span class="cs1-format">(PDF)</span>. <i>N. Engl. J. Med</i>. <b>371</b> (18): 1755–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMc1410239  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMc1410239'" tppabs="https://doi.org/10.1056%2FNEJMc1410239" class="external text external">10.1056/NEJMc1410239</a>. hdl:<a href="javascript:if(confirm('https://hdl.handle.net/2318%2F150443  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/2318%2F150443'" tppabs="https://hdl.handle.net/2318%2F150443" class="external text external">2318/150443</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25354111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25354111'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25354111" class="external text external">25354111</a>.</cite></span></li><li id="cite_note-pmid8560673-131"> <span id="mw-reference-text-cite_note-pmid8560673-131" class="mw-reference-text"><cite id="CITEREFFurrTucker1996" class="citation journal cs1">Furr BJ, Tucker H (1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". <i>Urology</i>. <b>47</b> (1A Suppl): 13–25, discussion 29–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2980003-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2980003-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2980003-3" class="external text external">10.1016/S0090-4295(96)80003-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560673'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560673" class="external text external">8560673</a>.</cite></span></li><li id="cite_note-LenzShulman2010-132"> <span id="mw-reference-text-cite_note-LenzShulman2010-132" class="mw-reference-text"><cite id="CITEREFLenzShulmanEugsterRahhal2010" class="citation journal cs1">Lenz AM, Shulman D, Eugster EA, Rahhal S, Fuqua JS, Pescovitz OH, Lewis KA (September 2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839" class="external text external">"Bicalutamide and third-generation aromatase inhibitors in testotoxicosis"</a>. <i>Pediatrics</i>. <b>126</b> (3): e728-33. doi:<a href="javascript:if(confirm('https://doi.org/10.1542%2Fpeds.2010-0596  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1542%2Fpeds.2010-0596'" tppabs="https://doi.org/10.1542%2Fpeds.2010-0596" class="external text external">10.1542/peds.2010-0596</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096839" class="external text external">4096839</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20713483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20713483'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20713483" class="external text external">20713483</a>.</cite></span></li><li id="cite_note-Greenblatt1973-133"> <span id="mw-reference-text-cite_note-Greenblatt1973-133" class="mw-reference-text"><cite id="CITEREFGreenblattKoch-Weser1973" class="citation journal cs1">Greenblatt DJ, Koch-Weser J (July 1973). "Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program". <i>JAMA</i>. <b>225</b> (1): 40–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.1973.03220280028007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.1973.03220280028007'" tppabs="https://doi.org/10.1001%2Fjama.1973.03220280028007" class="external text external">10.1001/jama.1973.03220280028007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4740303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4740303'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4740303" class="external text external">4740303</a>.</cite></span></li><li id="cite_note-MunozCruz2014-134"> <span id="mw-reference-text-cite_note-MunozCruz2014-134" class="mw-reference-text"><cite id="CITEREFMunozda_CruzVetterlyCooper2014" class="citation book cs1">Munoz R, da Cruz E, Vetterly CG,  et al. (26 June 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=wwPnAwAAQBAJ&pg=PA224  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=wwPnAwAAQBAJ&pg=PA224'" tppabs="https://books.google.com/books?id=wwPnAwAAQBAJ&pg=PA224" class="external text external"><i>Handbook of Pediatric Cardiovascular Drugs</i></a>. Springer. pp.<span>&nbsp;</span>224–. ISBN<span>&nbsp;</span><bdi>978-1-4471-2464-1</bdi>.</cite></span></li><li id="cite_note-BahceciTuzcu2004-135"> <span id="mw-reference-text-cite_note-BahceciTuzcu2004-135" class="mw-reference-text"><cite id="CITEREFBahceciTuzcuCanorucTuzun2004" class="citation journal cs1">Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C (2004). "Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance". <i>Hormone Research</i>. <b>62</b> (6): 283–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000081973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000081973'" tppabs="https://doi.org/10.1159%2F000081973" class="external text external">10.1159/000081973</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15542929  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15542929'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15542929" class="external text external">15542929</a>.</cite></span></li><li id="cite_note-Springhouse2000-136"> <span id="mw-reference-text-cite_note-Springhouse2000-136" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=I6Jt1THMB_4C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=I6Jt1THMB_4C'" tppabs="https://books.google.com/books?id=I6Jt1THMB_4C" class="external text external"><i>Nurse Practitioner's Drug Handbook</i></a>. Springhouse Corp. 2000.</cite></span></li><li id="cite_note-TYRRElLIversen2006-137"> <span id="mw-reference-text-cite_note-TYRRElLIversen2006-137" class="mw-reference-text"><cite id="CITEREFTyrrellIversenTammelaAnderson2006" class="citation journal cs1">Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T (September 2006). "Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration". <i>BJU International</i>. <b>98</b> (3): 563–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1464-410X.2006.06275.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1464-410X.2006.06275.x'" tppabs="https://doi.org/10.1111%2Fj.1464-410X.2006.06275.x" class="external text external">10.1111/j.1464-410X.2006.06275.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16771791  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16771791'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16771791" class="external text external">16771791</a>.</cite></span></li><li id="cite_note-Griffith2008-138"> <span id="mw-reference-text-cite_note-Griffith2008-138" class="mw-reference-text"><cite id="CITEREFHenry_Winter_Griffith2008" class="citation book cs1">Henry Winter Griffith (2008). <a href="javascript:if(confirm('https://books.google.com/books?id=YhAAet8Er4oC&pg=PA62  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YhAAet8Er4oC&pg=PA62'" tppabs="https://books.google.com/books?id=YhAAet8Er4oC&pg=PA62" class="external text external"><i>Complete Guide to Prescription &amp; Nonprescription Drugs 2009</i></a>. HP Books. pp.<span>&nbsp;</span>62–. ISBN<span>&nbsp;</span><bdi>978-0-399-53463-8</bdi>. <q>Overdose unlikely to threaten life [with NSAAs].</q></cite></span></li><li id="cite_note-Genrx1999-139"> <span id="mw-reference-text-cite_note-Genrx1999-139" class="mw-reference-text"><cite id="CITEREFGenrx1999" class="citation book cs1">Genrx (1999). <a href="javascript:if(confirm('https://books.google.com/books?id=Td6ZFsVsCswC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Td6ZFsVsCswC'" tppabs="https://books.google.com/books?id=Td6ZFsVsCswC" class="external text external"><i>1999 Mosby's GenRx</i></a>. Mosby. ISBN<span>&nbsp;</span><bdi>978-0-323-00625-5</bdi>. <q>A 79-year-old man attempted suicide by ingesting 13g of nilutamide (i.e., 43 times the maximum recommended dose). Despite immediate gastric lavage and oral administration of activated charcoal, plasma nilutamide levels peaked at 6 times the normal range 2 hours after ingestion. There were no clinical signs or symptoms or changes in parameters such as transaminases or chest x-ray. Maintenance treatment (150 mg/day) was resumed 30 days later.</q></cite></span></li><li id="cite_note-Weber2015-140"> <span id="mw-reference-text-cite_note-Weber2015-140" class="mw-reference-text"><cite id="CITEREFWeber2015" class="citation book cs1">Weber GF (22 July 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=dhs_CgAAQBAJ&pg=PA318  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=dhs_CgAAQBAJ&pg=PA318'" tppabs="https://books.google.com/books?id=dhs_CgAAQBAJ&pg=PA318" class="external text external"><i>Molecular Therapies of Cancer</i></a>. Springer. pp.<span>&nbsp;</span>318–. ISBN<span>&nbsp;</span><bdi>978-3-319-13278-5</bdi>. <q>Compared to flutamide and nilutamide, bicalutamide has a 2-fold increased affinity for the Androgen Receptor, a longer half-life, and substantially reduced toxicities. Based on a more favorable safety profile relative to flutamide, bicalutamide is indicated for use in combination therapy with a Gonadotropin Releasing Hormone analog for the treatment of advanced metastatic prostate carcinoma.</q></cite></span></li><li id="cite_note-Mosby2001-141"> <span id="mw-reference-text-cite_note-Mosby2001-141" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=QxsobYYgm8oC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QxsobYYgm8oC'" tppabs="https://books.google.com/books?id=QxsobYYgm8oC" class="external text external"><i>Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs</i></a>. Mosby. 2001. p.<span>&nbsp;</span>290. ISBN<span>&nbsp;</span><bdi>978-0-323-00629-3</bdi>. <q>In vitro studies have shown bicalutamide can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites. It is recommended that if bicalutamide is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.</q></cite></span></li><li id="cite_note-SprattoWoods2008-142"> <span id="mw-reference-text-cite_note-SprattoWoods2008-142" class="mw-reference-text"><cite id="CITEREFSprattoWoods2008" class="citation book cs1">Spratto G, Woods A (2 July 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=8MoIHiUja_oC&pg=PA175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=8MoIHiUja_oC&pg=PA175'" tppabs="https://books.google.com/books?id=8MoIHiUja_oC&pg=PA175" class="external text external"><i>2009 Edition Delmar's Nurse's Drug Handbook</i></a>. Cengage Learning. pp.<span>&nbsp;</span>175–. ISBN<span>&nbsp;</span><bdi>978-1-4283-6106-5</bdi>.</cite></span></li><li id="cite_note-Balaji2016-143"> <span id="mw-reference-text-cite_note-Balaji2016-143" class="mw-reference-text"><cite id="CITEREFBalaj2016" class="citation book cs1">Balaj K (25 April 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25'" tppabs="https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25" class="external text external"><i>Managing Metastatic Prostate Cancer In Your Urological Oncology Practice</i></a>. Springer. pp.<span>&nbsp;</span>24–25. ISBN<span>&nbsp;</span><bdi>978-3-319-31341-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908222331/https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908222331/https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25'" tppabs="https://web.archive.org/web/20170908222331/https://books.google.com/books?id=1U4WDAAAQBAJ&pg=PA25" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-MasielloCheng2002-144"> <span id="mw-reference-text-cite_note-MasielloCheng2002-144" class="mw-reference-text"><cite id="CITEREFMasielloChengBubleyLu2002" class="citation journal cs1">Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP (July 2002). <a href="javascript:if(confirm('https://doi.org/10.1074/jbc.M203310200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074/jbc.M203310200'" tppabs="https://doi.org/10.1074/jbc.M203310200" class="external text external">"Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor"</a>. <i>The Journal of Biological Chemistry</i>. <b>277</b> (29): 26321–6. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M203310200  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M203310200'" tppabs="https://doi.org/10.1074%2Fjbc.M203310200" class="external text external">10.1074/jbc.M203310200</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12015321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12015321'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12015321" class="external text external">12015321</a>.</cite></span></li><li id="cite_note-Denis2012-145"> <span id="mw-reference-text-cite_note-Denis2012-145" class="mw-reference-text"><cite id="CITEREFDenis2012" class="citation book cs1">Denis L (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT128'" tppabs="https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT128" class="external text external"><i>Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>128, 158, 203. ISBN<span>&nbsp;</span><bdi>978-3-642-45745-6</bdi>.</cite></span></li><li id="cite_note-SchellensMcLeod2005-146"> <span id="mw-reference-text-cite_note-SchellensMcLeod2005-146" class="mw-reference-text"><cite id="CITEREFSchellensMcLeodNewell2005" class="citation book cs1">Schellens JH, McLeod HL, Newell DR (5 May 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229'" tppabs="https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229" class="external text external"><i>Cancer Clinical Pharmacology</i></a>. OUP Oxford. pp.<span>&nbsp;</span>229–230. ISBN<span>&nbsp;</span><bdi>978-0-19-262966-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160610134202/https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160610134202/https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229'" tppabs="https://web.archive.org/web/20160610134202/https://books.google.com/books?id=co8Sgu9N0FMC&pg=PA229" class="external text external">Archived</a> from the original on 10 June 2016.</cite></span></li><li id="cite_note-Becker2001-147"> <span id="mw-reference-text-cite_note-Becker2001-147" class="mw-reference-text"><cite id="CITEREFBecker2001" class="citation book cs1">Becker KL (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208'" tppabs="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208" class="external text external"><i>Principles and Practice of Endocrinology and Metabolism</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1119, 1196, 1208. ISBN<span>&nbsp;</span><bdi>978-0-7817-1750-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170908222331/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170908222331/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208'" tppabs="https://web.archive.org/web/20170908222331/https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1208" class="external text external">Archived</a> from the original on 8 September 2017.</cite></span></li><li id="cite_note-FurrTucker1996-148"> <span id="mw-reference-text-cite_note-FurrTucker1996-148" class="mw-reference-text"><cite class="citation journal cs1">Furr BJ, Tucker H (January 1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". <i>Urology</i>. <b>47</b> (1A Suppl): 13–25, discussion 29–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2980003-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2980003-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2980003-3" class="external text external">10.1016/S0090-4295(96)80003-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560673'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560673" class="external text external">8560673</a>.</cite></span></li><li id="cite_note-pmid29497605-149"> <span id="mw-reference-text-cite_note-pmid29497605-149" class="mw-reference-text"><cite id="CITEREFItoSadar2018" class="citation journal cs1">Ito Y, Sadar MD (2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862" class="external text external">"Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens"</a>. <i>Res Rep Urol</i>. <b>10</b>: 23–32. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FRRU.S157116  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FRRU.S157116'" tppabs="https://doi.org/10.2147%2FRRU.S157116" class="external text external">10.2147/RRU.S157116</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818862" class="external text external">5818862</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29497605  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29497605'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29497605" class="external text external">29497605</a>.</cite></span></li><li id="cite_note-Furr1995-150"> <span id="mw-reference-text-cite_note-Furr1995-150" class="mw-reference-text"><cite id="CITEREFFurr1995" class="citation journal cs1">Furr BJ (June 1995). "Casodex: preclinical studies and controversies". <i>Annals of the New York Academy of Sciences</i>. <b>761</b> (1): 79–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x'" tppabs="https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x" class="external text external">10.1111/j.1749-6632.1995.tb31371.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7625752  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7625752'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7625752" class="external text external">7625752</a>.</cite></span></li><li id="cite_note-pmid18231613-151"> <span id="mw-reference-text-cite_note-pmid18231613-151" class="mw-reference-text"><cite id="CITEREFGuiseOefeleinEasthamCookson2007" class="citation journal cs1">Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR (2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888" class="external text external">"Estrogenic side effects of androgen deprivation therapy"</a>. <i>Reviews in Urology</i>. <b>9</b> (4): 163–80. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213888" class="external text external">2213888</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18231613  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18231613'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18231613" class="external text external">18231613</a>.</cite></span></li><li id="cite_note-pmid28943399-152"> <span id="mw-reference-text-cite_note-pmid28943399-152" class="mw-reference-text"><cite id="CITEREFBulldanMalviyaUpmanyuKonrad2017" class="citation journal cs1">Bulldan A, Malviya VN, Upmanyu N, Konrad L, Scheiner-Bobis G (2017). <a href="javascript:if(confirm('https://doi.org/10.1016/j.bbamcr.2017.09.012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.bbamcr.2017.09.012'" tppabs="https://doi.org/10.1016/j.bbamcr.2017.09.012" class="external text external">"Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9"</a>. <i>Biochim. Biophys. Acta</i>. <b>1864</b> (12): 2402–2414. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bbamcr.2017.09.012  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bbamcr.2017.09.012'" tppabs="https://doi.org/10.1016%2Fj.bbamcr.2017.09.012" class="external text external">10.1016/j.bbamcr.2017.09.012</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28943399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28943399'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28943399" class="external text external">28943399</a>.</cite></span></li><li id="cite_note-pmid20947496-153"> <span id="mw-reference-text-cite_note-pmid20947496-153" class="mw-reference-text"><cite id="CITEREFPiParrillQuarles2010" class="citation journal cs1">Pi M, Parrill AL, Quarles LD (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977" class="external text external">"GPRC6A mediates the non-genomic effects of steroids"</a>. <i>J. Biol. Chem</i>. <b>285</b> (51): 39953–64. doi:<a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M110.158063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M110.158063'" tppabs="https://doi.org/10.1074%2Fjbc.M110.158063" class="external text external">10.1074/jbc.M110.158063</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000977" class="external text external">3000977</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20947496  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20947496'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20947496" class="external text external">20947496</a>.</cite></span></li><li id="cite_note-Furr2009-154"> <span id="mw-reference-text-cite_note-Furr2009-154" class="mw-reference-text"><cite id="CITEREFFurr2009" class="citation journal cs1">Furr BJ (2009). "Research on reproductive medicine in the pharmaceutical industry". <i>Human Fertility</i>. <b>1</b> (1): 56–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F1464727982000198131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F1464727982000198131'" tppabs="https://doi.org/10.1080%2F1464727982000198131" class="external text external">10.1080/1464727982000198131</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11844311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11844311'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11844311" class="external text external">11844311</a>.</cite></span></li><li id="cite_note-pmid19359544-155"> <span id="mw-reference-text-cite_note-pmid19359544-155" class="mw-reference-text"><cite id="CITEREFTranOukCleggChen2009" class="citation journal cs1">Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508" class="external text external">"Development of a second-generation antiandrogen for treatment of advanced prostate cancer"</a>. <i>Science</i>. <b>324</b> (5928): 787–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1168175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1168175'" tppabs="https://doi.org/10.1126%2Fscience.1168175" class="external text external">10.1126/science.1168175</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981508" class="external text external">2981508</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19359544  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19359544'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19359544" class="external text external">19359544</a>. <q>[...] bicalutamide has relatively low affinity for AR (at least 30-fold reduced relative to the natural ligand dihydrotestosterone (DHT)) (7), [...]</q></cite></span></li><li id="cite_note-Furr1997-156"> <span id="mw-reference-text-cite_note-Furr1997-156" class="mw-reference-text"><cite id="CITEREFFurr1997" class="citation journal cs1">Furr, B J A (1997). "Relative potencies of flutamide and 'Casodex<span class="cs1-kern-right">'</span>". <i>Endocrine-Related Cancer</i>. <b>4</b> (2): 197–202. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Ferc.0.0040197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Ferc.0.0040197'" tppabs="https://doi.org/10.1677%2Ferc.0.0040197" class="external text external">10.1677/erc.0.0040197</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1351-0088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1351-0088'" tppabs="https://www.worldcat.org/issn/1351-0088" class="external text external">1351-0088</a>.</cite></span></li><li id="cite_note-FiggChau2010-157"> <span id="mw-reference-text-cite_note-FiggChau2010-157" class="mw-reference-text"><cite id="CITEREFFiggChauSmall2010" class="citation book cs1">Figg W, Chau CH, Small EJ (14 September 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA56  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA56'" tppabs="https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA56" class="external text external"><i>Drug Management of Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>56, 71–72, 75, 93. ISBN<span>&nbsp;</span><bdi>978-1-60327-829-4</bdi>.</cite></span></li><li id="cite_note-pmid8717469-158"> <span id="mw-reference-text-cite_note-pmid8717469-158" class="mw-reference-text"><cite id="CITEREFFurr1996" class="citation journal cs1">Furr BJ (1996). "The development of Casodex (bicalutamide): preclinical studies". <i>European Urology</i>. 29 Suppl 2: 83–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000473846  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000473846'" tppabs="https://doi.org/10.1159%2F000473846" class="external text external">10.1159/000473846</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8717469  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8717469'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8717469" class="external text external">8717469</a>.</cite></span></li><li id="cite_note-DenisMahler1996-159"> <span id="mw-reference-text-cite_note-DenisMahler1996-159" class="mw-reference-text"><cite id="CITEREFDenisMahler1996" class="citation journal cs1">Denis L, Mahler C (January 1996). "Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen". <i>Urology</i>. <b>47</b> (1A Suppl): 26–8, discussion 29–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2980004-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2980004-5'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2980004-5" class="external text external">10.1016/S0090-4295(96)80004-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560674  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560674'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560674" class="external text external">8560674</a>.</cite></span></li><li id="cite_note-pmid15838655-160"> <span id="mw-reference-text-cite_note-pmid15838655-160" class="mw-reference-text"><cite id="CITEREFBoccardoRubagottiContiPotenzoni2005" class="citation journal cs1">Boccardo F, Rubagotti A, Conti G, Potenzoni D, Manganelli A, Del Monaco D (2005). <a href="javascript:if(confirm('https://www.researchgate.net/publication/7897958  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.researchgate.net/publication/7897958'" tppabs="https://www.researchgate.net/publication/7897958" class="external text external">"Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer"</a>. <i>Cancer Chemotherapy and Pharmacology</i>. <b>56</b> (4): 415–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00280-005-1016-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00280-005-1016-1'" tppabs="https://doi.org/10.1007%2Fs00280-005-1016-1" class="external text external">10.1007/s00280-005-1016-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15838655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15838655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15838655" class="external text external">15838655</a>.</cite></span></li><li id="cite_note-LuoMartel1997-161"> <span id="mw-reference-text-cite_note-LuoMartel1997-161" class="mw-reference-text"><cite id="CITEREFLuoMartelChenLabrie1997" class="citation journal cs1">Luo S, Martel C, Chen C, Labrie C, Candas B, Singh SM, Labrie F (December 1997). "Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity". <i>Urology</i>. <b>50</b> (6): 913–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2897%2900393-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2897%2900393-2'" tppabs="https://doi.org/10.1016%2FS0090-4295%2897%2900393-2" class="external text external">10.1016/S0090-4295(97)00393-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9426723  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9426723'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9426723" class="external text external">9426723</a>.</cite></span></li><li id="cite_note-MelmedPolonsky2015-162"> <span id="mw-reference-text-cite_note-MelmedPolonsky2015-162" class="mw-reference-text"><cite id="CITEREFMelmedPolonskyReed_LarsenKronenberg2015" class="citation book cs1">Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM (30 November 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA704'" tppabs="https://books.google.com/books?id=YZ8_CwAAQBAJ&pg=PA704" class="external text external"><i>Williams Textbook of Endocrinology</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>704–708, 711, 1104. ISBN<span>&nbsp;</span><bdi>978-0-323-29738-7</bdi>.</cite></span></li><li id="cite_note-MorettiGuccione2016-163"> <span id="mw-reference-text-cite_note-MorettiGuccione2016-163" class="mw-reference-text"><cite id="CITEREFMorettiGuccioneDi_GiacintoCannuccia2016" class="citation conference cs1">Moretti CG, Guccione L, Di Giacinto P, Cannuccia A, Meleca C, Lanzolla G, Andreadi A, Lauro D (April 2016). <a href="javascript:if(confirm('https://endo.confex.com/endo/2016endo/webprogram/Paper26631.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://endo.confex.com/endo/2016endo/webprogram/Paper26631.html'" tppabs="https://endo.confex.com/endo/2016endo/webprogram/Paper26631.html" class="external text external"><i>Efficacy and Safety of Myo-Inositol Supplementation in the Treatment of Obese Hirsute PCOS Women: Comparative Evaluation with OCP+Bicalutamide Therapy</i></a>. ENDO 2016. Boston, Massachusetts.</cite></span></li><li id="cite_note-pmid7537602-164"> <span id="mw-reference-text-cite_note-pmid7537602-164" class="mw-reference-text"><cite id="CITEREFEriHaugTveter1995" class="citation journal cs1">Eri LM, Haug E, Tveter KJ (March 1995). "Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia". <i>British Journal of Urology</i>. <b>75</b> (3): 335–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1464-410X.1995.tb07345.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1464-410X.1995.tb07345.x'" tppabs="https://doi.org/10.1111%2Fj.1464-410X.1995.tb07345.x" class="external text external">10.1111/j.1464-410X.1995.tb07345.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7537602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7537602'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7537602" class="external text external">7537602</a>.</cite></span></li><li id="cite_note-WeinKavoussi2011-165"> <span id="mw-reference-text-cite_note-WeinKavoussi2011-165" class="mw-reference-text"><cite id="CITEREFWeinKavoussiNovickPartin2011" class="citation book cs1">Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 August 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939'" tppabs="https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939" class="external text external"><i>Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2938–2939, 2946. ISBN<span>&nbsp;</span><bdi>978-1-4160-6911-9</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160505225217/https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160505225217/https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939'" tppabs="https://web.archive.org/web/20160505225217/https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939" class="external text external">Archived</a> from the original on 5 May 2016.</cite></span></li><li id="cite_note-Diamanti-KandarakisNestler2009-166"> <span id="mw-reference-text-cite_note-Diamanti-KandarakisNestler2009-166" class="mw-reference-text"><cite id="CITEREFDiamanti-KandarakisNestlerPandasPasquale2009" class="citation book cs1">Diamanti-Kandarakis E, Nestler JE, Pandas D, Pasquale R (21 December 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75'" tppabs="https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75" class="external text external"><i>Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>75–. ISBN<span>&nbsp;</span><bdi>978-1-59745-310-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160519021821/https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160519021821/https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75'" tppabs="https://web.archive.org/web/20160519021821/https://books.google.com/books?id=7ej6ZgqiFEsC&pg=PA75" class="external text external">Archived</a> from the original on 19 May 2016.</cite></span></li><li id="cite_note-CarrellPeterson2010-167"> <span id="mw-reference-text-cite_note-CarrellPeterson2010-167" class="mw-reference-text"><cite id="CITEREFCarrellPeterson2010" class="citation book cs1">Carrell DT, Peterson CM (23 March 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=lcBEheiufVcC&pg=PA163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=lcBEheiufVcC&pg=PA163'" tppabs="https://books.google.com/books?id=lcBEheiufVcC&pg=PA163" class="external text external"><i>Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>163–. ISBN<span>&nbsp;</span><bdi>978-1-4419-1436-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140704201613/http://books.google.com/books?id=lcBEheiufVcC&pg=PA163  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140704201613/http://books.google.com/books?id=lcBEheiufVcC&pg=PA163'" tppabs="https://web.archive.org/web/20140704201613/http://books.google.com/books?id=lcBEheiufVcC&pg=PA163" class="external text external">Archived</a> from the original on 4 July 2014.</cite></span></li><li id="cite_note-BouchardCaraty1993-168"> <span id="mw-reference-text-cite_note-BouchardCaraty1993-168" class="mw-reference-text"><cite id="CITEREFBouchardCaraty1993" class="citation book cs1">Bouchard P, Caraty A (15 November 1993). <a href="javascript:if(confirm('https://books.google.com/books?id=uctURfWwTb4C&pg=PA455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=uctURfWwTb4C&pg=PA455'" tppabs="https://books.google.com/books?id=uctURfWwTb4C&pg=PA455" class="external text external"><i>GnRH, GnRH Analogs, Gonadotropins and Gonadal Peptides</i></a>. CRC Press. pp.<span>&nbsp;</span>455–456. ISBN<span>&nbsp;</span><bdi>978-0-203-09205-7</bdi>. <q>[...] when male levels of androgens are achieved in plasma, their effects on gonadotropin secretion are similar in women and men. [...] administration of flutamide in a group of normally-cycling women produced a clinical improvement of acne and hirsutism without any significant hormonal change. [...] All these data emphasize that physiological levels of androgens have no action on the regulation of gonadotropins in normal women. [...] Androgens do not directly play a role in gonadotropin regulation [in women].</q></cite></span></li><li id="cite_note-pmid18062751-169"> <span id="mw-reference-text-cite_note-pmid18062751-169" class="mw-reference-text"><cite id="CITEREFSieber2007" class="citation journal cs1">Sieber PR (December 2007). "Treatment of bicalutamide-induced breast events". <i>Expert Review of Anticancer Therapy</i>. <b>7</b> (12): 1773–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F14737140.7.12.1773  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F14737140.7.12.1773'" tppabs="https://doi.org/10.1586%2F14737140.7.12.1773" class="external text external">10.1586/14737140.7.12.1773</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18062751  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18062751'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18062751" class="external text external">18062751</a>.</cite></span></li><li id="cite_note-AsschemanGooren1989-170"> <span id="mw-reference-text-cite_note-AsschemanGooren1989-170" class="mw-reference-text"><cite id="CITEREFAsschemanGoorenPeereboom-Wynia1989" class="citation journal cs1">Asscheman H, Gooren LJ, Peereboom-Wynia JD (1989). "Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals—experiences with a novel androgen receptor blocker". <i>Clinical and Experimental Dermatology</i>. <b>14</b> (5): 361–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x" class="external text external">10.1111/j.1365-2230.1989.tb02585.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2612040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2612040'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2612040" class="external text external">2612040</a>.</cite></span></li><li id="cite_note-Raode_Voogt1988-171"> <span id="mw-reference-text-cite_note-Raode_Voogt1988-171" class="mw-reference-text"><cite id="CITEREFRaode_VoogtGeldofGooren1988" class="citation journal cs1">Rao BR, de Voogt HJ, Geldof AA, Gooren LJ, Bouman FG (1988). "Merits and considerations in the use of anti-androgen". <i>Journal of Steroid Biochemistry</i>. <b>31</b> (4B): 731–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2888%2990024-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2888%2990024-6'" tppabs="https://doi.org/10.1016%2F0022-4731%2888%2990024-6" class="external text external">10.1016/0022-4731(88)90024-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3143862  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3143862'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3143862" class="external text external">3143862</a>.</cite></span></li><li id="cite_note-WibowoSchellhammer2011-172"> <span id="mw-reference-text-cite_note-WibowoSchellhammer2011-172" class="mw-reference-text"><cite id="CITEREFWibowoSchellhammerWassersug2011" class="citation journal cs1">Wibowo E, Schellhammer P, Wassersug RJ (January 2011). "Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy". <i>The Journal of Urology</i>. <b>185</b> (1): 17–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.juro.2010.08.094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.juro.2010.08.094'" tppabs="https://doi.org/10.1016%2Fj.juro.2010.08.094" class="external text external">10.1016/j.juro.2010.08.094</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21074215  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21074215'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21074215" class="external text external">21074215</a>.</cite></span></li><li id="cite_note-MotofeiRowland2011-173"> <span id="mw-reference-text-cite_note-MotofeiRowland2011-173" class="mw-reference-text"><cite id="CITEREFMotofeiRowlandPopaKreienkamp2011" class="citation journal cs1">Motofei IG, Rowland DL, Popa F, Kreienkamp D, Paunica S (July 2011). "Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal". <i>BJU International</i>. <b>108</b> (1): 110–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1464-410X.2010.09764.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1464-410X.2010.09764.x'" tppabs="https://doi.org/10.1111%2Fj.1464-410X.2010.09764.x" class="external text external">10.1111/j.1464-410X.2010.09764.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20955264  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20955264'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20955264" class="external text external">20955264</a>.</cite></span></li><li id="cite_note-pmid23484454-174"> <span id="mw-reference-text-cite_note-pmid23484454-174" class="mw-reference-text"><cite id="CITEREFWibowoWassersug2013" class="citation journal cs1">Wibowo E, Wassersug RJ (September 2013). "The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy". <i>Critical Reviews in Oncology/Hematology</i>. <b>87</b> (3): 224–38. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.critrevonc.2013.01.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.critrevonc.2013.01.006'" tppabs="https://doi.org/10.1016%2Fj.critrevonc.2013.01.006" class="external text external">10.1016/j.critrevonc.2013.01.006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23484454  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23484454'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23484454" class="external text external">23484454</a>.</cite></span></li><li id="cite_note-King2008-175"> <span id="mw-reference-text-cite_note-King2008-175" class="mw-reference-text"><cite id="CITEREFKing2008" class="citation journal cs1">King SR (2008). "Emerging roles for neurosteroids in sexual behavior and function". <i>Journal of Andrology</i>. <b>29</b> (5): 524–33. doi:<a href="javascript:if(confirm('https://doi.org/10.2164%2Fjandrol.108.005660  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2164%2Fjandrol.108.005660'" tppabs="https://doi.org/10.2164%2Fjandrol.108.005660" class="external text external">10.2164/jandrol.108.005660</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18567641  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18567641'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18567641" class="external text external">18567641</a>.</cite></span></li><li id="cite_note-pmid7803627-176"> <span id="mw-reference-text-cite_note-pmid7803627-176" class="mw-reference-text"><cite id="CITEREFMoraliOropezaLemusPerez-Palacios1994" class="citation journal cs1">Morali G, Oropeza MV, Lemus AE, Perez-Palacios G (September 1994). <a href="javascript:if(confirm('https://doi.org/10.1095/biolreprod51.3.562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1095/biolreprod51.3.562'" tppabs="https://doi.org/10.1095/biolreprod51.3.562" class="external text external">"Mechanisms regulating male sexual behavior in the rat: role of 3 alpha- and 3 beta-androstanediols"</a>. <i>Biology of Reproduction</i>. <b>51</b> (3): 562–71. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1095%2Fbiolreprod51.3.562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1095%2Fbiolreprod51.3.562'" tppabs="https://doi.org/10.1095%2Fbiolreprod51.3.562" class="external text external">10.1095/biolreprod51.3.562</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7803627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7803627'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7803627" class="external text external">7803627</a>.</cite></span></li><li id="cite_note-pmid20646182-177"> <span id="mw-reference-text-cite_note-pmid20646182-177" class="mw-reference-text"><cite id="CITEREFSánchez_MontoyaHernándezBarreto-EstradaOrtiz2010" class="citation journal cs1">Sánchez Montoya EL, Hernández L, Barreto-Estrada JL, Ortiz JG, Jorge JC (November 2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968" class="external text external">"The testosterone metabolite 3α-diol enhances female rat sexual motivation when infused in the nucleus accumbens shell"</a>. <i>The Journal of Sexual Medicine</i>. <b>7</b> (11): 3598–609. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1743-6109.2010.01937.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1743-6109.2010.01937.x'" tppabs="https://doi.org/10.1111%2Fj.1743-6109.2010.01937.x" class="external text external">10.1111/j.1743-6109.2010.01937.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360968" class="external text external">4360968</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20646182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20646182'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20646182" class="external text external">20646182</a>.</cite></span></li><li id="cite_note-Chedrese2009-178"> <span id="mw-reference-text-cite_note-Chedrese2009-178" class="mw-reference-text"><cite id="CITEREFChedrese2009" class="citation book cs1">Chedrese PJ (13 June 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=3FJXUN6Vh44C&pg=PA233  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=3FJXUN6Vh44C&pg=PA233'" tppabs="https://books.google.com/books?id=3FJXUN6Vh44C&pg=PA233" class="external text external"><i>Reproductive Endocrinology: A Molecular Approach</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>233–. ISBN<span>&nbsp;</span><bdi>978-0-387-88186-7</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170905040216/https://books.google.com/books?id=3FJXUN6Vh44C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170905040216/https://books.google.com/books?id=3FJXUN6Vh44C'" tppabs="https://web.archive.org/web/20170905040216/https://books.google.com/books?id=3FJXUN6Vh44C" class="external text external">Archived</a> from the original on 5 September 2017.</cite></span></li><li id="cite_note-pmid20552051-179"> <span id="mw-reference-text-cite_note-pmid20552051-179" class="mw-reference-text"><cite id="CITEREFFryeEdingerLephartWalf2010" class="citation journal cs1">Frye CA, Edinger KL, Lephart ED, Walf AA (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398" class="external text external">"3alpha-androstanediol, but not testosterone, attenuates age-related decrements in cognitive, anxiety, and depressive behavior of male rats"</a>. <i>Frontiers in Aging Neuroscience</i>. <b>2</b>: 15. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffnagi.2010.00015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffnagi.2010.00015'" tppabs="https://doi.org/10.3389%2Ffnagi.2010.00015" class="external text external">10.3389/fnagi.2010.00015</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874398" class="external text external">2874398</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20552051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20552051'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20552051" class="external text external">20552051</a>.</cite></span></li><li id="cite_note-HuangZhu2008-180"> <span id="mw-reference-text-cite_note-HuangZhu2008-180" class="mw-reference-text"><cite id="CITEREFHuangZhuFischerZhou2008" class="citation journal cs1">Huang Q, Zhu H, Fischer DF, Zhou JN (June 2008). "An estrogenic effect of 5alpha-androstane-3beta, 17beta-diol on the behavioral response to stress and on CRH regulation". <i>Neuropharmacology</i>. <b>54</b> (8): 1233–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neuropharm.2008.03.016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neuropharm.2008.03.016'" tppabs="https://doi.org/10.1016%2Fj.neuropharm.2008.03.016" class="external text external">10.1016/j.neuropharm.2008.03.016</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18457850  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18457850'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18457850" class="external text external">18457850</a>.</cite></span></li><li id="cite_note-FryeKoonce2008-181"> <span id="mw-reference-text-cite_note-FryeKoonce2008-181" class="mw-reference-text"><cite id="CITEREFFryeKoonceEdingerOsborne2008" class="citation journal cs1">Frye CA, Koonce CJ, Edinger KL, Osborne DM, Walf AA (November 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974" class="external text external">"Androgens with activity at estrogen receptor beta have anxiolytic and cognitive-enhancing effects in male rats and mice"</a>. <i>Hormones and Behavior</i>. <b>54</b> (5): 726–34. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.yhbeh.2008.07.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.yhbeh.2008.07.013'" tppabs="https://doi.org/10.1016%2Fj.yhbeh.2008.07.013" class="external text external">10.1016/j.yhbeh.2008.07.013</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623974" class="external text external">3623974</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18775724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18775724'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18775724" class="external text external">18775724</a>.</cite></span></li><li id="cite_note-pmid25797385-182"> <span id="mw-reference-text-cite_note-pmid25797385-182" class="mw-reference-text"><cite id="CITEREFBamburyScher2015" class="citation journal cs1">Bambury RM, Scher HI (June 2015). "Enzalutamide: Development from bench to bedside". <i>Urologic Oncology</i>. <b>33</b> (6): 280–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.urolonc.2014.12.017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.urolonc.2014.12.017'" tppabs="https://doi.org/10.1016%2Fj.urolonc.2014.12.017" class="external text external">10.1016/j.urolonc.2014.12.017</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25797385  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25797385'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25797385" class="external text external">25797385</a>.</cite></span></li><li id="cite_note-BamburyRathkopf2015-183"> <span id="mw-reference-text-cite_note-BamburyRathkopf2015-183" class="mw-reference-text"><cite id="CITEREFBamburyRathkopf2016" class="citation journal cs1">Bambury RM, Rathkopf DE (August 2016). "Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide". <i>Urologic Oncology</i>. <b>34</b> (8): 348–55. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.urolonc.2015.05.025  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.urolonc.2015.05.025'" tppabs="https://doi.org/10.1016%2Fj.urolonc.2015.05.025" class="external text external">10.1016/j.urolonc.2015.05.025</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26162486  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26162486'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26162486" class="external text external">26162486</a>.</cite></span></li><li id="cite_note-pmid24100689-184"> <span id="mw-reference-text-cite_note-pmid24100689-184" class="mw-reference-text"><cite id="CITEREFPinto2014" class="citation journal cs1">Pinto Á (February 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129" class="external text external">"Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer"</a>. <i>Cancer Biology &amp; Therapy</i>. <b>15</b> (2): 149–55. doi:<a href="javascript:if(confirm('https://doi.org/10.4161%2Fcbt.26724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4161%2Fcbt.26724'" tppabs="https://doi.org/10.4161%2Fcbt.26724" class="external text external">10.4161/cbt.26724</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129" class="external text external">3928129</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24100689  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24100689'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24100689" class="external text external">24100689</a>.</cite></span></li><li id="cite_note-OrentreichDurr1974-185"> <span id="mw-reference-text-cite_note-OrentreichDurr1974-185" class="mw-reference-text"><cite id="CITEREFOrentreichDurr1974" class="citation journal cs1">Orentreich N, Durr NP (1974). "Mammogenesis in Transsexuals". <i>Journal of Investigative Dermatology</i>. <b>63</b> (1): 142–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2F1523-1747.ep12678272  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2F1523-1747.ep12678272'" tppabs="https://doi.org/10.1111%2F1523-1747.ep12678272" class="external text external">10.1111/1523-1747.ep12678272</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4365991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4365991'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4365991" class="external text external">4365991</a>.</cite></span></li><li id="cite_note-IIIBarbieri2013b-186"> <span id="mw-reference-text-cite_note-IIIBarbieri2013b-186" class="mw-reference-text"><cite class="citation book cs1">Strauss III JF, Barbieri RL (13 September 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236'" tppabs="https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236" class="external text external"><i>Yen and Jaffe's Reproductive Endocrinology</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>236–237. ISBN<span>&nbsp;</span><bdi>978-1-4557-2758-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170114164554/https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170114164554/https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236'" tppabs="https://web.archive.org/web/20170114164554/https://books.google.com/books?id=KZ95AAAAQBAJ&pg=PA236" class="external text external">Archived</a> from the original on 14 January 2017.</cite></span></li><li id="cite_note-WilsonNizet2015-187"> <span id="mw-reference-text-cite_note-WilsonNizet2015-187" class="mw-reference-text"><cite id="CITEREFWilsonNizetMaldonadoKlein2015" class="citation book cs1">Wilson CB, Nizet V, Maldonado Y, Klein JO, Remington JS (2015). <a href="javascript:if(confirm('https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190'" tppabs="https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190" class="external text external"><i>Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>190–. ISBN<span>&nbsp;</span><bdi>978-0-323-24147-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170114165129/https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170114165129/https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190'" tppabs="https://web.archive.org/web/20170114165129/https://books.google.com/books?id=VuZ1BwAAQBAJ&pg=PA190" class="external text external">Archived</a> from the original on 14 January 2017.</cite></span></li><li id="cite_note-KanhaiHage2000-188"> <span id="mw-reference-text-cite_note-KanhaiHage2000-188" class="mw-reference-text"><cite id="CITEREFKanhaiHagevan_DiestBloemena2000" class="citation journal cs1">Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW (January 2000). "Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men". <i>The American Journal of Surgical Pathology</i>. <b>24</b> (1): 74–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2F00000478-200001000-00009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2F00000478-200001000-00009'" tppabs="https://doi.org/10.1097%2F00000478-200001000-00009" class="external text external">10.1097/00000478-200001000-00009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10632490  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10632490'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10632490" class="external text external">10632490</a>.</cite></span></li><li id="cite_note-Lawrence2007-189"> <span id="mw-reference-text-cite_note-Lawrence2007-189" class="mw-reference-text"><cite id="CITEREFLawrence2006" class="citation book cs1">Lawrence AA (2006). "Transgender Health Concerns".  In Meyer IH, Northridge ME (eds.). <i>The Health of Sexual Minorities Public Health Perspectives on Lesbian, Gay, Bisexual and Transgender Populations</i>. New York: Springer. p.<span>&nbsp;</span>476. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-0-387-31334-4_19  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-0-387-31334-4_19'" tppabs="https://doi.org/10.1007%2F978-0-387-31334-4_19" class="external text external">10.1007/978-0-387-31334-4_19</a>. ISBN<span>&nbsp;</span><bdi>978-0-387-28871-0</bdi>.</cite></span></li><li id="cite_note-Rosen2009-190"> <span id="mw-reference-text-cite_note-Rosen2009-190" class="mw-reference-text"><cite id="CITEREFRosen2009" class="citation book cs1">Rosen PP (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=_swaovkfRMMC&pg=PA31  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_swaovkfRMMC&pg=PA31'" tppabs="https://books.google.com/books?id=_swaovkfRMMC&pg=PA31" class="external text external"><i>Rosen's Breast Pathology</i></a> (3 ed.). Philadelphia: Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>31–. ISBN<span>&nbsp;</span><bdi>978-0-7817-7137-5</bdi>.</cite></span></li><li id="cite_note-MorganteGradini2001-191"> <span id="mw-reference-text-cite_note-MorganteGradini2001-191" class="mw-reference-text"><cite id="CITEREFMorganteGradiniRealacciSale2001" class="citation journal cs1">Morgante E, Gradini R, Realacci M, Sale P, D'Eramo G, Perrone GA, Cardillo MR, Petrangeli E, Russo M, Di Silverio F (March 2001). "Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study". <i>Histopathology</i>. <b>38</b> (3): 195–201. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1365-2559.2001.01077.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1365-2559.2001.01077.x'" tppabs="https://doi.org/10.1046%2Fj.1365-2559.2001.01077.x" class="external text external">10.1046/j.1365-2559.2001.01077.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11260298  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11260298'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11260298" class="external text external">11260298</a>.</cite></span></li><li id="cite_note-Mulhall2013-192"> <span id="mw-reference-text-cite_note-Mulhall2013-192" class="mw-reference-text"><cite id="CITEREFMulhall2013" class="citation book cs1">Mulhall JP (21 February 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84'" tppabs="https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84" class="external text external"><i>Fertility Preservation in Male Cancer Patients</i></a>. Cambridge University Press. pp.<span>&nbsp;</span>84–. ISBN<span>&nbsp;</span><bdi>978-1-139-61952-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160429171718/https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160429171718/https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84'" tppabs="https://web.archive.org/web/20160429171718/https://books.google.com/books?id=97wgAwAAQBAJ&pg=PA84" class="external text external">Archived</a> from the original on 29 April 2016.</cite></span></li><li id="cite_note-SchillComhaire2006-193"> <span id="mw-reference-text-cite_note-SchillComhaire2006-193" class="mw-reference-text"><cite id="CITEREFSchillComhaireHargreave2006" class="citation book cs1">Schill W, Comhaire FH, Hargreave TB (26 August 2006). <a href="javascript:if(confirm('https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76'" tppabs="https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76" class="external text external"><i>Andrology for the Clinician</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>76–. ISBN<span>&nbsp;</span><bdi>978-3-540-33713-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160526220017/https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160526220017/https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76'" tppabs="https://web.archive.org/web/20160526220017/https://books.google.com/books?id=5Ts_AAAAQBAJ&pg=PA76" class="external text external">Archived</a> from the original on 26 May 2016.</cite></span></li><li id="cite_note-NieschlagBehre2012-194"> <span id="mw-reference-text-cite_note-NieschlagBehre2012-194" class="mw-reference-text"><cite id="CITEREFNieschlagBehre2012" class="citation book cs1">Nieschlag E, Behre HM (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=jn3nCAAAQBAJ&pg=PA276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=jn3nCAAAQBAJ&pg=PA276'" tppabs="https://books.google.com/books?id=jn3nCAAAQBAJ&pg=PA276" class="external text external"><i>Testosterone: Action – Deficiency – Substitution</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>130, 276. ISBN<span>&nbsp;</span><bdi>978-3-642-72185-4</bdi>.</cite></span></li><li id="cite_note-Cheng2009-195"> <span id="mw-reference-text-cite_note-Cheng2009-195" class="mw-reference-text"><cite id="CITEREFCheng2009" class="citation book cs1">Cheng C (24 October 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=tdpVNN80_r0C&pg=PA258  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=tdpVNN80_r0C&pg=PA258'" tppabs="https://books.google.com/books?id=tdpVNN80_r0C&pg=PA258" class="external text external"><i>Molecular Mechanisms in Spermatogenesis</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>258–. ISBN<span>&nbsp;</span><bdi>978-0-387-09597-4</bdi>.</cite></span></li><li id="cite_note-NeumannSchenck1980-196"> <span id="mw-reference-text-cite_note-NeumannSchenck1980-196" class="mw-reference-text"><cite id="CITEREFNeumannSchenck1980" class="citation book cs1">Neumann, F.; Schenck, B. (1980). <a href="javascript:if(confirm('https://books.google.com/books?id=AXArBgAAQBAJ&lpg=PA93&pg=PA93  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=AXArBgAAQBAJ&lpg=PA93&pg=PA93'" tppabs="https://books.google.com/books?id=AXArBgAAQBAJ&lpg=PA93&pg=PA93" class="external text external">"Antiandrogens: Basic Concepts and Clinical Trials"</a>. <i>Regulation of Male Fertility</i>. pp.<span>&nbsp;</span>93–106. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-94-009-8875-0_10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-94-009-8875-0_10'" tppabs="https://doi.org/10.1007%2F978-94-009-8875-0_10" class="external text external">10.1007/978-94-009-8875-0_10</a>. ISBN<span>&nbsp;</span><bdi>978-94-009-8877-4</bdi>.</cite></span></li><li id="cite_note-Johnson2003-197"> <span id="mw-reference-text-cite_note-Johnson2003-197" class="mw-reference-text"><cite id="CITEREFJohnson2003" class="citation book cs1">Johnson LR (14 October 2003). <a href="javascript:if(confirm('https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731'" tppabs="https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731" class="external text external"><i>Essential Medical Physiology</i></a>. Academic Press. pp.<span>&nbsp;</span>731–. ISBN<span>&nbsp;</span><bdi>978-0-08-047270-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20170215093206/https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170215093206/https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731'" tppabs="https://web.archive.org/web/20170215093206/https://books.google.com/books?id=Ql10m-_q3nMC&pg=PA731" class="external text external">Archived</a> from the original on 15 February 2017.</cite></span></li><li id="cite_note-JonesReiter2016-198"> <span id="mw-reference-text-cite_note-JonesReiter2016-198" class="mw-reference-text"><cite id="CITEREFJonesReiterGreenblatt2016" class="citation journal cs1">Jones CA, Reiter L, Greenblatt E (2016). "Fertility preservation in transgender patients". <i>International Journal of Transgenderism</i>. <b>17</b> (2): 76–82. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F15532739.2016.1153992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F15532739.2016.1153992'" tppabs="https://doi.org/10.1080%2F15532739.2016.1153992" class="external text external">10.1080/15532739.2016.1153992</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1553-2739  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1553-2739'" tppabs="https://www.worldcat.org/issn/1553-2739" class="external text external">1553-2739</a>. <q>Traditionally, patients have been advised to cryopreserve sperm prior to starting cross-sex hormone therapy as there is a potential for a decline in sperm motility with high-dose estrogen therapy over time (Lubbert et al., 1992). However, this decline in fertility due to estrogen therapy is controversial due to limited studies.</q></cite></span></li><li id="cite_note-PayneHardy2007-199"> <span id="mw-reference-text-cite_note-PayneHardy2007-199" class="mw-reference-text"><cite id="CITEREFPayneHardy2007" class="citation book cs1">Payne AH, Hardy MP (28 October 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=x4ttqKIAOg0C&pg=PA422  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=x4ttqKIAOg0C&pg=PA422'" tppabs="https://books.google.com/books?id=x4ttqKIAOg0C&pg=PA422" class="external text external"><i>The Leydig Cell in Health and Disease</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>422–431. ISBN<span>&nbsp;</span><bdi>978-1-59745-453-7</bdi>. <q>Estrogens are highly efficient inhibitors of the hypothalamic-hypophyseal-testicular axis (212–214). Aside from their negative feedback action at the level of the hypothalamus and pituitary, direct inhibitory effects on the testis are likely (215,216). [...] The histology of the testes [with estrogen treatment] showed disorganization of the seminiferous tubules, vacuolization and absence of lumen, and compartmentalization of spermatogenesis.</q></cite></span></li><li id="cite_note-WakelinMaibach2002-200"> <span id="mw-reference-text-cite_note-WakelinMaibach2002-200" class="mw-reference-text"><cite id="CITEREFWakelinMaibachArcher2002" class="citation book cs1">Wakelin SH, Maibach HI, Archer CB (1 June 2002). <a href="javascript:if(confirm('https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32'" tppabs="https://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32" class="external text external"><i>Systemic Drug Treatment in Dermatology: A Handbook</i></a>. CRC Press. pp.<span>&nbsp;</span>32–. ISBN<span>&nbsp;</span><bdi>978-1-84076-013-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140725205131/http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140725205131/http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32'" tppabs="https://web.archive.org/web/20140725205131/http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32" class="external text external">Archived</a> from the original on 25 July 2014. <q>[Cyproterone acetate] inhibits spermatogenesis and produces reversible infertility (but is not a male contraceptive).</q></cite></span></li><li id="cite_note-pmid8005205-201"> <span id="mw-reference-text-cite_note-pmid8005205-201" class="mw-reference-text"><cite id="CITEREFNeumann1994" class="citation journal cs1">Neumann F (1994). "The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research". <i>Exp. Clin. Endocrinol</i>. <b>102</b> (1): 1–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-0029-1211261  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-0029-1211261'" tppabs="https://doi.org/10.1055%2Fs-0029-1211261" class="external text external">10.1055/s-0029-1211261</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8005205  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8005205'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8005205" class="external text external">8005205</a>. <q>Spermatogenesis is also androgen-dependent and is inhibited by CPA, meaning that patients treated with high doses of CPA are sterile (Figure 23). All the effects of CPA are fully reversible.</q></cite></span></li><li id="cite_note-Salam2003-202"> <span id="mw-reference-text-cite_note-Salam2003-202" class="mw-reference-text"><cite id="CITEREFSalam2003" class="citation book cs1">Salam MA (2003). <a href="javascript:if(confirm('https://books.google.com/books?id=y50kTcCCfEcC&pg=PA684  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=y50kTcCCfEcC&pg=PA684'" tppabs="https://books.google.com/books?id=y50kTcCCfEcC&pg=PA684" class="external text external"><i>Principles &amp; Practice of Urology: A Comprehensive Text</i></a>. Universal-Publishers. pp.<span>&nbsp;</span>684–. ISBN<span>&nbsp;</span><bdi>978-1-58112-412-5</bdi>. <q>Estrogens act primarily through negative feedback at the hypothalamic-pituitary level to reduce LH secretion and testicular androgen synthesis. [...] Interestingly, if the treatment with estrogens is discontinued after 3 yr. of uninterrupted exposure, serum testosterone may remain at castration levels for up to another 3 yr. This prolonged suppression is thought to result from a direct effect of estrogens on the Leydig cells.</q></cite></span></li><li id="cite_note-pmid26082378-203"> <span id="mw-reference-text-cite_note-pmid26082378-203" class="mw-reference-text"><cite id="CITEREFMastLinPikuleva2015" class="citation journal cs1">Mast N, Lin JB, Pikuleva IA (September 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053" class="external text external">"Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy"</a>. <i>Molecular Pharmacology</i>. <b>88</b> (3): 428–36. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fmol.115.099598  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fmol.115.099598'" tppabs="https://doi.org/10.1124%2Fmol.115.099598" class="external text external">10.1124/mol.115.099598</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551053" class="external text external">4551053</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26082378  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26082378'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26082378" class="external text external">26082378</a>.</cite></span></li><li id="cite_note-MastZheng2013-204"> <span id="mw-reference-text-cite_note-MastZheng2013-204" class="mw-reference-text"><cite id="CITEREFMastZhengStoutPikuleva2013" class="citation journal cs1">Mast N, Zheng W, Stout CD, Pikuleva IA (February 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067" class="external text external">"Binding of a cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response"</a>. <i>The Journal of Biological Chemistry</i>. <b>288</b> (7): 4613–24. doi:<a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M112.438754  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M112.438754'" tppabs="https://doi.org/10.1074%2Fjbc.M112.438754" class="external text external">10.1074/jbc.M112.438754</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576067" class="external text external">3576067</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23288837  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23288837'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23288837" class="external text external">23288837</a>.</cite></span></li><li id="cite_note-ZhuLiu2015-205"> <span id="mw-reference-text-cite_note-ZhuLiu2015-205" class="mw-reference-text"><cite id="CITEREFZhuLiuArmstrongLou2015" class="citation journal cs1">Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC (September 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793" class="external text external">"Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer"</a>. <i>Clinical Cancer Research</i>. <b>21</b> (18): 4133–42. doi:<a href="javascript:if(confirm('https://doi.org/10.1158%2F1078-0432.CCR-15-0269  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1078-0432.CCR-15-0269'" tppabs="https://doi.org/10.1158%2F1078-0432.CCR-15-0269" class="external text external">10.1158/1078-0432.CCR-15-0269</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573793" class="external text external">4573793</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25995342  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25995342'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25995342" class="external text external">25995342</a>.</cite></span></li><li id="cite_note-Fenner2015-206"> <span id="mw-reference-text-cite_note-Fenner2015-206" class="mw-reference-text"><cite id="CITEREFFenner2015" class="citation journal cs1">Fenner A (July 2015). "Prostate cancer: Antiandrogens reverse docetaxel resistance via ABCB1 inhibition". <i>Nature Reviews. Urology</i>. <b>12</b> (7): 361. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrurol.2015.135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrurol.2015.135'" tppabs="https://doi.org/10.1038%2Fnrurol.2015.135" class="external text external">10.1038/nrurol.2015.135</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26057062  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26057062'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26057062" class="external text external">26057062</a>.</cite></span></li><li id="cite_note-pmid26309896-207"> <span id="mw-reference-text-cite_note-pmid26309896-207" class="mw-reference-text"><cite id="CITEREFArmstrongGao2015" class="citation journal cs1">Armstrong CM, Gao AC (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108" class="external text external">"Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies"</a>. <i>American Journal of Clinical and Experimental Urology</i>. <b>3</b> (2): 64–76. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539108" class="external text external">4539108</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26309896  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26309896'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26309896" class="external text external">26309896</a>.</cite></span></li><li id="cite_note-FosterCar2011-208"> <span id="mw-reference-text-cite_note-FosterCar2011-208" class="mw-reference-text"><cite class="citation journal cs1">Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM (April 2011). "Drug safety is a barrier to the discovery and development of new androgen receptor antagonists". <i>The Prostate</i>. <b>71</b> (5): 480–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpros.21263  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpros.21263'" tppabs="https://doi.org/10.1002%2Fpros.21263" class="external text external">10.1002/pros.21263</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20878947  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20878947'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20878947" class="external text external">20878947</a>.</cite></span></li><li id="cite_note-BarrishCarter2010-209"> <span id="mw-reference-text-cite_note-BarrishCarter2010-209" class="mw-reference-text"><cite id="CITEREFBarrishCarterCheng2010" class="citation book cs1">Barrish J, Carter P, Cheng P (2010). <a href="javascript:if(confirm('https://books.google.com/books?id=GlrOSAvRlJsC&pg=PA127  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GlrOSAvRlJsC&pg=PA127'" tppabs="https://books.google.com/books?id=GlrOSAvRlJsC&pg=PA127" class="external text external"><i>Accounts in Drug Discovery: Case Studies in Medicinal Chemistry</i></a>. Royal Society of Chemistry. pp.<span>&nbsp;</span>127–. ISBN<span>&nbsp;</span><bdi>978-1-84973-126-3</bdi>.</cite></span></li><li id="cite_note-KolvenbagBlackledge1998-210"> <span id="mw-reference-text-cite_note-KolvenbagBlackledge1998-210" class="mw-reference-text"><cite id="CITEREFKolvenbagBlackledgeGotting-Smith1998" class="citation journal cs1">Kolvenbag GJ, Blackledge GR, Gotting-Smith K (January 1998). "Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development". <i>The Prostate</i>. <b>34</b> (1): 61–72. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N'" tppabs="https://doi.org/10.1002%2F%28SICI%291097-0045%2819980101%2934%3A1%3C61%3A%3AAID-PROS8%3E3.0.CO%3B2-N" class="external text external">10.1002/(SICI)1097-0045(19980101)34:1<span>&lt;</span>61::AID-PROS8<span>&gt;</span>3.0.CO;2-N</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9428389  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9428389'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9428389" class="external text external">9428389</a>.</cite></span></li><li id="cite_note-pmid8717470-211"> <span id="mw-reference-text-cite_note-pmid8717470-211" class="mw-reference-text"><cite id="CITEREFBlackledge1996" class="citation journal cs1">Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". <i>Eur. Urol</i>. 29 Suppl 2: 96–104. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000473847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000473847'" tppabs="https://doi.org/10.1159%2F000473847" class="external text external">10.1159/000473847</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8717470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8717470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8717470" class="external text external">8717470</a>.</cite></span></li><li id="cite_note-Jr.Lawrence2015-212"> <span id="mw-reference-text-cite_note-Jr.Lawrence2015-212" class="mw-reference-text"><cite id="CITEREFDeVita_Jr.LawrenceRosenberg2015" class="citation book cs1">DeVita Jr VT, Lawrence TS, Rosenberg SA (7 January 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1142  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1142'" tppabs="https://books.google.com/books?id=HEAYBgAAQBAJ&pg=PT1142" class="external text external"><i>DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology</i></a>. Wolters Kluwer Health. pp.<span>&nbsp;</span>1142–. ISBN<span>&nbsp;</span><bdi>978-1-4698-9455-3</bdi>.</cite></span></li><li id="cite_note-ChuJr.2012-213"> <span id="mw-reference-text-cite_note-ChuJr.2012-213" class="mw-reference-text"><cite id="CITEREFChuDeVita_Jr.2012" class="citation book cs1">Chu E, DeVita Jr VT (28 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=E_Q8eIxYlHcC&pg=PA51  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=E_Q8eIxYlHcC&pg=PA51'" tppabs="https://books.google.com/books?id=E_Q8eIxYlHcC&pg=PA51" class="external text external"><i>Physicians' Cancer Chemotherapy Drug Manual 2013</i></a>. Jones &amp; Bartlett Publishers. pp.<span>&nbsp;</span>51–. ISBN<span>&nbsp;</span><bdi>978-1-284-04039-5</bdi>.</cite></span></li><li id="cite_note-HelsenVan_den_Broeck2014-214"> <span id="mw-reference-text-cite_note-HelsenVan_den_Broeck2014-214" class="mw-reference-text"><cite id="CITEREFHelsenVan_den_BroeckVoetPrekovic2014" class="citation journal cs1">Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F (August 2014). <a href="javascript:if(confirm('https://doi.org/10.1530/ERC-13-0545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/ERC-13-0545'" tppabs="https://doi.org/10.1530/ERC-13-0545" class="external text external">"Androgen receptor antagonists for prostate cancer therapy"</a>. <i>Endocrine-Related Cancer</i>. <b>21</b> (4): T105-18. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2FERC-13-0545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2FERC-13-0545'" tppabs="https://doi.org/10.1530%2FERC-13-0545" class="external text external">10.1530/ERC-13-0545</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24639562  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24639562'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24639562" class="external text external">24639562</a>.</cite></span></li><li id="cite_note-Furr1989-215"> <span id="mw-reference-text-cite_note-Furr1989-215" class="mw-reference-text"><cite id="CITEREFFurr1989" class="citation journal cs1">Furr BJ (1989). "<span class="cs1-kern-left">"</span>Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies". <i>Hormone Research</i>. 32 Suppl 1 (1): 69–76. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000181315  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000181315'" tppabs="https://doi.org/10.1159%2F000181315" class="external text external">10.1159/000181315</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2533159  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2533159'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2533159" class="external text external">2533159</a>.</cite></span></li><li id="cite_note-FurrValcaccia1987-216"> <span id="mw-reference-text-cite_note-FurrValcaccia1987-216" class="mw-reference-text"><cite id="CITEREFFurrValcacciaCurryWoodburn1987" class="citation journal cs1">Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H (June 1987). "ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen". <i>The Journal of Endocrinology</i>. <b>113</b> (3): R7-9. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Fjoe.0.113R007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Fjoe.0.113R007'" tppabs="https://doi.org/10.1677%2Fjoe.0.113R007" class="external text external">10.1677/joe.0.113R007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3625091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3625091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3625091" class="external text external">3625091</a>.</cite></span></li><li id="cite_note-SolowaySchellhammer1995-217"> <span id="mw-reference-text-cite_note-SolowaySchellhammer1995-217" class="mw-reference-text"><cite id="CITEREFSolowaySchellhammerSmithChodak1995" class="citation journal cs1">Soloway MS, Schellhammer PF, Smith JA, Chodak GW, Vogelzang NJ, Kennealey GT (December 1995). "Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy". <i>The Journal of Urology</i>. <b>154</b> (6): 2110–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0022-5347%2801%2966709-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0022-5347%2801%2966709-0'" tppabs="https://doi.org/10.1016%2FS0022-5347%2801%2966709-0" class="external text external">10.1016/S0022-5347(01)66709-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7500470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7500470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7500470" class="external text external">7500470</a>.</cite></span></li><li id="cite_note-GaoDalton2007-218"> <span id="mw-reference-text-cite_note-GaoDalton2007-218" class="mw-reference-text"><cite id="CITEREFGaoDalton2007" class="citation journal cs1">Gao W, Dalton JT (March 2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879" class="external text external">"Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)"</a>. <i>Drug Discovery Today</i>. <b>12</b> (5–6): 241–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.drudis.2007.01.003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.drudis.2007.01.003'" tppabs="https://doi.org/10.1016%2Fj.drudis.2007.01.003" class="external text external">10.1016/j.drudis.2007.01.003</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072879" class="external text external">2072879</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17331889  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17331889'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17331889" class="external text external">17331889</a>.</cite></span></li><li id="cite_note-pmid16896883-219"> <span id="mw-reference-text-cite_note-pmid16896883-219" class="mw-reference-text"><cite id="CITEREFMason2006" class="citation journal cs1">Mason M (August 2006). "What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?". <i>Journal of Cancer Research and Clinical Oncology</i>. 132 Suppl 1: S27-35. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00432-006-0134-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00432-006-0134-4'" tppabs="https://doi.org/10.1007%2Fs00432-006-0134-4" class="external text external">10.1007/s00432-006-0134-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16896883  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16896883'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16896883" class="external text external">16896883</a>.</cite></span></li><li id="cite_note-LemkeWilliams2012-220"> <span id="mw-reference-text-cite_note-LemkeWilliams2012-220" class="mw-reference-text"><cite id="CITEREFLemkeWilliams2012" class="citation book cs1">Lemke TL, Williams DA (24 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372'" tppabs="https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372" class="external text external"><i>Foye's Principles of Medicinal Chemistry</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1372–1373. ISBN<span>&nbsp;</span><bdi>978-1-60913-345-0</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160503223616/https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160503223616/https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372'" tppabs="https://web.archive.org/web/20160503223616/https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1372" class="external text external">Archived</a> from the original on 3 May 2016.</cite></span></li><li id="cite_note-ButlerGovindan2010-221"> <span id="mw-reference-text-cite_note-ButlerGovindan2010-221" class="mw-reference-text"><cite id="CITEREFButlerGovindan2010" class="citation book cs1">Butler SK, Govindan R (25 October 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=ZC0oMwt1ZKgC&pg=PA49  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ZC0oMwt1ZKgC&pg=PA49'" tppabs="https://books.google.com/books?id=ZC0oMwt1ZKgC&pg=PA49" class="external text external"><i>Essential Cancer Pharmacology: The Prescriber's Guide</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>49–. ISBN<span>&nbsp;</span><bdi>978-1-60913-704-5</bdi>.</cite></span></li><li id="cite_note-pmid14748655-222"> <span id="mw-reference-text-cite_note-pmid14748655-222" class="mw-reference-text"><cite id="CITEREFFradet2004" class="citation journal cs1">Fradet Y (February 2004). "Bicalutamide (Casodex) in the treatment of prostate cancer". <i>Expert Review of Anticancer Therapy</i>. <b>4</b> (1): 37–48. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F14737140.4.1.37  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F14737140.4.1.37'" tppabs="https://doi.org/10.1586%2F14737140.4.1.37" class="external text external">10.1586/14737140.4.1.37</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14748655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14748655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14748655" class="external text external">14748655</a>. <q>In contrast, the incidence of diarrhea was comparable between the bicalutamide and placebo groups (6.3 vs. 6.4%, respectively) in the EPC program [71].</q></cite></span></li><li id="cite_note-pmid22495777-223"> <span id="mw-reference-text-cite_note-pmid22495777-223" class="mw-reference-text"><cite id="CITEREFSharmaPawarGiriRajagopal2012" class="citation journal cs1">Sharma K, Pawar GV, Giri S, Rajagopal S, Mullangi R (2012). "Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study". <i>Biomedical Chromatography</i>. <b>26</b> (12): 1589–95. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fbmc.2736  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fbmc.2736'" tppabs="https://doi.org/10.1002%2Fbmc.2736" class="external text external">10.1002/bmc.2736</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22495777  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22495777'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22495777" class="external text external">22495777</a>.</cite></span></li><li id="cite_note-AndersonKnoben2001-224"> <span id="mw-reference-text-cite_note-AndersonKnoben2001-224" class="mw-reference-text"><cite id="CITEREFAndersonKnobenTroutman2001" class="citation book cs1">Anderson PO, Knoben JE, Troutman WG (22 August 2001). <a href="javascript:if(confirm('https://books.google.com/books?id=40UJmr_6WQ4C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=40UJmr_6WQ4C'" tppabs="https://books.google.com/books?id=40UJmr_6WQ4C" class="external text external"><i>Handbook of Clinical Drug Data</i></a>. <i>Canadian Medical Association Journal</i>. <b>128</b>. McGraw Hill Professional. p.<span>&nbsp;</span>245. ISBN<span>&nbsp;</span><bdi>978-0-07-138942-6</bdi>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1875767  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1875767'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1875767" class="external text external">1875767</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20313924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20313924'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20313924" class="external text external">20313924</a>. <q>With an oral dose of 50 mg/day, bicalutamide attains a peak serum level of 8.9 mg/L (21 μmol/L) 31 hr after a dose at steady state. CI of (R)-bicalutamide is 0.32 L/hr. The active (R)-enantiomer of bicalutamide is oxidized to an inactive metabolite, which, like the inactive (S)-enantiomer, is glucuronidated and cleared rapidly by elimination in the urine and feces.165</q></cite></span></li><li id="cite_note-Publishing2013-225"> <span id="mw-reference-text-cite_note-Publishing2013-225" class="mw-reference-text"><cite id="CITEREFMcPherson2013" class="citation book cs1">McPherson EM (22 October 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627'" tppabs="https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627" class="external text external"><i>Pharmaceutical Manufacturing Encyclopedia</i></a> (3rd ed.). William Andrew Publishing. pp.<span>&nbsp;</span>627, 1695. ISBN<span>&nbsp;</span><bdi>978-0-8155-1856-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160609223817/https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160609223817/https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627'" tppabs="https://web.archive.org/web/20160609223817/https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA627" class="external text external">Archived</a> from the original on 9 June 2016.</cite></span></li><li id="cite_note-KomstaWaksmundzka-Hajnos2013-226"> <span id="mw-reference-text-cite_note-KomstaWaksmundzka-Hajnos2013-226" class="mw-reference-text"><cite id="CITEREFKomstaWaksmundzka-HajnosSherma2013" class="citation book cs1">Komsta L, Waksmundzka-Hajnos M, Sherma J (20 December 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=LSEtAgAAQBAJ&pg=PA652  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=LSEtAgAAQBAJ&pg=PA652'" tppabs="https://books.google.com/books?id=LSEtAgAAQBAJ&pg=PA652" class="external text external"><i>Thin Layer Chromatography in Drug Analysis</i></a>. CRC Press. pp.<span>&nbsp;</span>652–. ISBN<span>&nbsp;</span><bdi>978-1-4665-0715-9</bdi>.</cite></span></li><li id="cite_note-pmid21369450-227"> <span id="mw-reference-text-cite_note-pmid21369450-227" class="mw-reference-text"><cite id="CITEREFSanchetiVyasShahKarekar2008" class="citation journal cs1">Sancheti PP, Vyas VM, Shah M, Karekar P, Pore YV (2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883" class="external text external">"Spectrophotometric estimation of bicalutamide in tablets"</a>. <i>Indian Journal of Pharmaceutical Sciences</i>. <b>70</b> (6): 810–2. doi:<a href="javascript:if(confirm('https://doi.org/10.4103%2F0250-474X.49131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4103%2F0250-474X.49131'" tppabs="https://doi.org/10.4103%2F0250-474X.49131" class="external text external">10.4103/0250-474X.49131</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040883" class="external text external">3040883</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21369450  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21369450'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21369450" class="external text external">21369450</a>.</cite></span></li><li id="cite_note-MohlerBohl2009-228"> <span id="mw-reference-text-cite_note-MohlerBohl2009-228" class="mw-reference-text"><cite id="CITEREFMohlerBohlJonesCoss2009" class="citation journal cs1">Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD (June 2009). "Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit". <i>Journal of Medicinal Chemistry</i>. <b>52</b> (12): 3597–617. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm900280m  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm900280m'" tppabs="https://doi.org/10.1021%2Fjm900280m" class="external text external">10.1021/jm900280m</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19432422  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19432422'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19432422" class="external text external">19432422</a>. <q>[C]linically relevant antiandrogens currently are nonsteroidal anilide derivatives. Antiandrogens used for prostate cancer include the monoarylpropionamide flutamide (1) (a prodrug of hydroxyflutamide (2)),29–31 the hydantoin nilutamide(3),32–34 and the diarylpropionamide bicalutamide (4) (Chart1).35–37</q></cite></span></li><li id="cite_note-BéguéBonnet-Delpon2008-229"> <span id="mw-reference-text-cite_note-BéguéBonnet-Delpon2008-229" class="mw-reference-text"><cite id="CITEREFBéguéBonnet-Delpon2008" class="citation book cs1">Bégué J, Bonnet-Delpon D (2 June 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327'" tppabs="https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327" class="external text external"><i>Bioorganic and Medicinal Chemistry of Fluorine</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>327–. ISBN<span>&nbsp;</span><bdi>978-0-470-28187-1</bdi>.</cite></span></li><li id="cite_note-BallKamalian2016-230"> <span id="mw-reference-text-cite_note-BallKamalian2016-230" class="mw-reference-text"><cite id="CITEREFBallKamalianAlfirevicLyon2016" class="citation journal cs1">Ball AL, Kamalian L, Alfirevic A, Lyon JJ, Chadwick AE (July 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617" class="external text external">"Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells"</a>. <i>Toxicological Sciences</i>. <b>153</b> (2): 341–351. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Ftoxsci%2Fkfw126  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Ftoxsci%2Fkfw126'" tppabs="https://doi.org/10.1093%2Ftoxsci%2Fkfw126" class="external text external">10.1093/toxsci/kfw126</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036617" class="external text external">5036617</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27413113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27413113'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27413113" class="external text external">27413113</a>.</cite></span></li><li id="cite_note-pmid16821162-231"> <span id="mw-reference-text-cite_note-pmid16821162-231" class="mw-reference-text"><cite id="CITEREFHermkensKampLusherVeeneman2006" class="citation journal cs1">Hermkens PH, Kamp S, Lusher S, Veeneman GH (July 2006). "Non-steroidal steroid receptor modulators". <i>IDrugs</i>. <b>9</b> (7): 488–94. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F0929867053764671  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F0929867053764671'" tppabs="https://doi.org/10.2174%2F0929867053764671" class="external text external">10.2174/0929867053764671</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16821162  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16821162'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16821162" class="external text external">16821162</a>.</cite></span></li><li id="cite_note-AvramRogers2009-232"> <span id="mw-reference-text-cite_note-AvramRogers2009-232" class="mw-reference-text"><cite id="CITEREFAvramRogers2009" class="citation book cs1">Avram MR, Rogers NE (30 November 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=j1XF1bnABFcC&pg=PA11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=j1XF1bnABFcC&pg=PA11'" tppabs="https://books.google.com/books?id=j1XF1bnABFcC&pg=PA11" class="external text external"><i>Hair Transplantation</i></a>. Cambridge University Press. pp.<span>&nbsp;</span>11–. ISBN<span>&nbsp;</span><bdi>978-1-139-48339-1</bdi>.</cite></span></li><li id="cite_note-HaberStough2006-233"> <span id="mw-reference-text-cite_note-HaberStough2006-233" class="mw-reference-text"><cite id="CITEREFHaberStough2006" class="citation book cs1">Haber RS, Stough DB (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6'" tppabs="https://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6" class="external text external"><i>Hair Transplantation</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>6–7. ISBN<span>&nbsp;</span><bdi>978-1-4160-3104-8</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140704201433/http://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140704201433/http://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6'" tppabs="https://web.archive.org/web/20140704201433/http://books.google.com/books?id=PXJMqrbk-fAC&pg=PA6" class="external text external">Archived</a> from the original on 4 July 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">28 May</span> 2012</span>.</cite></span></li><li id="cite_note-KawaharaMiyamoto2014-234"> <span id="mw-reference-text-cite_note-KawaharaMiyamoto2014-234" class="mw-reference-text"><cite id="CITEREFKawaharaMinamoto2014" class="citation journal cs1">Kawahara T, Minamoto H (2014). "Androgen Receptor Antagonists in the Treatment of Prostate Cancer". <i>Clinical Immunology, Endocrine &amp; Metabolic Drugs</i>. <b>1</b> (1): 11–19. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F22127070114019990002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F22127070114019990002'" tppabs="https://doi.org/10.2174%2F22127070114019990002" class="external text external">10.2174/22127070114019990002</a>.</cite></span></li><li id="cite_note-pmid26137992-235"> <span id="mw-reference-text-cite_note-pmid26137992-235" class="mw-reference-text"><cite id="CITEREFMoilanenRiikonenOksalaRavanti2015" class="citation journal cs1">Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykänen PS, Törmäkangas OP, Palvimo JJ, Kallio PJ (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394" class="external text external">"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies"</a>. <i>Sci Rep</i>. <b>5</b>: 12007. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsrep12007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsrep12007'" tppabs="https://doi.org/10.1038%2Fsrep12007" class="external text external">10.1038/srep12007</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490394" class="external text external">4490394</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26137992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26137992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26137992" class="external text external">26137992</a>.</cite></span></li><li id="cite_note-SegalNarayanan2006-236"> <span id="mw-reference-text-cite_note-SegalNarayanan2006-236" class="mw-reference-text"><cite id="CITEREFSegalNarayananDalton2006" class="citation journal cs1">Segal S, Narayanan R, Dalton JT (April 2006). "Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery". <i>Expert Opinion on Investigational Drugs</i>. <b>15</b> (4): 377–87. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F13543784.15.4.377  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F13543784.15.4.377'" tppabs="https://doi.org/10.1517%2F13543784.15.4.377" class="external text external">10.1517/13543784.15.4.377</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16548787  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16548787'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16548787" class="external text external">16548787</a>. <q>Structural modifications of bicalutamide led to the discovery of the first nonsteroidal androgens (the aryl propionamides) in 1998. Lead compounds in this class (denoted S1 and S4 in published literature) not only bind to the AR with high affinity (low nanomolar range), but also demonstrate tissue selectivity in animal models [46,50].</q></cite></span></li><li id="cite_note-Yin2002-237"> <span id="mw-reference-text-cite_note-Yin2002-237" class="mw-reference-text"><cite id="CITEREFYinGaoKearbeyXu2003" class="citation journal cs1">Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT (March 2003). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238" class="external text external">"Pharmacodynamics of selective androgen receptor modulators"</a>. <i>The Journal of Pharmacology and Experimental Therapeutics</i>. <b>304</b> (3): 1334–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fjpet.102.040840  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fjpet.102.040840'" tppabs="https://doi.org/10.1124%2Fjpet.102.040840" class="external text external">10.1124/jpet.102.040840</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040238" class="external text external">2040238</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12604714  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12604714'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12604714" class="external text external">12604714</a>.</cite></span></li><li id="cite_note-OttowWeinmann2008-238"> <span id="mw-reference-text-cite_note-OttowWeinmann2008-238" class="mw-reference-text"><cite id="CITEREFOttowWeinmann2008" class="citation book cs1">Ottow E, Weinmann H (8 September 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=iATfLbPgRugC&pg=PA257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=iATfLbPgRugC&pg=PA257'" tppabs="https://books.google.com/books?id=iATfLbPgRugC&pg=PA257" class="external text external"><i>Nuclear Receptors as Drug Targets</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>257–258. ISBN<span>&nbsp;</span><bdi>978-3-527-62330-3</bdi>.</cite></span></li><li id="cite_note-pmid17328524-239"> <span id="mw-reference-text-cite_note-pmid17328524-239" class="mw-reference-text"><cite id="CITEREFParentDenceJenksSharp2007" class="citation journal cs1">Parent EE, Dence CS, Jenks C, Sharp TL, Welch MJ, Katzenellenbogen JA (2007). "Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging". <i>J. Med. Chem</i>. <b>50</b> (5): 1028–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm060847r  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm060847r'" tppabs="https://doi.org/10.1021%2Fjm060847r" class="external text external">10.1021/jm060847r</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17328524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17328524'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17328524" class="external text external">17328524</a>.</cite></span></li><li id="cite_note-DierckxOtte2014-240"> <span id="mw-reference-text-cite_note-DierckxOtte2014-240" class="mw-reference-text"><cite id="CITEREFDierckxOttede_Vriesvan_Waarde2014" class="citation book cs1">Dierckx RA, Otte A, de Vries EF, van Waarde A, Luiten PG (15 February 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=LN64BAAAQBAJ&pg=PA394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=LN64BAAAQBAJ&pg=PA394'" tppabs="https://books.google.com/books?id=LN64BAAAQBAJ&pg=PA394" class="external text external"><i>PET and SPECT of Neurobiological Systems</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>394–. ISBN<span>&nbsp;</span><bdi>978-3-642-42014-6</bdi>.</cite></span></li><li id="cite_note-pmid28981251-241"> <span id="mw-reference-text-cite_note-pmid28981251-241" class="mw-reference-text"><cite id="CITEREFde_Jesus_CortezNguyenTruilletTian2017" class="citation journal cs1">de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, Webb P, Jacobson MP, Fletterick RJ, England PM (2017). "Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen". <i>ACS Chem. Biol</i>. <b>12</b> (12): 2934–2939. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Facschembio.7b00702  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Facschembio.7b00702'" tppabs="https://doi.org/10.1021%2Facschembio.7b00702" class="external text external">10.1021/acschembio.7b00702</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28981251  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28981251'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28981251" class="external text external">28981251</a>.</cite></span></li><li id="cite_note-US20170101384-242"> <span id="mw-reference-text-cite_note-US20170101384-242" class="mw-reference-text">Pamela, M., Fletterick, R. J., Kuchenbecker, K., &amp; de Jesus Cortez, F. (2016). U.S. Patent Application No. 15/382,942. <a href="javascript:if(confirm('https://www.google.com/patents/US20170101384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.google.com/patents/US20170101384'" tppabs="https://www.google.com/patents/US20170101384" class="external free external">https://www.google.com/patents/US20170101384</a></span></li><li id="cite_note-pmid3361581-243"> <span id="mw-reference-text-cite_note-pmid3361581-243" class="mw-reference-text"><cite id="CITEREFTuckerCrookChesterson1988" class="citation journal cs1">Tucker H, Crook JW, Chesterson GJ (1988). "Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides". <i>Journal of Medicinal Chemistry</i>. <b>31</b> (5): 954–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm00400a011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm00400a011'" tppabs="https://doi.org/10.1021%2Fjm00400a011" class="external text external">10.1021/jm00400a011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3361581  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3361581'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3361581" class="external text external">3361581</a>.</cite></span></li><li id="cite_note-JamesEkwuribe2002-244"> <span id="mw-reference-text-cite_note-JamesEkwuribe2002-244" class="mw-reference-text"><cite id="CITEREFJamesEkwuribe2002" class="citation journal cs1">James KD, Ekwuribe NN (2002). "A Two-step Synthesis of the Anti-cancer Drug (R,S)-Bicalutamide". <i>Synthesis</i>. <b>2002</b> (7): 850–2. doi:<a href="javascript:if(confirm('https://doi.org/10.1055%2Fs-2002-28508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1055%2Fs-2002-28508'" tppabs="https://doi.org/10.1055%2Fs-2002-28508" class="external text external">10.1055/s-2002-28508</a>.</cite></span></li><li id="cite_note-245"> <span id="mw-reference-text-cite_note-245" class="mw-reference-text"><span class="citation patent" id="CITEREFPizzetti_E,_Vigano_E,_Lussana_M,_Landonio_E2020"><a href="javascript:if(confirm('https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060223&CC=US&NR=2006041161A1&KC=A1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060223&CC=US&NR=2006041161A1&KC=A1'" tppabs="https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060223&CC=US&NR=2006041161A1&KC=A1" class="external text external">US<span> </span>application 2006/0041161</a>,<span> </span>Pizzetti E, Vigano E, Lussana M, Landonio  E,<span> </span>"Procedure for the synthesis of bicalutamide",<span> </span>published 23 February 2006</span></span></li><li id="cite_note-ChandShukla2012-246"> <span id="mw-reference-text-cite_note-ChandShukla2012-246" class="mw-reference-text"><cite id="CITEREFChandShukla2012" class="citation report cs1">Chand M, Shukla AK (2012). Novel Synthesis of Bicalutamide Drug Substance and their Impurities using Imidazolium Type of Ionic Liquid (Report). doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.2139%2Fssrn.2160199  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2139%2Fssrn.2160199'" tppabs="https://doi.org/10.2139%2Fssrn.2160199" class="external text external">10.2139/ssrn.2160199</a></span>. SSRN<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://ssrn.com/abstract=2160199  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ssrn.com/abstract=2160199'" tppabs="https://ssrn.com/abstract=2160199" class="external text external">2160199</a></span>.</cite></span></li><li id="cite_note-Diamanti-Kandarakis_1999-247"> <span id="mw-reference-text-cite_note-Diamanti-Kandarakis_1999-247" class="mw-reference-text"><cite id="CITEREFDiamanti-Kandarakis1999" class="citation journal cs1">Diamanti-Kandarakis E (September 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717'" tppabs="https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA717" class="external text external">"Current aspects of antiandrogen therapy in women"</a>. <i>Current Pharmaceutical Design</i>. <b>5</b> (9): 707–23. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10495361  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10495361'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10495361" class="external text external">10495361</a>. <q>Several trials demonstrated complete clearing of acne with flutamide [62,77]. Flutamide used in combination with an [oral contraceptive], at a dose of 500mg/d, flutamide caused a dramatic decrease (80%) in total acne, seborrhea and hair loss score after only 3 months of therapy [53]. When used as a monotherapy in lean and obese PCOS, it significantly improves the signs of hyperandrogenism, hirsutism and particularly acne [48]. [...] flutamide 500mg/d combined with an [oral contraceptive] caused an increase in cosmetically acceptable hair density, in sex of seven women suffering from diffuse androgenetic alopecia [53].</q></cite></span></li><li id="cite_note-DenisGriffiths1999-248"> <span id="mw-reference-text-cite_note-DenisGriffiths1999-248" class="mw-reference-text"><cite id="CITEREFDenisGriffithsKaisaryMurphy1999" class="citation book cs1">Denis LJ, Griffiths K, Kaisary AV, Murphy GP (1 March 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=GreZlojD-tYC&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GreZlojD-tYC&pg=PA280'" tppabs="https://books.google.com/books?id=GreZlojD-tYC&pg=PA280" class="external text external"><i>Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment</i></a>. CRC Press. pp.<span>&nbsp;</span>55, 279–280. ISBN<span>&nbsp;</span><bdi>978-1-85317-422-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160603180141/https://books.google.com/books?id=GreZlojD-tYC&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160603180141/https://books.google.com/books?id=GreZlojD-tYC&pg=PA280'" tppabs="https://web.archive.org/web/20160603180141/https://books.google.com/books?id=GreZlojD-tYC&pg=PA280" class="external text external">Archived</a> from the original on 3 June 2016.</cite></span></li><li id="cite_note-Elks2014-2-249"> <span id="mw-reference-text-cite_note-Elks2014-2-249" class="mw-reference-text"><cite id="CITEREFElks2014" class="citation book cs1">Elks J (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. pp.<span>&nbsp;</span>573–. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160515085843/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160515085843/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573'" tppabs="https://web.archive.org/web/20160515085843/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA573" class="external text external">Archived</a> from the original on 15 May 2016.</cite></span></li><li id="cite_note-pmid11844311-250"> <span id="mw-reference-text-cite_note-pmid11844311-250" class="mw-reference-text"><cite id="CITEREFFurr1998" class="citation journal cs1">Furr BJ (1998). "Research on reproductive medicine in the pharmaceutical industry". <i>Hum Fertil (Camb)</i>. <b>1</b> (1): 56–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F1464727982000198131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F1464727982000198131'" tppabs="https://doi.org/10.1080%2F1464727982000198131" class="external text external">10.1080/1464727982000198131</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11844311  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11844311'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11844311" class="external text external">11844311</a>.</cite></span></li><li id="cite_note-pmid16515480-251"> <span id="mw-reference-text-cite_note-pmid16515480-251" class="mw-reference-text"><cite id="CITEREFCadillaTurnbull2006" class="citation journal cs1">Cadilla R, Turnbull P (2006). <a href="javascript:if(confirm('https://zenodo.org/record/1154960  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://zenodo.org/record/1154960'" tppabs="https://zenodo.org/record/1154960" class="external text external">"Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential"</a>. <i>Curr Top Med Chem</i>. <b>6</b> (3): 245–70. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F156802606776173456  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F156802606776173456'" tppabs="https://doi.org/10.2174%2F156802606776173456" class="external text external">10.2174/156802606776173456</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16515480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16515480'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16515480" class="external text external">16515480</a>.</cite></span></li><li id="cite_note-EngelKleemann2014-252"> <span id="mw-reference-text-cite_note-EngelKleemann2014-252" class="mw-reference-text"><cite id="CITEREFEngelKleemannKutscherReichert2009" class="citation book cs1">Engel J, Kleemann A, Kutscher B, Reichert D (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA153'" tppabs="https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA153" class="external text external"><i>Pharmaceutical Substances: Syntheses, Patents and Applications of the most relevant APIs</i></a> (5th ed.). Thieme. pp.<span>&nbsp;</span>153–154. ISBN<span>&nbsp;</span><bdi>978-3-13-179275-4</bdi>.</cite></span></li><li id="cite_note-pmid3625091-253"> <span id="mw-reference-text-cite_note-pmid3625091-253" class="mw-reference-text"><cite class="citation journal cs1">Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H (June 1987). "ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen". <i>The Journal of Endocrinology</i>. <b>113</b> (3): R7-9. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Fjoe.0.113r007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Fjoe.0.113r007'" tppabs="https://doi.org/10.1677%2Fjoe.0.113r007" class="external text external">10.1677/joe.0.113r007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3625091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3625091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3625091" class="external text external">3625091</a>.</cite></span></li><li id="cite_note-pmid2094607-254"> <span id="mw-reference-text-cite_note-pmid2094607-254" class="mw-reference-text"><cite id="CITEREFNewling1990" class="citation journal cs1">Newling DW (1990). "The response of advanced prostatic cancer to a new non-steroidal antiandrogen: results of a multicenter open phase II study of Casodex. European/Australian Co-operative Group". <i>European Urology</i>. 18 Suppl 3: 18–21. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000463973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000463973'" tppabs="https://doi.org/10.1159%2F000463973" class="external text external">10.1159/000463973</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2094607  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2094607'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2094607" class="external text external">2094607</a>.</cite></span></li><li id="cite_note-Patents1997-255"> <span id="mw-reference-text-cite_note-Patents1997-255" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=kNlKAQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=kNlKAQAAIAAJ'" tppabs="https://books.google.com/books?id=kNlKAQAAIAAJ" class="external text external"><i>The United States Patents Quarterly</i></a>. Associated Industry Publications. 1997.</cite></span></li><li id="cite_note-ChaurasiyaSingh2012-256"> <span id="mw-reference-text-cite_note-ChaurasiyaSingh2012-256" class="mw-reference-text"><cite id="CITEREFChaurasiyaSinghUpadhyayAsati2012" class="citation journal cs1">Chaurasiya A, Singh AK, Upadhyay SC, Asati D, Ahmad FJ, Mukherjee R, Khar RK (2012). "Lipidic Nanocarrier for Oral Bioavailability Enhancement of an Anticancer Agent: Formulation Design and Evaluation". <i>Advanced Science Letters</i>. <b>11</b> (1): 43–52. doi:<a href="javascript:if(confirm('https://doi.org/10.1166%2Fasl.2012.2170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1166%2Fasl.2012.2170'" tppabs="https://doi.org/10.1166%2Fasl.2012.2170" class="external text external">10.1166/asl.2012.2170</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1936-6612  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1936-6612'" tppabs="https://www.worldcat.org/issn/1936-6612" class="external text external">1936-6612</a>.</cite></span></li><li id="cite_note-Klotz2006-257"> <span id="mw-reference-text-cite_note-Klotz2006-257" class="mw-reference-text"><cite id="CITEREFKlotz2006" class="citation journal cs1">Klotz L (May 2006). "Combined androgen blockade: an update". <i>The Urologic Clinics of North America</i>. <b>33</b> (2): 161–6, v–vi. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ucl.2005.12.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ucl.2005.12.001'" tppabs="https://doi.org/10.1016%2Fj.ucl.2005.12.001" class="external text external">10.1016/j.ucl.2005.12.001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16631454  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16631454'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16631454" class="external text external">16631454</a>.</cite></span></li><li id="cite_note-pmid26236143-258"> <span id="mw-reference-text-cite_note-pmid26236143-258" class="mw-reference-text"><cite id="CITEREFGohil2015" class="citation journal cs1">Gohil K (August 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537" class="external text external">"Exciting Therapies Ahead in Prostate Cancer"</a>. <i>P &amp; T</i>. <b>40</b> (8): 530–1. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517537" class="external text external">4517537</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26236143  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26236143'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26236143" class="external text external">26236143</a>.</cite></span></li><li id="cite_note-pmid11502439-259"> <span id="mw-reference-text-cite_note-pmid11502439-259" class="mw-reference-text"><cite id="CITEREFKolvenbagIversenNewling2001" class="citation journal cs1">Kolvenbag GJ, Iversen P, Newling DW (2001). "Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer". <i>Urology</i>. <b>58</b> (2 Suppl 1): 16–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0090-4295%2801%2901237-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0090-4295%2801%2901237-7'" tppabs="https://doi.org/10.1016%2Fs0090-4295%2801%2901237-7" class="external text external">10.1016/s0090-4295(01)01237-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11502439  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11502439'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11502439" class="external text external">11502439</a>.</cite></span></li><li id="cite_note-CarswellFiggitt2002-260"> <span id="mw-reference-text-cite_note-CarswellFiggitt2002-260" class="mw-reference-text"><cite id="CITEREFCarswellFiggitt2002" class="citation journal cs1">Carswell CI, Figgitt DP (2002). "Bicalutamide: in early-stage prostate cancer". <i>Drugs</i>. <b>62</b> (17): 2471–79, discussion 2480–1. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200262170-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200262170-00006'" tppabs="https://doi.org/10.2165%2F00003495-200262170-00006" class="external text external">10.2165/00003495-200262170-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12421104  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12421104'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12421104" class="external text external">12421104</a>.</cite></span></li><li id="cite_note-JasminCapanna2005-261"> <span id="mw-reference-text-cite_note-JasminCapanna2005-261" class="mw-reference-text"><cite id="CITEREFJasminCapannaCoiaColeman2005" class="citation book cs1">Jasmin C, Capanna R, Coia L, Coleman R, Saillant G (27 September 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=7vPj2a_93tEC&pg=PA493  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7vPj2a_93tEC&pg=PA493'" tppabs="https://books.google.com/books?id=7vPj2a_93tEC&pg=PA493" class="external text external"><i>Textbook of Bone Metastases</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>493–. ISBN<span>&nbsp;</span><bdi>978-0-470-01160-7</bdi>.</cite></span></li><li id="cite_note-pmid17199134-262"> <span id="mw-reference-text-cite_note-pmid17199134-262" class="mw-reference-text"><cite id="CITEREFUsamiAkazaAraiHirano2007" class="citation journal cs1">Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y (2007). <a href="javascript:if(confirm('https://doi.org/10.1038/sj.pcan.4500934  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/sj.pcan.4500934'" tppabs="https://doi.org/10.1038/sj.pcan.4500934" class="external text external">"Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients"</a>. <i>Prostate Cancer Prostatic Dis</i>. <b>10</b> (2): 194–201. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.pcan.4500934  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.pcan.4500934'" tppabs="https://doi.org/10.1038%2Fsj.pcan.4500934" class="external text external">10.1038/sj.pcan.4500934</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17199134  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17199134'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17199134" class="external text external">17199134</a>. <q>In most countries, bicalutamide is given at a dose of 50 mg when used in combination with an LHRH-A. However, based on pharmacokinetic and pharmacodynamic data, the approved dose of bicalutamide in Japanese men is 80 mg per day.</q></cite></span></li><li id="cite_note-pmid18093474-263"> <span id="mw-reference-text-cite_note-pmid18093474-263" class="mw-reference-text"><cite id="CITEREFShahaniFleshnerZlotta2007" class="citation journal cs1">Shahani R, Fleshner NE, Zlotta AR (2007). <a href="javascript:if(confirm('http://www.discoverymedicine.com/Rohan-Shahani/2009/07/29/pharmacotherapy-for-prostate-cancer-the-role-of-hormonal-treatment/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.discoverymedicine.com/Rohan-Shahani/2009/07/29/pharmacotherapy-for-prostate-cancer-the-role-of-hormonal-treatment/'" tppabs="http://www.discoverymedicine.com/Rohan-Shahani/2009/07/29/pharmacotherapy-for-prostate-cancer-the-role-of-hormonal-treatment/" class="external text external">"Pharmacotherapy for prostate cancer: the role of hormonal treatment"</a>. <i>Discovery Medicine</i>. <b>7</b> (39): 118–24. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18093474  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18093474'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18093474" class="external text external">18093474</a>.</cite></span></li><li id="cite_note-BowsherCarter2008-264"> <span id="mw-reference-text-cite_note-BowsherCarter2008-264" class="mw-reference-text"><cite id="CITEREFBowsherCarter2008" class="citation book cs1">Bowsher W, Carter A (15 April 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=E3VNhLkqPmUC&pg=PA146  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=E3VNhLkqPmUC&pg=PA146'" tppabs="https://books.google.com/books?id=E3VNhLkqPmUC&pg=PA146" class="external text external"><i>Challenges in Prostate Cancer</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>146–. ISBN<span>&nbsp;</span><bdi>978-1-4051-7177-9</bdi>.</cite></span></li><li id="cite_note-Nations2005-265"> <span id="mw-reference-text-cite_note-Nations2005-265" class="mw-reference-text"><cite id="CITEREFUnited_Nations2005" class="citation book cs1">United Nations (2005). <a href="javascript:if(confirm('https://books.google.com/books?id=SH80iutLs98C&pg=PA4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=SH80iutLs98C&pg=PA4'" tppabs="https://books.google.com/books?id=SH80iutLs98C&pg=PA4" class="external text external"><i>Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments: Pharmaceuticals</i></a>. United Nations Publications. pp.<span>&nbsp;</span>4–. ISBN<span>&nbsp;</span><bdi>978-92-1-130241-7</bdi>.</cite></span></li><li id="cite_note-Bono2004-266"> <span id="mw-reference-text-cite_note-Bono2004-266" class="mw-reference-text"><cite id="CITEREFBono2004" class="citation journal cs1">Bono AV (2004). "Overview of Current Treatment Strategies in Prostate Cancer". <i>European Urology Supplements</i>. <b>3</b> (1): 2–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.eursup.2003.12.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.eursup.2003.12.002'" tppabs="https://doi.org/10.1016%2Fj.eursup.2003.12.002" class="external text external">10.1016/j.eursup.2003.12.002</a>. <q>The Canadian Health Authorities have withdrawn the approval for antiandrogen monotherapy with bicalutamide for the treatment of localised prostate cancer [5]. Several European countries have also withdrawn approval for bicalutamide for this indication.</q></cite></span></li><li id="cite_note-NargundRaghavan2015-267"> <span id="mw-reference-text-cite_note-NargundRaghavan2015-267" class="mw-reference-text"><cite id="CITEREFNargundRaghavanSandler2015" class="citation book cs1">Nargund VH, Raghavan D, Sandler HM (17 January 2015). <a href="javascript:if(confirm('https://books.google.com/books?id=WmgzBgAAQBAJ&pg=PA823  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WmgzBgAAQBAJ&pg=PA823'" tppabs="https://books.google.com/books?id=WmgzBgAAQBAJ&pg=PA823" class="external text external"><i>Urological Oncology</i></a>. Springer. pp.<span>&nbsp;</span>823–. ISBN<span>&nbsp;</span><bdi>978-0-85729-482-1</bdi>. <q>On the other hand, the 150 mg dose of bicalutamide has been associated with some safety concerns, such as a higher death rate when added to active surveillance in the early prostate cancer trialists group study [29], which has led the United States and Canada to recommend against prescribing the 150 mg dose [30].</q></cite></span></li><li id="cite_note-Moul2009-268"> <span id="mw-reference-text-cite_note-Moul2009-268" class="mw-reference-text"><cite id="CITEREFMoul2009" class="citation journal cs1">Moul JW (August 2009). "Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer". <i>Cancer</i>. <b>115</b> (15): 3376–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcncr.24393  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcncr.24393'" tppabs="https://doi.org/10.1002%2Fcncr.24393" class="external text external">10.1002/cncr.24393</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19484788  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19484788'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19484788" class="external text external">19484788</a>.</cite></span></li><li id="cite_note-Kampel2012-269"> <span id="mw-reference-text-cite_note-Kampel2012-269" class="mw-reference-text"><cite id="CITEREFKampel2012" class="citation book cs1">Kampel LJ (20 March 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=ueWH2bOXmEQC&pg=PA178  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=ueWH2bOXmEQC&pg=PA178'" tppabs="https://books.google.com/books?id=ueWH2bOXmEQC&pg=PA178" class="external text external"><i>Dx/Rx: Prostate Cancer</i></a>. Jones &amp; Bartlett Publishers. pp.<span>&nbsp;</span>178–. ISBN<span>&nbsp;</span><bdi>978-0-7637-9453-8</bdi>.</cite></span></li><li id="cite_note-TobiasHochhauser2014-270"> <span id="mw-reference-text-cite_note-TobiasHochhauser2014-270" class="mw-reference-text"><cite id="CITEREFTobiasHochhauser2014" class="citation book cs1">Tobias JS, Hochhauser D (3 October 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=CXjDBAAAQBAJ&pg=PA379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=CXjDBAAAQBAJ&pg=PA379'" tppabs="https://books.google.com/books?id=CXjDBAAAQBAJ&pg=PA379" class="external text external"><i>Cancer and its Management</i></a>. Wiley. pp.<span>&nbsp;</span>379–. ISBN<span>&nbsp;</span><bdi>978-1-118-46871-5</bdi>.</cite></span></li><li id="cite_note-Neal1994-271"> <span id="mw-reference-text-cite_note-Neal1994-271" class="mw-reference-text"><cite id="CITEREFNeal1994" class="citation book cs1">Neal DE (1994). <a href="javascript:if(confirm('https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233'" tppabs="https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233" class="external text external"><i>Tumours in Urology</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>233–. ISBN<span>&nbsp;</span><bdi>978-1-4471-2086-5</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160427062731/https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160427062731/https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233'" tppabs="https://web.archive.org/web/20160427062731/https://books.google.com/books?id=k28yBwAAQBAJ&pg=PT233" class="external text external">Archived</a> from the original on 27 April 2016.</cite></span></li><li id="cite_note-Regitz-Zagrosek2012-272"> <span id="mw-reference-text-cite_note-Regitz-Zagrosek2012-272" class="mw-reference-text"><cite id="CITEREFRegitz-Zagrosek2012" class="citation book cs1">Regitz-Zagrosek V (2 October 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575'" tppabs="https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575" class="external text external"><i>Sex and Gender Differences in Pharmacology</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>575–. ISBN<span>&nbsp;</span><bdi>978-3-642-30725-6</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160624054637/https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160624054637/https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575'" tppabs="https://web.archive.org/web/20160624054637/https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575" class="external text external">Archived</a> from the original on 24 June 2016.</cite></span></li><li id="cite_note-pmid15833816-273"> <span id="mw-reference-text-cite_note-pmid15833816-273" class="mw-reference-text"><cite id="CITEREFBohlGaoMillerBell2005" class="citation journal cs1">Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (April 2005). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923" class="external text external">"Structural basis for antagonism and resistance of bicalutamide in prostate cancer"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>102</b> (17): 6201–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.0500381102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.0500381102'" tppabs="https://doi.org/10.1073%2Fpnas.0500381102" class="external text external">10.1073/pnas.0500381102</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923" class="external text external">1087923</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15833816  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15833816'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15833816" class="external text external">15833816</a>.</cite></span></li><li id="cite_note-pmid26585581-274"> <span id="mw-reference-text-cite_note-pmid26585581-274" class="mw-reference-text"><cite id="CITEREFKolinskyde_Bono2016" class="citation journal cs1">Kolinsky M, de Bono JS (2016). <a href="javascript:if(confirm('http://www.europeanurology.com/article/S0302-2838(15)01086-6/pdf/the-ongoing-challenges-of-targeting-the-androgen-receptor  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.europeanurology.com/article/S0302-2838(15)01086-6/pdf/the-ongoing-challenges-of-targeting-the-androgen-receptor'" tppabs="http://www.europeanurology.com/article/S0302-2838(15)01086-6/pdf/the-ongoing-challenges-of-targeting-the-androgen-receptor" class="external text external">"The Ongoing Challenges of Targeting the Androgen Receptor"</a>. <i>European Urology</i>. <b>69</b> (5): 841–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.eururo.2015.10.052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.eururo.2015.10.052'" tppabs="https://doi.org/10.1016%2Fj.eururo.2015.10.052" class="external text external">10.1016/j.eururo.2015.10.052</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26585581  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26585581'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26585581" class="external text external">26585581</a>.</cite></span></li><li id="cite_note-KEGG-275"> <span id="mw-reference-text-cite_note-KEGG-275" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('http://www.kegg.jp/entry/D00961  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.kegg.jp/entry/D00961'" tppabs="http://www.kegg.jp/entry/D00961" class="external text external">"Bicalutamide"</a>. <i>Kyoto Encyclopedia of Genes and Genomes (KEGG)</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20161126002030/http://www.kegg.jp/entry/D00961  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161126002030/http://www.kegg.jp/entry/D00961'" tppabs="https://web.archive.org/web/20161126002030/http://www.kegg.jp/entry/D00961" class="external text external">Archived</a> from the original on 26 November 2016.</cite></span></li><li id="cite_note-MortonHall2012-276"> <span id="mw-reference-text-cite_note-MortonHall2012-276" class="mw-reference-text"><cite id="CITEREFMortonHal2012" class="citation book cs1">Morton I, Hal JM (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51'" tppabs="https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51" class="external text external"><i>Concise Dictionary of Pharmacological Agents: Properties and Synonyms</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>51–. ISBN<span>&nbsp;</span><bdi>978-94-011-4439-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160514090313/https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160514090313/https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51'" tppabs="https://web.archive.org/web/20160514090313/https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA51" class="external text external">Archived</a> from the original on 14 May 2016.</cite></span></li><li id="cite_note-GanellinTriggle1996-277"> <span id="mw-reference-text-cite_note-GanellinTriggle1996-277" class="mw-reference-text"><cite id="CITEREFGanellinTriggle1996" class="citation book cs1">Ganellin C, Triggle DJ (21 November 1996). <a href="javascript:if(confirm('https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570'" tppabs="https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570" class="external text external"><i>Dictionary of Pharmacological Agents</i></a>. CRC Press. pp.<span>&nbsp;</span>570–. ISBN<span>&nbsp;</span><bdi>978-0-412-46630-4</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160507003409/https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160507003409/https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570'" tppabs="https://web.archive.org/web/20160507003409/https://books.google.com/books?id=Z_mfTTIApVEC&pg=PA570" class="external text external">Archived</a> from the original on 7 May 2016.</cite></span></li><li id="cite_note-WHO2013-278"> <span id="mw-reference-text-cite_note-WHO2013-278" class="mw-reference-text"><cite class="citation report cs1"><a href="javascript:if(confirm('https://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf'" tppabs="https://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf" class="external text external">The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances</a> <span class="cs1-format">(PDF)</span> (Report). World Health Organisation. 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">6 June</span> 2020</span>.</cite></span></li><li id="cite_note-NLM-DrugPortal-279"> <span id="mw-reference-text-cite_note-NLM-DrugPortal-279" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/endswith/lutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/endswith/lutamide'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/endswith/lutamide" class="external text external">"21 results for Name/Synonym ends with LUTAMIDE"</a>. <i>Drug Information Portal</i>.</cite></span></li><li id="cite_note-HuangJo2009-280"> <span id="mw-reference-text-cite_note-HuangJo2009-280" class="mw-reference-text"><cite id="CITEREFFerraroOrendtFacelli2009" class="citation book cs1">Ferraro MB, Orendt AM, Facelli JC (19 September 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=gRFtCQAAQBAJ&pg=PA120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=gRFtCQAAQBAJ&pg=PA120'" tppabs="https://books.google.com/books?id=gRFtCQAAQBAJ&pg=PA120" class="external text external">"Parallel Genetic Algorithms for Crystal Structure Prediction: Successes and Failures in Predicting Bicalutamide Polymorphs"</a>.  In Huang D, Jo K, Lee H, Kang H, Bevilacqua V (eds.). <i>Emerging Intelligent Computing Technology and Applications: 5th International Conference on Intelligent Computing, ICIC 2009 Ulsan, South Korea, September 16–19, 2009 Proceedings</i>. Springer. pp.<span>&nbsp;</span>120–. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-04070-2_14  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-04070-2_14'" tppabs="https://doi.org/10.1007%2F978-3-642-04070-2_14" class="external text external">10.1007/978-3-642-04070-2_14</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-04070-2</bdi>.</cite></span></li><li id="cite_note-DhasIge2015-281"> <span id="mw-reference-text-cite_note-DhasIge2015-281" class="mw-reference-text"><cite id="CITEREFDhasIgeKudarha2015" class="citation journal cs1">Dhas NL, Ige PP, Kudarha RR (2015). "Design, optimization and in-vitro study of folic acid conjugated-chitosan functionalized PLGA nanoparticle for delivery of bicalutamide in prostate cancer". <i>Powder Technology</i>. <b>283</b>: 234–245. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.powtec.2015.04.053  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.powtec.2015.04.053'" tppabs="https://doi.org/10.1016%2Fj.powtec.2015.04.053" class="external text external">10.1016/j.powtec.2015.04.053</a>.</cite></span></li><li id="cite_note-Drugs.com-1-282"> <span id="mw-reference-text-cite_note-Drugs.com-1-282" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/price-guide/bicalutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/price-guide/bicalutamide'" tppabs="https://www.drugs.com/price-guide/bicalutamide" class="external text external">"Bicalutamide Prices, Coupons and Patient Assistance Programs"</a>. Drugs.com. <a href="javascript:if(confirm('https://web.archive.org/web/20150906121626/http://www.drugs.com/price-guide/bicalutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150906121626/http://www.drugs.com/price-guide/bicalutamide'" tppabs="https://web.archive.org/web/20150906121626/http://www.drugs.com/price-guide/bicalutamide" class="external text external">Archived</a> from the original on 6 September 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">31 August</span> 2015</span>.</cite></span></li><li id="cite_note-NADAC2016-283"> <span id="mw-reference-text-cite_note-NADAC2016-283" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78'" tppabs="https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78" class="external text external">"NADAC as of 2016-12-07 | Data.Medicaid.gov"</a>. <i>Centers for Medicare and Medicaid Services</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78'" tppabs="https://web.archive.org/web/20161221003023/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-12-07/ry9m-tx78" class="external text external">Archived</a> from the original on 21 December 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2017</span>.</cite></span></li><li id="cite_note-Drugs.com-4-284"> <span id="mw-reference-text-cite_note-Drugs.com-4-284" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/price-guide/casodex  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/price-guide/casodex'" tppabs="https://www.drugs.com/price-guide/casodex" class="external text external">"Casodex Prices, Coupons and Patient Assistance Programs"</a>. <i>Drugs.com</i>. <a href="javascript:if(confirm('https://web.archive.org/web/20160417050012/http://www.drugs.com/price-guide/casodex  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160417050012/http://www.drugs.com/price-guide/casodex'" tppabs="https://web.archive.org/web/20160417050012/http://www.drugs.com/price-guide/casodex" class="external text external">Archived</a> from the original on 17 April 2016.</cite></span></li><li id="cite_note-RamadanKabbara2015-285"> <span id="mw-reference-text-cite_note-RamadanKabbara2015-285" class="mw-reference-text"><cite id="CITEREFRamadanKabbaraAl_Basiouni_Al_Masri2015" class="citation journal cs1">Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758" class="external text external">"Enzalutamide for patients with metastatic castration-resistant prostate cancer"</a>. <i>OncoTargets and Therapy</i>. <b>8</b>: 871–6. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FOTT.S80488  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FOTT.S80488'" tppabs="https://doi.org/10.2147%2FOTT.S80488" class="external text external">10.2147/OTT.S80488</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758" class="external text external">4407758</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25945058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25945058'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25945058" class="external text external">25945058</a>.</cite></span></li><li id="cite_note-Stuhan2013-286"> <span id="mw-reference-text-cite_note-Stuhan2013-286" class="mw-reference-text"><cite id="CITEREFStuhan2013" class="citation book cs1">Stuhan MA (2 April 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=L902nod-xOIC&pg=PT268  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=L902nod-xOIC&pg=PT268'" tppabs="https://books.google.com/books?id=L902nod-xOIC&pg=PT268" class="external text external"><i>Understanding Pharmacology for Pharmacy Technicians</i></a>. ASHP. pp.<span>&nbsp;</span>268–. ISBN<span>&nbsp;</span><bdi>978-1-58528-360-6</bdi>.</cite></span></li><li id="cite_note-pmid16604181-287"> <span id="mw-reference-text-cite_note-pmid16604181-287" class="mw-reference-text"><cite id="CITEREFAllanSui2003" class="citation journal cs1">Allan GF, Sui Z (2003). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218" class="external text external">"Therapeutic androgen receptor ligands"</a>. <i>Nucl Recept Signal</i>. <b>1</b>: e009. doi:<a href="javascript:if(confirm('https://doi.org/10.1621%2Fnrs.01009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1621%2Fnrs.01009'" tppabs="https://doi.org/10.1621%2Fnrs.01009" class="external text external">10.1621/nrs.01009</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402218" class="external text external">1402218</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16604181  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16604181'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16604181" class="external text external">16604181</a>.</cite></span></li><li id="cite_note-EmansLaufer2012-288"> <span id="mw-reference-text-cite_note-EmansLaufer2012-288" class="mw-reference-text"><cite id="CITEREFEmansLaufer2012" class="citation book cs1">Emans SJ, Laufer MR (5 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=pdNh7ieMJzQC&pg=PT365  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=pdNh7ieMJzQC&pg=PT365'" tppabs="https://books.google.com/books?id=pdNh7ieMJzQC&pg=PT365" class="external text external"><i>Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>365–. ISBN<span>&nbsp;</span><bdi>978-1-4511-5406-1</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20160516152443/https://books.google.com/books?id=pdNh7ieMJzQC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160516152443/https://books.google.com/books?id=pdNh7ieMJzQC'" tppabs="https://web.archive.org/web/20160516152443/https://books.google.com/books?id=pdNh7ieMJzQC" class="external text external">Archived</a> from the original on 16 May 2016. <q>Therapy with GnRH analogs is expensive and requires intramuscular injections of depot formulations, the insert of a subcutaneous implant yearly, or, much less commonly, daily subcutaneous injections.</q></cite></span></li><li id="cite_note-Hillard2013-289"> <span id="mw-reference-text-cite_note-Hillard2013-289" class="mw-reference-text"><cite id="CITEREFHillard2013" class="citation book cs1">Hillard PJ (29 March 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT182'" tppabs="https://books.google.com/books?id=vAA5Z5aqlUQC&pg=PT182" class="external text external"><i>Practical Pediatric and Adolescent Gynecology</i></a>. John Wiley &amp; Sons. pp.<span>&nbsp;</span>182–. ISBN<span>&nbsp;</span><bdi>978-1-118-53857-9</bdi>. <q>Treatment is expensive, with costs typicall in the range of $10,000–$15,000 per year.</q></cite></span></li><li id="cite_note-AstraZeneca2007-290"> <span id="mw-reference-text-cite_note-AstraZeneca2007-290" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2007-Annual-Report-English.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2007-Annual-Report-English.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2007-Annual-Report-English.pdf" class="external text external">"Annual Report and Form 20-F 2007"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-Evaluate2008-291"> <span id="mw-reference-text-cite_note-Evaluate2008-291" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=159824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=159824'" tppabs="http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=159824" class="external text external">"Actavis Generic Prostate Cancer Drug Bicalutamide First to Market in UK, Germany, France"</a>. <i>Press Release</i>. AstraZeneca, Actavis. 10 July 2008.</cite></span></li><li id="cite_note-NewMedicine1996-292"> <span id="mw-reference-text-cite_note-NewMedicine1996-292" class="mw-reference-text"><cite class="citation journal cs1"><a href="javascript:if(confirm('http://www.newmedinc.com/pdfs/Future_Oncology.Vol.2.No.2.3.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.newmedinc.com/pdfs/Future_Oncology.Vol.2.No.2.3.pdf'" tppabs="http://www.newmedinc.com/pdfs/Future_Oncology.Vol.2.No.2.3.pdf" class="external text external">"Hormonal Therapies"</a> <span class="cs1-format">(PDF)</span>. <i>Future Oncology</i>. <b>2</b> (2–3): 306. June 1996.</cite></span></li><li id="cite_note-NewYorkTimes1997-293"> <span id="mw-reference-text-cite_note-NewYorkTimes1997-293" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.nytimes.com/1997/03/12/business/zeneca-of-britain-posts-strong-drug-profits.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/1997/03/12/business/zeneca-of-britain-posts-strong-drug-profits.html'" tppabs="https://www.nytimes.com/1997/03/12/business/zeneca-of-britain-posts-strong-drug-profits.html" class="external text external">"Zeneca of Britain Posts Strong Drug Profits"</a>. <i>The New York Times</i>. 12 March 1997.</cite></span></li><li id="cite_note-AstraZeneca2001-294"> <span id="mw-reference-text-cite_note-AstraZeneca2001-294" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://ddd.uab.cat/pub/infanu/40172/iaASTZENa2001ieng.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ddd.uab.cat/pub/infanu/40172/iaASTZENa2001ieng.pdf'" tppabs="https://ddd.uab.cat/pub/infanu/40172/iaASTZENa2001ieng.pdf" class="external text external">"Annual Report and Form 20-F 2001"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-AstraZeneca2004-295"> <span id="mw-reference-text-cite_note-AstraZeneca2004-295" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2004-Annual-Report-English.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2004-Annual-Report-English.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2004-Annual-Report-English.pdf" class="external text external">"Annual Report and Form 20-F 2004"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-AstraZeneca2010-296"> <span id="mw-reference-text-cite_note-AstraZeneca2010-296" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2010-Annual-Report-English.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2010-Annual-Report-English.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2010-Annual-Report-English.pdf" class="external text external">"Annual Report and Form 20-F 2010"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-AstraZeneca2013-297"> <span id="mw-reference-text-cite_note-AstraZeneca2013-297" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2013-Annual-report-English.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2013-Annual-report-English.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-reports-homepage/2013-Annual-report-English.pdf" class="external text external">"Annual Report and Form 20-F 2013"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-AstraZeneca2016-298"> <span id="mw-reference-text-cite_note-AstraZeneca2016-298" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf" class="external text external">"Annual Report and Form 20-F 2016"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca. <a href="javascript:if(confirm('https://web.archive.org/web/20170403111027/https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170403111027/https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf'" tppabs="https://web.archive.org/web/20170403111027/https://www.astrazeneca.com/content/dam/az/Investor_Relations/Annual-report-2016/AZ_AR2016_Full_Report.pdf" class="external text external">Archived</a> <span class="cs1-format">(PDF)</span> from the original on 3 April 2017.</cite></span></li><li id="cite_note-AstraZeneca2017-299"> <span id="mw-reference-text-cite_note-AstraZeneca2017-299" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf" class="external text external">"AstraZeneca Full-Year 2017 Results"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-AstraZeneca2018-300"> <span id="mw-reference-text-cite_note-AstraZeneca2018-300" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf'" tppabs="https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf" class="external text external">"AstraZeneca Full-Year 2018 Results"</a> <span class="cs1-format">(PDF)</span>. AstraZeneca.</cite></span></li><li id="cite_note-YagielaDowd2010-301"> <span id="mw-reference-text-cite_note-YagielaDowd2010-301" class="mw-reference-text"><cite id="CITEREFYagielaDowdJohnsonMariotti2010" class="citation book cs1">Yagiela JA, Dowd FJ, Johnson B, Mariotti A, Neidle EA (19 March 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=utVOHYuhxioC&pg=PA851  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=utVOHYuhxioC&pg=PA851'" tppabs="https://books.google.com/books?id=utVOHYuhxioC&pg=PA851" class="external text external"><i>Pharmacology and Therapeutics for Dentistry</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>851–. ISBN<span>&nbsp;</span><bdi>978-0-323-07824-5</bdi>.</cite></span></li><li id="cite_note-HeplerSegal2003-302"> <span id="mw-reference-text-cite_note-HeplerSegal2003-302" class="mw-reference-text"><cite id="CITEREFHeplerSegal2003" class="citation book cs1">Hepler CD, Segal R (25 February 2003). <a href="javascript:if(confirm('https://books.google.com/books?id=pvpZeDkaaIEC&pg=PA136  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=pvpZeDkaaIEC&pg=PA136'" tppabs="https://books.google.com/books?id=pvpZeDkaaIEC&pg=PA136" class="external text external"><i>Preventing Medication Errors and Improving Drug Therapy Outcomes: A Management Systems Approach</i></a>. CRC Press. pp.<span>&nbsp;</span>136–137. ISBN<span>&nbsp;</span><bdi>978-0-203-01073-0</bdi>.</cite></span></li><li id="cite_note-DukesDukes1998-303"> <span id="mw-reference-text-cite_note-DukesDukes1998-303" class="mw-reference-text"><cite id="CITEREFDukesDukesMildredSwartz1998" class="citation book cs1">Dukes G, Dukes MN, Mildred M, Swartz B (January 1998). <a href="javascript:if(confirm('https://books.google.com/books?id=EQ3CZ1NaoQgC&pg=PA241  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=EQ3CZ1NaoQgC&pg=PA241'" tppabs="https://books.google.com/books?id=EQ3CZ1NaoQgC&pg=PA241" class="external text external"><i>Responsibility for Drug-induced Injury: A Reference Book for Lawyers, the Health Professions and Manufacturers</i></a>. IOS Press. pp.<span>&nbsp;</span>241–8. ISBN<span>&nbsp;</span><bdi>978-90-5199-387-5</bdi>.</cite></span></li><li id="cite_note-pmid15138573-304"> <span id="mw-reference-text-cite_note-pmid15138573-304" class="mw-reference-text"><cite id="CITEREFWangMencherMcCarronFerrari2004" class="citation journal cs1">Wang LG, Mencher SK, McCarron JP, Ferrari AC (2004). "The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review". <i>Oncology Reports</i>. <b>11</b> (6): 1325–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3892%2For.11.6.1325  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3892%2For.11.6.1325'" tppabs="https://doi.org/10.3892%2For.11.6.1325" class="external text external">10.3892/or.11.6.1325</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15138573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15138573'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15138573" class="external text external">15138573</a>.</cite></span></li><li id="cite_note-pmid15151957-305"> <span id="mw-reference-text-cite_note-pmid15151957-305" class="mw-reference-text"><cite id="CITEREFTayKaufmanReganLeibowitz2004" class="citation journal cs1">Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK (2004). <a href="javascript:if(confirm('https://doi.org/10.1093/annonc/mdh221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/annonc/mdh221'" tppabs="https://doi.org/10.1093/annonc/mdh221" class="external text external">"Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate"</a>. <i>Annals of Oncology</i>. <b>15</b> (6): 974–8. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Fannonc%2Fmdh221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fannonc%2Fmdh221'" tppabs="https://doi.org/10.1093%2Fannonc%2Fmdh221" class="external text external">10.1093/annonc/mdh221</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15151957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15151957'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15151957" class="external text external">15151957</a>.</cite></span></li><li id="cite_note-pmid16844453-306"> <span id="mw-reference-text-cite_note-pmid16844453-306" class="mw-reference-text"><cite id="CITEREFMerrickButlerWallnerGalbreath2006" class="citation journal cs1">Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B (2006). "Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy". <i>Urology</i>. <b>68</b> (1): 116–20. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.urology.2006.01.061  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.urology.2006.01.061'" tppabs="https://doi.org/10.1016%2Fj.urology.2006.01.061" class="external text external">10.1016/j.urology.2006.01.061</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16844453  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16844453'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16844453" class="external text external">16844453</a>.</cite></span></li><li id="cite_note-pmid19796455-307"> <span id="mw-reference-text-cite_note-pmid19796455-307" class="mw-reference-text"><cite id="CITEREFSartorGomellaGagnierMelich2009" class="citation journal cs1">Sartor O, Gomella LG, Gagnier P, Melich K, Dann R (2009). "Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design". <i>The Canadian Journal of Urology</i>. <b>16</b> (5): 4806–12. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19796455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19796455'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19796455" class="external text external">19796455</a>.</cite></span></li><li id="cite_note-pmid26048455-308"> <span id="mw-reference-text-cite_note-pmid26048455-308" class="mw-reference-text"><cite id="CITEREFChuSartorGomellaRudo2015" class="citation journal cs1">Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ (2015). "A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer". <i>European Journal of Cancer</i>. <b>51</b> (12): 1555–69. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejca.2015.04.028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejca.2015.04.028'" tppabs="https://doi.org/10.1016%2Fj.ejca.2015.04.028" class="external text external">10.1016/j.ejca.2015.04.028</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26048455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26048455'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26048455" class="external text external">26048455</a>.</cite></span></li><li id="cite_note-pmid26702991-309"> <span id="mw-reference-text-cite_note-pmid26702991-309" class="mw-reference-text"><cite id="CITEREFGaudetVigneaultFosterMeyer2016" class="citation journal cs1">Gaudet M, Vigneault É, Foster W, Meyer F, Martin AG (2016). "Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer". <i>Radiotherapy and Oncology<span>&nbsp;</span>: Journal of the European Society for Therapeutic Radiology and Oncology</i>. <b>118</b> (1): 141–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.radonc.2015.11.022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.radonc.2015.11.022'" tppabs="https://doi.org/10.1016%2Fj.radonc.2015.11.022" class="external text external">10.1016/j.radonc.2015.11.022</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26702991  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26702991'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26702991" class="external text external">26702991</a>.</cite></span></li><li id="cite_note-pmid27330919-310"> <span id="mw-reference-text-cite_note-pmid27330919-310" class="mw-reference-text"><cite id="CITEREFDijkstraWitjesRoosVijverberg2016" class="citation journal cs1">Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, Smits GA, Vergunst H, Mulders PF (2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485" class="external text external">"The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis"</a>. <i>SpringerPlus</i>. <b>5</b>: 653. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2Fs40064-016-2280-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2Fs40064-016-2280-8'" tppabs="https://doi.org/10.1186%2Fs40064-016-2280-8" class="external text external">10.1186/s40064-016-2280-8</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870485" class="external text external">4870485</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27330919  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27330919'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27330919" class="external text external">27330919</a>.</cite></span></li><li id="cite_note-FujimuraTakayama2018-311"> <span id="mw-reference-text-cite_note-FujimuraTakayama2018-311" class="mw-reference-text"><cite id="CITEREFFujimuraTakayamaTakahashiInoue2018" class="citation journal cs1">Fujimura, Tetsuya; Takayama, Kenichi; Takahashi, Satoru; Inoue, Satoshi (2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061" class="external text external">"Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine"</a>. <i>Cancers</i>. <b>10</b> (2): 29. doi:<a href="javascript:if(confirm('https://doi.org/10.3390%2Fcancers10020029  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3390%2Fcancers10020029'" tppabs="https://doi.org/10.3390%2Fcancers10020029" class="external text external">10.3390/cancers10020029</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2072-6694  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2072-6694'" tppabs="https://www.worldcat.org/issn/2072-6694" class="external text external">2072-6694</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836061" class="external text external">5836061</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29360794  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29360794'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29360794" class="external text external">29360794</a>.</cite></span></li><li id="cite_note-HoNunez-Nateras2017-312"> <span id="mw-reference-text-cite_note-HoNunez-Nateras2017-312" class="mw-reference-text"><cite id="CITEREFHoNunez-NaterasHouBryce2017" class="citation journal cs1">Ho, Thai H.; Nunez-Nateras, Rafael; Hou, Yue-Xian; Bryce, Alan H.; Northfelt, Donald W.; Dueck, Amylou C.; Wong, Bryan; Stanton, Melissa L.; Joseph, Richard W.; Castle, Erik P. (2017). "A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer". <i>Clinical Genitourinary Cancer</i>. <b>15</b> (2): 196–202.e1. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.clgc.2016.08.026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.clgc.2016.08.026'" tppabs="https://doi.org/10.1016%2Fj.clgc.2016.08.026" class="external text external">10.1016/j.clgc.2016.08.026</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1558-7673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1558-7673'" tppabs="https://www.worldcat.org/issn/1558-7673" class="external text external">1558-7673</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27771244  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27771244'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27771244" class="external text external">27771244</a>.</cite></span></li><li id="cite_note-313"> <span id="mw-reference-text-cite_note-313" class="mw-reference-text"><cite id="CITEREFTranslational_Breast_Cancer_Research_Consortium_(TBCRC)2012" class="citation journal cs1">Translational Breast Cancer Research Consortium (TBCRC) (2012). <a href="javascript:if(confirm('http://meetinglibrary.asco.org/content/94715-114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://meetinglibrary.asco.org/content/94715-114'" tppabs="http://meetinglibrary.asco.org/content/94715-114" class="external text external">"Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC)"</a>. <i>J Clin Oncol</i> (suppl): abstract 1006. <a href="javascript:if(confirm('https://web.archive.org/web/20150710035954/http://meetinglibrary.asco.org/content/94715-114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20150710035954/http://meetinglibrary.asco.org/content/94715-114'" tppabs="https://web.archive.org/web/20150710035954/http://meetinglibrary.asco.org/content/94715-114" class="external text external">Archived</a> from the original on 10 July 2015.</cite></span></li><li id="cite_note-314"> <span id="mw-reference-text-cite_note-314" class="mw-reference-text"><span>Clinical trial number </span><i><a href="javascript:if(confirm('https://www.clinicaltrials.gov/show/NCT00468715  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.clinicaltrials.gov/show/NCT00468715'" tppabs="https://www.clinicaltrials.gov/show/NCT00468715" class="external text external">NCT00468715</a></i><span> for "Bicalutamide in Treating Patients With Metastatic Breast Cancer" at </span>ClinicalTrials.gov</span></li><li id="cite_note-315"> <span id="mw-reference-text-cite_note-315" class="mw-reference-text"><cite id="CITEREFGucalpTolaneyIsakoffIngle2013" class="citation journal cs1">Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA (October 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643" class="external text external">"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer"</a>. <i>Clinical Cancer Research</i>. <b>19</b> (19): 5505–12. doi:<a href="javascript:if(confirm('https://doi.org/10.1158%2F1078-0432.CCR-12-3327  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1078-0432.CCR-12-3327'" tppabs="https://doi.org/10.1158%2F1078-0432.CCR-12-3327" class="external text external">10.1158/1078-0432.CCR-12-3327</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643" class="external text external">4086643</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23965901  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23965901'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23965901" class="external text external">23965901</a>.</cite></span></li><li id="cite_note-CaiazzaMurray2016-316"> <span id="mw-reference-text-cite_note-CaiazzaMurray2016-316" class="mw-reference-text"><cite id="CITEREFCaiazzaMurrayMaddenSynnott2016" class="citation journal cs1">Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ (April 2016). <a href="javascript:if(confirm('https://doi.org/10.1530/ERC-16-0068  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/ERC-16-0068'" tppabs="https://doi.org/10.1530/ERC-16-0068" class="external text external">"Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells"</a>. <i>Endocrine-Related Cancer</i>. <b>23</b> (4): 323–34. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2FERC-16-0068  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2FERC-16-0068'" tppabs="https://doi.org/10.1530%2FERC-16-0068" class="external text external">10.1530/ERC-16-0068</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26932782  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26932782'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26932782" class="external text external">26932782</a>.</cite></span></li><li id="cite_note-317"> <span id="mw-reference-text-cite_note-317" class="mw-reference-text"><cite id="CITEREFTraina2015" class="citation journal cs1">Traina TA,  et al. (2015). <a href="javascript:if(confirm('http://meetinglibrary.asco.org/content/150040-156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://meetinglibrary.asco.org/content/150040-156'" tppabs="http://meetinglibrary.asco.org/content/150040-156" class="external text external">"Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)"</a>. <i>Journal of Clinical Oncology</i>. <b>33</b> (suppl): abstr 1003. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2Fjco.2015.33.15_suppl.1003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2Fjco.2015.33.15_suppl.1003'" tppabs="https://doi.org/10.1200%2Fjco.2015.33.15_suppl.1003" class="external text external">10.1200/jco.2015.33.15_suppl.1003</a>. <a href="javascript:if(confirm('https://web.archive.org/web/20160530074130/http://meetinglibrary.asco.org/content/150040-156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20160530074130/http://meetinglibrary.asco.org/content/150040-156'" tppabs="https://web.archive.org/web/20160530074130/http://meetinglibrary.asco.org/content/150040-156" class="external text external">Archived</a> from the original on 30 May 2016.</cite></span></li><li id="cite_note-pmid17918264-318"> <span id="mw-reference-text-cite_note-pmid17918264-318" class="mw-reference-text"><cite id="CITEREFLevineParkJuretzkaEsch2007" class="citation journal cs1">Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P (December 2007). "A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission". <i>Cancer</i>. <b>110</b> (11): 2448–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fcncr.23072  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fcncr.23072'" tppabs="https://doi.org/10.1002%2Fcncr.23072" class="external text external">10.1002/cncr.23072</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17918264  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17918264'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17918264" class="external text external">17918264</a>.</cite></span></li><li id="cite_note-Becker2001-2-319"> <span id="mw-reference-text-cite_note-Becker2001-2-319" class="mw-reference-text"><cite class="citation book cs1">Becker KL (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1209  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1209'" tppabs="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1209" class="external text external"><i>Principles and Practice of Endocrinology and Metabolism</i></a>. Lippincott Williams &amp; Wilkins. p.<span>&nbsp;</span>1209. ISBN<span>&nbsp;</span><bdi>978-0-7817-1750-2</bdi>. <a href="javascript:if(confirm('https://web.archive.org/web/20140628110255/http://books.google.com/books?id=FVfzRvaucq8C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140628110255/http://books.google.com/books?id=FVfzRvaucq8C'" tppabs="https://web.archive.org/web/20140628110255/http://books.google.com/books?id=FVfzRvaucq8C" class="external text external">Archived</a> from the original on 28 June 2014.</cite></span></li><li id="cite_note-pmid7694413-320"> <span id="mw-reference-text-cite_note-pmid7694413-320" class="mw-reference-text"><cite id="CITEREFLepor1993" class="citation journal cs1">Lepor H (1993). "Medical therapy for benign prostatic hyperplasia". <i>Urology</i>. <b>42</b> (5): 483–501. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2893%2990258-c  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2893%2990258-c'" tppabs="https://doi.org/10.1016%2F0090-4295%2893%2990258-c" class="external text external">10.1016/0090-4295(93)90258-c</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7694413  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7694413'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7694413" class="external text external">7694413</a>. <q>The clinically significant adverse events reported in the casodex group included breast tenderness (93%), breast enlargement (54%), and sexual dysfunction (60%). In none of the patients in the placebo group did any of these adverse events develop. None of the subjects discontinued therapy owing to an adverse event.</q></cite></span></li><li id="cite_note-pmid9101011-321"> <span id="mw-reference-text-cite_note-pmid9101011-321" class="mw-reference-text"><cite id="CITEREFLeeSharifi1997" class="citation journal cs1">Lee M, Sharifi R (1997). "Benign prostatic hyperplasia: diagnosis and treatment guideline". <i>Ann Pharmacother</i>. <b>31</b> (4): 481–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809703100415  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809703100415'" tppabs="https://doi.org/10.1177%2F106002809703100415" class="external text external">10.1177/106002809703100415</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9101011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9101011'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9101011" class="external text external">9101011</a>.</cite></span></li><li id="cite_note-pmid9135028-322"> <span id="mw-reference-text-cite_note-pmid9135028-322" class="mw-reference-text"><cite id="CITEREFKennyBallardBlaggFox1997" class="citation journal cs1">Kenny B, Ballard S, Blagg J, Fox D (1997). "Pharmacological options in the treatment of benign prostatic hyperplasia". <i>J. Med. Chem</i>. <b>40</b> (9): 1293–315. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm960697s  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm960697s'" tppabs="https://doi.org/10.1021%2Fjm960697s" class="external text external">10.1021/jm960697s</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9135028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9135028'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9135028" class="external text external">9135028</a>.</cite></span></li><li id="cite_note-pmid32333494-323"> <span id="mw-reference-text-cite_note-pmid32333494-323" class="mw-reference-text"><cite id="CITEREFMcCoyWambierVano-GalvanShapiro2020" class="citation journal cs1">McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Müller Ramos P, Washenik K, Andrade M, Herrera S, Goren A (April 2020). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367" class="external text external">"Racial Variations in COVID-19 Deaths May Be Due to Androgen Receptor Genetic Variants Associated with Prostate Cancer and Androgenetic Alopecia. Are Anti-Androgens a Potential Treatment for COVID-19?"</a>. <i>J Cosmet Dermatol</i>. <b>19</b>: 1542–1543. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1111%2Fjocd.13455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fjocd.13455'" tppabs="https://doi.org/10.1111%2Fjocd.13455" class="external text external">10.1111/jocd.13455</a></span>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267367" class="external text external">7267367</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/32333494  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/32333494'" tppabs="https://pubmed.ncbi.nlm.nih.gov/32333494" class="external text external">32333494</a>.</cite></span></li><li id="cite_note-NCT04374279-324"> <span id="mw-reference-text-cite_note-NCT04374279-324" class="mw-reference-text"><a href="javascript:if(confirm('https://clinicaltrials.gov/ct2/show/NCT04374279  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clinicaltrials.gov/ct2/show/NCT04374279'" tppabs="https://clinicaltrials.gov/ct2/show/NCT04374279" class="external free external">https://clinicaltrials.gov/ct2/show/NCT04374279</a></span></li><li id="cite_note-BonaguraTwedt2013-325"> <span id="mw-reference-text-cite_note-BonaguraTwedt2013-325" class="mw-reference-text"><cite id="CITEREFBonaguraTwedt2013" class="citation book cs1">Bonagura JD, Twedt DC (1 December 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=KlJKAgAAQBAJ&pg=PT908  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KlJKAgAAQBAJ&pg=PT908'" tppabs="https://books.google.com/books?id=KlJKAgAAQBAJ&pg=PT908" class="external text external"><i>Kirk's Current Veterinary Therapy XV</i></a>. Elsevier Health Sciences. p.<span>&nbsp;</span>908. ISBN<span>&nbsp;</span><bdi>978-0-323-22762-9</bdi>.</cite></span></li><li id="cite_note-MitchellTully2009-326"> <span id="mw-reference-text-cite_note-MitchellTully2009-326" class="mw-reference-text"><cite id="CITEREFMitchellTully2009" class="citation book cs1">Mitchell MA, Tully TN (2009). <a href="javascript:if(confirm('https://books.google.com/books?id=JMTUKwzPEvwC&pg=PA363  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=JMTUKwzPEvwC&pg=PA363'" tppabs="https://books.google.com/books?id=JMTUKwzPEvwC&pg=PA363" class="external text external"><i>Manual of Exotic Pet Practice</i></a>. Elsevier Health Sciences. p.<span>&nbsp;</span>363. ISBN<span>&nbsp;</span><bdi>978-1-4160-0119-5</bdi>.</cite></span></li><li id="cite_note-Pilny2014-327"> <span id="mw-reference-text-cite_note-Pilny2014-327" class="mw-reference-text"><cite id="CITEREFPilny2014" class="citation book cs1">Pilny AA (9 February 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=2MraAgAAQBAJ&pg=PA17  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2MraAgAAQBAJ&pg=PA17'" tppabs="https://books.google.com/books?id=2MraAgAAQBAJ&pg=PA17" class="external text external"><i>Endocrinology, An Issue of Veterinary Clinics: Exotic Animal Practice</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>16–17. ISBN<span>&nbsp;</span><bdi>978-0-323-26419-8</bdi>. <q>In ferrets, 5 mg/kg [of bicalutamide] orally every 24 hours has been used clinically, but no controlled toxicologic or pharmacologic studies have been published at this time.</q></cite></span></li><li id="cite_note-FoxMarini2014-328"> <span id="mw-reference-text-cite_note-FoxMarini2014-328" class="mw-reference-text"><cite id="CITEREFFoxMarini2014" class="citation book cs1">Fox JG, Marini RP (26 March 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=2J06AwAAQBAJ&pg=PT980  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=2J06AwAAQBAJ&pg=PT980'" tppabs="https://books.google.com/books?id=2J06AwAAQBAJ&pg=PT980" class="external text external"><i>Biology and Diseases of the Ferret</i></a>. Wiley. p.<span>&nbsp;</span>980. ISBN<span>&nbsp;</span><bdi>978-1-118-78273-6</bdi>. <q>Other agents have been proposed for medical management of [adrenal-associated endocrinopathy] but have not been studied. Possibly medications include the androgen receptor blockers flutamide and bicalutamide, the anti-androgen finasteride, estrogen-inhibiting anastrozole, and another GnRH analog, goserelin. [...] None of these drugs have been tested in controlled clinical trials in ferrets.</q></cite></span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<style data-mw-deduplicate="TemplateStyles:r886047268">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class="refbegin reflist   columns references-column-width" style="-moz-column-width: 33em; -webkit-column-width: 33em; column-width: 33em;">
<ul><li><cite class="citation book cs1"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK547970/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK547970/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK547970/" class="external text external">"Bicalutamide"</a>. <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/books/NBK547852/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/books/NBK547852/'" tppabs="https://www.ncbi.nlm.nih.gov/books/NBK547852/" class="external text external"><i>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</i></a>. <i>NCBI Bookshelf</i>. 2017. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31643303  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31643303'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31643303" class="external text external">31643303</a>. NBK547970.</cite></li>
<li><cite id="CITEREFBlackledge1996" class="citation journal cs1">Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". <i>European Urology</i>. 29 Suppl 2: 96–104. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000473847  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000473847'" tppabs="https://doi.org/10.1159%2F000473847" class="external text external">10.1159/000473847</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8717470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8717470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8717470" class="external text external">8717470</a>.</cite></li>
<li><cite id="CITEREFCockshott2004" class="citation journal cs1">Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". <i>Clinical Pharmacokinetics</i>. <b>43</b> (13): 855–78. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-200443130-00003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-200443130-00003'" tppabs="https://doi.org/10.2165%2F00003088-200443130-00003" class="external text external">10.2165/00003088-200443130-00003</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15509184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15509184'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15509184" class="external text external">15509184</a>.</cite></li>
<li><cite id="CITEREFFradet2004" class="citation journal cs1">Fradet Y (February 2004). "Bicalutamide (Casodex) in the treatment of prostate cancer". <i>Expert Review of Anticancer Therapy</i>. <b>4</b> (1): 37–48. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F14737140.4.1.37  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F14737140.4.1.37'" tppabs="https://doi.org/10.1586%2F14737140.4.1.37" class="external text external">10.1586/14737140.4.1.37</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14748655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14748655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14748655" class="external text external">14748655</a>.</cite></li>
<li><cite id="CITEREFFurr1995" class="citation journal cs1">Furr BJ (June 1995). "Casodex: preclinical studies and controversies". <i>Annals of the New York Academy of Sciences</i>. <b>761</b> (1): 79–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x'" tppabs="https://doi.org/10.1111%2Fj.1749-6632.1995.tb31371.x" class="external text external">10.1111/j.1749-6632.1995.tb31371.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7625752  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7625752'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7625752" class="external text external">7625752</a>.</cite></li>
<li><cite id="CITEREFFurrTucker1996" class="citation journal cs1">Furr BJ, Tucker H (January 1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". <i>Urology</i>. <b>47</b> (1A Suppl): 13–25, discussion 29–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2980003-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2980003-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2980003-3" class="external text external">10.1016/S0090-4295(96)80003-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560673'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560673" class="external text external">8560673</a>.</cite></li>
<li><cite id="CITEREFKolvenbagBlackledge1996" class="citation journal cs1">Kolvenbag GJ, Blackledge GR (January 1996). "Worldwide activity and safety of bicalutamide: a summary review". <i>Urology</i>. <b>47</b> (1A Suppl): 70–9, discussion 80–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4'" tppabs="https://doi.org/10.1016%2Fs0090-4295%2896%2980012-4" class="external text external">10.1016/s0090-4295(96)80012-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8560681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8560681'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8560681" class="external text external">8560681</a>.</cite></li>
<li><cite id="CITEREFSchellhammerDavis2004" class="citation journal cs1">Schellhammer PF, Davis JW (March 2004). "An evaluation of bicalutamide in the treatment of prostate cancer". <i>Clinical Prostate Cancer</i>. <b>2</b> (4): 213–9. doi:<a href="javascript:if(confirm('https://doi.org/10.3816%2FCGC.2004.n.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3816%2FCGC.2004.n.002'" tppabs="https://doi.org/10.3816%2FCGC.2004.n.002" class="external text external">10.3816/CGC.2004.n.002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15072604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15072604'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15072604" class="external text external">15072604</a>.</cite></li>
<li><cite id="CITEREFTuckerCrookChesterson1988" class="citation journal cs1">Tucker H, Crook JW, Chesterson GJ (1988). "Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides". <i>J. Med. Chem</i>. <b>31</b> (5): 954–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fjm00400a011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fjm00400a011'" tppabs="https://doi.org/10.1021%2Fjm00400a011" class="external text external">10.1021/jm00400a011</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3361581  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3361581'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3361581" class="external text external">3361581</a>.</cite></li>
<li><cite id="CITEREFWellingtonKeam2006" class="citation journal cs1">Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". <i>Drugs</i>. <b>66</b> (6): 837–50. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200666060-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200666060-00007'" tppabs="https://doi.org/10.2165%2F00003495-200666060-00007" class="external text external">10.2165/00003495-200666060-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16706554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16706554'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16706554" class="external text external">16706554</a>.</cite></li></ul>
</div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/bicalutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/bicalutamide'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/bicalutamide" class="external text external">"Bicalutamide"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Bicalutamide" style="padding:3px"><table class="nowraplinks mw-collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Bicalutamide" style="font-size:114%;margin:0 4em"><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Topics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Medical uses of bicalutamide</li>
<li>Side effects of bicalutamide</li>
<li>Pharmacology of bicalutamide</li>
<li>Comparison of bicalutamide with other antiandrogens</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Related drugs</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Nonsteroidal antiandrogens: <i>First-generation:</i> <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Topilutamide; <i>Second-generation:</i> Apalutamide</li>
<li>Enzalutamide</li></ul>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Androgens_and_antiandrogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgens_and_antiandrogens" style="font-size:114%;margin:0 4em">Androgens and antiandrogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Androgens<br>(incl. <abbr>AAS</abbr>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> Androstenediol dipropionate</li>
<li>Boldenone undecylenate</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a></li>
<li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li>
<li>Cloxotestosterone acetate</li>
<li>Prasterone (dehydroepiandrosterone, DHEA)</li>
<li>Prasterone enanthate (DHEA enanthate)</li>
<li>Prasterone sulfate (DHEA sulfate)</li>
<li>Quinbolone</li>
<li>Testosterone<sup>#</sup></li>
<li>Testosterone esters (e.g., testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone undecanoate, testosterone ester mixtures (Deposterona, Omnadren, Sustanon, Testoviron Depot))</li></ul>

<ul><li><i>Dihydrotestosterone derivatives:</i> Androstanolone (stanolone, dihydrotestosterone, DHT)</li>
<li>Androstanolone esters</li>
<li>Bolazine capronate</li>
<li>Drostanolone propionate (dromostanolone propionate)</li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a></li>
<li>Metenolone acetate (methenolone acetate)</li>
<li>Metenolone enanthate (methenolone enanthate)</li>
<li>Stenbolone acetate</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> Bolandiol dipropionate</li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norclostebol</li>
<li>Norclostebol acetate</li>
<li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li>
<li>Trenbolone acetate</li>
<li>Trenbolone hexahydrobenzylcarbonate (trenbolone cyclohexylmethylcarbonate)</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Metandienone (methandienone, methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)</li>
<li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a></li>
<li>Methyltestosterone 3-hexyl ether</li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone (thiomesterone)</li></ul>

<ul><li><i>17α-Alkylated dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Mibolerone</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li>Propetandrol (propethandrol)</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li>Progestins (e.g., <a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">ethisterone (ethynyltestosterone)</a>, <a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">levonorgestrel</a>, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">norgestrel</a>, <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone (norethindrone)</a>, lynestrenol, norgestrienone)</li>
<li>Tibolone</li></ul>

<ul><li><i>Progesterone derivatives:</i> <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Progonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiestrogens (e.g., <a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="Clomifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomifene" title="Clomifene">clomifene</a>)</li>
<li>GnRH agonists (e.g., <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">GnRH (gonadorelin)</a>, <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>Gonadotropins (e.g., <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone"><abbr>LH</abbr></a>, <a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin"><abbr>hCG</abbr></a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiandrogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Abiraterone acetate</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Nomegestrol acetate</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>

<ul><li><i>Nonsteroidal:</i> Apalutamide</li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Darolutamide</li>
<li>Enzalutamide</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li>Topilutamide (fluridil)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Steroidogenesis<br>inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">5α-Reductase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li>Epristeride</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abiraterone acetate</li>
<li><a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">Aminoglutethimide</a></li>
<li>Bifluranol</li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Antigonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>D<sub>2</sub> receptor antagonists (prolactin releasers) (e.g., <a href="Domperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Domperidone" title="Domperidone">domperidone</a>, <a href="Metoclopramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>, <a href="Haloperidol.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloperidol" title="Haloperidol">haloperidol</a>, <a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="Sulpiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulpiride" title="Sulpiride">sulpiride</a>)</li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., bifluranol, <a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>, <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)</li>
<li>GnRH agonists (e.g., <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>GnRH antagonists (e.g., <a href="Cetrorelix.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetrorelix" title="Cetrorelix">cetrorelix</a>)</li>
<li>Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, megestrol acetate)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Androstenedione immunogens:</i> Androvax (androstenedione albumin)</li>
<li>Ovandrotone albumin (Fecundin)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Androgen receptor modulators</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>List of androgens/anabolic steroids</dd></dl></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Acne-treating_agents_(D10)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Acne-treating_agents_(D10)" style="font-size:114%;margin:0 4em">Acne-treating agents (D10)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibacterial</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Azelaic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Azelaic_acid" title="Azelaic acid">Azelaic acid</a></li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">8-Hydroxyquinoline</a></li>
<li>Blue light therapy</li>
<li><a href="Tea_tree_oil.htm" tppabs="https://ptable.com/wiki/compounds/A/Tea_tree_oil" title="Tea tree oil">Tea tree oil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Keratolytic</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Glycolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycolic_acid" title="Glycolic acid">Glycolic acid</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a><sup>#</sup></li>
<li>Sulfur</li>
<li><a href="Benzoyl_peroxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl_peroxide" title="Benzoyl peroxide">Benzoyl peroxide</a><sup>#</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatory</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Nicotinamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotinamide" title="Nicotinamide">Nicotinamide</a></li>
<li><a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">Ibuprofen</a><sup>#</sup></li>
<li><a href="Aspirin.htm" tppabs="https://ptable.com/wiki/compounds/A/Aspirin" title="Aspirin">Aspirin</a><sup>#</sup></li>
<li>Red light therapy</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Antibiotics</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Clindamycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Clindamycin" title="Clindamycin">Clindamycin</a></li>
<li><a href="Dapsone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dapsone" title="Dapsone">Dapsone</a></li>
<li><a href="Erythromycin.htm" tppabs="https://ptable.com/wiki/compounds/A/Erythromycin" title="Erythromycin">Erythromycin</a></li>
<li><a href="Sulfacetamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfacetamide" title="Sulfacetamide">Sulfacetamide</a></li>
<li>Tetracyclines (<a href="Lymecycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Lymecycline" title="Lymecycline">Lymecycline</a></li>
<li><a href="Minocycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Minocycline" title="Minocycline">Minocycline</a></li>
<li><a href="Doxycycline.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxycycline" title="Doxycycline">Doxycycline</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hormonal</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiandrogens
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a>)</li></ul></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a>
<ul><li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li>Ethinylestradiol</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Retinoids</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Adapalene.htm" tppabs="https://ptable.com/wiki/compounds/A/Adapalene" title="Adapalene">Adapalene</a></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li>Motretinide</li>
<li><a href="Tazarotene.htm" tppabs="https://ptable.com/wiki/compounds/A/Tazarotene" title="Tazarotene">Tazarotene</a></li>
<li><a href="Tretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Tretinoin" title="Tretinoin">Tretinoin</a></li>
<li>Trifarotene</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benzamycin</li>
<li>Epristeride</li>
<li>Mesulfen</li>
<li>Pelretin</li>
<li>Stridex</li>
<li><a href="Tioxolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Tioxolone" title="Tioxolone">Tioxolone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adapalene/benzoyl peroxide</li>
<li>Benzoyl peroxide/clindamycin</li>
<li>Clindamycin/tretinoin</li>
<li>Erythromycin/isotretinoin</li>
<li>Sulfacetamide/sulfur</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Other_dermatological_preparations_(D11)" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Other_dermatological_preparations_(D11)" style="font-size:114%;margin:0 4em">Other dermatological preparations (D11)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-seborrheics</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><i>Antifungals</i>
<ul><li><a href="Bifonazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Bifonazole" title="Bifonazole">Bifonazole</a></li>
<li>Cetrimonium bromide (cetrimide)</li>
<li>Ciclopirox olamine (ciclopirox)</li>
<li>Climbazole</li>
<li><a href="Clotrimazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Clotrimazole" title="Clotrimazole">Clotrimazole</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Miconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Miconazole" title="Miconazole">Miconazole</a></li>
<li>Piroctone olamine</li>
<li><a href="Selenium_disulfide.htm" tppabs="https://ptable.com/wiki/compounds/A/Selenium_disulfide" title="Selenium disulfide">Selenium disulfide (selenium sulfide)</a></li>
<li><span class="new">Xenysalate</span></li>
<li><a href="Zinc_pyrithione.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc_pyrithione" title="Zinc pyrithione">Zinc pyrithione (pyrithione zinc)</a></li></ul></li>
<li><i>Antihistamines</i></li>
<li><i>Calcineurin inhibitors</i>
<ul><li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclosporin" title="Cyclosporin" class="mw-redirect">Cyclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li></ul></li>
<li><a href="Isotretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Isotretinoin" title="Isotretinoin">Isotretinoin</a></li>
<li><i>Keratolytics</i>
<ul><li>Coal tar</li>
<li><a href="Resorcinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Resorcinol" title="Resorcinol">Resorcinol</a></li>
<li><a href="Salicylic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Salicylic_acid" title="Salicylic acid">Salicylic acid</a></li>
<li><a href="Sulfur.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulfur" title="Sulfur">Sulfur</a></li>
<li><a href="Urea.htm" tppabs="https://ptable.com/wiki/compounds/A/Urea" title="Urea">Urea</a> (urea-containing cream)</li></ul></li>
<li><i>Lithium salts</i>
<ul><li>Lithium gluconate</li>
<li>Lithium succinate</li></ul></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin lightening</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Hydroquinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Hydroquinone" title="Hydroquinone">Hydroquinone</a></li>
<li><a href="Mequinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Mequinol" title="Mequinol">Mequinol</a></li>
<li><a href="Monobenzone.htm" tppabs="https://ptable.com/wiki/compounds/A/Monobenzone" title="Monobenzone">Monobenzone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Skin darkening</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afamelanotide</li>
<li>Melanotan II</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Anti-inflammatories</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Oxaceprol.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxaceprol" title="Oxaceprol">Oxaceprol</a></li>
<li><a href="Gamma-Linolenic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Gamma-Linolenic_acid" title="Gamma-Linolenic acid">Gamolenic acid</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
<li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Alitretinoin.htm" tppabs="https://ptable.com/wiki/compounds/A/Alitretinoin" title="Alitretinoin">Alitretinoin</a></li>
<li><i>Topical corticosteroids</i> (e.g., hydrocortisone)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alopecia treatments</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i> 
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Topilutamide (fluridil)</li></ul></li>
<li><i>Potassium channel openers</i>
<ul><li><a href="Minoxidil.htm" tppabs="https://ptable.com/wiki/compounds/A/Minoxidil" title="Minoxidil">Minoxidil</a></li></ul></li>
<li><i>Others</i>
<ul><li>Nepidermin</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Hair growth inhibitors</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>5α-Reductase inhibitors</i>
<ul><li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li></ul></li>
<li><i>Antiandrogens</i>
<ul><li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul></li>
<li><a href="Eflornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Eflornithine" title="Eflornithine">Eflornithine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Androgens (e.g., testosterone)</li>
<li><a href="Brimonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Brimonidine" title="Brimonidine">Brimonidine</a></li>
<li><a href="Calcium_gluconate.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium_gluconate" title="Calcium gluconate">Calcium gluconate</a></li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>)</li>
<li>Hyaluronic acid</li>
<li><a href="Magnesium_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium_sulfate" title="Magnesium sulfate">Magnesium sulfate</a></li>
<li>Pregnenolone acetate</li>
<li>Progestogens (e.g., progesterone)</li>
<li><a href="Povidone-iodine.htm" tppabs="https://ptable.com/wiki/compounds/A/Povidone-iodine" title="Povidone-iodine">Povidone-iodine</a></li>
<li>Tiratricol</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Androgen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgen_receptor_modulators" style="font-size:114%;margin:0 4em">Androgen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> <a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li>4-Dehydroepiandrosterone (4-DHEA)</li>
<li>4-Hydroxytestosterone</li>
<li><span class="new">4,17α-Dimethyltestosterone</span></li>
<li>5-Androstenedione</li>
<li>11-Ketotestosterone</li>
<li>11β-Hydroxyandrostenedione</li>
<li><a href="Adrenosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenosterone" title="Adrenosterone">Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)</a></li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">Androstenediol (5-androstenediol)</a>
<ul><li>Androstenediol 3β-acetate</li>
<li>Androstenediol 17β-acetate</li>
<li>Androstenediol diacetate</li>
<li>Androstenediol dipropionate</li></ul></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">Androstenedione (4-androstenedione)</a></li>
<li>Atamestane</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Boldenone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Boldenone'" tppabs="https://ptable.com/wiki/compounds/A/Boldenone" title="Boldenone">Boldenone</a>
<ul><li>Boldenone undecylenate</li></ul></li>
<li>Boldione (1,4-androstadienedione)</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a>
<ul><li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li></ul></li>
<li>Cloxotestosterone
<ul><li>Cloxotestosterone acetate</li></ul></li>
<li>Dehydroandrosterone</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA (androstenolone, prasterone; 5-DHEA)</a>
<ul><li>DHEA enanthate (prasterone enanthate)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA sulfate</a></li></ul></li>
<li><a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">Exemestane</a></li>
<li><a href="Formestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Formestane" title="Formestane">Formestane</a></li>
<li>Plomestane</li>
<li>Quinbolone</li>
<li>Silandrone</li>
<li>Testosterone<sup>#</sup> (+dutasteride)
<ul><li>Testosterone esters</li>
<li>Polytestosterone phloretin phosphate</li></ul></li></ul>

<ul><li><i>5α-Dihydrotestosterone derivatives:</i> 1-Androstenediol</li>
<li>1-Androstenedione</li>
<li>1-Androsterone (1-andro, 1-DHEA)</li>
<li>1-Testosterone</li>
<li>3α-Androstanediol</li>
<li>5α-Androst-2-en-17-one</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>11-Ketodihydrotestosterone</li>
<li><a href="Androsterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Androsterone" title="Androsterone">Androsterone</a></li>
<li>Bolazine
<ul><li>Bolazine capronate</li></ul></li>
<li><span class="new">Dihydroethyltestosterone</span></li>
<li>Dihydrofluoxymesterone</li>
<li><span class="new">Dihydromethylandrostenediol</span></li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone (DHT)</a> (androstanolone, stanolone)
<ul><li>Dihydrotestosterone esters</li></ul></li>
<li><a href="Drostanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drostanolone" title="Drostanolone">Drostanolone</a>
<ul><li>Drostanolone propionate</li></ul></li>
<li><a href="Epiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Epiandrosterone" title="Epiandrosterone">Epiandrosterone</a></li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li>Mesabolone</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a>
<ul><li>Mesterolone cipionate</li></ul></li>
<li>Methyldiazinol</li>
<li>Nisterime
<ul><li>Nisterime acetate</li></ul></li>
<li>Prostanozol</li>
<li>Stenbolone
<ul><li>Stenbolone acetate</li></ul></li>
<li>Testifenon (testiphenon, testiphenone)</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> 7α-Methyl-19-norandrostenedione (MENT dione, trestione)</li>
<li>11β-Methyl-19-nortestosterone
<ul><li>11β-Methyl-19-nortestosterone dodecylcarbonate</li></ul></li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol
<ul><li>Bolandiol dipropionate</li></ul></li>
<li>Bolandione (19-nor-4-androstenedione)</li>
<li>Bolmantalate (nandrolone adamantoate)</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone
<ul><li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li></ul></li>
<li>LS-1727 (nandrolone 17β-<i>N</i>-(2-chloroethyl)-<i>N</i>-nitrosocarbamate)</li>
<li>Methoxydienone (methoxygonadiene)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a>
<ul><li>Nandrolone esters</li></ul></li>
<li>Norclostebol
<ul><li>Norclostebol acetate</li></ul></li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li><a href="Oxabolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone" title="Oxabolone">Oxabolone</a>
<ul><li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li></ul></li>
<li>Trenbolone
<ul><li>Trenbolone acetate</li>
<li>Trenbolone enanthate</li>
<li>Trenbolone hexahydrobenzylcarbonate</li>
<li>Trenbolone undecanoate</li></ul></li>
<li>Trendione</li>
<li>Trestolone (MENT)
<ul><li>Trestolone acetate</li>
<li>Trestolone enanthate</li></ul></li></ul>

<ul><li><i>5α-Dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronandrolone</li>
<li><span class="new">5α-Dihydrotrestolone</span></li>
<li>19-Norandrosterone</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethylandrostenediol (CDMA)</li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li>Chloromethylandrostenediol (CMA)</li>
<li>Enestebol</li>
<li>Ethyltestosterone</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Hydroxystenozole</li>
<li>Metandienone (methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)
<ul><li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol diacetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li></ul></li>
<li>Methylclostebol (chloromethyltestosterone)</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a> (+esterified estrogens)
<ul><li>Methyltestosterone 3-hexyl ether</li></ul></li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li>Desoxymethyltestosterone</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li>Metenolone
<ul><li>Metenolone acetate</li>
<li>Metenolone enanthate</li></ul></li>
<li>Methasterone</li>
<li>Methyl-1-testosterone</li>
<li>Methylepitiostanol</li>
<li>Methylstenbolone</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> Bolenol</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Methyldienolone</li>
<li>Methylhydroxynandrolone (MOHN, MHN)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mibolerone</li>
<li>Norboletone</li>
<li>Norethandrolone</li>
<li>Propetandrol</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronorethandrolone</li>
<li>5α-Dihydronormethandrone</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Vinyl-19-nortestosterone derivatives:</i> Vinyltestosterone</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone (ethynyltestosterone)</a></li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyltestosterone derivatives:</i> 17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>Dihydroethisterone</li></ul>

<ul><li><i>17α-Ethynyl-19-nortestosterone derivatives:</i> Δ<sup>4</sup>-Tibolone</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol
<ul><li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li></ul></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol
<ul><li>Lynestrenol phenylpropionate</li></ul></li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Quingestanol
<ul><li>Quingestanol acetate</li></ul></li>
<li>Tibolone</li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives:</i> 5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li></ul>

<ul><li><i>Progesterone derivatives:</i> 6α-Methylprogesterone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li></ul>

<ul><li><i>Others/unsorted:</i> 3-Keto-5α-abiraterone</li>
<li><a href="Androstane.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Androstane" title="5α-Androstane" class="mw-redirect">5α-Androstane</a></li>
<li>Alternariol</li>
<li>Cl-4AS-1</li>
<li>Drupanol</li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li>
<li>ZM-182345</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SARMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nonsteroidal:</i> <span class="new">198RL26</span></li>
<li><span class="new">ACP-105</span></li>
<li><span class="new">AC-262536</span></li>
<li>Acetothiolutamide</li>
<li>Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)</li>
<li><span class="new">BMS-564929</span></li>
<li><span class="new">DTIB</span></li>
<li>Enobosarm (ostarine, MK-2866, GTx-024, S-22)</li>
<li><span class="new">FTBU-1</span></li>
<li>GSK2881078</li>
<li><span class="new">GSK-4336A</span></li>
<li><span class="new">GSK-8698</span></li>
<li>LG-121071 (LGD-121071)</li>
<li>LGD-2226</li>
<li><span class="new">LGD-2941 (LGD-122941)</span></li>
<li>LGD-3303</li>
<li>LGD-4033</li>
<li>LY-2452473</li>
<li><span class="new">JNJ-26146900</span></li>
<li>JNJ-28330835</li>
<li><span class="new">JNJ-37654032</span></li>
<li><span class="new">ORM-11984</span></li>
<li><span class="new">R-1</span></li>
<li>RAD140</li>
<li>RU-59063</li>
<li><span class="new">S-1</span></li>
<li>S-23</li>
<li>S-40503</li>
<li><span class="new">S-101479</span></li>
<li>Triclosan</li></ul>

<ul><li><i>Steroidal:</i> <span class="new">EM-9017</span></li>
<li>MK-0773</li>
<li>TFM-4AS-1</li>
<li>YK-11</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 7α-Thioprogesterone</li>
<li>7α-Thiospironolactone</li>
<li>7α-Thiomethylspironolactone</li>
<li>11α-Hydroxyprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Allyltestosterone</li>
<li>Benorterone</li>
<li>BOMT</li>
<li>Canrenoic acid</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Clascoterone</li>
<li>Clometerone</li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li>Delanterone</li>
<li>Delmadinone acetate</li>
<li>Dicirenone</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>DU-41165</li>
<li>Edogestrone</li>
<li><span class="new">EM-4350</span></li>
<li>EM-5854</li>
<li><span class="new">EM-5855</span></li>
<li><span class="new">EM-6537</span></li>
<li>Epitestosterone</li>
<li>Galeterone</li>
<li>Guggulsterone</li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Mespirenone</li>
<li>Metogest</li>
<li>Mexrenone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li>Nomegestrol acetate</li>
<li>Nordinone</li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Prorenone</li>
<li>Rosterolone</li>
<li><span class="new">RU-15328</span></li>
<li>SC-5233 (spirolactone)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li>
<li>Spiroxasone</li>
<li>Topterone</li>
<li>Trimegestone</li>
<li>Trimethyltrienolone (R-2956)</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> 5<i>N</i>-Bicalutamide</li>
<li>AA560</li>
<li><span class="new">Antarlides</span></li>
<li><span class="new">Arabilin</span></li>
<li>Apalutamide</li>
<li>Atraric acid</li>
<li><span class="new">AZD-3514</span></li>
<li>Bakuchiol</li>
<li><span class="new">BAY-1024767</span></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">Bisphenols</a> (e.g., <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a>, <span class="new">BFDGE</span>, <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">bisphenol A</a>, bisphenol F, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">bisphenol S</a>)</li>
<li><span class="new">BMS-501949</span></li>
<li><span class="new">BMS-570511</span></li>
<li>BMS-641988</li>
<li><span class="new">CH5137291</span></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Cioteronel</li>
<li>Cyanonilutamide</li>
<li>Darolutamide</li>
<li>DDT (via metabolite p,p’-DDE)</li>
<li><a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">Dieldrin</a></li>
<li>DIMP</li>
<li><a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">Endosulfan</a></li>
<li>Enzalutamide</li>
<li>EPI-001</li>
<li>EPI-7386</li>
<li><a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">Fenarimol</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Hydroxyflutamide</li>
<li>Inocoterone</li>
<li>Inocoterone acetate</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Ketodarolutamide</li>
<li>Lavender oil</li>
<li><span class="new">LG-105</span></li>
<li>LG-120907</li>
<li><span class="new">LGD-1331</span></li>
<li>Linuron</li>
<li><a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">Methiocarb</a></li>
<li><span class="new"><i>N</i>-Butylbenzenesulfonamide</span></li>
<li><i>N</i>-Desmethylapalutamide</li>
<li><i>N</i>-Desmethylenzalutamide</li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li><span class="new">ONC1-13B</span></li>
<li>Pentomone</li>
<li><span class="new">PF-998425</span></li>
<li><a href="Phenothrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenothrin" title="Phenothrin">Phenothrin</a></li>
<li>Prochloraz</li>
<li><a href="Procymidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Procymidone" title="Procymidone">Procymidone</a></li>
<li>Proxalutamide</li>
<li>Ralaniten (EPI-002)</li>
<li>Ralaniten acetate (EPI-506)</li>
<li>RD-162</li>
<li><span class="new">Ro 2-7239</span></li>
<li><span class="new">Ro 5-2537</span></li>
<li>RU-22930</li>
<li>RU-56187</li>
<li>RU-57073</li>
<li>RU-58642</li>
<li>RU-58841</li>
<li>Seviteronel</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li>Topilutamide (fluridil)</li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li>Vinclozolin</li>
<li><span class="new">YM-580</span></li>
<li><span class="new">YM-92088</span></li>
<li><span class="new">YM-175735</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPRC6A</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center;">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cations (incl. aluminum, <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a>, <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>, <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium</a>, <a href="Strontium.htm" tppabs="https://ptable.com/wiki/compounds/A/Strontium" title="Strontium">strontium</a>, <a href="Zinc.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc" title="Zinc">zinc</a>)</li>
<li>Dehydroandrosterone</li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li><small>L</small>-α-Amino acids (incl. <a href="Arginine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arginine" title="Arginine"><small>L</small>-arginine</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, <a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine"><small>L</small>-ornithine</a>)</li>
<li>Osteocalcin</li>
<li><abbr>SHBG</abbr></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of androgens/anabolic steroids</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Progesterone_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Progesterone_receptor_modulators" style="font-size:114%;margin:0 4em">Progesterone receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>PR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Progesterone derivatives:</i> 3β-Dihydroprogesterone</li>
<li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>6α-Methylprogesterone</li>
<li>9α-Bromo-11-ketoprogesterone</li>
<li>11-Dehydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycorticosterone</a></li>
<li>16α-Hydroxyprogesterone</li>
<li><span class="new">17α-Methyl-11-deoxycorticosterone acetate</span></li>
<li>20α-Dihydroprogesterone</li>
<li>20β-Dihydroprogesterone</li>
<li>Dimepregnen</li>
<li><a href="Diosgenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Diosgenin" title="Diosgenin">Diosgenin</a></li>
<li>P1-185</li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li>
<li>Progesterone 3-acetyl enol ether</li>
<li>Quingestrone</li></ul>

<ul><li><i>Retroprogesterone derivatives:</i> 20α-Dihydrodydrogesterone</li>
<li>20α-Dihydrotrengestone</li>
<li>DU-41164</li>
<li>DU-41165</li>
<li><a href="Dydrogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dydrogesterone" title="Dydrogesterone">Dydrogesterone</a></li>
<li>Retroprogesterone</li>
<li>Ro 6-3129</li>
<li>Trengestone</li></ul>

<ul><li><i>17α-Substituted progesterone derivatives:</i> 6α-Methyl-17α-bromoprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>16-Methylene-17α-hydroxyprogesterone acetate</li>
<li>17α-Bromoprogesterone</li>
<li>17α-Hydroxyprogesterone (hydroxyprogesterone)</li>
<li>17α-Methylprogesterone</li>
<li>Acetomepregenol (mepregenol diacetate)</li>
<li>Algestone</li>
<li>Algestone acetonide</li>
<li>Algestone acetophenide</li>
<li>Anagestone</li>
<li>Anagestone acetate</li>
<li><span class="new">Bromethenmadinone</span></li>
<li>Bromethenmadinone acetate</li>
<li>Butagest (buterol)</li>
<li>Chlormadinone</li>
<li>Chlormadinone acetate</li>
<li>Chlormadinone caproate</li>
<li><span class="new">Chlormethenmadinone</span></li>
<li>Chlormethenmadinone acetate</li>
<li>Cismadinone</li>
<li>Cismadinone acetate</li>
<li>Clogestone</li>
<li>Clogestone acetate</li>
<li>Clomegestone</li>
<li>Clomegestone acetate</li>
<li>Cymegesolate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone</li>
<li>Delmadinone acetate</li>
<li>Edogestrone</li>
<li>Flugestone</li>
<li>Flugestone acetate</li>
<li><a href="Fluorometholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluorometholone" title="Fluorometholone">Fluorometholone</a></li>
<li>Fluorometholone acetate</li>
<li>Flumedroxone</li>
<li>Flumedroxone acetate</li>
<li>Fluoromedroxyprogesterone acetate</li>
<li>Gestaclone</li>
<li>Haloprogesterone</li>
<li>Hydromadinone</li>
<li>Hydromadinone acetate</li>
<li>Hydroxyprogesterone acetate</li>
<li>Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate)</li>
<li>Hydroxyprogesterone heptanoate (hydroxyprogesterone enanthate)</li>
<li>Hydroxyprogesterone heptanoate benzilic acid hydrazone</li>
<li>Mecigestone (pentarane B)</li>
<li>Medrogestone</li>
<li><a href="Medroxyprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone" title="Medroxyprogesterone">Medroxyprogesterone</a></li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Medroxyprogesterone caproate</li>
<li><a href="Megestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Megestrol" title="Megestrol">Megestrol</a></li>
<li>Megestrol acetate</li>
<li>Megestrol caproate</li>
<li>Melengestrol</li>
<li>Melengestrol acetate</li>
<li>Methenmadinone</li>
<li>Methenmadinone acetate</li>
<li>Methenmadinone caproate</li>
<li>Mometasone</li>
<li><a href="Mometasone_furoate.htm" tppabs="https://ptable.com/wiki/compounds/A/Mometasone_furoate" title="Mometasone furoate" class="mw-redirect">Mometasone furoate</a></li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Pentagestrone</li>
<li>Pentagestrone acetate</li>
<li>Pentarane A</li>
<li>Proligestone</li></ul>

<ul><li><i>19-Norprogesterone derivatives:</i> 17α-Methyl-19-norprogesterone</li>
<li>18-Methylsegesterone acetate</li>
<li>19-Norprogesterone</li>
<li>Amadinone</li>
<li>Amadinone acetate</li>
<li>Demegestone</li>
<li><span class="new">Fluoro ethyl norprogesterone</span></li>
<li><span class="new">Fluoro furanyl norprogesterone</span></li>
<li>Gestadienol</li>
<li>Gestadienol acetate</li>
<li>Gestonorone acetate (gestronol acetate)</li>
<li>Gestonorone caproate (gestronol hexanoate)</li>
<li>Gestronol (gestonorone)</li>
<li>Nomegestrol</li>
<li>Nomegestrol acetate</li>
<li>Norgestomet</li>
<li>ORG-2058</li>
<li>Oxogestone</li>
<li>Oxogestone phenpropionate (xinogestone)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Segesterone</li>
<li>Segesterone acetate (nestorone)</li>
<li>Trimegestone</li></ul>

<ul><li><i>Testosterone derivatives:</i> Progestins: 6,6-Difluoronorethisterone</li>
<li>6,6-Difluoronorethisterone acetate</li>
<li>17α-Allyl-19-nortestosterone</li>
<li><a href="Allylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Allylestrenol" title="Allylestrenol">Allylestrenol</a></li>
<li>Altrenogest</li>
<li>Chloroethynylnorgestrel</li>
<li>Cingestol</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li>Dienogest</li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone</a></li>
<li>Ethynerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol</li>
<li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol</li>
<li>Lynestrenol phenylpropionate</li>
<li>Metynodiol</li>
<li>Metynodiol diacetate</li>
<li>Norelgestromin</li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone (norethindrone)</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li>Noretynodrel</li>
<li>Norgesterone</li>
<li><a href="Norgestimate.htm" tppabs="https://ptable.com/wiki/compounds/A/Norgestimate" title="Norgestimate">Norgestimate</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Norvinisterone</li>
<li>Oxendolone</li>
<li>Quingestanol</li>
<li>Quingestanol acetate</li>
<li>Tibolone</li>
<li>Tigestol</li>
<li>Tosagestin; Anabolic–androgenic steroids: 11β-Methyl-19-nortestosterone</li>
<li>11β-Methyl-19-nortestosterone dodecylcarbonate</li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol</li>
<li>Bolandiol dipropionate</li>
<li>Bolandione</li>
<li>Dimethisterone</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone</li>
<li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol (ethylnandrol)</a></li>
<li>Methyldienolone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone (R-1881)</a></li>
<li>Methoxydienone (methoxygonadiene)</li>
<li>Mibolerone</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a></li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethandrolone, normethisterone)</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li>
<li>Trenbolone (trienolone)</li>
<li>Trenbolone esters (e.g., trenbolone acetate, trenbolone enanthate)</li>
<li>Trendione</li>
<li>Trestolone</li>
<li>Trestolone acetate</li></ul>

<ul><li><i>Spirolactone derivatives:</i> Canrenoic acid</li>
<li>Canrenone</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Mespirenone</li>
<li>Potassium canrenoate</li>
<li>Prorenone</li>
<li>SC-5233 (spirolactone)</li>
<li>SC-8109</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li></ul>

<ul><li><i>Nonsteroidal:</i> 3,8-Dihydrodiligustilide</li>
<li>LG-2527</li>
<li><span class="new">LG-100128</span></li>
<li>Riligustilide</li>
<li><span class="new">RWJ-26819</span></li>
<li><span class="new">RWJ-49853</span></li>
<li><span class="new">RWJ-60130</span></li>
<li>Tanaproget</li>
<li>ZM-182345</li></ul>

<ul><li><i>Unknown:</i> ORG-47241</li>
<li>ORG-201745</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SPRMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Dihydroethisterone</li>
<li>5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li>
<li>Asoprisnil</li>
<li>Asoprisnil ecamate</li>
<li>Guggulsterone</li>
<li><span class="new">J1042</span></li>
<li><span class="new">LG-120838</span></li>
<li>Metapristone (RU-42633)</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone (RU-486)</a></li>
<li><span class="new">ORF-9371</span></li>
<li>ORF-9326</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RMI-12936</span></li>
<li>Telapristone</li>
<li>Ulipristal acetate</li>
<li>Vilaprisan</li>
<li><span class="new">ZK-137316</span></li></ul>

<ul><li><i>Nonsteroidal:</i> <a href="Apigenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Apigenin" title="Apigenin">Apigenin</a></li>
<li><a href="Kaempferol.htm" tppabs="https://ptable.com/wiki/compounds/A/Kaempferol" title="Kaempferol">Kaempferol</a></li>
<li><span class="new">LG-120920</span></li>
<li><a href="Naringenin.htm" tppabs="https://ptable.com/wiki/compounds/A/Naringenin" title="Naringenin">Naringenin</a></li>
<li><span class="new">PRA-910</span></li>
<li><a href="Syringic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Syringic_acid" title="Syringic acid">Syringic acid</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Aglepristone</li>
<li>Lilopristone</li>
<li>Lonaprisan</li>
<li>Onapristone</li>
<li><span class="new">ORG-31710</span></li>
<li><span class="new">ORG-31806</span></li>
<li><span class="new">ORG-33628</span></li>
<li><span class="new">RTI 3021–022</span></li>
<li>Toripristone</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> Darolutamide</li>
<li><span class="new">LG-001447</span></li>
<li><span class="new">LG-100127</span></li>
<li><span class="new">LG-100128</span></li>
<li><span class="new">LG-120830</span></li>
<li><span class="new">LG-121046</span></li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li><span class="new">ZM-150271</span></li>
<li><span class="new">ZM-172406</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>mPR</abbr><br>(<abbr>PAQR</abbr>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="5α-Dihydroprogesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Dihydroprogesterone" title="5α-Dihydroprogesterone">5α-Dihydroprogesterone</a></li>
<li>5β-Dihydroprogesterone</li>
<li><a href="11-Deoxycorticosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/11-Deoxycorticosterone" title="11-Deoxycorticosterone">11-Deoxycortisone (21-hydroxyprogesterone)</a></li>
<li>11-Deoxycortisol (17α,21-dihydroxyprogesterone)</li>
<li>17α-Hydroxyprogesterone</li>
<li><a href="Allopregnanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Allopregnanolone" title="Allopregnanolone">Allopregnanolone</a></li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li><a href="Pregnenolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pregnenolone" title="Pregnenolone">Pregnenolone</a></li>
<li><a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">Progesterone</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>Androgen receptor modulators</dd>
<dd>Estrogen receptor modulators</dd>
<dd>List of progestogens</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="AstraZeneca" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="AstraZeneca" style="font-size:114%;margin:0 4em">AstraZeneca</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anastrozole.htm" tppabs="https://ptable.com/wiki/compounds/A/Anastrozole" title="Anastrozole">Anastrozole</a></li>
<li><a href="Atenolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Atenolol" title="Atenolol">Atenolol</a></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Brompheniramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Brompheniramine" title="Brompheniramine">Brompheniramine</a></li>
<li><a href="Budesonide.htm" tppabs="https://ptable.com/wiki/compounds/A/Budesonide" title="Budesonide">Budesonide</a></li>
<li>Disufenton sodium</li>
<li><a href="Esomeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Esomeprazole" title="Esomeprazole">Esomeprazole</a></li>
<li>FluMist</li>
<li><a href="Fulvestrant.htm" tppabs="https://ptable.com/wiki/compounds/A/Fulvestrant" title="Fulvestrant">Fulvestrant</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li><a href="Goserelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Goserelin" title="Goserelin">Goserelin</a></li>
<li><a href="Isosorbide_mononitrate.htm" tppabs="https://ptable.com/wiki/compounds/A/Isosorbide_mononitrate" title="Isosorbide mononitrate">Isosorbide mononitrate</a></li>
<li>Motavizumab</li>
<li><a href="Omeprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Omeprazole" title="Omeprazole">Omeprazole</a></li>
<li>Palivizumab</li>
<li><a href="Propofol.htm" tppabs="https://ptable.com/wiki/compounds/A/Propofol" title="Propofol">Propofol</a></li>
<li><a href="Rosuvastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rosuvastatin" title="Rosuvastatin">Rosuvastatin</a></li>
<li><a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">Tamoxifen</a></li>
<li>Ticagrelor</li>
<li>Vandetanib</li>
<li><a href="Ximelagatran.htm" tppabs="https://ptable.com/wiki/compounds/A/Ximelagatran" title="Ximelagatran">Ximelagatran</a></li>
<li><a href="Zafirlukast.htm" tppabs="https://ptable.com/wiki/compounds/A/Zafirlukast" title="Zafirlukast">Zafirlukast</a></li>
<li><a href="Zolmitriptan.htm" tppabs="https://ptable.com/wiki/compounds/A/Zolmitriptan" title="Zolmitriptan">Zolmitriptan</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Predecessors and<br>acquired companies</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Astra AB</li>
<li>Cambridge Antibody Technology</li>
<li>MedImmune</li>
<li>Zeneca</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">People</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Tom McKillop</li>
<li>Louis Schweitzer</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="font-weight: bold;"><div>
<ul><li><figure-inline><span><img src="../I/m/Folder_Hexagonal_Icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Folder_Hexagonal_Icon.svg.png" data-file-width="36" data-file-height="31" data-file-type="drawing" height="14" width="16"></span></figure-inline> Category</li>
<li><figure-inline><span><img src="../I/m/Commons-logo.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Commons-logo.svg.png" data-file-width="1024" data-file-height="1376" data-file-type="drawing" height="16" width="12"></span></figure-inline> <a href="javascript:if(confirm('https://commons.wikimedia.org/wiki/Category:AstraZeneca  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://commons.wikimedia.org/wiki/Category:AstraZeneca'" tppabs="https://commons.wikimedia.org/wiki/Category:AstraZeneca" title="commons:Category:AstraZeneca" class="external">Commons</a></li></ul>
</div></td></tr></tbody></table></div>






















<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-07" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Bicalutamide&oldid=971725725  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Bicalutamide&oldid=971725725'" tppabs="https://en.wikipedia.org/wiki/?title=Bicalutamide&oldid=971725725">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>